activity_id,assay_chembl_id,assay_description,assay_type,molecule_chembl_id,relation,units,IC50,target_chembl_id,target_organism,type
32262,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL68920,=,nM,16500.0,CHEMBL279,Homo sapiens,IC50
32335,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69638,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
33033,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL419526,=,nM,1880.0,CHEMBL279,Homo sapiens,IC50
33408,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL443268,=,nM,10100.0,CHEMBL279,Homo sapiens,IC50
34276,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL330621,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
34671,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL304271,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
35519,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98896,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
37861,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98653,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
37862,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL319065,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
39110,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL328644,=,nM,124.0,CHEMBL279,Homo sapiens,IC50
40257,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98385,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
40693,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL419082,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
41449,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL318728,=,nM,134.0,CHEMBL279,Homo sapiens,IC50
41979,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL304760,=,nM,2720.0,CHEMBL279,Homo sapiens,IC50
41986,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL307982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
42683,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98633,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
42689,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL431073,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
45078,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98995,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
45079,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98996,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
46268,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL329713,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
47935,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL67057,=,nM,2050.0,CHEMBL279,Homo sapiens,IC50
48768,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL100174,=,nM,151.0,CHEMBL279,Homo sapiens,IC50
49322,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL432903,=,nM,3470.0,CHEMBL279,Homo sapiens,IC50
49328,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL65848,=,nM,3460.0,CHEMBL279,Homo sapiens,IC50
49412,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69129,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
50202,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98538,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
51439,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL97888,=,nM,259.0,CHEMBL279,Homo sapiens,IC50
51440,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL99832,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
51886,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69827,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
53296,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL306380,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
53967,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101464,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
53974,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL100775,=,nM,1274.0,CHEMBL279,Homo sapiens,IC50
54404,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL305194,=,nM,8920.0,CHEMBL279,Homo sapiens,IC50
55130,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL319789,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
55137,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL97889,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
55138,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98475,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
57679,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL420087,=,nM,194.0,CHEMBL279,Homo sapiens,IC50
58124,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL67003,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
60800,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL306012,=,nM,2680.0,CHEMBL279,Homo sapiens,IC50
62146,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL47940,=,nM,1570.0,CHEMBL279,Homo sapiens,IC50
63369,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69358,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
66035,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69071,=,nM,1630.0,CHEMBL279,Homo sapiens,IC50
66113,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL302281,=,nM,2290.0,CHEMBL279,Homo sapiens,IC50
66857,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101544,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
67213,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69709,=,nM,5820.0,CHEMBL279,Homo sapiens,IC50
68472,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL264382,=,nM,3470.0,CHEMBL279,Homo sapiens,IC50
69859,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL308672,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
70767,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101924,=,nM,137.0,CHEMBL279,Homo sapiens,IC50
78008,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL432941,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
79177,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL420609,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
83548,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88462,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50
84545,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL431996,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
85631,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL91250,=,nM,12100.0,CHEMBL279,Homo sapiens,IC50
85640,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88771,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
87619,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL91815,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
88630,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL328029,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
88639,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL314995,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
91569,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88483,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
91587,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL89363,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
92599,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL276711,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
98654,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL89010,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
98663,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL86531,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
99526,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL315753,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
104503,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88606,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
104512,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL313821,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
108862,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329201,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
109722,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL221736,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
110154,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92973,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
110155,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92516,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
111164,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL324489,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
111618,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL96150,=,nM,265.0,CHEMBL279,Homo sapiens,IC50
113043,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92623,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
114343,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329350,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
114352,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329142,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
116878,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL330042,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
117675,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL420528,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
118084,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL96569,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
120047,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118748,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
120054,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL117052,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
120115,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL327029,=,nM,355.0,CHEMBL279,Homo sapiens,IC50
121338,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL119552,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
122558,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118832,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
122965,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL317566,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
124201,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329457,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
125121,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL323838,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
126536,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL333297,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
128961,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118569,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
130786,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92238,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
130787,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL94542,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
132885,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118440,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
133267,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL83656,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
135300,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL325003,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
135730,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL328790,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
136543,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL119276,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
139354,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92279,=,nM,224.0,CHEMBL279,Homo sapiens,IC50
140398,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92564,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
141152,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL117983,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
141620,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92461,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
184214,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL432548,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
193034,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL84332,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
201317,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL83171,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
203611,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL316384,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
204863,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL81026,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
204865,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL82433,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
209582,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL83279,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
213122,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL79475,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
216622,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL430812,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
217880,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL82069,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
230638,CHEMBL818935,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL44577,=,nM,5320.0,CHEMBL279,Homo sapiens,IC50
233271,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL47787,=,nM,34200.0,CHEMBL279,Homo sapiens,IC50
234547,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL45683,=,nM,435.0,CHEMBL279,Homo sapiens,IC50
242449,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL46785,=,nM,3810.0,CHEMBL279,Homo sapiens,IC50
250611,CHEMBL818935,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL45177,=,nM,1190.0,CHEMBL279,Homo sapiens,IC50
257550,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL295528,=,nM,34600.0,CHEMBL279,Homo sapiens,IC50
258863,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL45651,=,nM,263.0,CHEMBL279,Homo sapiens,IC50
307857,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448064,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
309315,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25579,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
309324,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24026,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
309331,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL26050,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
314570,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL428534,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
316938,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL281872,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
316966,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL281990,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
316973,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL422758,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
316980,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25450,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
316987,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907763,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
316994,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24137,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
318307,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24828,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
321869,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1744349,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
321877,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24979,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
321886,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448065,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
323341,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907764,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
324427,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL283088,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
324434,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448067,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
325573,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202477,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
326803,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL416191,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
328340,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL533849,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
328371,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907944,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
330834,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1744347,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
332169,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25610,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
334915,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL26641,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
337410,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL279459,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
338667,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202473,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
338674,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25425,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
340146,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL286160,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
340161,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448066,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
342467,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202478,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
438322,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67598,=,nM,9110.0,CHEMBL279,Homo sapiens,IC50
439638,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67268,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
439645,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL70034,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
442412,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69068,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
446437,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL302279,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50
446444,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL304113,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
447791,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL305748,=,nM,9820.0,CHEMBL279,Homo sapiens,IC50
447798,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL302481,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
447805,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71541,=,nM,144.0,CHEMBL279,Homo sapiens,IC50
447812,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67211,=,nM,5060.0,CHEMBL279,Homo sapiens,IC50
450344,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL303195,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
451604,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL66716,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
451611,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68888,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
455619,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69649,=,nM,1310.0,CHEMBL279,Homo sapiens,IC50
460757,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69544,=,nM,4240.0,CHEMBL279,Homo sapiens,IC50
460764,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL433097,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
460771,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71722,=,nM,161.0,CHEMBL279,Homo sapiens,IC50
463232,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69868,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50
463239,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67560,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50
463246,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68773,=,nM,6890.0,CHEMBL279,Homo sapiens,IC50
464569,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68663,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50
464576,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL66102,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
465916,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68430,=,nM,16900.0,CHEMBL279,Homo sapiens,IC50
468582,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68082,=,nM,677.0,CHEMBL279,Homo sapiens,IC50
472854,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71985,=,nM,129.0,CHEMBL279,Homo sapiens,IC50
476316,CHEMBL818399,Inhibition of VEGF-receptor 2 (KDR),B,CHEMBL94678,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
477356,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL432491,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
477455,CHEMBL818399,Inhibition of VEGF-receptor 2 (KDR),B,CHEMBL281948,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
478715,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL60541,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
482439,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL418301,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
487121,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL58224,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
493113,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL258805,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
496461,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL293068,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50
496465,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL292864,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
501314,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL299032,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50
506175,CHEMBL811947,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL21156,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
507371,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL58483,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
510999,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL59110,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
512671,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL435227,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
512706,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL147761,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
514073,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL450622,=,nM,28300.0,CHEMBL279,Homo sapiens,IC50
514081,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL274654,=,nM,2430.0,CHEMBL279,Homo sapiens,IC50
520420,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL357803,=,nM,1730.0,CHEMBL279,Homo sapiens,IC50
523088,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL146697,=,nM,920.0,CHEMBL279,Homo sapiens,IC50
523096,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL146694,=,nM,4370.0,CHEMBL279,Homo sapiens,IC50
524401,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148514,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
529801,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL443296,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
529809,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149243,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50
531099,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149073,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
533733,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148984,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
536421,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL347074,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
537822,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL344319,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50
541591,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL356245,=,nM,8290.0,CHEMBL279,Homo sapiens,IC50
543019,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL150151,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
544197,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL358728,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
546997,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149201,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
548224,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148744,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
548232,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL150177,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50
550328,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL147112,=,nM,1470.0,CHEMBL279,Homo sapiens,IC50
592890,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL48834,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50
595279,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46694,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
599248,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45752,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
600263,CHEMBL811943,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein),B,CHEMBL297769,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
600444,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297012,=,nM,392.0,CHEMBL279,Homo sapiens,IC50
601678,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45405,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50
604197,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45388,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
605519,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45015,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
607864,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45942,=,nM,3080.0,CHEMBL279,Homo sapiens,IC50
607865,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297856,=,nM,6830.0,CHEMBL279,Homo sapiens,IC50
610190,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295679,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
610191,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296204,=,nM,3570.0,CHEMBL279,Homo sapiens,IC50
611402,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295973,=,nM,279.0,CHEMBL279,Homo sapiens,IC50
611403,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295247,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
612648,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47832,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
612656,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46642,=,nM,1870.0,CHEMBL279,Homo sapiens,IC50
618142,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44915,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
618144,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297156,=,nM,1808.0,CHEMBL279,Homo sapiens,IC50
619425,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297675,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
620467,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45389,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
620468,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296475,=,nM,232.0,CHEMBL279,Homo sapiens,IC50
621614,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47852,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
621616,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL445327,=,nM,276.5,CHEMBL279,Homo sapiens,IC50
622933,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45750,=,nM,289.0,CHEMBL279,Homo sapiens,IC50
622934,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45214,=,nM,273.0,CHEMBL279,Homo sapiens,IC50
624219,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47110,=,nM,1610.0,CHEMBL279,Homo sapiens,IC50
624220,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47965,=,nM,765.0,CHEMBL279,Homo sapiens,IC50
624221,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44622,=,nM,4220.0,CHEMBL279,Homo sapiens,IC50
625436,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296430,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
626693,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44608,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
627977,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL431930,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
630567,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46696,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50
630568,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295816,=,nM,892.0,CHEMBL279,Homo sapiens,IC50
631919,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL43949,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
631927,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47166,=,nM,135.0,CHEMBL279,Homo sapiens,IC50
631928,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47962,=,nM,149.0,CHEMBL279,Homo sapiens,IC50
653058,CHEMBL820700,Inhibition of vascular endothelial growth factor receptor 2 autophosphorylation in intact cells,B,CHEMBL352308,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
676635,CHEMBL820701,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL330608,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50
703251,CHEMBL820701,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL319347,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
714091,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL293712,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
714099,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL291759,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
716441,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL56109,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
717181,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176702,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
717799,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL56569,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
718313,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL367442,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
719756,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL430155,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
719766,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13354,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
720613,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176705,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
721878,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13485,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
722192,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL59042,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
722684,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176309,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
724249,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL267293,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
724589,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL292930,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
725110,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL369014,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
726658,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13629,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
726668,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13608,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
727034,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL55496,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
732858,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL296185,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
735351,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL300853,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
735359,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL57143,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
738131,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL52513,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
739283,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL54283,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
740163,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13983,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
741552,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13976,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
744624,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL301143,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
745573,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL275117,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
745972,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL298566,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
746478,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL169757,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
749668,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL55594,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
751792,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
752112,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL301271,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
754755,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL324335,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
761433,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL331465,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
762408,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL118386,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
765667,CHEMBL820211,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL388978,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
769104,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL445062,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
771180,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL117166,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
771192,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL116324,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
776797,CHEMBL819550,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL103055,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50
776901,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL333021,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
780349,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL115480,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
784771,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL333640,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
785952,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL324153,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
787094,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL118400,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
789808,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL354895,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
789815,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL366452,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
792535,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL173856,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
793644,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL170137,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
794737,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171616,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
796992,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL423072,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
800513,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL415756,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
802942,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL172292,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
806831,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171188,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
813242,CHEMBL817616,Inhibition of phosphorylation of poly-Glu/Tyr (4:1) peptide substrate by VEGF-receptor 2 (KDR) kinase,B,CHEMBL353281,=,nM,2840.0,CHEMBL279,Homo sapiens,IC50
814419,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL170589,=,nM,242.0,CHEMBL279,Homo sapiens,IC50
814420,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL173550,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
815627,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171736,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
819264,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL435702,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
822595,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL354070,=,nM,99.0,CHEMBL279,Homo sapiens,IC50
826331,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL422918,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
1027860,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL348218,=,nM,163.0,CHEMBL279,Homo sapiens,IC50
1029215,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL347999,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1031601,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL2112040,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1034057,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150405,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
1034059,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151358,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1034060,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL346631,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1035360,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL148471,=,nM,414.0,CHEMBL279,Homo sapiens,IC50
1036579,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359084,=,nM,187.0,CHEMBL279,Homo sapiens,IC50
1036580,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL358843,=,nM,309.0,CHEMBL279,Homo sapiens,IC50
1037726,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151219,=,nM,107.0,CHEMBL279,Homo sapiens,IC50
1038858,CHEMBL820693,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL150894,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1038886,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL149636,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1038888,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359316,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
1041266,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151863,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1042391,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL357813,=,nM,276.0,CHEMBL279,Homo sapiens,IC50
1043633,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL148880,=,nM,208.0,CHEMBL279,Homo sapiens,IC50
1043634,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150085,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
1047511,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL424323,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1047514,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL149742,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
1049913,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151959,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1051128,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL357490,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1056031,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151656,=,nM,111.0,CHEMBL279,Homo sapiens,IC50
1057389,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151835,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
1057390,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL358038,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1057391,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150291,=,nM,411.0,CHEMBL279,Homo sapiens,IC50
1058611,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL356626,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1063707,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL2448133,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1063709,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL424321,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1064912,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL423221,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
1066073,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151713,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1068009,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101683,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
1070524,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101253,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
1085416,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101682,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50
1104968,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150817,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1107488,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL127907,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1110886,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL345943,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1113207,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150315,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1116825,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL148869,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1118074,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150581,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
1119359,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL151015,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
1121632,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL346200,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
1122749,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150657,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1122782,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150187,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1125129,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL356658,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1127643,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150826,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1127648,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147192,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1130032,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150825,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
1135051,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147138,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
1135085,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL357815,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1135095,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL358672,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
1135101,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL301018,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
1137564,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150606,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1137569,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL440727,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1138815,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147180,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1140148,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL151067,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1140177,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL434311,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1142532,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74850,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
1142534,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74034,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50
1144043,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL369360,=,nM,17030.0,CHEMBL279,Homo sapiens,IC50
1145258,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171558,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
1145260,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL354145,=,nM,77000.0,CHEMBL279,Homo sapiens,IC50
1146668,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL173799,=,nM,42640.0,CHEMBL279,Homo sapiens,IC50
1150437,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169643,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50
1150441,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL422564,=,nM,91350.0,CHEMBL279,Homo sapiens,IC50
1151500,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL78303,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
1151655,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL172518,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1151658,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL353070,=,nM,2320.0,CHEMBL279,Homo sapiens,IC50
1151662,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352877,=,nM,73820.0,CHEMBL279,Homo sapiens,IC50
1152810,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1152861,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169186,=,nM,2170.0,CHEMBL279,Homo sapiens,IC50
1153965,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74391,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
1154176,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171745,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
1155307,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL77555,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
1155480,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352977,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50
1155484,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171125,=,nM,4960.0,CHEMBL279,Homo sapiens,IC50
1157855,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL433321,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1160548,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL309331,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
1161916,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306707,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
1163437,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75034,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1164810,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL78160,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1164812,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74143,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
1164814,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306295,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
1164971,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL172450,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50
1166092,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75232,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
1167464,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL307476,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50
1167468,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74587,=,nM,950.0,CHEMBL279,Homo sapiens,IC50
1168751,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL419458,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
1168753,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL77933,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1168760,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74646,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
1170096,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75196,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1170242,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352992,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
1171397,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL355282,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
1173843,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74550,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
1174055,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169797,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50
1174059,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL167890,=,nM,8160.0,CHEMBL279,Homo sapiens,IC50
1175200,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306512,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50
1175204,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL431006,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1176715,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL170984,=,nM,15600.0,CHEMBL279,Homo sapiens,IC50
1177825,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75077,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1179008,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74197,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1181738,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL312526,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
1181740,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75462,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
1183183,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL347537,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1185316,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL317438,=,nM,111.0,CHEMBL279,Homo sapiens,IC50
1189635,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318263,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
1189636,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327720,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1191693,CHEMBL818932,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL2111784,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
1192018,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL432196,=,nM,186.0,CHEMBL279,Homo sapiens,IC50
1195757,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101221,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1200651,CHEMBL818932,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL121405,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1202492,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318733,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50
1202493,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL431038,=,nM,4040.0,CHEMBL279,Homo sapiens,IC50
1203788,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL323345,=,nM,4860.0,CHEMBL279,Homo sapiens,IC50
1210313,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL103595,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1210322,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL316671,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1210331,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318835,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1213062,CHEMBL811944,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL47203,=,nM,1190.0,CHEMBL279,Homo sapiens,IC50
1218273,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101461,=,nM,575.0,CHEMBL279,Homo sapiens,IC50
1218274,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327721,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1220866,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101325,=,nM,8320.0,CHEMBL279,Homo sapiens,IC50
1222156,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327518,=,nM,126.0,CHEMBL279,Homo sapiens,IC50
1236587,CHEMBL812622,Inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) autophosphorylation,B,CHEMBL102301,=,nM,17300.0,CHEMBL279,Homo sapiens,IC50
1400110,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL177688,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
1400290,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL178743,=,nM,497.0,CHEMBL279,Homo sapiens,IC50
1400294,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL177434,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1400296,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL178484,=,nM,761.0,CHEMBL279,Homo sapiens,IC50
1400301,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL368786,=,nM,708.0,CHEMBL279,Homo sapiens,IC50
1400303,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL368936,=,nM,2110.0,CHEMBL279,Homo sapiens,IC50
1401239,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL366359,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
1401248,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175760,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
1401253,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL177298,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1401264,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175506,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
1401269,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175862,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
1401280,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL539425,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1401285,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL176078,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
1401296,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL176019,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1401311,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175914,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
1401316,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175830,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
1414219,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794060,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1414221,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL176553,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1414223,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL443563,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1414225,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL275473,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1414227,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL369751,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1414229,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179453,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1414231,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL178507,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
1414233,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL361642,=,nM,141.0,CHEMBL279,Homo sapiens,IC50
1414235,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179311,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1414238,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179465,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
1417965,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179593,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
1417967,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179603,=,nM,2.2,CHEMBL279,Homo sapiens,IC50
1417969,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362486,=,nM,5.9,CHEMBL279,Homo sapiens,IC50
1417973,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL180331,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
1418079,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179450,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1418081,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL368252,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
1418083,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL426047,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
1418089,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179061,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
1418091,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL369760,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
1418093,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362634,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
1418095,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360781,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1418097,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179360,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
1418099,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL178568,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
1418101,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179227,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
1418103,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL426602,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
1418105,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362188,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
1418109,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179165,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
1418111,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179698,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
1418217,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360526,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
1418219,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179522,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
1418221,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179307,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
1418223,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179719,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
1418225,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179816,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
1418227,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL178981,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
1418229,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179422,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
1418231,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL369747,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1418235,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179082,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
1418237,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL359617,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
1418239,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL440202,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
1418241,CHEMBL829563,Inhibition of vascular endothelial growth factor receptor 2 in cell-intact assay,B,CHEMBL178455,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
1418368,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL279351,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
1418372,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360349,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
1425182,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181567,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
1425183,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178789,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1425184,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178248,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1425185,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181122,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1425186,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL359507,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1425187,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178899,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
1425284,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360503,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
1425288,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL359652,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1425290,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178596,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1425292,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360769,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
1425294,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181636,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1425296,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178583,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1425299,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360450,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
1425301,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL179517,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1427800,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180807,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1427803,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180603,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1427806,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178174,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1427812,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178607,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1427918,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL369322,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1427921,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180978,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1427924,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360118,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1440875,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL362030,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50
1440878,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL181959,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50
1440890,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL181856,=,nM,12300.0,CHEMBL279,Homo sapiens,IC50
1440893,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL427325,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50
1441324,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL360534,=,nM,830.0,CHEMBL279,Homo sapiens,IC50
1441327,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL182904,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50
1441330,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL182283,=,nM,630.0,CHEMBL279,Homo sapiens,IC50
1441333,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL183504,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50
1441336,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL361196,=,nM,3240.0,CHEMBL279,Homo sapiens,IC50
1442711,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185477,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
1442715,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185569,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1442724,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184997,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
1443405,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184918,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50
1443406,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183051,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
1443407,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL360724,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
1443408,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL181654,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
1443409,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL410711,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1443411,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL364626,=,nM,161.0,CHEMBL279,Homo sapiens,IC50
1443412,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL182468,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1443413,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL427321,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1443414,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL182648,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
1443415,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL360032,=,nM,570.0,CHEMBL279,Homo sapiens,IC50
1443416,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184143,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
1443417,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184847,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1443418,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184226,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
1443419,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL427139,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
1443420,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184170,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1443535,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185197,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1443536,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184706,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
1443537,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185331,=,nM,770.0,CHEMBL279,Homo sapiens,IC50
1443538,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183844,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1443540,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185059,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
1443541,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183174,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1443542,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185614,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
1443543,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185522,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1443545,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184604,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
1443547,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183803,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
1443826,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL359795,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
1443974,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184021,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1443975,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183025,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1443976,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184274,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1443985,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL359947,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1443986,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184223,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1443988,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL365448,=,nM,126.0,CHEMBL279,Homo sapiens,IC50
1449228,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL162,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
1449229,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184971,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1458170,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL359592,=,nM,40010.0,CHEMBL279,Homo sapiens,IC50
1458172,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL364411,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1458181,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL366079,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1458183,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL365064,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1458582,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL425356,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
1458585,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL187279,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
1458588,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL187130,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
1458590,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL185592,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1462344,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL185853,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50
1462470,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL188522,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1462475,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL184750,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
1462485,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL186001,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
1472456,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187930,=,nM,3114.0,CHEMBL279,Homo sapiens,IC50
1472819,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL185695,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1472821,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189305,=,nM,176.0,CHEMBL279,Homo sapiens,IC50
1472823,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187033,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
1472846,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL364115,=,nM,4490.0,CHEMBL279,Homo sapiens,IC50
1472848,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187627,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1472850,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187494,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1472862,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL363316,=,nM,990.0,CHEMBL279,Homo sapiens,IC50
1472937,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189199,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
1472939,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187361,=,nM,269.0,CHEMBL279,Homo sapiens,IC50
1472941,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188421,=,nM,324.0,CHEMBL279,Homo sapiens,IC50
1472954,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL2096808,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1472956,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189291,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
1472958,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188997,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1473217,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189354,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1473219,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL185716,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1474066,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189862,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1474068,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187609,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1474070,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188381,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1474072,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188025,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1474480,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188149,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1474482,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL365866,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
1474484,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188042,=,nM,681.0,CHEMBL279,Homo sapiens,IC50
1474493,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189353,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
1474495,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189408,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1474497,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL425718,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1474499,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL186369,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1481554,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL371169,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
1481578,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL372657,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
1481688,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190473,=,nM,2277.0,CHEMBL279,Homo sapiens,IC50
1481694,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL364161,=,nM,568.0,CHEMBL279,Homo sapiens,IC50
1481698,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL361898,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
1481702,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188901,=,nM,251.0,CHEMBL279,Homo sapiens,IC50
1481708,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189125,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50
1481712,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191251,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
1481818,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL186412,=,nM,2380.0,CHEMBL279,Homo sapiens,IC50
1482877,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189825,=,nM,168.0,CHEMBL279,Homo sapiens,IC50
1482881,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360401,=,nM,740.0,CHEMBL279,Homo sapiens,IC50
1482885,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL187571,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50
1482889,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365631,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1482893,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189947,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1482897,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189017,=,nM,189.0,CHEMBL279,Homo sapiens,IC50
1482901,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188536,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50
1483012,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188284,=,nM,275.0,CHEMBL279,Homo sapiens,IC50
1483026,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188386,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
1483147,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL364000,=,nM,135.0,CHEMBL279,Homo sapiens,IC50
1483161,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190984,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
1483177,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365411,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
1483287,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL370951,=,nM,346.0,CHEMBL279,Homo sapiens,IC50
1483291,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190960,=,nM,303.0,CHEMBL279,Homo sapiens,IC50
1483295,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL363764,=,nM,593.0,CHEMBL279,Homo sapiens,IC50
1483305,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189998,=,nM,236.0,CHEMBL279,Homo sapiens,IC50
1483309,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189226,=,nM,123.0,CHEMBL279,Homo sapiens,IC50
1483313,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191107,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1483317,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191160,=,nM,399.0,CHEMBL279,Homo sapiens,IC50
1483411,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188387,=,nM,391.0,CHEMBL279,Homo sapiens,IC50
1483415,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL187684,=,nM,266.0,CHEMBL279,Homo sapiens,IC50
1483429,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188502,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1487622,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL363607,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
1487654,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL363130,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
1487888,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL261720,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
1489542,CHEMBL830126,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL191003,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1489635,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL425363,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1489645,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365727,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1489654,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188431,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50
1489758,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190210,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1489763,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190443,=,nM,55000.0,CHEMBL279,Homo sapiens,IC50
1489768,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL363304,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
1489773,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191372,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
1489778,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL192668,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50
1489784,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189851,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1489893,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189059,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1489903,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190783,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1489913,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189584,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
1490028,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365140,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
1490659,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL339856,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1490668,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191265,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1490677,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188087,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
1490794,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189995,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1490804,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL363551,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1490814,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL187396,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1490902,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365937,=,nM,2010.0,CHEMBL279,Homo sapiens,IC50
1490904,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL363590,=,nM,4140.0,CHEMBL279,Homo sapiens,IC50
1490906,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191377,=,nM,5030.0,CHEMBL279,Homo sapiens,IC50
1490918,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191336,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50
1490934,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190161,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1490943,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188978,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
1490952,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190389,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1491033,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190805,=,nM,1067.0,CHEMBL279,Homo sapiens,IC50
1491069,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191023,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1491079,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191070,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1491088,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189691,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1491097,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL192856,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1491211,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190132,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
1491216,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL425552,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
1491221,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL361886,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50
1491226,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190351,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
1491336,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189542,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1491341,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191189,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
1491346,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190188,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1491351,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191389,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
1491356,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188648,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1491361,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190162,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1491465,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365377,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1491470,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190866,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
1491475,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189325,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
1491480,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL362502,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
1491485,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189628,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
1491587,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365133,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50
1491592,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190991,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1491597,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189322,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1491602,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190405,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
1491608,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL278472,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1494143,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL191437,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
1494241,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL363153,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1494244,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL191523,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1494247,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL192893,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
1494250,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL189633,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
1494253,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL193094,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
1494263,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL426078,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1494269,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL86755,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1509752,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL365585,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
1509756,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL370493,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1509760,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113062,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1509884,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113063,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1509889,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113065,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
1512240,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL364962,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
1512241,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365178,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1512242,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365336,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
1512243,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193256,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
1512244,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365109,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1512245,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL363639,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1512246,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195700,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1512247,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195853,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1512248,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195845,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1512249,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192100,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1512250,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195254,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1512251,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL366019,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
1512253,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL436117,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1512255,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192318,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1512257,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195218,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1512378,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370266,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
1512391,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL191594,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1512395,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193306,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1512402,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370515,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
1512406,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194929,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1512514,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365318,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1512529,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195771,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
1512533,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL371373,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1512537,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL373365,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
1512541,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192101,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1512545,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL190980,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1512652,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL191913,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1512656,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194498,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
1512673,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370023,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1512677,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194872,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1512681,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195847,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1512685,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL372662,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
1512789,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195398,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1512797,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195903,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
1512928,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193136,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
1516606,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL370328,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
1516764,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193912,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
1516766,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794062,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1516768,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794061,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
1516770,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191626,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50
1516772,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194113,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1516774,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL371374,=,nM,720.0,CHEMBL279,Homo sapiens,IC50
1516776,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL192417,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
1516778,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194062,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1516782,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191779,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
1516787,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL364259,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
1516789,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194883,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1516791,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL370744,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
1516793,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL190872,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1516795,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193955,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1516900,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191705,=,nM,91.0,CHEMBL279,Homo sapiens,IC50
1516902,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193609,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1516904,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194939,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1516906,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194176,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
1516929,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193386,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1517039,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL195237,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
1517041,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL365815,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1517043,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL364082,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1517045,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL372474,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
1517063,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191993,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
1519839,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196021,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50
1519841,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196022,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
1519847,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL363389,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1519851,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194150,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
1519853,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194057,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1519972,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196841,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1519981,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194149,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1519983,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194911,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1519990,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL195567,=,nM,186.0,CHEMBL279,Homo sapiens,IC50
1519992,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL193752,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
1600068,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193342,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1600071,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196668,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1600074,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL370586,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
1600077,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL197158,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1600080,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL371639,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
1600081,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL407008,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
1600082,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196025,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
1600083,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL370193,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1600086,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194746,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
1600087,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194747,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
1600088,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL195917,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1600091,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196610,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
1600093,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196705,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50
1600104,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196994,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
1600105,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL427550,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
1600106,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196609,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1600107,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196939,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50
1600109,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL382710,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
1600110,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193747,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
1600113,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194042,=,nM,630.0,CHEMBL279,Homo sapiens,IC50
1600117,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193346,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1605372,CHEMBL880642,In vitro inhibitory concentration against VEGFR2 with ATP concentration at 1/2Km,B,CHEMBL401930,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1609070,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370006,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
1609071,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372634,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
1609094,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197592,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1609099,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371329,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1609105,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL193920,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50
1609106,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370738,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
1609108,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195964,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1609109,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL373272,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
1609110,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196020,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1609116,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198036,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
1609117,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372765,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
1609118,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197847,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
1609119,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL366241,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1609122,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372960,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1609123,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196363,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1609153,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL363393,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1609154,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196396,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
1609155,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL438797,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
1609158,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198267,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
1609166,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL445394,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1609169,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371889,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1609172,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL365784,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
1609175,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194270,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1609177,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196747,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
1609180,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196499,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1609183,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194321,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
1609186,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382517,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
1609191,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372174,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
1609195,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195955,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1609203,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194236,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
1609206,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370325,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1609211,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195828,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
1609214,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371206,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1609217,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL381034,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
1609220,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL381207,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
1609239,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197635,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1609242,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198601,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
1609245,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382112,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1609248,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194842,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1609258,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372388,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
1609261,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL425387,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1609262,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371225,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1609265,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371890,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1609267,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372755,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
1609269,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371379,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1609272,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL369908,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
1609275,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197353,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1609278,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198155,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1609281,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198297,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1609290,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196636,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1609293,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL425749,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1609296,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371332,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1609299,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194366,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1609302,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371510,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1609307,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196615,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
1613368,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370545,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1613371,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL262468,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1613373,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL199031,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
1613376,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372744,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1613379,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197828,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1613384,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382979,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1615801,CHEMBL881957,Inhibitory concentration against human Vascular endothelial growth factor receptor 2,B,CHEMBL2303627,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
1656104,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113166,=,nM,4.4,CHEMBL279,Homo sapiens,IC50
1656108,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706821,=,nM,13.5,CHEMBL279,Homo sapiens,IC50
1656109,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113172,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1656114,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113173,=,nM,67.1,CHEMBL279,Homo sapiens,IC50
1656117,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706822,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
1656120,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706833,=,nM,109.4,CHEMBL279,Homo sapiens,IC50
1656123,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113178,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1656125,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113183,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
1656126,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706827,=,nM,111.9,CHEMBL279,Homo sapiens,IC50
1656130,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706829,=,nM,15.8,CHEMBL279,Homo sapiens,IC50
1656133,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706830,=,nM,30.1,CHEMBL279,Homo sapiens,IC50
1656138,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706818,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1656141,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113167,=,nM,1144.1,CHEMBL279,Homo sapiens,IC50
1656145,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113168,=,nM,101.2,CHEMBL279,Homo sapiens,IC50
1656147,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706824,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1656151,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113174,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
1656155,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL371551,=,nM,236.5,CHEMBL279,Homo sapiens,IC50
1656157,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL242555,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1656160,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706825,=,nM,240.9,CHEMBL279,Homo sapiens,IC50
1656165,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113180,=,nM,359.4,CHEMBL279,Homo sapiens,IC50
1656168,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113186,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
1656173,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113187,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
1656174,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL202389,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
1656176,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706831,=,nM,540.2,CHEMBL279,Homo sapiens,IC50
1656179,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113165,=,nM,298.6,CHEMBL279,Homo sapiens,IC50
1656182,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113170,=,nM,84.8,CHEMBL279,Homo sapiens,IC50
1656187,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL200818,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
1656191,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706820,=,nM,371.9,CHEMBL279,Homo sapiens,IC50
1656194,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113175,=,nM,9.1,CHEMBL279,Homo sapiens,IC50
1656199,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113176,=,nM,88.7,CHEMBL279,Homo sapiens,IC50
1656204,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706819,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
1656208,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113169,=,nM,491.3,CHEMBL279,Homo sapiens,IC50
1656213,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113171,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
1656218,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706823,=,nM,6.8,CHEMBL279,Homo sapiens,IC50
1656221,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL200765,=,nM,21.3,CHEMBL279,Homo sapiens,IC50
1656223,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113190,=,nM,52.4,CHEMBL279,Homo sapiens,IC50
1656226,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL396472,=,nM,31.2,CHEMBL279,Homo sapiens,IC50
1656230,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113182,=,nM,23.6,CHEMBL279,Homo sapiens,IC50
1656243,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113188,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
1656247,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706840,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
1656250,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706835,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
1656259,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706837,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
1656265,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706839,=,nM,10.3,CHEMBL279,Homo sapiens,IC50
1656270,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706834,=,nM,16.1,CHEMBL279,Homo sapiens,IC50
1656273,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113192,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
1656276,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113191,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
1656279,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706832,=,nM,1.9,CHEMBL279,Homo sapiens,IC50
1656282,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL200723,=,nM,239.3,CHEMBL279,Homo sapiens,IC50
1656287,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706826,=,nM,5.1,CHEMBL279,Homo sapiens,IC50
1656292,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113184,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
1656296,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706843,=,nM,13.6,CHEMBL279,Homo sapiens,IC50
1656300,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL199455,=,nM,271.8,CHEMBL279,Homo sapiens,IC50
1656305,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113193,=,nM,6.4,CHEMBL279,Homo sapiens,IC50
1656308,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706842,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
1656312,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113199,=,nM,9.6,CHEMBL279,Homo sapiens,IC50
1656315,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706836,=,nM,16.9,CHEMBL279,Homo sapiens,IC50
1656318,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706841,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
1656321,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706816,=,nM,3.6,CHEMBL279,Homo sapiens,IC50
1656325,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706817,=,nM,5.1,CHEMBL279,Homo sapiens,IC50
1656328,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706814,=,nM,70.7,CHEMBL279,Homo sapiens,IC50
1656331,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706815,=,nM,35.9,CHEMBL279,Homo sapiens,IC50
1656334,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113163,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
1656337,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113164,=,nM,3.2,CHEMBL279,Homo sapiens,IC50
1660163,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL200217,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
1660195,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL199016,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50
1660196,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL199110,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50
1660197,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198701,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50
1660198,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL383593,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
1660199,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL371688,=,nM,570.0,CHEMBL279,Homo sapiens,IC50
1660200,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198752,=,nM,680.0,CHEMBL279,Homo sapiens,IC50
1660201,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198946,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
1660202,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL424839,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
1660203,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL425209,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
1660204,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL200231,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
1660206,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL197186,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
1660207,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL197287,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1660208,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL369899,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1660209,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL424664,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
1660210,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL381206,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1661760,CHEMBL867552,Inhibitory activity against KDR,B,CHEMBL199886,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50
1662505,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL200586,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50
1662510,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199996,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50
1662513,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371695,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
1662514,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL382070,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
1662515,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199759,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
1662516,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL370199,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50
1662517,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199737,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50
1662518,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371239,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
1662519,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199383,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
1662520,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL197923,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1662521,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL200499,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1662522,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199755,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
1662523,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199528,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1662524,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL373001,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
1662527,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371242,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50
1662528,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL198022,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50
1663060,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL199725,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
1663061,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL200085,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
1663062,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL199460,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
1677084,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL203095,=,nM,1850.0,CHEMBL279,Homo sapiens,IC50
1677088,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201303,=,nM,1920.0,CHEMBL279,Homo sapiens,IC50
1677089,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL425930,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50
1677090,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201713,=,nM,860.0,CHEMBL279,Homo sapiens,IC50
1677091,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL370600,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
1677092,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202153,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1677093,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL382308,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50
1677094,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202466,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
1677095,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202109,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50
1677096,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL383215,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1677097,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202714,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50
1677098,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202408,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
1677099,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL382647,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50
1677102,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL380700,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
1677104,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL379674,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1677105,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL424672,=,nM,1770.0,CHEMBL279,Homo sapiens,IC50
1677106,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201906,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1677107,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201659,=,nM,1610.0,CHEMBL279,Homo sapiens,IC50
1677109,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201014,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50
1677110,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202384,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1677112,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202234,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50
1677114,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL203149,=,nM,3380.0,CHEMBL279,Homo sapiens,IC50
1677115,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL205114,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1677615,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202011,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1677872,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL201865,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
1677875,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL78257,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
1677876,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL200976,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
1677877,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL202244,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
1677878,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL383030,=,nM,15500.0,CHEMBL279,Homo sapiens,IC50
1677879,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL202162,=,nM,12600.0,CHEMBL279,Homo sapiens,IC50
1678210,CHEMBL862111,Inhibitory activity against KDR,B,CHEMBL201307,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1680652,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201511,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
1680855,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL202378,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
1680856,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL380898,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1680857,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201708,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
1680858,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL446182,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
1680859,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201264,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
1680861,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201512,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
1686560,CHEMBL860566,Inhibition of KDR,B,CHEMBL202748,=,nM,990.0,CHEMBL279,Homo sapiens,IC50
1686563,CHEMBL860566,Inhibition of KDR,B,CHEMBL380735,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1686564,CHEMBL860566,Inhibition of KDR,B,CHEMBL204700,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1686565,CHEMBL860566,Inhibition of KDR,B,CHEMBL204446,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1686566,CHEMBL860566,Inhibition of KDR,B,CHEMBL379896,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1686567,CHEMBL860566,Inhibition of KDR,B,CHEMBL203907,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
1686568,CHEMBL860566,Inhibition of KDR,B,CHEMBL204163,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1686569,CHEMBL860566,Inhibition of KDR,B,CHEMBL381817,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1686570,CHEMBL860566,Inhibition of KDR,B,CHEMBL427025,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1686571,CHEMBL860566,Inhibition of KDR,B,CHEMBL204867,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1686572,CHEMBL860566,Inhibition of KDR,B,CHEMBL380944,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1686573,CHEMBL860566,Inhibition of KDR,B,CHEMBL203585,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1686574,CHEMBL860566,Inhibition of KDR,B,CHEMBL203404,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
1686575,CHEMBL860566,Inhibition of KDR,B,CHEMBL437322,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
1686576,CHEMBL860566,Inhibition of KDR,B,CHEMBL203000,=,nM,557.0,CHEMBL279,Homo sapiens,IC50
1694651,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203056,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
1694681,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL382672,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
1694683,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL204874,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1694684,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203796,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1694685,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203789,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
1694686,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL206538,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1694687,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL380131,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
1694688,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL383255,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
1694689,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205884,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1694690,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203119,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
1694691,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203731,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1694692,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL378165,=,nM,3540.0,CHEMBL279,Homo sapiens,IC50
1694693,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL206118,=,nM,2370.0,CHEMBL279,Homo sapiens,IC50
1694694,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203394,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50
1694695,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205464,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50
1694696,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205463,=,nM,730.0,CHEMBL279,Homo sapiens,IC50
1694697,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL202892,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1694698,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL379908,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
1694699,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205127,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1694700,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL378592,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1698150,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL380316,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1698153,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL202950,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1698155,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL206658,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1698156,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL380508,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
1698157,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL383616,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
1698158,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL205823,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1698159,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL203438,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
1698161,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL202998,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
1698162,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL382818,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1698163,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL203346,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1698164,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL206536,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
1698200,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203429,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50
1698201,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL380503,=,nM,1550.0,CHEMBL279,Homo sapiens,IC50
1698202,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382478,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
1698203,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382584,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1698204,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203063,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
1698205,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203167,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1698206,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL425587,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1698207,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206403,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1698208,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206348,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
1698209,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206185,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
1698210,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL437889,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1698211,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205984,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
1698212,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL204548,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
1698213,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206279,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1698214,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL377081,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
1698217,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202643,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1698218,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202805,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1698219,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205413,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
1698220,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205610,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
1698221,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL204099,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1698222,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203243,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
1698223,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL380932,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
1698224,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203965,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1698226,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202682,=,nM,4280.0,CHEMBL279,Homo sapiens,IC50
1698227,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382855,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
1698228,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203003,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
1698230,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206567,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50
1698280,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL381603,=,nM,2660.0,CHEMBL279,Homo sapiens,IC50
1699764,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL207842,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
1699765,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL383671,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1699766,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205283,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
1699767,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL381973,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1699768,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL377302,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1699769,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL381104,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1699770,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL380905,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1699771,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206545,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
1699772,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL383077,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
1699773,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205710,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
1699774,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL427202,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1699775,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL377300,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1699776,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL380957,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1699777,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206146,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
1699778,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206145,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
1699779,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205142,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1704006,CHEMBL861197,Inhibitory activity against recombinant human KDR,B,CHEMBL606964,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1706297,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL208229,=,nM,2630.0,CHEMBL279,Homo sapiens,IC50
1707945,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL206627,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
1707946,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380465,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
1707947,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL206463,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
1707948,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL381562,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
1707949,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204334,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1707950,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL207600,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1707951,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL383435,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1707952,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380915,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1707953,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL378403,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1707954,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL208500,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1707955,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL438970,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1707956,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204726,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1707957,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205097,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1707963,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205509,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
1708041,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204678,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
1708834,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205421,=,nM,720.0,CHEMBL279,Homo sapiens,IC50
1708835,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381577,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
1708836,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383334,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1708857,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383123,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
1708858,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382218,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
1708859,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382610,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
1708860,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204621,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
1708861,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205050,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1708862,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204425,=,nM,770.0,CHEMBL279,Homo sapiens,IC50
1708863,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381293,=,nM,550.0,CHEMBL279,Homo sapiens,IC50
1708864,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205639,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
1708865,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL206123,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
1708866,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205244,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
1708867,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL207772,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1708868,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382142,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
1708869,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL208363,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
1708870,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383434,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1708871,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205544,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
1708872,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381182,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
1708873,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL380536,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
1708874,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205502,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
1708875,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383333,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1708876,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL207975,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
1708877,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204984,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1708878,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL377995,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
1708879,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205325,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1708880,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL206136,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1708881,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205647,=,nM,5640.0,CHEMBL279,Homo sapiens,IC50
1708882,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382797,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50
1709130,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205658,=,nM,157.0,CHEMBL279,Homo sapiens,IC50
1709145,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380334,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1744651,CHEMBL866820,Inhibition of FLK1,B,CHEMBL377734,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1744678,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL212267,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
1744687,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL211060,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
1744696,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL208788,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1744705,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL384909,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1744711,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL208911,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1744718,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL209555,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
1744726,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379370,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1744736,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL212304,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1744744,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL207520,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
1744753,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379320,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
1744763,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379661,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
1744773,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379495,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
1748792,CHEMBL870980,Inhibition of KDR,B,CHEMBL211460,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1748793,CHEMBL870980,Inhibition of KDR,B,CHEMBL215847,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
1748795,CHEMBL870980,Inhibition of KDR,B,CHEMBL263769,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
1748796,CHEMBL870980,Inhibition of KDR,B,CHEMBL213100,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
1748797,CHEMBL870980,Inhibition of KDR,B,CHEMBL442485,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
1748798,CHEMBL870980,Inhibition of KDR,B,CHEMBL377481,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
1748799,CHEMBL870980,Inhibition of KDR,B,CHEMBL209908,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
1748800,CHEMBL870980,Inhibition of KDR,B,CHEMBL215726,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
1748801,CHEMBL870980,Inhibition of KDR,B,CHEMBL215730,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1748802,CHEMBL870980,Inhibition of KDR,B,CHEMBL385898,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1748803,CHEMBL870980,Inhibition of KDR,B,CHEMBL211845,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
1748804,CHEMBL870980,Inhibition of KDR,B,CHEMBL212721,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
1748805,CHEMBL870980,Inhibition of KDR,B,CHEMBL214775,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1748806,CHEMBL870980,Inhibition of KDR,B,CHEMBL212668,=,nM,570.0,CHEMBL279,Homo sapiens,IC50
1748807,CHEMBL870980,Inhibition of KDR,B,CHEMBL212143,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1748808,CHEMBL870980,Inhibition of KDR,B,CHEMBL264803,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1748809,CHEMBL870980,Inhibition of KDR,B,CHEMBL379733,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
1748810,CHEMBL870980,Inhibition of KDR,B,CHEMBL379080,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
1748811,CHEMBL870980,Inhibition of KDR,B,CHEMBL386760,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1748812,CHEMBL870980,Inhibition of KDR,B,CHEMBL215289,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
1748813,CHEMBL870980,Inhibition of KDR,B,CHEMBL215411,=,nM,620.0,CHEMBL279,Homo sapiens,IC50
1748877,CHEMBL870980,Inhibition of KDR,B,CHEMBL427047,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1752973,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212899,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
1753084,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL216020,=,nM,14100.0,CHEMBL279,Homo sapiens,IC50
1753085,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL441369,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
1753086,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL427050,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
1753087,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212961,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
1753088,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212962,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1753089,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL413581,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1753090,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL413772,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
1753091,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213195,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50
1753092,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL377959,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
1753093,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213743,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1753094,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215658,=,nM,2840.0,CHEMBL279,Homo sapiens,IC50
1753095,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209806,=,nM,7480.0,CHEMBL279,Homo sapiens,IC50
1753096,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209861,=,nM,16640.0,CHEMBL279,Homo sapiens,IC50
1753097,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212880,=,nM,5470.0,CHEMBL279,Homo sapiens,IC50
1753098,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL378058,=,nM,12540.0,CHEMBL279,Homo sapiens,IC50
1753101,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL379103,=,nM,1005000.0,CHEMBL279,Homo sapiens,IC50
1753102,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215901,=,nM,143000.0,CHEMBL279,Homo sapiens,IC50
1753103,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213531,=,nM,824000.0,CHEMBL279,Homo sapiens,IC50
1753104,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209912,=,nM,190000.0,CHEMBL279,Homo sapiens,IC50
1753105,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL378007,=,nM,4081000.0,CHEMBL279,Homo sapiens,IC50
1753106,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL211089,=,nM,665000.0,CHEMBL279,Homo sapiens,IC50
1753107,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL377327,=,nM,190000.0,CHEMBL279,Homo sapiens,IC50
1753108,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213014,=,nM,108000.0,CHEMBL279,Homo sapiens,IC50
1753109,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212084,=,nM,147000.0,CHEMBL279,Homo sapiens,IC50
1753110,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215971,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1753746,CHEMBL864248,Inhibition of KDR,B,CHEMBL376951,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1753747,CHEMBL864248,Inhibition of KDR,B,CHEMBL211327,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50
1753748,CHEMBL864248,Inhibition of KDR,B,CHEMBL211378,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
1753749,CHEMBL864248,Inhibition of KDR,B,CHEMBL213504,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1753750,CHEMBL864248,Inhibition of KDR,B,CHEMBL213505,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
1753751,CHEMBL864248,Inhibition of KDR,B,CHEMBL213510,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
1753752,CHEMBL864248,Inhibition of KDR,B,CHEMBL378941,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
1753753,CHEMBL864248,Inhibition of KDR,B,CHEMBL387300,=,nM,22000.0,CHEMBL279,Homo sapiens,IC50
1753754,CHEMBL864248,Inhibition of KDR,B,CHEMBL540203,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50
1753755,CHEMBL864248,Inhibition of KDR,B,CHEMBL445570,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1753756,CHEMBL864248,Inhibition of KDR,B,CHEMBL379372,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1753757,CHEMBL864248,Inhibition of KDR,B,CHEMBL214258,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1753758,CHEMBL864248,Inhibition of KDR,B,CHEMBL262433,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1753761,CHEMBL864248,Inhibition of KDR,B,CHEMBL210003,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1753762,CHEMBL864248,Inhibition of KDR,B,CHEMBL378687,=,nM,225.0,CHEMBL279,Homo sapiens,IC50
1753764,CHEMBL864248,Inhibition of KDR,B,CHEMBL374206,=,nM,46000.0,CHEMBL279,Homo sapiens,IC50
1755408,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL213910,=,nM,195.0,CHEMBL279,Homo sapiens,IC50
1755410,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL214063,=,nM,171.0,CHEMBL279,Homo sapiens,IC50
1755411,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL380068,=,nM,198.0,CHEMBL279,Homo sapiens,IC50
1755412,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL379088,=,nM,218.0,CHEMBL279,Homo sapiens,IC50
1755413,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL378895,=,nM,233.0,CHEMBL279,Homo sapiens,IC50
1755414,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL213507,=,nM,146.0,CHEMBL279,Homo sapiens,IC50
1755415,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL225248,=,nM,146.0,CHEMBL279,Homo sapiens,IC50
1755420,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL378440,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1755506,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL214161,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1755508,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215563,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1755509,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211307,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
1755510,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211515,=,nM,12285.0,CHEMBL279,Homo sapiens,IC50
1755511,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213138,=,nM,2777.0,CHEMBL279,Homo sapiens,IC50
1755512,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212499,=,nM,212.0,CHEMBL279,Homo sapiens,IC50
1755513,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213230,=,nM,22795.0,CHEMBL279,Homo sapiens,IC50
1755515,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL384939,=,nM,24158.0,CHEMBL279,Homo sapiens,IC50
1755519,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213796,=,nM,459.0,CHEMBL279,Homo sapiens,IC50
1755520,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL425615,=,nM,444.0,CHEMBL279,Homo sapiens,IC50
1755521,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL415047,=,nM,308.0,CHEMBL279,Homo sapiens,IC50
1755522,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215417,=,nM,2882.0,CHEMBL279,Homo sapiens,IC50
1755523,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212986,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
1755524,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212762,=,nM,281.0,CHEMBL279,Homo sapiens,IC50
1755525,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209922,=,nM,199.0,CHEMBL279,Homo sapiens,IC50
1755526,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209919,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
1755527,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL380397,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
1755529,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL425262,=,nM,4807.0,CHEMBL279,Homo sapiens,IC50
1755530,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212987,=,nM,7458.0,CHEMBL279,Homo sapiens,IC50
1755531,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209421,=,nM,122.0,CHEMBL279,Homo sapiens,IC50
1755532,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209971,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1755535,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213430,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
1755537,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL377400,=,nM,123.0,CHEMBL279,Homo sapiens,IC50
1755539,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL210070,=,nM,164.0,CHEMBL279,Homo sapiens,IC50
1755540,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213909,=,nM,262.0,CHEMBL279,Homo sapiens,IC50
1755541,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL214109,=,nM,259.0,CHEMBL279,Homo sapiens,IC50
1755542,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213270,=,nM,171.0,CHEMBL279,Homo sapiens,IC50
1755543,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL210113,=,nM,184.0,CHEMBL279,Homo sapiens,IC50
1755544,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212985,=,nM,159.0,CHEMBL279,Homo sapiens,IC50
1755545,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL2096839,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
1755546,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL223220,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
1755548,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL378831,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1755549,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL384294,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1755550,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212932,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1755551,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215948,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1755552,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211464,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1755553,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL380243,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1765167,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212964,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1765168,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212181,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1765169,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215863,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1765170,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215691,=,nM,103.0,CHEMBL279,Homo sapiens,IC50
1765171,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214556,=,nM,246.0,CHEMBL279,Homo sapiens,IC50
1765172,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL384942,=,nM,173.0,CHEMBL279,Homo sapiens,IC50
1765173,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212195,=,nM,292.0,CHEMBL279,Homo sapiens,IC50
1765174,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214530,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1765175,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213290,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1765176,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215943,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1765177,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215813,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1765178,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385937,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1765179,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215952,=,nM,4966.0,CHEMBL279,Homo sapiens,IC50
1765180,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213478,=,nM,1438.0,CHEMBL279,Homo sapiens,IC50
1765181,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL424719,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1765182,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212128,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1765183,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385055,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1765184,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212953,=,nM,306.0,CHEMBL279,Homo sapiens,IC50
1765185,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213831,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
1765186,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385598,=,nM,461.0,CHEMBL279,Homo sapiens,IC50
1765187,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214495,=,nM,1415.0,CHEMBL279,Homo sapiens,IC50
1765188,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL386661,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1765189,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212183,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1765190,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215019,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1765191,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL427226,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1765192,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL427233,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1765193,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215969,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1779198,CHEMBL855514,Inhibition of KDR,B,CHEMBL214665,=,nM,21500.0,CHEMBL279,Homo sapiens,IC50
1779199,CHEMBL855514,Inhibition of KDR,B,CHEMBL426161,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
1779200,CHEMBL855514,Inhibition of KDR,B,CHEMBL217092,=,nM,20900.0,CHEMBL279,Homo sapiens,IC50
1779201,CHEMBL855514,Inhibition of KDR,B,CHEMBL386996,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
1779202,CHEMBL855514,Inhibition of KDR,B,CHEMBL436968,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
1779203,CHEMBL855514,Inhibition of KDR,B,CHEMBL214376,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1779204,CHEMBL855514,Inhibition of KDR,B,CHEMBL216693,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1779205,CHEMBL855514,Inhibition of KDR,B,CHEMBL217091,=,nM,21500.0,CHEMBL279,Homo sapiens,IC50
1779206,CHEMBL855514,Inhibition of KDR,B,CHEMBL262371,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1779207,CHEMBL855514,Inhibition of KDR,B,CHEMBL387093,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
1779208,CHEMBL855514,Inhibition of KDR,B,CHEMBL216105,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1779209,CHEMBL855514,Inhibition of KDR,B,CHEMBL266188,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1779210,CHEMBL855514,Inhibition of KDR,B,CHEMBL217090,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
1779211,CHEMBL855514,Inhibition of KDR,B,CHEMBL385958,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
1779212,CHEMBL855514,Inhibition of KDR,B,CHEMBL262721,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
1779213,CHEMBL855514,Inhibition of KDR,B,CHEMBL384260,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
1779214,CHEMBL855514,Inhibition of KDR,B,CHEMBL214893,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1779216,CHEMBL855514,Inhibition of KDR,B,CHEMBL216703,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1779217,CHEMBL855514,Inhibition of KDR,B,CHEMBL217493,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
1781994,CHEMBL911844,Inhibition of VEGFR2,B,CHEMBL402548,=,nM,432.0,CHEMBL279,Homo sapiens,IC50
1793595,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219293,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1793596,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218817,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1793625,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL373397,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1793716,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL216891,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1793717,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL437876,=,nM,159.0,CHEMBL279,Homo sapiens,IC50
1793718,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218252,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
1793719,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219555,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1793720,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL387174,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1793721,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL375311,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1793722,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219332,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
1793723,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL374736,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
1793724,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218816,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1793725,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218201,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1793726,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL424757,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1793727,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218799,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1793750,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL375570,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1793751,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219253,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1793752,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219581,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1793753,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL424910,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1793754,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL426528,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1793755,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL374745,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1793756,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL265600,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
1793765,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL373575,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1793766,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219493,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1793767,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219492,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1793768,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL265284,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1793769,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218557,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1793770,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219080,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1793771,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL425109,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1793772,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL426703,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1793773,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL220406,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1793799,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219543,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
1807174,CHEMBL908991,Inhibition of VEGFR2,B,CHEMBL436137,=,nM,555.0,CHEMBL279,Homo sapiens,IC50
1810695,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220523,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
1810698,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223622,=,nM,121.0,CHEMBL279,Homo sapiens,IC50
1810699,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL374240,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
1810700,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223534,=,nM,1038.0,CHEMBL279,Homo sapiens,IC50
1810701,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223486,=,nM,146.0,CHEMBL279,Homo sapiens,IC50
1810702,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219729,=,nM,1189.0,CHEMBL279,Homo sapiens,IC50
1810703,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL387313,=,nM,276.0,CHEMBL279,Homo sapiens,IC50
1810704,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219886,=,nM,1588.0,CHEMBL279,Homo sapiens,IC50
1810726,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL222076,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1810727,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220890,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
1810728,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220988,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
1810729,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220951,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1810730,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219983,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1810731,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220444,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
1810732,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220391,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
1810733,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223086,=,nM,214.0,CHEMBL279,Homo sapiens,IC50
1810734,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL222828,=,nM,187.0,CHEMBL279,Homo sapiens,IC50
1810735,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223535,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
1810736,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL435748,=,nM,201.0,CHEMBL279,Homo sapiens,IC50
1810737,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219677,=,nM,413.0,CHEMBL279,Homo sapiens,IC50
1810738,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219676,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1810739,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL221224,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1810740,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL373826,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
1810741,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL426929,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1810742,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223892,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
1815085,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL278965,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
1815087,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL373882,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
1815090,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL385956,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1815093,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL426211,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
1815094,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218646,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
1815096,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218431,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
1815097,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218576,=,nM,461.0,CHEMBL279,Homo sapiens,IC50
1815098,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL374997,=,nM,675.0,CHEMBL279,Homo sapiens,IC50
1815099,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL374259,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
1815105,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220550,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
1815106,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL219158,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
1815108,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218632,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1815109,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL276395,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
1815110,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220549,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
1815111,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL375447,=,nM,705.0,CHEMBL279,Homo sapiens,IC50
1815112,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218425,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
1815114,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL219996,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
1815115,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL221484,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1815116,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL222067,=,nM,177.0,CHEMBL279,Homo sapiens,IC50
1815117,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220540,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1815118,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL385178,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1815154,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL221121,=,nM,435.0,CHEMBL279,Homo sapiens,IC50
1815253,CHEMBL910167,Inhibition of KDR,B,CHEMBL427998,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1815277,CHEMBL910167,Inhibition of KDR,B,CHEMBL220750,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
1815278,CHEMBL910167,Inhibition of KDR,B,CHEMBL221544,=,nM,890.0,CHEMBL279,Homo sapiens,IC50
1815279,CHEMBL910167,Inhibition of KDR,B,CHEMBL374079,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
1815280,CHEMBL910167,Inhibition of KDR,B,CHEMBL220532,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50
1815281,CHEMBL910167,Inhibition of KDR,B,CHEMBL386637,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50
1815282,CHEMBL910167,Inhibition of KDR,B,CHEMBL218110,=,nM,810.0,CHEMBL279,Homo sapiens,IC50
1815283,CHEMBL910167,Inhibition of KDR,B,CHEMBL221193,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
1815284,CHEMBL910167,Inhibition of KDR,B,CHEMBL376475,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
1815285,CHEMBL910167,Inhibition of KDR,B,CHEMBL373621,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1815286,CHEMBL910167,Inhibition of KDR,B,CHEMBL375617,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
1815287,CHEMBL910167,Inhibition of KDR,B,CHEMBL374985,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
1815290,CHEMBL910167,Inhibition of KDR,B,CHEMBL218631,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1815292,CHEMBL910167,Inhibition of KDR,B,CHEMBL221019,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1815293,CHEMBL910167,Inhibition of KDR,B,CHEMBL219584,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1815294,CHEMBL910167,Inhibition of KDR,B,CHEMBL450024,=,nM,169.0,CHEMBL279,Homo sapiens,IC50
1815296,CHEMBL910167,Inhibition of KDR,B,CHEMBL220874,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
1816434,CHEMBL911984,Inhibition of VEGFR2,B,CHEMBL416056,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
1826088,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222778,=,nM,4790.0,CHEMBL279,Homo sapiens,IC50
1826091,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222315,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
1826092,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL426887,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
1826093,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376307,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1826094,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220057,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1826095,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219722,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
1826096,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220317,=,nM,4620.0,CHEMBL279,Homo sapiens,IC50
1826103,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223361,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
1826113,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL426004,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1826114,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374044,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1826115,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223360,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1826116,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223304,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1826117,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL424943,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1826118,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222728,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1826119,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL375670,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1826120,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL221053,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1826121,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374330,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1826122,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376077,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
1826123,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220049,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
1826124,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373798,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1826125,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223583,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
1826156,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223236,=,nM,3090.0,CHEMBL279,Homo sapiens,IC50
1826157,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223237,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
1826158,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219999,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
1826159,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL387312,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1826285,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373845,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
1826286,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223572,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
1826287,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223528,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1826288,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376245,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1826289,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223478,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1826290,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223790,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
1826291,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219774,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
1826292,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL438653,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1826293,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219727,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1826294,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374752,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1826295,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219998,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1826296,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219887,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1826418,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223129,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1826421,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL375284,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
1826422,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222974,=,nM,465.0,CHEMBL279,Homo sapiens,IC50
1826423,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222918,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
1826424,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373435,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
1826425,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL221574,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
1826426,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222817,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1838895,CHEMBL913856,Inhibition of KDR,B,CHEMBL376722,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1838896,CHEMBL913856,Inhibition of KDR,B,CHEMBL224842,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1838897,CHEMBL913856,Inhibition of KDR,B,CHEMBL222852,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1838898,CHEMBL913856,Inhibition of KDR,B,CHEMBL375248,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
1838899,CHEMBL913856,Inhibition of KDR,B,CHEMBL221468,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1838900,CHEMBL913856,Inhibition of KDR,B,CHEMBL375306,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1838901,CHEMBL913856,Inhibition of KDR,B,CHEMBL373693,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1838902,CHEMBL913856,Inhibition of KDR,B,CHEMBL222225,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1838903,CHEMBL913856,Inhibition of KDR,B,CHEMBL224036,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1838904,CHEMBL913856,Inhibition of KDR,B,CHEMBL224035,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
1838905,CHEMBL913856,Inhibition of KDR,B,CHEMBL221926,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1838906,CHEMBL913856,Inhibition of KDR,B,CHEMBL221875,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1849744,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225311,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
1849745,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL426009,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1849746,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223998,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1849747,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223219,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
1849748,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224497,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
1849749,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387929,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
1849750,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225319,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
1849751,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225318,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
1849752,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225090,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
1849753,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225036,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1849754,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL374627,=,nM,2370.0,CHEMBL279,Homo sapiens,IC50
1849755,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225639,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1849756,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223997,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
1849757,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223943,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1849759,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224496,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
1849760,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL434180,=,nM,962.0,CHEMBL279,Homo sapiens,IC50
1849761,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375692,=,nM,108.0,CHEMBL279,Homo sapiens,IC50
1849762,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375491,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
1849763,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375890,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
1849764,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390156,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1849770,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387971,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1849771,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223971,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1849772,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL445404,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
1849773,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225335,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1849774,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225193,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
1849775,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225192,=,nM,7960.0,CHEMBL279,Homo sapiens,IC50
1849776,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225240,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
1849777,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224918,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
1849778,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224917,=,nM,124.0,CHEMBL279,Homo sapiens,IC50
1849779,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224889,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
1849780,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224834,=,nM,195.0,CHEMBL279,Homo sapiens,IC50
1849781,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL374690,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
1849782,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223604,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
1849783,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224027,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
1849784,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390735,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
1849785,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225334,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1849786,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225278,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1849787,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225261,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1849788,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223999,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1849789,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387972,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
1849790,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390353,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1849791,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224547,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1849792,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL389499,=,nM,4680.0,CHEMBL279,Homo sapiens,IC50
1849793,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225336,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1849794,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224968,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1849795,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL376779,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
1894730,CHEMBL907546,Inhibition of KDR,B,CHEMBL427267,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1894731,CHEMBL907546,Inhibition of KDR,B,CHEMBL231128,=,nM,388.0,CHEMBL279,Homo sapiens,IC50
1894732,CHEMBL907546,Inhibition of KDR,B,CHEMBL231127,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
1894733,CHEMBL907546,Inhibition of KDR,B,CHEMBL268826,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1894734,CHEMBL907546,Inhibition of KDR,B,CHEMBL231612,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1894735,CHEMBL907546,Inhibition of KDR,B,CHEMBL398196,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
1894736,CHEMBL907546,Inhibition of KDR,B,CHEMBL231511,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1894737,CHEMBL907546,Inhibition of KDR,B,CHEMBL231412,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
1894738,CHEMBL907546,Inhibition of KDR,B,CHEMBL396737,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1894739,CHEMBL907546,Inhibition of KDR,B,CHEMBL231411,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1894740,CHEMBL907546,Inhibition of KDR,B,CHEMBL231410,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
1894741,CHEMBL907546,Inhibition of KDR,B,CHEMBL231415,=,nM,491.0,CHEMBL279,Homo sapiens,IC50
1894742,CHEMBL907546,Inhibition of KDR,B,CHEMBL231310,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
1894743,CHEMBL907546,Inhibition of KDR,B,CHEMBL231309,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1894744,CHEMBL907546,Inhibition of KDR,B,CHEMBL231308,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1894745,CHEMBL907546,Inhibition of KDR,B,CHEMBL396494,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
1894746,CHEMBL907546,Inhibition of KDR,B,CHEMBL394790,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
1894747,CHEMBL907546,Inhibition of KDR,B,CHEMBL231209,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1894748,CHEMBL907546,Inhibition of KDR,B,CHEMBL231109,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
1894749,CHEMBL907546,Inhibition of KDR,B,CHEMBL394789,=,nM,152.0,CHEMBL279,Homo sapiens,IC50
1894750,CHEMBL907546,Inhibition of KDR,B,CHEMBL231456,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1894751,CHEMBL907546,Inhibition of KDR,B,CHEMBL389524,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
1894753,CHEMBL907546,Inhibition of KDR,B,CHEMBL231454,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
1894754,CHEMBL907546,Inhibition of KDR,B,CHEMBL389299,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
1894755,CHEMBL907546,Inhibition of KDR,B,CHEMBL231357,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
1894756,CHEMBL907546,Inhibition of KDR,B,CHEMBL394620,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
1894757,CHEMBL907546,Inhibition of KDR,B,CHEMBL231356,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
1894758,CHEMBL907546,Inhibition of KDR,B,CHEMBL231355,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
1894759,CHEMBL907546,Inhibition of KDR,B,CHEMBL394619,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
1894760,CHEMBL907546,Inhibition of KDR,B,CHEMBL231255,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
1894761,CHEMBL907546,Inhibition of KDR,B,CHEMBL231254,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
1894762,CHEMBL907546,Inhibition of KDR,B,CHEMBL231153,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
1897042,CHEMBL887535,Inhibition of KDR,B,CHEMBL230414,=,nM,15400.0,CHEMBL279,Homo sapiens,IC50
1897043,CHEMBL887535,Inhibition of KDR,B,CHEMBL230520,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
1897044,CHEMBL887535,Inhibition of KDR,B,CHEMBL306284,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
1897045,CHEMBL887535,Inhibition of KDR,B,CHEMBL388936,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1897047,CHEMBL887535,Inhibition of KDR,B,CHEMBL410186,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1897051,CHEMBL887535,Inhibition of KDR,B,CHEMBL396219,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
1897058,CHEMBL887535,Inhibition of KDR,B,CHEMBL230413,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
1897062,CHEMBL887535,Inhibition of KDR,B,CHEMBL396788,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50
1897063,CHEMBL887535,Inhibition of KDR,B,CHEMBL321359,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50
1897072,CHEMBL887535,Inhibition of KDR,B,CHEMBL231650,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1897074,CHEMBL887535,Inhibition of KDR,B,CHEMBL230081,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
1897078,CHEMBL887535,Inhibition of KDR,B,CHEMBL231649,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
1897086,CHEMBL887535,Inhibition of KDR,B,CHEMBL537435,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
1897087,CHEMBL887535,Inhibition of KDR,B,CHEMBL231139,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
1897595,CHEMBL887591,Inhibition of KDR,B,CHEMBL541643,=,nM,91000.0,CHEMBL279,Homo sapiens,IC50
1922383,CHEMBL895913,Inhibition of KDR,B,CHEMBL231568,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
1926764,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243891,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
1926771,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244300,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
1926772,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL390696,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
1926773,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL389333,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
1926774,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244106,=,nM,5.4,CHEMBL279,Homo sapiens,IC50
1926775,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244486,=,nM,16.5,CHEMBL279,Homo sapiens,IC50
1926776,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244297,=,nM,5.1,CHEMBL279,Homo sapiens,IC50
1926777,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243919,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
1926778,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243917,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
1926779,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243916,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
1926780,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL387817,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1926781,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL387604,=,nM,5.4,CHEMBL279,Homo sapiens,IC50
1926782,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244101,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
1926783,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243915,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
1926784,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243914,=,nM,4.8,CHEMBL279,Homo sapiens,IC50
1926785,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244482,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
1926786,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244481,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
1926787,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244291,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
1926788,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244100,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1926790,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244098,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50
1926791,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243912,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
1926793,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL397757,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
1926794,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243910,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1926795,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244289,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
1926796,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244288,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1926798,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244287,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
1926799,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244097,=,nM,603.0,CHEMBL279,Homo sapiens,IC50
1926800,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396284,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
1926801,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244096,=,nM,5.4,CHEMBL279,Homo sapiens,IC50
1926802,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244095,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
1926803,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243909,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
1926804,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396283,=,nM,6.3,CHEMBL279,Homo sapiens,IC50
1926805,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243908,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
1926806,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243907,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
1926807,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244286,=,nM,3.3,CHEMBL279,Homo sapiens,IC50
1926808,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396056,=,nM,3.5,CHEMBL279,Homo sapiens,IC50
1926809,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244079,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
1943159,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL607707,=,nM,3131.0,CHEMBL279,Homo sapiens,IC50
1943236,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL242349,=,nM,50.2,CHEMBL279,Homo sapiens,IC50
1943240,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL29197,=,nM,1489.0,CHEMBL279,Homo sapiens,IC50
1943241,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL242131,=,nM,4389.0,CHEMBL279,Homo sapiens,IC50
1943242,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL241919,=,nM,188.7,CHEMBL279,Homo sapiens,IC50
1943243,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL241918,=,nM,371.5,CHEMBL279,Homo sapiens,IC50
1943244,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243839,=,nM,76.2,CHEMBL279,Homo sapiens,IC50
1943245,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243837,=,nM,80.2,CHEMBL279,Homo sapiens,IC50
1943246,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL398154,=,nM,135.0,CHEMBL279,Homo sapiens,IC50
1943247,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243629,=,nM,102.3,CHEMBL279,Homo sapiens,IC50
1943248,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243628,=,nM,111.6,CHEMBL279,Homo sapiens,IC50
1943249,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL428741,=,nM,113.4,CHEMBL279,Homo sapiens,IC50
1943250,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243410,=,nM,109.3,CHEMBL279,Homo sapiens,IC50
1943251,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL428039,=,nM,378.7,CHEMBL279,Homo sapiens,IC50
1943252,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL180022,=,nM,858.2,CHEMBL279,Homo sapiens,IC50
1952449,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL398989,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
1956299,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL411829,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1956301,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL394577,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
1956302,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231824,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
1956303,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231801,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
1956304,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231800,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
1956305,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234699,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
1956306,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL390186,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
1956307,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234697,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
1956308,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234489,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
1956309,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234275,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
1956310,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234067,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1956311,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234065,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
1956312,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL389102,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
1956313,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL245174,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
1956314,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL243017,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
1956319,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233875,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
1956320,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL390467,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
1956321,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233874,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
1956322,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL279574,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
1956323,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233669,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
1956324,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233668,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
1956325,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL389343,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
1956326,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233667,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
1956327,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233456,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
1956328,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233455,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
1956329,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL387829,=,nM,91.0,CHEMBL279,Homo sapiens,IC50
1956330,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233454,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
1956405,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234944,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
1960989,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234443,=,nM,348.0,CHEMBL279,Homo sapiens,IC50
1960996,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233213,=,nM,314.0,CHEMBL279,Homo sapiens,IC50
1960997,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234626,=,nM,455.0,CHEMBL279,Homo sapiens,IC50
1960998,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234625,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
1960999,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234624,=,nM,103.0,CHEMBL279,Homo sapiens,IC50
1961000,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL392743,=,nM,216.0,CHEMBL279,Homo sapiens,IC50
1961001,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234452,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1961002,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234451,=,nM,797.0,CHEMBL279,Homo sapiens,IC50
1961003,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233380,=,nM,159.0,CHEMBL279,Homo sapiens,IC50
1961004,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL392306,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
1961005,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233209,=,nM,148.0,CHEMBL279,Homo sapiens,IC50
1961006,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233208,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
1961007,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL393462,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
1961008,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL393460,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
1961009,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233205,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
1961084,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233225,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
1961085,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233224,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
1964500,CHEMBL897114,Inhibition of KDR,B,CHEMBL395665,=,nM,18500.0,CHEMBL279,Homo sapiens,IC50
1964521,CHEMBL897124,Inhibition of VEGFR2,B,CHEMBL391437,=,nM,1460.0,CHEMBL279,Homo sapiens,IC50
1965882,CHEMBL897423,Inhibition of human VEGFR2,B,CHEMBL234655,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
1986213,CHEMBL899833,Inhibition of VEGFR2,B,CHEMBL237570,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
2011583,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241681,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2011587,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241682,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
2011588,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL391692,=,nM,933.0,CHEMBL279,Homo sapiens,IC50
2011603,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241517,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2018103,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240818,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50
2018104,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240608,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50
2018105,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240607,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50
2018106,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393963,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50
2018107,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240406,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50
2018108,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238720,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
2018109,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238719,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
2018110,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL429455,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50
2018111,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392513,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
2018112,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241492,=,nM,1690.0,CHEMBL279,Homo sapiens,IC50
2018113,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241314,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
2018114,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL400216,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
2018115,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241313,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50
2018116,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240209,=,nM,920.0,CHEMBL279,Homo sapiens,IC50
2018117,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241084,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
2018118,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL391127,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
2018119,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241265,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
2018120,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL429643,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50
2018121,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393924,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
2018122,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240643,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
2018123,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL401041,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
2018124,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394436,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50
2018125,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240456,=,nM,2440.0,CHEMBL279,Homo sapiens,IC50
2018126,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL401040,=,nM,1870.0,CHEMBL279,Homo sapiens,IC50
2018127,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240455,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
2018128,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238531,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50
2018129,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393418,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50
2018130,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392789,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50
2018131,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238737,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
2018132,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394204,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
2018133,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394203,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50
2018134,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238530,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
2018135,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238529,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
2018136,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238528,=,nM,550.0,CHEMBL279,Homo sapiens,IC50
2018137,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394020,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
2018138,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238735,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50
2018139,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238526,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
2018140,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238522,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
2018141,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393779,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2018142,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL396144,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50
2018143,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241669,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50
2018144,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392987,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50
2018145,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241668,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
2018146,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241667,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
2018147,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241466,=,nM,2550.0,CHEMBL279,Homo sapiens,IC50
2018148,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241465,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50
2019851,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249622,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
2019852,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250610,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2019853,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL429481,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2019854,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399692,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
2019855,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398460,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2019856,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398459,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
2019857,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398458,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2019858,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250198,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2019859,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250197,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2019860,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250196,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2019861,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249994,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2019862,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL427709,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
2019863,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398436,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2019864,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399119,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
2019865,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249381,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
2019866,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249176,=,nM,174.0,CHEMBL279,Homo sapiens,IC50
2019867,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398296,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
2019868,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249175,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
2019869,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400253,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2019870,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250395,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
2019871,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400061,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2019872,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250394,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
2019873,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398610,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
2019874,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL404005,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2019875,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250853,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
2019876,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL402049,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
2019877,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL402048,=,nM,137.0,CHEMBL279,Homo sapiens,IC50
2019878,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250837,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
2019879,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250836,=,nM,152.0,CHEMBL279,Homo sapiens,IC50
2019880,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398301,=,nM,99.0,CHEMBL279,Homo sapiens,IC50
2019909,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400398,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
2019910,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399787,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
2019911,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400400,=,nM,197.0,CHEMBL279,Homo sapiens,IC50
2021943,CHEMBL903615,Inhibition of KDR,B,CHEMBL240429,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50
2021957,CHEMBL903615,Inhibition of KDR,B,CHEMBL239591,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
2021958,CHEMBL903615,Inhibition of KDR,B,CHEMBL437754,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
2021959,CHEMBL903615,Inhibition of KDR,B,CHEMBL427687,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50
2021960,CHEMBL903615,Inhibition of KDR,B,CHEMBL393596,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2021961,CHEMBL903615,Inhibition of KDR,B,CHEMBL239590,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
2021962,CHEMBL903615,Inhibition of KDR,B,CHEMBL240432,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2021963,CHEMBL903615,Inhibition of KDR,B,CHEMBL240431,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
2021964,CHEMBL903615,Inhibition of KDR,B,CHEMBL240430,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
2021965,CHEMBL903615,Inhibition of KDR,B,CHEMBL392990,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
2022019,CHEMBL903615,Inhibition of KDR,B,CHEMBL247272,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
2022207,CHEMBL902561,Inhibition of KDR,B,CHEMBL247468,=,nM,3096.0,CHEMBL279,Homo sapiens,IC50
2022215,CHEMBL902561,Inhibition of KDR,B,CHEMBL247866,=,nM,537.0,CHEMBL279,Homo sapiens,IC50
2025924,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246152,=,nM,442.0,CHEMBL279,Homo sapiens,IC50
2025944,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL397090,=,nM,233.0,CHEMBL279,Homo sapiens,IC50
2025945,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246356,=,nM,1002.0,CHEMBL279,Homo sapiens,IC50
2025946,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246355,=,nM,1126.0,CHEMBL279,Homo sapiens,IC50
2025947,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL397089,=,nM,309.0,CHEMBL279,Homo sapiens,IC50
2025948,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246151,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2025949,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246150,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2025950,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245949,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50
2025951,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394694,=,nM,128.0,CHEMBL279,Homo sapiens,IC50
2025952,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245948,=,nM,456.0,CHEMBL279,Homo sapiens,IC50
2025953,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245947,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2025954,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245746,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
2025955,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394693,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2025956,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245745,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2025957,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245744,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2025958,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394692,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
2025959,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245549,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
2027264,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL393862,=,nM,7040.0,CHEMBL279,Homo sapiens,IC50
2027267,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245768,=,nM,920.0,CHEMBL279,Homo sapiens,IC50
2027268,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247585,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2027269,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395695,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
2027270,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247389,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2027271,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247388,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
2027272,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395694,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
2027273,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL396586,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
2027274,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL442273,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
2027275,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245362,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
2027276,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246546,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
2027277,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246343,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
2027278,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246342,=,nM,580.0,CHEMBL279,Homo sapiens,IC50
2027279,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245934,=,nM,27890.0,CHEMBL279,Homo sapiens,IC50
2027280,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245734,=,nM,4840.0,CHEMBL279,Homo sapiens,IC50
2027309,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245377,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2027310,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395427,=,nM,263.0,CHEMBL279,Homo sapiens,IC50
2027311,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246166,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2027312,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245968,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
2027313,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245769,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
2034013,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249518,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
2034041,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249519,=,nM,4670.0,CHEMBL279,Homo sapiens,IC50
2034044,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248713,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
2034045,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248712,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2034046,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400569,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2034048,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400749,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
2034050,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL251739,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2034051,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249502,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
2034053,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL399042,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
2034054,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249500,=,nM,1070.0,CHEMBL279,Homo sapiens,IC50
2034055,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249304,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2034056,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249303,=,nM,1550.0,CHEMBL279,Homo sapiens,IC50
2034057,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL401064,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2034058,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249302,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2034059,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249096,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2034060,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400859,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2034062,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249094,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2034063,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248891,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
2034065,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400858,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2036543,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL428225,=,nM,970.0,CHEMBL279,Homo sapiens,IC50
2036574,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245376,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2036575,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL246167,=,nM,3060.0,CHEMBL279,Homo sapiens,IC50
2036577,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL246165,=,nM,29000.0,CHEMBL279,Homo sapiens,IC50
2036578,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL394465,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
2036579,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245967,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
2036580,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245966,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50
2036581,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL397549,=,nM,1280.0,CHEMBL279,Homo sapiens,IC50
2036582,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245770,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
2036583,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL395393,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
2036584,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL395392,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
2036585,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245574,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
2036741,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247619,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
2036753,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247797,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
2036758,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247250,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2036759,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247798,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2039056,CHEMBL923217,Inhibition of VEGFR2,B,CHEMBL248108,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
2071596,CHEMBL928532,Inhibition of KDR,B,CHEMBL253429,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
2071597,CHEMBL928532,Inhibition of KDR,B,CHEMBL254494,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
2071598,CHEMBL928532,Inhibition of KDR,B,CHEMBL254704,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
2080196,CHEMBL929551,Inhibition of KDR,B,CHEMBL253292,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
2081886,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL253969,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2081888,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401860,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2081913,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257787,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2081914,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401897,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
2081915,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258436,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
2081916,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL429138,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2081917,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401896,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2081918,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258222,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
2081919,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL403823,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2081920,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL428433,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2081921,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL403606,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2081922,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258015,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2081923,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401876,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2081924,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258014,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2081925,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255283,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2081926,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255282,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2081927,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255281,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2081928,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258433,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2081929,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258000,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2081930,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL404322,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2081931,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257794,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2081932,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257793,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2081933,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL404718,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2081934,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257789,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2081935,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257788,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2088231,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404223,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
2088234,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256682,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
2088235,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255526,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
2088236,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403070,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
2088237,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257533,=,nM,12.7,CHEMBL279,Homo sapiens,IC50
2088238,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL439068,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2088239,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL272767,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2088240,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404257,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2088241,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404571,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
2088242,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256825,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2088243,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256824,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
2088244,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL402846,=,nM,7.7,CHEMBL279,Homo sapiens,IC50
2088245,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404366,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
2088246,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404367,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
2088247,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404669,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
2088248,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256246,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2088249,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL271441,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
2088250,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404342,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
2088251,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL272938,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
2088252,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256205,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
2088253,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403439,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2088254,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL273187,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
2088255,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403402,=,nM,2.4,CHEMBL279,Homo sapiens,IC50
2088256,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255743,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2088257,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255744,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2088258,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL258141,=,nM,6.3,CHEMBL279,Homo sapiens,IC50
2088259,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256043,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
2088260,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255955,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
2088261,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255746,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2088262,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255956,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
2088263,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257479,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2088264,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257292,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
2096373,CHEMBL948989,Inhibition of KDR,B,CHEMBL269936,=,nM,6679.0,CHEMBL279,Homo sapiens,IC50
2096374,CHEMBL948989,Inhibition of KDR,B,CHEMBL257858,=,nM,255.0,CHEMBL279,Homo sapiens,IC50
2096375,CHEMBL948989,Inhibition of KDR,B,CHEMBL270793,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50
2096376,CHEMBL948989,Inhibition of KDR,B,CHEMBL271018,=,nM,8330.0,CHEMBL279,Homo sapiens,IC50
2101403,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL439428,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
2101404,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL257836,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
2101405,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL404402,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
2101406,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255547,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2101407,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255764,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2101408,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255974,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
2101409,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL401857,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2101410,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL404401,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2101421,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL258046,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2101422,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270368,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2101423,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL402279,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2101424,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL256195,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
2101425,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL429845,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2101426,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271864,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2101427,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270193,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2101428,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271310,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2101429,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271512,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2101430,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL402319,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2101431,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270869,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2101432,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271087,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
2101433,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271941,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
2101434,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL407708,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2101435,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL407944,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2101436,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255394,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
2108928,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL407485,=,nM,18840.0,CHEMBL279,Homo sapiens,IC50
2108931,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL406404,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
2108932,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270489,=,nM,365.0,CHEMBL279,Homo sapiens,IC50
2108933,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL273048,=,nM,158.0,CHEMBL279,Homo sapiens,IC50
2108934,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL260305,=,nM,211.0,CHEMBL279,Homo sapiens,IC50
2108935,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL260307,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
2108937,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269884,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
2108938,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL430090,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2108939,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270084,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2108940,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270506,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2108941,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272453,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2108942,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269862,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
2108943,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL273077,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
2108944,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410663,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2108945,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410664,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2108946,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271386,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
2108947,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL409349,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2108948,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271955,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
2108949,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL406660,=,nM,134.0,CHEMBL279,Homo sapiens,IC50
2108950,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269885,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
2108951,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269886,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
2108952,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272645,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2108953,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271600,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2108954,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272802,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2108955,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270086,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
2108956,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272183,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2108957,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269894,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2108958,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410130,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2108959,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270302,=,nM,6161.0,CHEMBL279,Homo sapiens,IC50
2108960,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL409912,=,nM,806.0,CHEMBL279,Homo sapiens,IC50
2108961,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410504,=,nM,318.0,CHEMBL279,Homo sapiens,IC50
2108962,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL411725,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2108963,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272425,=,nM,247.0,CHEMBL279,Homo sapiens,IC50
2108964,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271795,=,nM,628.0,CHEMBL279,Homo sapiens,IC50
2108965,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271796,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
2108966,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271170,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2108969,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270070,=,nM,12500.0,CHEMBL279,Homo sapiens,IC50
2108975,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271381,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2111934,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL270777,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2111987,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260963,=,nM,8300.0,CHEMBL279,Homo sapiens,IC50
2111990,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL254674,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
2111991,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL406661,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
2111992,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260306,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
2111993,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL405430,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
2111994,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL408030,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
2111995,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL406804,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
2111996,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL407516,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50
2111997,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260956,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
2111998,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL407279,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
2111999,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL261174,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50
2112000,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL410892,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
2112001,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL403522,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
2112002,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL410295,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
2112038,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL270692,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2112039,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL271131,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2112571,CHEMBL951024,Inhibition of VEGFR2,B,CHEMBL258081,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50
2118549,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL230685,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
2118559,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250213,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
2118560,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250625,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
2118561,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250214,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
2118562,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL249821,=,nM,4.7,CHEMBL279,Homo sapiens,IC50
2118563,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL400402,=,nM,2.2,CHEMBL279,Homo sapiens,IC50
2118564,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL230686,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
2118566,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL268825,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2118810,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL429430,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118816,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL409933,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
2118817,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270306,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118818,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270093,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2118819,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272874,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
2118820,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270545,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
2118821,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272875,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118822,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272609,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
2118823,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL405040,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
2118824,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272822,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2118825,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270548,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
2118826,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272878,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118827,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270550,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2118828,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL411630,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
2118829,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270057,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118830,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270058,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2118930,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272688,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
2118931,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL271960,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
2118932,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272170,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2118933,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270953,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
2118934,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270954,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
2118935,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL409867,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2119059,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL429743,=,nM,0.03,CHEMBL279,Homo sapiens,IC50
2120375,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL438016,=,nM,2540.0,CHEMBL279,Homo sapiens,IC50
2120376,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271154,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2120377,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272850,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
2120378,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL405401,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
2120379,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271141,=,nM,272.0,CHEMBL279,Homo sapiens,IC50
2120380,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271140,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
2120381,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL407063,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2120382,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL409734,=,nM,1123.0,CHEMBL279,Homo sapiens,IC50
2120383,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271760,=,nM,947.0,CHEMBL279,Homo sapiens,IC50
2120384,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL411050,=,nM,3784.0,CHEMBL279,Homo sapiens,IC50
2120385,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL405666,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
2120386,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271375,=,nM,587.0,CHEMBL279,Homo sapiens,IC50
2120387,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL409914,=,nM,169.0,CHEMBL279,Homo sapiens,IC50
2120388,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272888,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
2120389,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL411632,=,nM,125.0,CHEMBL279,Homo sapiens,IC50
2120390,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL429582,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2120391,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL408070,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2120392,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272902,=,nM,205.0,CHEMBL279,Homo sapiens,IC50
2120608,CHEMBL951280,Inhibition of KDR,B,CHEMBL260532,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
2120609,CHEMBL951280,Inhibition of KDR,B,CHEMBL260531,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
2120610,CHEMBL951280,Inhibition of KDR,B,CHEMBL272250,=,nM,0.37,CHEMBL279,Homo sapiens,IC50
2120611,CHEMBL951280,Inhibition of KDR,B,CHEMBL272252,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
2120612,CHEMBL951280,Inhibition of KDR,B,CHEMBL272251,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
2120613,CHEMBL951280,Inhibition of KDR,B,CHEMBL270342,=,nM,0.45,CHEMBL279,Homo sapiens,IC50
2120614,CHEMBL951280,Inhibition of KDR,B,CHEMBL270556,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
2120615,CHEMBL951280,Inhibition of KDR,B,CHEMBL412278,=,nM,314.0,CHEMBL279,Homo sapiens,IC50
2120616,CHEMBL951280,Inhibition of KDR,B,CHEMBL411284,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
2120617,CHEMBL951280,Inhibition of KDR,B,CHEMBL271984,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
2120618,CHEMBL951280,Inhibition of KDR,B,CHEMBL271189,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
2120619,CHEMBL951280,Inhibition of KDR,B,CHEMBL271188,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2120620,CHEMBL951280,Inhibition of KDR,B,CHEMBL410840,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
2120621,CHEMBL951280,Inhibition of KDR,B,CHEMBL406914,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
2120622,CHEMBL951280,Inhibition of KDR,B,CHEMBL408211,=,nM,5.9,CHEMBL279,Homo sapiens,IC50
2120623,CHEMBL951280,Inhibition of KDR,B,CHEMBL409103,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
2120624,CHEMBL951280,Inhibition of KDR,B,CHEMBL269871,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
2120625,CHEMBL951280,Inhibition of KDR,B,CHEMBL270754,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
2120626,CHEMBL951280,Inhibition of KDR,B,CHEMBL270755,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2120627,CHEMBL951280,Inhibition of KDR,B,CHEMBL428961,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2120628,CHEMBL951280,Inhibition of KDR,B,CHEMBL410903,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2120629,CHEMBL951280,Inhibition of KDR,B,CHEMBL259252,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
2120630,CHEMBL951280,Inhibition of KDR,B,CHEMBL272198,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2120940,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL429410,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2120941,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL271181,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2120949,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL408478,=,nM,0.8,CHEMBL279,Homo sapiens,IC50
2120950,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270978,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2120951,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL259461,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2120952,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL409538,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
2120953,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272691,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
2120954,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272693,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2120955,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL406388,=,nM,0.8,CHEMBL279,Homo sapiens,IC50
2120956,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269915,=,nM,0.8,CHEMBL279,Homo sapiens,IC50
2120957,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269914,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2120958,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269916,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
2120959,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270983,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2120960,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL407715,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
2120961,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270985,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
2120962,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL271563,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
2120963,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL411091,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
2120964,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270092,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
2120965,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL410841,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2120966,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL412291,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2120967,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270547,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2120968,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272824,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
2120969,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272823,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2120970,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL409512,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
2120971,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272449,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2120973,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL273062,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2120974,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL273064,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2120975,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL410093,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
2120976,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272670,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2120977,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL413933,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
2120978,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270258,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
2120979,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272827,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2120980,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269891,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2121083,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270277,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2121084,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL446367,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2121085,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270745,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
2121086,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL429585,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
2122334,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL258437,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2122355,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL411520,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2122356,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL410100,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2122357,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271849,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2122358,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271861,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2122359,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL401881,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2122360,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL403158,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2122361,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL269924,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2122362,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL444105,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2122363,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL402182,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2122364,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255959,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2122365,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL402531,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2122366,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL428876,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2122367,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL401900,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2122368,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255404,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
2122369,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255406,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2122370,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255405,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2122371,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL406909,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2122372,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271301,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2122373,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL404497,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
2122374,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL270827,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2122375,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271042,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2122376,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL270828,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2132659,CHEMBL921283,Inhibition of KDR at 100 uM,B,CHEMBL410659,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
2137051,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL408565,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
2137113,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL406381,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2137254,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL101797,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
2137379,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL261508,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
2159776,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL262623,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2159782,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL260620,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
2159783,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL259381,=,nM,21000.0,CHEMBL279,Homo sapiens,IC50
2159784,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL259380,=,nM,35000.0,CHEMBL279,Homo sapiens,IC50
2159785,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL407265,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2159786,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL407532,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
2159787,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL405233,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
2159788,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL263902,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2159816,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260093,=,nM,951.0,CHEMBL279,Homo sapiens,IC50
2159820,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL403706,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2159821,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260848,=,nM,126.0,CHEMBL279,Homo sapiens,IC50
2159822,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL263374,=,nM,888.0,CHEMBL279,Homo sapiens,IC50
2159823,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL411903,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2159824,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL262607,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
2159825,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL412102,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2159826,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL429516,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2159827,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL410731,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
2159828,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL409872,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2159829,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL259013,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2159830,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260092,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2164835,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL409442,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2164836,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL265431,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
2164837,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL259951,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2164838,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL410686,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2164839,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL261592,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2164840,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL258694,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2164841,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL258695,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
2164842,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL264943,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
2164843,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL412081,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2164844,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL409673,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2164845,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL412082,=,nM,121.0,CHEMBL279,Homo sapiens,IC50
2164846,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL265191,=,nM,165.0,CHEMBL279,Homo sapiens,IC50
2164847,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL259996,=,nM,223.0,CHEMBL279,Homo sapiens,IC50
2164848,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL260199,=,nM,122.0,CHEMBL279,Homo sapiens,IC50
2164849,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL255902,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
2164850,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL256116,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2166435,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL256556,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2166436,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL402002,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
2166437,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL427725,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
2167835,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257802,=,nM,1134.0,CHEMBL279,Homo sapiens,IC50
2167836,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256920,=,nM,346.0,CHEMBL279,Homo sapiens,IC50
2167839,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256715,=,nM,561.0,CHEMBL279,Homo sapiens,IC50
2167840,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257546,=,nM,127.0,CHEMBL279,Homo sapiens,IC50
2167841,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256972,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
2167845,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404881,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
2167853,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254761,=,nM,344.0,CHEMBL279,Homo sapiens,IC50
2167854,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254964,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2167855,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL401838,=,nM,289.0,CHEMBL279,Homo sapiens,IC50
2167856,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402504,=,nM,386.0,CHEMBL279,Homo sapiens,IC50
2167857,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402036,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2167858,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL438877,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
2167859,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256974,=,nM,129.0,CHEMBL279,Homo sapiens,IC50
2167875,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256786,=,nM,175.0,CHEMBL279,Homo sapiens,IC50
2167876,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL403747,=,nM,593.0,CHEMBL279,Homo sapiens,IC50
2167877,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258185,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2167878,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402004,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
2167879,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257987,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
2167880,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256767,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
2167881,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402042,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
2167882,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404639,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2167883,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402550,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2167884,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258396,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
2167885,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402792,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2167886,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404495,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2167887,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258240,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2167888,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258453,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2167889,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254760,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2198001,CHEMBL1005544,Inhibition of Tel-fused KDR kinase-mediated mouse BaF3 cell proliferation,B,CHEMBL509032,=,nM,2123.0,CHEMBL279,Homo sapiens,IC50
2206773,CHEMBL989732,Inhibition of Flk1,B,CHEMBL450786,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
2227939,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL497114,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50
2227940,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL526925,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
2227941,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL502279,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50
2227942,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL502543,=,nM,35000.0,CHEMBL279,Homo sapiens,IC50
2227944,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL505610,=,nM,77000.0,CHEMBL279,Homo sapiens,IC50
2227946,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL524708,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
2227947,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL503074,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50
2227950,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL497290,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50
2227951,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL507202,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50
2227952,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL444654,=,nM,70000.0,CHEMBL279,Homo sapiens,IC50
2227954,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL499891,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50
2227955,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL500153,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50
2227958,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL524322,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
2227959,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL525065,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
2227968,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL499864,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
2227969,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL500152,=,nM,98000.0,CHEMBL279,Homo sapiens,IC50
2227970,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL453195,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
2231451,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL508643,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231453,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452569,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2231454,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL509707,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231455,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452088,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2231459,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL459896,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2231460,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462169,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231461,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462168,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2231462,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL450163,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231463,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL518203,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231464,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462175,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2231465,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462003,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2231466,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462349,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2231467,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462348,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2231468,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462563,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2231469,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462562,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2231470,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462382,=,nM,344.0,CHEMBL279,Homo sapiens,IC50
2231471,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462381,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
2231472,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL516639,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
2231473,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL460077,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2231474,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462359,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2231475,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL458330,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
2231476,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL453354,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2231477,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452828,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50
2232141,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452827,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
2232142,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452570,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
2234582,CHEMBL1003891,Inhibition of VEGFR2,B,CHEMBL509101,=,nM,4.27,CHEMBL279,Homo sapiens,IC50
2250131,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495749,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2250132,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495763,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2250133,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495762,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2250134,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498013,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2250135,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498551,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2250136,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496764,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2250137,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495735,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
2250138,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498214,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2250139,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495961,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
2250140,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495962,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
2250141,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL204427,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
2250142,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523745,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
2250143,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526507,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
2250144,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496762,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
2250145,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL204426,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
2250146,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL383417,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
2250147,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496150,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
2250148,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL522892,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
2250149,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523071,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
2250150,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526658,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
2250151,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496763,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
2250152,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498347,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
2250153,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495529,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2250154,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495984,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
2250155,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL522732,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
2250156,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498206,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
2250157,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL521552,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
2250158,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498205,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
2250159,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL377345,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
2250160,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526836,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
2250161,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495983,=,nM,860.0,CHEMBL279,Homo sapiens,IC50
2250162,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526285,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
2250163,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495530,=,nM,980.0,CHEMBL279,Homo sapiens,IC50
2250164,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL449593,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2250166,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498348,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50
2250167,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523571,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50
2250168,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL457985,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
2251221,CHEMBL1009919,Inhibition of VEGFR2,B,CHEMBL495727,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2251522,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL521887,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2254022,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL524057,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
2254023,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL495544,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
2254024,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL495545,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
2254025,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL524086,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
2254026,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL496360,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
2254027,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL496575,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2261816,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL523559,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
2261884,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL526639,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
2264745,CHEMBL963872,Binding affinity to VEGFR2,B,CHEMBL465465,=,nM,18000.0,CHEMBL279,Homo sapiens,IC50
2264747,CHEMBL963872,Binding affinity to VEGFR2,B,CHEMBL481968,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2268430,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL464620,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
2268432,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516836,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
2270409,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL462338,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2270433,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL475352,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
2270434,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL512933,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50
2270435,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL461991,=,nM,8800.0,CHEMBL279,Homo sapiens,IC50
2270444,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL491686,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50
2270451,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473351,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50
2270452,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473556,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
2270475,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL464210,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
2270478,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL514942,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
2270487,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL460746,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2270504,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL522785,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2270522,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL518803,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
2270530,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473354,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2270534,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL475351,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
2270539,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL443906,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
2270546,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473557,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2270555,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL474543,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
2270559,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL514016,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
2270628,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL490965,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
2270629,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464510,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2270630,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL465130,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2270631,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL465131,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2270632,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462667,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
2270633,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL518209,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
2270634,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL459478,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2270635,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462023,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2270636,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462231,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2270637,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462232,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2270638,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL453613,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2270639,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL445871,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2270640,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL503524,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
2270641,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL449757,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2270642,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL510676,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2270643,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL455655,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
2270644,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL448276,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2270645,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL447616,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2270646,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL503016,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2270647,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL508395,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2270648,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL448993,=,nM,880.0,CHEMBL279,Homo sapiens,IC50
2270649,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL502621,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2270650,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL508776,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
2270651,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464211,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2270652,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL517469,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2270653,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462835,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2270654,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL518676,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2270655,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464409,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
2270688,CHEMBL960947,Inhibition of VEGFR2,B,CHEMBL489326,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2273600,CHEMBL960871,Inhibition of human VEGFR2,B,CHEMBL1615278,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2273601,CHEMBL960871,Inhibition of human VEGFR2,B,CHEMBL1794070,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
2280504,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL473826,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
2280514,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474863,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
2280516,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515109,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
2280518,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL514511,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
2280520,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL493315,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50
2280523,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475796,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
2280526,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515258,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
2280527,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL523684,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
2280529,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL492956,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50
2280531,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474046,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
2280533,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL514351,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
2280534,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475820,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50
2280537,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL473825,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
2280539,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL1080580,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
2280542,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474208,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
2280546,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL521652,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50
2280550,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474015,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50
2280551,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL941,=,nM,25800.0,CHEMBL279,Homo sapiens,IC50
2280557,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475051,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50
2280558,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515432,=,nM,46000.0,CHEMBL279,Homo sapiens,IC50
2288957,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522629,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
2288960,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL489329,=,nM,4230.0,CHEMBL279,Homo sapiens,IC50
2288966,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL490968,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
2288975,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491502,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
2288978,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491680,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
2288981,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522304,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
2288984,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491681,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50
2288987,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL518652,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2288990,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461391,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
2288993,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461392,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
2288996,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461605,=,nM,770.0,CHEMBL279,Homo sapiens,IC50
2288999,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516645,=,nM,680.0,CHEMBL279,Homo sapiens,IC50
2289002,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522133,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
2289005,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491871,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
2289008,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491872,=,nM,630.0,CHEMBL279,Homo sapiens,IC50
2289011,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL523320,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
2289014,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL454403,=,nM,980.0,CHEMBL279,Homo sapiens,IC50
2289026,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516635,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
2289029,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL517021,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
2298344,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525203,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
2298345,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL502835,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2298346,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497049,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2298347,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL524453,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2298348,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498088,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2298349,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525909,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2298350,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498265,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2298351,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498266,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
2298352,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525550,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
2298353,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498105,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
2298354,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465015,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
2298355,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465016,=,nM,119.0,CHEMBL279,Homo sapiens,IC50
2298356,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL518867,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
2298357,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465217,=,nM,245.0,CHEMBL279,Homo sapiens,IC50
2298358,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL485642,=,nM,248.0,CHEMBL279,Homo sapiens,IC50
2298359,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL519213,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
2298808,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497949,=,nM,763.0,CHEMBL279,Homo sapiens,IC50
2298809,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525443,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
2298810,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL501751,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2298811,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL501752,=,nM,129.0,CHEMBL279,Homo sapiens,IC50
2298812,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500952,=,nM,248.0,CHEMBL279,Homo sapiens,IC50
2298813,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500169,=,nM,1752.0,CHEMBL279,Homo sapiens,IC50
2298814,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500435,=,nM,2112.0,CHEMBL279,Homo sapiens,IC50
2298816,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL524647,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50
2298817,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL1203981,=,nM,1312.0,CHEMBL279,Homo sapiens,IC50
2298818,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL496862,=,nM,1447.0,CHEMBL279,Homo sapiens,IC50
2298819,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL1203982,=,nM,2099.0,CHEMBL279,Homo sapiens,IC50
2298820,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497739,=,nM,132.0,CHEMBL279,Homo sapiens,IC50
2298822,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497055,=,nM,791.0,CHEMBL279,Homo sapiens,IC50
2301965,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL519976,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50
2301989,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL501256,=,nM,58000.0,CHEMBL279,Homo sapiens,IC50
2302085,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL485246,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50
2302109,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL521155,=,nM,81000.0,CHEMBL279,Homo sapiens,IC50
2339040,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL499067,=,nM,24900.0,CHEMBL279,Homo sapiens,IC50
2339045,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL504416,=,nM,132100.0,CHEMBL279,Homo sapiens,IC50
2339046,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL483108,=,nM,198300.0,CHEMBL279,Homo sapiens,IC50
2339048,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL484109,=,nM,16800.0,CHEMBL279,Homo sapiens,IC50
2339049,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL482489,=,nM,42300.0,CHEMBL279,Homo sapiens,IC50
2339102,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL474538,=,nM,5080.0,CHEMBL279,Homo sapiens,IC50
2339103,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL499345,=,nM,5580.0,CHEMBL279,Homo sapiens,IC50
2355803,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL493986,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
2355813,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL494821,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
2356839,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL497343,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
2356840,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL525744,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
2356841,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL497958,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
2356842,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL498557,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
2356843,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL496494,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2361600,CHEMBL980902,Inhibition of GST-tagged KDR,B,CHEMBL459729,=,nM,369.0,CHEMBL279,Homo sapiens,IC50
2367458,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494072,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
2367474,CHEMBL1024854,Inhibition of KDR,B,CHEMBL495330,=,nM,6292.0,CHEMBL279,Homo sapiens,IC50
2367475,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493708,=,nM,505.0,CHEMBL279,Homo sapiens,IC50
2367476,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493671,=,nM,2680.0,CHEMBL279,Homo sapiens,IC50
2367477,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493670,=,nM,1145.0,CHEMBL279,Homo sapiens,IC50
2367479,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494469,=,nM,8553.0,CHEMBL279,Homo sapiens,IC50
2367480,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494272,=,nM,3042.0,CHEMBL279,Homo sapiens,IC50
2367481,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494270,=,nM,5145.0,CHEMBL279,Homo sapiens,IC50
2369777,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484677,=,nM,5940.0,CHEMBL279,Homo sapiens,IC50
2369778,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL507927,=,nM,142.0,CHEMBL279,Homo sapiens,IC50
2372053,CHEMBL990802,Inhibition of KDR,B,CHEMBL491429,=,nM,353.0,CHEMBL279,Homo sapiens,IC50
2373123,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL491045,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
2373126,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484678,=,nM,11260.0,CHEMBL279,Homo sapiens,IC50
2373127,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL482621,=,nM,144.0,CHEMBL279,Homo sapiens,IC50
2373128,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL443338,=,nM,119.0,CHEMBL279,Homo sapiens,IC50
2373129,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL520975,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
2373130,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL483451,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
2373131,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL485081,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
2373132,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484876,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
2373133,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL449663,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2373134,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL522601,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2373135,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL489820,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2379751,CHEMBL1000444,Inhibition of human VEGFR2 expressed in baculovirus insect cell system,B,CHEMBL460989,=,nM,4175.0,CHEMBL279,Homo sapiens,IC50
2379812,CHEMBL1000444,Inhibition of human VEGFR2 expressed in baculovirus insect cell system,B,CHEMBL290352,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
2387934,CHEMBL1001090,Inhibition of KDR expressed in baculovirus system by ELISA,B,CHEMBL461776,=,nM,1480.0,CHEMBL279,Homo sapiens,IC50
2393712,CHEMBL957096,Inhibition of VEGFR2,B,CHEMBL460702,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
2396040,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL204220,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2401983,CHEMBL1016206,Inhibition of KDR,B,CHEMBL504547,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2419451,CHEMBL1022373,Inhibition of VEGFR2,B,CHEMBL1421,=,nM,2360.0,CHEMBL279,Homo sapiens,IC50
2449045,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460465,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
2449064,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL445799,=,nM,921.0,CHEMBL279,Homo sapiens,IC50
2449065,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL461293,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
2449066,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460468,=,nM,208.0,CHEMBL279,Homo sapiens,IC50
2449067,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL518174,=,nM,236.0,CHEMBL279,Homo sapiens,IC50
2449068,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL459647,=,nM,329.0,CHEMBL279,Homo sapiens,IC50
2449069,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460466,=,nM,143.0,CHEMBL279,Homo sapiens,IC50
2449093,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460472,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
2449671,CHEMBL946389,Inhibition of KDR,B,CHEMBL487864,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
2449682,CHEMBL946389,Inhibition of KDR,B,CHEMBL512840,=,nM,3530.0,CHEMBL279,Homo sapiens,IC50
2449727,CHEMBL946389,Inhibition of KDR,B,CHEMBL487863,=,nM,748.0,CHEMBL279,Homo sapiens,IC50
2449728,CHEMBL946389,Inhibition of KDR,B,CHEMBL470483,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
2449730,CHEMBL946389,Inhibition of KDR,B,CHEMBL469883,=,nM,294.0,CHEMBL279,Homo sapiens,IC50
2453489,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL507936,=,nM,168.0,CHEMBL279,Homo sapiens,IC50
2453490,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472302,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
2453492,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL513422,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2453493,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL505698,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
2453496,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452287,=,nM,72.0,CHEMBL279,Homo sapiens,IC50
2453500,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469469,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
2453501,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472504,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
2453502,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL511843,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2453503,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472503,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
2453504,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL507533,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
2453505,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453577,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
2453506,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL508928,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2453507,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453578,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2453508,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL510814,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2453509,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452783,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
2453510,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452522,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
2453511,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452288,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2453512,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469468,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
2453514,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL470073,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50
2453515,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469467,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
2453527,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452284,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
2453528,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452283,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
2453529,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452035,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
2453530,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL510788,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
2453531,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL513031,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
2453532,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL470076,=,nM,810.0,CHEMBL279,Homo sapiens,IC50
2453537,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452914,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
2453540,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453057,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2453543,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469456,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2453544,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469455,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2453545,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL512839,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2453546,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453058,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2457833,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494873,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2457834,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494872,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
2457835,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494903,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2457836,CHEMBL1009458,Inhibition of KDR,B,CHEMBL492857,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
2457837,CHEMBL1009458,Inhibition of KDR,B,CHEMBL492856,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2457838,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494084,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2457839,CHEMBL1009458,Inhibition of KDR,B,CHEMBL522855,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
2457840,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495300,=,nM,225.0,CHEMBL279,Homo sapiens,IC50
2457841,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495299,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2457842,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493877,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2457843,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493876,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2457844,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493253,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2457845,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493047,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
2457846,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493046,=,nM,165.0,CHEMBL279,Homo sapiens,IC50
2457847,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494267,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2457848,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495089,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2465070,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL507056,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50
2465071,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL452812,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
2465072,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL509435,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50
2465073,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL453593,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50
2465074,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL509635,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
2465075,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL453336,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
2465076,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488811,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
2465077,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488646,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
2465078,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488645,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
2465079,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL529217,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50
2465080,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL519590,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
2465081,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL486437,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50
2465082,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL505253,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50
2465083,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL521201,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
2465084,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL529663,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
2466414,CHEMBL994995,Inhibition of TEL fused KDR-mediated proliferation of TEL-KDR transformed mouse BA/F3 cells after 48 hrs by bright-glo luciferase assay,B,CHEMBL473250,=,nM,1012.0,CHEMBL279,Homo sapiens,IC50
2466415,CHEMBL994995,Inhibition of TEL fused KDR-mediated proliferation of TEL-KDR transformed mouse BA/F3 cells after 48 hrs by bright-glo luciferase assay,B,CHEMBL447107,=,nM,356.0,CHEMBL279,Homo sapiens,IC50
2467253,CHEMBL991656,Inhibition of KDR in presence of 1 uM ATP,B,CHEMBL489058,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2488855,CHEMBL1028054,Inhibition of VEGFR2,B,CHEMBL480356,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
2488856,CHEMBL1028054,Inhibition of VEGFR2,B,CHEMBL231526,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
2505608,CHEMBL941567,Inhibition of VEGFR2,B,CHEMBL514499,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
2526446,CHEMBL981442,Inhibition of VEGFR2,B,CHEMBL482967,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
2526447,CHEMBL981442,Inhibition of VEGFR2,B,CHEMBL482968,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2560136,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477197,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
2560157,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL478611,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
2560162,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477768,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
2560163,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477560,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
2561487,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL477611,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2561488,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL477563,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
2561489,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL478612,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
2561490,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL478402,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
2561491,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL476572,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
2561492,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL1794074,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
2561493,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL1794073,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
2561533,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL475924,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
2561534,CHEMBL981072,Inhibition of human recombinant VEGFR2,B,CHEMBL478442,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
2561535,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL444138,=,nM,6.3,CHEMBL279,Homo sapiens,IC50
2561539,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL515625,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
2561540,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL479079,=,nM,6.3,CHEMBL279,Homo sapiens,IC50
2561550,CHEMBL981072,Inhibition of human recombinant VEGFR2,B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2564593,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467549,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
2564595,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469023,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
2564598,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467983,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
2564599,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468829,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
2564600,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511251,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
2564602,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513169,=,nM,950.0,CHEMBL279,Homo sapiens,IC50
2564603,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468420,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
2564604,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469272,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
2564605,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513495,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50
2564606,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467365,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2564607,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469261,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50
2564608,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511910,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2564609,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467164,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2564612,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468185,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
2564613,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468184,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
2564614,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511414,=,nM,540.0,CHEMBL279,Homo sapiens,IC50
2564615,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468183,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
2564616,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469043,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
2564617,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469038,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
2564618,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469037,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
2564619,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468173,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
2564620,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513680,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
2564621,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469025,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
2564622,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL466943,=,nM,8500.0,CHEMBL279,Homo sapiens,IC50
2564623,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL466942,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
2564626,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467805,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
2564627,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469172,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2564628,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL512124,=,nM,730.0,CHEMBL279,Homo sapiens,IC50
2564629,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469171,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
2564655,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL512605,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
2567203,CHEMBL970789,Inhibition of KDR,B,CHEMBL223147,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
2582014,CHEMBL962248,Inhibition of human VEGFR2,B,CHEMBL487254,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
2582030,CHEMBL962248,Inhibition of human VEGFR2,B,CHEMBL489083,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
2584884,CHEMBL955794,Inhibition of KDR,B,CHEMBL461139,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
2584912,CHEMBL955794,Inhibition of KDR,B,CHEMBL461140,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
2602364,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL515880,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
2602365,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL514986,=,nM,4230.0,CHEMBL279,Homo sapiens,IC50
2602367,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475704,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
2602370,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475509,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
2602371,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL516243,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
2602372,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475510,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
2602373,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475708,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
2602374,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475709,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
2602375,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473287,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
2602376,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473288,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2602378,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL474709,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
2602379,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL443921,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
2602380,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473268,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2602381,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL512862,=,nM,890.0,CHEMBL279,Homo sapiens,IC50
2602382,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL470440,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
2602383,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL470441,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
2602384,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL512863,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
2602385,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL460191,=,nM,1980.0,CHEMBL279,Homo sapiens,IC50
2602386,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL462315,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
2602390,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL517399,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
2602391,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL458531,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
2616273,CHEMBL1029839,Inhibition of KDR,B,CHEMBL468612,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
2616278,CHEMBL1029839,Inhibition of KDR,B,CHEMBL517559,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50
2616279,CHEMBL1029839,Inhibition of KDR,B,CHEMBL468618,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
2616294,CHEMBL1029839,Inhibition of KDR,B,CHEMBL456683,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
2616295,CHEMBL1029839,Inhibition of KDR,B,CHEMBL456463,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2616296,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457984,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
2616297,CHEMBL1029839,Inhibition of KDR,B,CHEMBL463323,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
2616298,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457100,=,nM,1570.0,CHEMBL279,Homo sapiens,IC50
2616299,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457099,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
2616300,CHEMBL1029839,Inhibition of KDR,B,CHEMBL465793,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
2921919,CHEMBL1047420,Inhibition of KDR,B,CHEMBL3215582,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
2921920,CHEMBL1047420,Inhibition of KDR,B,CHEMBL576985,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
2921921,CHEMBL1047420,Inhibition of KDR,B,CHEMBL569882,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
2921923,CHEMBL1047420,Inhibition of KDR,B,CHEMBL570573,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
2921924,CHEMBL1047420,Inhibition of KDR,B,CHEMBL571278,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
2921926,CHEMBL1047420,Inhibition of KDR,B,CHEMBL565885,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
2921928,CHEMBL1047420,Inhibition of KDR,B,CHEMBL571703,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
2943671,CHEMBL1044062,Inhibition of KDR,B,CHEMBL569880,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
2943674,CHEMBL1044062,Inhibition of KDR,B,CHEMBL571040,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
2983204,CHEMBL1046249,Inhibition of KDR,B,CHEMBL1163016,=,nM,3.3,CHEMBL279,Homo sapiens,IC50
2989868,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566621,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
2989869,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566010,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
2989870,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565785,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
2989871,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566623,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
2989872,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566003,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
2989873,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565990,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2989874,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL576504,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2989875,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL570869,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
2989876,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL585205,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2989877,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566215,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
2989878,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565603,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
2989879,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL567475,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
2989880,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566844,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2989881,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL577742,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
2989882,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL584701,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
2989883,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565807,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
2989884,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565782,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
2989885,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566836,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
2992490,CHEMBL1040923,Inhibition of human recombinant KDR,B,CHEMBL565612,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50
3055911,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL7724,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50
3055922,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL595757,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
3055923,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL610181,=,nM,10300.0,CHEMBL279,Homo sapiens,IC50
3055933,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL595497,=,nM,17800.0,CHEMBL279,Homo sapiens,IC50
3056043,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL603198,=,nM,13700.0,CHEMBL279,Homo sapiens,IC50
3056059,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL606039,=,nM,30300.0,CHEMBL279,Homo sapiens,IC50
3064709,CHEMBL1068588,Inhibition of FLK1,B,CHEMBL611649,=,nM,9600.0,CHEMBL279,Homo sapiens,IC50
3072666,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593293,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50
3072668,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595615,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
3072669,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595406,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
3072670,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595142,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
3072671,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593221,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
3072673,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL594228,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
3072674,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL596087,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
3072675,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL606466,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
3072676,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593860,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
3072677,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593987,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
3072678,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593274,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
3072679,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593306,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
3072680,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL604992,=,nM,335.0,CHEMBL279,Homo sapiens,IC50
3072681,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593275,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
3072682,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL596292,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
3072684,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593909,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50
3072686,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL604483,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
3072687,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595143,=,nM,147.0,CHEMBL279,Homo sapiens,IC50
3072688,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595373,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
3089511,CHEMBL1067369,Inhibition of VEGFR2,B,CHEMBL606245,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50
3098370,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600632,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
3098372,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602703,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3098374,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL591924,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3098376,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602704,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3098378,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602905,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3098380,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600398,=,nM,860.0,CHEMBL279,Homo sapiens,IC50
3098382,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600603,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
3098384,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600604,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
3098386,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL603082,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
3098388,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL612137,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
3102184,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL597492,=,nM,24.89,CHEMBL279,Homo sapiens,IC50
3102185,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL605957,=,nM,22.5,CHEMBL279,Homo sapiens,IC50
3102187,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL606168,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
3104154,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL600795,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50
3104209,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL599993,=,nM,33000.0,CHEMBL279,Homo sapiens,IC50
3104213,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL591457,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50
3104225,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL598911,=,nM,26000.0,CHEMBL279,Homo sapiens,IC50
3104242,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL598727,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50
3104244,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL602471,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
3121093,CHEMBL1065593,Inhibition of KDR,B,CHEMBL598797,=,nM,849.0,CHEMBL279,Homo sapiens,IC50
3122667,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL590769,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
3122668,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599247,=,nM,630.0,CHEMBL279,Homo sapiens,IC50
3122669,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599248,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
3122670,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603259,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
3122671,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598434,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
3122672,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL591896,=,nM,87000.0,CHEMBL279,Homo sapiens,IC50
3122673,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598435,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50
3122682,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL610512,=,nM,66000.0,CHEMBL279,Homo sapiens,IC50
3122684,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603255,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
3122685,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598024,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
3122686,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598025,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
3122687,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596807,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
3122688,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596808,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
3122689,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605324,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
3122690,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605841,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
3122691,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597586,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
3122692,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606410,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
3122693,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL604545,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
3122694,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599844,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
3122695,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599027,=,nM,57000.0,CHEMBL279,Homo sapiens,IC50
3122696,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603545,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
3122697,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603463,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
3122698,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598000,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
3122699,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598201,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
3122700,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598418,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
3122701,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606395,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
3122702,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597191,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
3122703,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL604912,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
3122704,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597393,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
3122705,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597596,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
3122706,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597597,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
3122707,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596988,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
3122708,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605118,=,nM,99.0,CHEMBL279,Homo sapiens,IC50
3122709,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL602043,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
3122710,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599446,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
3122711,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598633,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
3122712,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606255,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
3122713,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598837,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
3122714,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606185,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
3122715,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598431,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
3123975,CHEMBL1067544,Inhibition of KDR,B,CHEMBL597592,=,nM,196.0,CHEMBL279,Homo sapiens,IC50
3123976,CHEMBL1067544,Inhibition of KDR,B,CHEMBL602123,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
3123977,CHEMBL1067544,Inhibition of KDR,B,CHEMBL598626,=,nM,1370.0,CHEMBL279,Homo sapiens,IC50
3185748,CHEMBL1106057,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL1077291,=,nM,1530.0,CHEMBL279,Homo sapiens,IC50
3186213,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1080403,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
3186236,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1081312,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
3186270,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
3196270,CHEMBL1102006,Inhibition of KDR,B,CHEMBL1081831,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
3210376,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1080639,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3210377,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1079850,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
3210378,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1079846,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
3210379,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1081198,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
3219927,CHEMBL1115834,Inhibition of KDR,B,CHEMBL1079428,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
3219937,CHEMBL1115834,Inhibition of KDR,B,CHEMBL1076330,=,nM,84000.0,CHEMBL279,Homo sapiens,IC50
3227173,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079422,=,nM,576.0,CHEMBL279,Homo sapiens,IC50
3227174,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079945,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
3227175,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079946,=,nM,6365.0,CHEMBL279,Homo sapiens,IC50
3227176,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1080299,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
3227179,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076432,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
3227180,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1086731,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3227181,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1086860,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
3227182,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088153,=,nM,451.0,CHEMBL279,Homo sapiens,IC50
3227183,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076433,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
3227184,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1075628,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
3227185,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076436,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
3227186,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076437,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
3227187,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088429,=,nM,9069.0,CHEMBL279,Homo sapiens,IC50
3227189,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087636,=,nM,1748.0,CHEMBL279,Homo sapiens,IC50
3227190,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076465,=,nM,1472.0,CHEMBL279,Homo sapiens,IC50
3227191,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076466,=,nM,599.0,CHEMBL279,Homo sapiens,IC50
3227192,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076468,=,nM,1726.0,CHEMBL279,Homo sapiens,IC50
3227193,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076469,=,nM,1365.0,CHEMBL279,Homo sapiens,IC50
3227194,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076470,=,nM,885.0,CHEMBL279,Homo sapiens,IC50
3227195,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076471,=,nM,318.0,CHEMBL279,Homo sapiens,IC50
3227196,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076472,=,nM,941.0,CHEMBL279,Homo sapiens,IC50
3227197,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076473,=,nM,609.0,CHEMBL279,Homo sapiens,IC50
3227198,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076474,=,nM,1712.0,CHEMBL279,Homo sapiens,IC50
3227199,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076475,=,nM,549.0,CHEMBL279,Homo sapiens,IC50
3227201,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076477,=,nM,605.0,CHEMBL279,Homo sapiens,IC50
3227202,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076478,=,nM,582.0,CHEMBL279,Homo sapiens,IC50
3227203,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087638,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
3227204,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076480,=,nM,296.0,CHEMBL279,Homo sapiens,IC50
3227205,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087002,=,nM,1015.0,CHEMBL279,Homo sapiens,IC50
3227206,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087127,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
3227207,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087128,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
3227208,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088027,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
3227209,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088028,=,nM,464.0,CHEMBL279,Homo sapiens,IC50
3227210,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087524,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
3227211,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087649,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
3227212,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1081090,=,nM,516.0,CHEMBL279,Homo sapiens,IC50
3227213,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076533,=,nM,8817.0,CHEMBL279,Homo sapiens,IC50
3227214,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1081436,=,nM,10577.0,CHEMBL279,Homo sapiens,IC50
3227216,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079424,=,nM,135.0,CHEMBL279,Homo sapiens,IC50
3227217,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076193,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3227218,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076194,=,nM,1497.0,CHEMBL279,Homo sapiens,IC50
3227219,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076195,=,nM,1364.0,CHEMBL279,Homo sapiens,IC50
3227220,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076196,=,nM,2094.0,CHEMBL279,Homo sapiens,IC50
3227221,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076197,=,nM,1113.0,CHEMBL279,Homo sapiens,IC50
3227222,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076198,=,nM,249.0,CHEMBL279,Homo sapiens,IC50
3227223,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076199,=,nM,243.0,CHEMBL279,Homo sapiens,IC50
3227224,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076200,=,nM,185.0,CHEMBL279,Homo sapiens,IC50
3227225,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076201,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
3227226,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076202,=,nM,245.0,CHEMBL279,Homo sapiens,IC50
3227227,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1080294,=,nM,8181.0,CHEMBL279,Homo sapiens,IC50
3227228,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076203,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
3240814,CHEMBL1109690,Inhibition of KDR,B,CHEMBL1090360,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
3242698,CHEMBL1115350,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA,B,CHEMBL1093099,=,nM,22600.0,CHEMBL279,Homo sapiens,IC50
3242705,CHEMBL1115350,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA,B,CHEMBL1093100,=,nM,56300.0,CHEMBL279,Homo sapiens,IC50
3251255,CHEMBL1107910,Inhibition of VEGFR2,B,CHEMBL1092754,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
3287547,CHEMBL1115551,Inhibition of KDR after 2 hrs incubation,B,CHEMBL1098561,=,nM,70700.0,CHEMBL279,Homo sapiens,IC50
3288506,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098119,=,nM,2830.0,CHEMBL279,Homo sapiens,IC50
3288507,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098120,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50
3288509,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098121,=,nM,2170.0,CHEMBL279,Homo sapiens,IC50
3288510,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094194,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50
3288511,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094195,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50
3288512,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094196,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50
3288513,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1095154,=,nM,1170.0,CHEMBL279,Homo sapiens,IC50
3288514,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1095957,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50
3288516,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094835,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50
3288517,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL3216254,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50
3288518,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094492,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
3288519,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094825,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50
3288520,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL3216699,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50
3288521,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1097189,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50
3288522,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1097190,=,nM,27140.0,CHEMBL279,Homo sapiens,IC50
3294586,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086932,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
3294587,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086675,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
3294588,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086676,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3294589,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1097824,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
3294590,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1098157,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
3294591,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1098158,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
3294592,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095034,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3294593,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095035,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
3294594,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095036,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
3294595,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095356,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3294596,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095357,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
3294597,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095358,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
3294598,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095359,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
3294599,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095360,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50
3294600,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095361,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3295283,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1094423,=,nM,112300.0,CHEMBL279,Homo sapiens,IC50
3295285,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096972,=,nM,49400.0,CHEMBL279,Homo sapiens,IC50
3295287,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1097743,=,nM,22100.0,CHEMBL279,Homo sapiens,IC50
3295289,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096737,=,nM,25200.0,CHEMBL279,Homo sapiens,IC50
3295291,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096415,=,nM,57500.0,CHEMBL279,Homo sapiens,IC50
3295293,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096416,=,nM,40500.0,CHEMBL279,Homo sapiens,IC50
3295295,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1097368,=,nM,31600.0,CHEMBL279,Homo sapiens,IC50
3299606,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095762,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
3299607,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095761,=,nM,28100.0,CHEMBL279,Homo sapiens,IC50
3299608,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095130,=,nM,45700.0,CHEMBL279,Homo sapiens,IC50
3299609,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095131,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
3299611,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1094475,=,nM,85600.0,CHEMBL279,Homo sapiens,IC50
3299612,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1094808,=,nM,113100.0,CHEMBL279,Homo sapiens,IC50
3299613,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095463,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3299616,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50
3299669,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095464,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
3299686,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095465,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
3299687,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095466,=,nM,27200.0,CHEMBL279,Homo sapiens,IC50
3302665,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084451,=,nM,1754.0,CHEMBL279,Homo sapiens,IC50
3302674,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084452,=,nM,2059.0,CHEMBL279,Homo sapiens,IC50
3302683,CHEMBL1120723,Inhibition of KDR,B,CHEMBL458023,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
3302692,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084453,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
3302710,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1086334,=,nM,6358.0,CHEMBL279,Homo sapiens,IC50
3302755,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084633,=,nM,2218.0,CHEMBL279,Homo sapiens,IC50
3302764,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084634,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
3308290,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082503,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
3308291,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082826,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
3308292,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083757,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
3308293,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084061,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
3308294,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084062,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
3308295,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082829,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
3308296,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084337,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
3308297,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084338,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
3308298,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083144,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
3308299,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083454,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
3308300,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085291,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
3308301,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085292,=,nM,149.0,CHEMBL279,Homo sapiens,IC50
3308302,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082755,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
3308303,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082756,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
3308304,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085293,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
3308305,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085540,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
3308306,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085541,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
3308307,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083071,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
3308308,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082437,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
3308309,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082438,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
3308310,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083042,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3308311,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083350,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
3308312,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083386,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
3308313,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085294,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
3308314,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085295,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
3308315,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085296,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
3315017,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083091,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
3315021,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083092,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
3315025,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084974,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50
3315029,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085316,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
3315033,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085240,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
3315037,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085317,=,nM,5350.0,CHEMBL279,Homo sapiens,IC50
3315041,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085564,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
3315049,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084028,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
3315053,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084302,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
3315057,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083001,=,nM,1015.0,CHEMBL279,Homo sapiens,IC50
3315061,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085733,=,nM,8300.0,CHEMBL279,Homo sapiens,IC50
3315065,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085511,=,nM,4233.0,CHEMBL279,Homo sapiens,IC50
3315069,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085512,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
3315081,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082693,=,nM,435.0,CHEMBL279,Homo sapiens,IC50
3315103,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085996,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
3315107,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083022,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
3315111,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083023,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
3315115,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083344,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
3315119,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083644,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
3315127,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082404,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
3315131,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082958,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
3315887,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082959,=,nM,7350.0,CHEMBL279,Homo sapiens,IC50
3316814,CHEMBL1120373,Inhibition of KDR,B,CHEMBL1084450,=,nM,1058.0,CHEMBL279,Homo sapiens,IC50
3329242,CHEMBL1166749,Inhibition of VEGFR2,B,CHEMBL1164957,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
3359788,CHEMBL1177359,Inhibition KDR,B,CHEMBL1172957,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
3370060,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173411,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
3370062,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173149,=,nM,30.6,CHEMBL279,Homo sapiens,IC50
3370063,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172814,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
3370064,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172815,=,nM,271.9,CHEMBL279,Homo sapiens,IC50
3370065,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172886,=,nM,13.7,CHEMBL279,Homo sapiens,IC50
3370066,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172887,=,nM,31.5,CHEMBL279,Homo sapiens,IC50
3370067,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172837,=,nM,20.4,CHEMBL279,Homo sapiens,IC50
3370068,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172838,=,nM,22.1,CHEMBL279,Homo sapiens,IC50
3370069,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173107,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
3370070,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173174,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
3370071,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172420,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
3370072,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172421,=,nM,7.9,CHEMBL279,Homo sapiens,IC50
3370073,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172422,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
3370074,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173150,=,nM,4.7,CHEMBL279,Homo sapiens,IC50
3370075,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173541,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3370080,CHEMBL1176708,Inhibition of KDR,B,CHEMBL124660,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50
3423085,CHEMBL1227384,Inhibition of recombinant KDR after 1 hr,B,CHEMBL1221633,=,nM,33200.0,CHEMBL279,Homo sapiens,IC50
3423086,CHEMBL1227384,Inhibition of recombinant KDR after 1 hr,B,CHEMBL185140,=,nM,26000.0,CHEMBL279,Homo sapiens,IC50
3439114,CHEMBL1247961,Inhibition of KDR by HTRF assay,B,CHEMBL1242977,=,nM,3270.0,CHEMBL279,Homo sapiens,IC50
3440725,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242285,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
3440739,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242286,=,nM,2020.0,CHEMBL279,Homo sapiens,IC50
3440753,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241299,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
3440767,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242287,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
3440781,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242376,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
3440795,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242377,=,nM,68.0,CHEMBL279,Homo sapiens,IC50
3440809,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242378,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
3440823,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242468,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50
3440837,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242469,=,nM,2130.0,CHEMBL279,Homo sapiens,IC50
3440851,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242470,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
3440865,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242566,=,nM,517.0,CHEMBL279,Homo sapiens,IC50
3440879,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242567,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50
3440893,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242568,=,nM,106.0,CHEMBL279,Homo sapiens,IC50
3440907,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242656,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
3440921,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242657,=,nM,369.0,CHEMBL279,Homo sapiens,IC50
3440935,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242658,=,nM,1750.0,CHEMBL279,Homo sapiens,IC50
3440949,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242748,=,nM,401.0,CHEMBL279,Homo sapiens,IC50
3440963,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242749,=,nM,555.0,CHEMBL279,Homo sapiens,IC50
3440977,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242750,=,nM,178.0,CHEMBL279,Homo sapiens,IC50
3440991,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242844,=,nM,11800.0,CHEMBL279,Homo sapiens,IC50
3441005,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242845,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3441019,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241482,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3441033,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241483,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3441047,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241484,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3441061,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241579,=,nM,554.0,CHEMBL279,Homo sapiens,IC50
3441075,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240544,=,nM,1140.0,CHEMBL279,Homo sapiens,IC50
3441625,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241481,=,nM,2230.0,CHEMBL279,Homo sapiens,IC50
3441639,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241578,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
3441667,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1233882,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
3441681,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1233881,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50
3441695,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241674,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
3441866,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1230790,=,nM,213.0,CHEMBL279,Homo sapiens,IC50
3441880,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1234815,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
3441978,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241241,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50
3442034,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242024,=,nM,213.0,CHEMBL279,Homo sapiens,IC50
3442048,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242025,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442062,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241270,=,nM,237.0,CHEMBL279,Homo sapiens,IC50
3442076,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241271,=,nM,151.0,CHEMBL279,Homo sapiens,IC50
3442090,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242026,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3442104,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242109,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
3442118,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242110,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50
3442132,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242111,=,nM,901.0,CHEMBL279,Homo sapiens,IC50
3442146,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242198,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
3442160,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242199,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
3442174,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242200,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50
3442184,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242380,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442198,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242381,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
3442212,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240553,=,nM,1690.0,CHEMBL279,Homo sapiens,IC50
3442226,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242471,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442240,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242472,=,nM,13400.0,CHEMBL279,Homo sapiens,IC50
3442254,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242569,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442268,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240554,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50
3442282,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242659,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442296,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242660,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442310,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242751,=,nM,5290.0,CHEMBL279,Homo sapiens,IC50
3442324,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242752,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442338,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242753,=,nM,12600.0,CHEMBL279,Homo sapiens,IC50
3442366,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242847,=,nM,4360.0,CHEMBL279,Homo sapiens,IC50
3442394,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242848,=,nM,2160.0,CHEMBL279,Homo sapiens,IC50
3442408,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241485,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
3442422,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241486,=,nM,194.0,CHEMBL279,Homo sapiens,IC50
3442436,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241487,=,nM,566.0,CHEMBL279,Homo sapiens,IC50
3442450,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241581,=,nM,752.0,CHEMBL279,Homo sapiens,IC50
3442520,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241582,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442534,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241583,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
3442548,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240545,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
3442561,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241679,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50
3442575,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241680,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
3442589,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241771,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442603,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241772,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442617,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241390,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442631,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241391,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442645,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241773,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442659,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241860,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
3442673,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241861,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3442687,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241862,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442701,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241946,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442715,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241439,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50
3442729,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241947,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50
3442742,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241948,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3442755,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242030,=,nM,5890.0,CHEMBL279,Homo sapiens,IC50
3442769,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242031,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
3442783,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242032,=,nM,98800.0,CHEMBL279,Homo sapiens,IC50
3442797,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242115,=,nM,1680.0,CHEMBL279,Homo sapiens,IC50
3442948,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241580,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
3442962,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241676,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
3442976,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241677,=,nM,174.0,CHEMBL279,Homo sapiens,IC50
3442990,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241678,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
3443004,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241768,=,nM,103.0,CHEMBL279,Homo sapiens,IC50
3443018,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241769,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50
3443032,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241770,=,nM,435.0,CHEMBL279,Homo sapiens,IC50
3443046,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241858,=,nM,7160.0,CHEMBL279,Homo sapiens,IC50
3443060,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241859,=,nM,3780.0,CHEMBL279,Homo sapiens,IC50
3443074,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241943,=,nM,1280.0,CHEMBL279,Homo sapiens,IC50
3443088,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241944,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3443102,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241945,=,nM,1530.0,CHEMBL279,Homo sapiens,IC50
3443116,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242027,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50
3443130,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242028,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50
3443144,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242029,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3443158,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242112,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3443172,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241300,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50
3443200,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242113,=,nM,279.0,CHEMBL279,Homo sapiens,IC50
3443214,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242114,=,nM,119.0,CHEMBL279,Homo sapiens,IC50
3443228,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242201,=,nM,259.0,CHEMBL279,Homo sapiens,IC50
3443242,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242202,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
3443256,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242203,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50
3443270,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242288,=,nM,872.0,CHEMBL279,Homo sapiens,IC50
3443284,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242289,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
3443298,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242290,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3443312,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242379,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3443773,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242661,=,nM,550.0,CHEMBL279,Homo sapiens,IC50
3443787,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242662,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3443801,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242663,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3443815,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242754,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
3443829,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242755,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
3443843,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242756,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
3443997,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241681,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
3444011,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241682,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
3444025,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241683,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
3444039,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241774,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
3444053,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241775,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
3444067,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241776,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50
3444081,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241863,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444095,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241864,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444109,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241949,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
3444123,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241950,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50
3444137,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242033,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444151,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242034,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50
3444165,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242117,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444179,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242118,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444193,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242119,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50
3444207,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242207,=,nM,49000.0,CHEMBL279,Homo sapiens,IC50
3444221,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242208,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50
3444235,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242209,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444249,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240565,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
3444263,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242293,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
3444277,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242294,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
3444291,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242295,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
3444305,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242384,=,nM,715.0,CHEMBL279,Homo sapiens,IC50
3444319,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242385,=,nM,172.0,CHEMBL279,Homo sapiens,IC50
3444333,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242386,=,nM,295.0,CHEMBL279,Homo sapiens,IC50
3444347,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242475,=,nM,411.0,CHEMBL279,Homo sapiens,IC50
3444361,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242476,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50
3444375,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242477,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
3444389,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242572,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
3444403,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242573,=,nM,215.0,CHEMBL279,Homo sapiens,IC50
3444417,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240566,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
3444431,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242574,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
3444445,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242664,=,nM,134.0,CHEMBL279,Homo sapiens,IC50
3444459,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242665,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444473,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242666,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
3444487,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242757,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50
3444501,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242758,=,nM,4130.0,CHEMBL279,Homo sapiens,IC50
3444515,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242852,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
3444529,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242853,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
3444543,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241490,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
3444557,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241491,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50
3444571,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241492,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444585,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241586,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50
3444599,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241587,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
3444627,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241588,=,nM,21000.0,CHEMBL279,Homo sapiens,IC50
3444655,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241684,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50
3444668,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL939,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
3447190,CHEMBL1249718,Inhibition of Kdr kinase,B,CHEMBL1242557,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
3465416,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254097,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
3465417,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254098,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
3465418,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254192,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
3465419,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254193,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
3465420,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254277,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
3465421,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254278,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
3465422,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254355,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3465423,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254356,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
3465424,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253194,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
3465425,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254437,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
3465426,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254190,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
3465427,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254515,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
3465428,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254595,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
3465429,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254671,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
3465430,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254755,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
3465431,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254839,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
3465432,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254840,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
3465433,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254927,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
3465434,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255013,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
3465435,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255097,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
3465465,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254006,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
3465466,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253917,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
3465467,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255098,=,nM,9.7,CHEMBL279,Homo sapiens,IC50
3465468,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253837,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
3465469,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253838,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
3465470,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253916,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3468975,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1254199,=,nM,89200.0,CHEMBL279,Homo sapiens,IC50
3468979,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1254364,=,nM,116300.0,CHEMBL279,Homo sapiens,IC50
3471560,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254511,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
3471561,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254924,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
3471562,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255010,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
3471563,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255011,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
3471564,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255093,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50
3471567,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253834,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
3471568,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253914,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50
3471569,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253915,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50
3471570,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254590,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50
3471571,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254591,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50
3471572,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254669,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
3471573,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254670,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
3471574,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254752,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
3471575,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254753,=,nM,5.3,CHEMBL279,Homo sapiens,IC50
3471576,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254835,=,nM,4.4,CHEMBL279,Homo sapiens,IC50
3471577,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254836,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
3471578,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254923,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
3471589,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254002,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
3471590,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254003,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
3471592,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254096,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
3471596,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254191,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
3471597,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254276,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
3471598,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254007,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
3503195,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1258821,=,nM,72.0,CHEMBL279,Homo sapiens,IC50
3503196,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257795,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
3503197,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257911,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
3503198,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257912,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
3504219,CHEMBL1260166,Inhibition of VEGFR2,B,CHEMBL1258913,=,nM,162.0,CHEMBL279,Homo sapiens,IC50
3504686,CHEMBL1261353,Inhibition of KDR autophosphorylation in HUVEC by Western blot analysis,B,CHEMBL1258603,=,nM,186.0,CHEMBL279,Homo sapiens,IC50
3518582,CHEMBL1274259,Inhibition of KDR phosphorylation in HUVEC,B,CHEMBL1269858,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
3521247,CHEMBL1272501,Inhibition of VEGFR2,B,CHEMBL1270399,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
3521772,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1169656,=,nM,134.6,CHEMBL279,Homo sapiens,IC50
3521773,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271559,=,nM,112.7,CHEMBL279,Homo sapiens,IC50
3521774,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269633,=,nM,124.6,CHEMBL279,Homo sapiens,IC50
3521775,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269634,=,nM,23.6,CHEMBL279,Homo sapiens,IC50
3521776,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271560,=,nM,16.5,CHEMBL279,Homo sapiens,IC50
3521777,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271615,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
3521778,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271616,=,nM,9.6,CHEMBL279,Homo sapiens,IC50
3521779,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271617,=,nM,26.5,CHEMBL279,Homo sapiens,IC50
3521780,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271667,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
3521781,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271668,=,nM,13.5,CHEMBL279,Homo sapiens,IC50
3521782,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269661,=,nM,84.9,CHEMBL279,Homo sapiens,IC50
3521783,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269662,=,nM,208.8,CHEMBL279,Homo sapiens,IC50
3521784,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269663,=,nM,107.2,CHEMBL279,Homo sapiens,IC50
3521785,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271669,=,nM,28.4,CHEMBL279,Homo sapiens,IC50
3521786,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271719,=,nM,325.6,CHEMBL279,Homo sapiens,IC50
3521787,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271720,=,nM,32.4,CHEMBL279,Homo sapiens,IC50
3521788,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271721,=,nM,72.8,CHEMBL279,Homo sapiens,IC50
3521789,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271780,=,nM,12.4,CHEMBL279,Homo sapiens,IC50
3521790,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271781,=,nM,23.4,CHEMBL279,Homo sapiens,IC50
3521791,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271782,=,nM,102.1,CHEMBL279,Homo sapiens,IC50
3521792,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269716,=,nM,88.5,CHEMBL279,Homo sapiens,IC50
3521793,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271836,=,nM,112.6,CHEMBL279,Homo sapiens,IC50
3521794,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271837,=,nM,32.7,CHEMBL279,Homo sapiens,IC50
3521841,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271838,=,nM,25.5,CHEMBL279,Homo sapiens,IC50
3526791,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL478629,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3526807,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271480,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
3526815,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271532,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3526823,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271533,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
3526831,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271641,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
3526839,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271642,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
3561688,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278146,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
3561689,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278147,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3561690,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278233,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
3561691,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278234,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
3561692,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276890,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
3561693,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276891,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
3561694,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276980,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
3561695,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276981,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
3561696,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277071,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
3561697,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277072,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
3561698,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277161,=,nM,112.0,CHEMBL279,Homo sapiens,IC50
3595742,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290471,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
3595743,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290361,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
3595744,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290362,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
3595745,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290470,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
3595746,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290247,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
3595747,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290246,=,nM,5.9,CHEMBL279,Homo sapiens,IC50
3595748,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290137,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
3595749,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290031,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
3595750,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290136,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
3595751,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290030,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
3595752,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289926,=,nM,0.25,CHEMBL279,Homo sapiens,IC50
3595754,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289925,=,nM,0.34,CHEMBL279,Homo sapiens,IC50
3595756,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289705,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
3595757,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL2079588,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
3595758,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL572881,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
3595759,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3595762,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289494,=,nM,0.16,CHEMBL279,Homo sapiens,IC50
3595763,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL491473,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
3601448,CHEMBL1292422,Inhibition of VEGFR2,B,CHEMBL1288582,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
5138169,CHEMBL1647901,Inhibition of KDR,B,CHEMBL1645476,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
5143827,CHEMBL1656202,Inhibition of KDR,B,CHEMBL1650545,=,nM,550.0,CHEMBL279,Homo sapiens,IC50
5143833,CHEMBL1656202,Inhibition of KDR,B,CHEMBL1650551,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
5152430,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL2012519,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
5152442,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651521,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
5152454,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651522,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
5152466,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651523,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
5203070,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668411,=,nM,0.49,CHEMBL279,Homo sapiens,IC50
5203071,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668413,=,nM,93000.0,CHEMBL279,Homo sapiens,IC50
5203073,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668415,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
5203074,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668416,=,nM,82000.0,CHEMBL279,Homo sapiens,IC50
5203075,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668417,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50
5203076,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668418,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
5203077,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668419,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
5203078,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668420,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
5236369,CHEMBL1686403,Inhibition of human recombinant His-tagged VEGFR2 assessed as infrared absorption by ELISA assay in presence of 20 uM ATP,B,CHEMBL1558704,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
5238775,CHEMBL1687577,Inhibition of KDR assessed as phosphorylation level of substrate by ELISA,B,CHEMBL1683339,=,nM,309.0,CHEMBL279,Homo sapiens,IC50
5248388,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681931,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
5248389,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681932,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
5248390,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681933,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
5248391,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681934,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
5248392,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681935,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
5248393,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681936,=,nM,168.0,CHEMBL279,Homo sapiens,IC50
5248394,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681937,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
5248395,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681938,=,nM,285.0,CHEMBL279,Homo sapiens,IC50
5248396,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681939,=,nM,759.0,CHEMBL279,Homo sapiens,IC50
5248397,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681940,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
5248398,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681941,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
5248399,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681942,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
5248400,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681943,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
5248401,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681944,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
5248402,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
5248403,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681946,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
5248404,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681947,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
5248405,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681948,=,nM,7.9,CHEMBL279,Homo sapiens,IC50
5248406,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681949,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
5248407,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681950,=,nM,3.3,CHEMBL279,Homo sapiens,IC50
5248408,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681951,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
5248409,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681952,=,nM,2.8,CHEMBL279,Homo sapiens,IC50
5248410,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681953,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
5248411,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681954,=,nM,10.3,CHEMBL279,Homo sapiens,IC50
5248412,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681955,=,nM,6.5,CHEMBL279,Homo sapiens,IC50
5248413,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681956,=,nM,2210.0,CHEMBL279,Homo sapiens,IC50
5248415,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681958,=,nM,152.0,CHEMBL279,Homo sapiens,IC50
5248417,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681960,=,nM,19700.0,CHEMBL279,Homo sapiens,IC50
5248418,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681961,=,nM,142.0,CHEMBL279,Homo sapiens,IC50
5248419,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681962,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
5248421,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681964,=,nM,142.0,CHEMBL279,Homo sapiens,IC50
5249844,CHEMBL1687367,inhibition of KDR,B,CHEMBL1684800,=,nM,9.42,CHEMBL279,Homo sapiens,IC50
5293780,CHEMBL1696440,Inhibition of VEGFR2,B,CHEMBL1688215,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
5293863,CHEMBL1697609,Inhibition of VEGFR2 after 60 mins by radiometric assay,B,CHEMBL1448,=,nM,23100.0,CHEMBL279,Homo sapiens,IC50
5294045,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688246,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
5294047,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688248,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
5294048,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688249,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
5294049,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688250,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50
5294050,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL204710,=,nM,1890.0,CHEMBL279,Homo sapiens,IC50
5294051,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1087349,=,nM,830.0,CHEMBL279,Homo sapiens,IC50
5294052,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688344,=,nM,3160.0,CHEMBL279,Homo sapiens,IC50
5294056,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688346,=,nM,3410.0,CHEMBL279,Homo sapiens,IC50
5294058,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL204754,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
5294061,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1087218,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
5294062,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL203642,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
5294065,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688350,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
5294066,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688351,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
5294067,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688352,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
5294068,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688353,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
5294069,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688354,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
5294070,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688355,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
5294071,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688356,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50
5294072,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688357,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
5310429,CHEMBL1693592,Inhibition of KDR,B,CHEMBL1688860,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
5310430,CHEMBL1693592,Inhibition of KDR,B,CHEMBL1688861,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
6151114,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762549,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
6151115,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762535,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
6151116,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762534,=,nM,989.0,CHEMBL279,Homo sapiens,IC50
6151117,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762532,=,nM,589.0,CHEMBL279,Homo sapiens,IC50
6151118,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762531,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
6151119,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762530,=,nM,818.0,CHEMBL279,Homo sapiens,IC50
6151120,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762529,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
6151121,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762528,=,nM,141.0,CHEMBL279,Homo sapiens,IC50
6151122,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762527,=,nM,231.0,CHEMBL279,Homo sapiens,IC50
6151123,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762526,=,nM,965.0,CHEMBL279,Homo sapiens,IC50
6151124,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762525,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
6151125,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762524,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
6151126,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762523,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
6151127,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762522,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
6151128,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762521,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
6154048,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL98798,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50
6154051,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1278148,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50
6154052,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277620,=,nM,1650.0,CHEMBL279,Homo sapiens,IC50
6154054,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1278149,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
6154057,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761929,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50
6154058,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761930,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
6154059,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761931,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
6154060,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761932,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
6154061,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761933,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
6154063,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277162,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
6154064,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761934,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50
6154068,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277253,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
6154070,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277254,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
6154071,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761936,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
6154072,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761937,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
6154073,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761938,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
6154074,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761939,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
6154075,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761940,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
6154076,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761941,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
6154077,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761942,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
6154078,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761943,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
6154079,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL205089,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
6154080,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761944,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
6154885,CHEMBL1762898,Inhibition of KDR,B,CHEMBL1762110,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50
6157555,CHEMBL1763568,Inhibition of KDR at 1 uM relative to control,B,CHEMBL1615182,=,nM,40000.0,CHEMBL279,Homo sapiens,IC50
6157888,CHEMBL1764784,Inhibition of KDR,B,CHEMBL1760035,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
6157889,CHEMBL1764784,Inhibition of KDR,B,CHEMBL1760057,=,nM,1370.0,CHEMBL279,Homo sapiens,IC50
6201869,CHEMBL1781088,Inhibition of KDR assessed as biotin-EGPWLEEEEEAYGWMDF peptide phosphorylation by TR-FRET assay,B,CHEMBL1779202,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
6219897,CHEMBL1785585,Inhibition of human VEGFR2 using poly[Glu:Tyr] by Hotspot assay,B,CHEMBL1784637,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
6268175,CHEMBL1805367,Inhibition of VEGFR2,B,CHEMBL1270795,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
6281542,CHEMBL1804195,Inhibition of human KDR,B,CHEMBL1822792,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
6286505,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807469,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
6286507,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807471,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
6286509,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807473,=,nM,2720.0,CHEMBL279,Homo sapiens,IC50
6286511,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807475,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
6286513,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807477,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
6286514,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807478,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
6286516,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807480,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
6286517,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807483,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
6286521,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807786,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
6302219,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807392,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
6302220,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807467,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
6307661,CHEMBL1816877,Inhibition of recombinant VEGF-R2 assessed as 33Pi incorporation after 60 mins by scintillation counting,B,CHEMBL466154,=,nM,11700.0,CHEMBL279,Homo sapiens,IC50
6307662,CHEMBL1816877,Inhibition of recombinant VEGF-R2 assessed as 33Pi incorporation after 60 mins by scintillation counting,B,CHEMBL454440,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
6310981,CHEMBL1816345,Inhibition of VEGFR2,B,CHEMBL558752,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
6339275,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1823220,=,nM,455.0,CHEMBL279,Homo sapiens,IC50
6339276,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1823219,=,nM,60.8,CHEMBL279,Homo sapiens,IC50
6339277,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1779201,=,nM,137.0,CHEMBL279,Homo sapiens,IC50
6386451,CHEMBL1837857,Inhibition of VEGFR2 juxtamembrane domain-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,B,CHEMBL1834657,=,nM,938.0,CHEMBL279,Homo sapiens,IC50
7847079,CHEMBL1912531,Inhibition of KDR,B,CHEMBL1910893,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
7847080,CHEMBL1912531,Inhibition of KDR,B,CHEMBL1910892,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50
7925717,CHEMBL1920332,Inhibition of KDR,B,CHEMBL1614710,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
7936848,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914676,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
7936849,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914686,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
7936854,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914911,=,nM,6580.0,CHEMBL279,Homo sapiens,IC50
7948012,CHEMBL1924443,Inhibition of KDR,B,CHEMBL1923983,=,nM,1490.0,CHEMBL279,Homo sapiens,IC50
7951438,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL1922224,=,nM,4950.0,CHEMBL279,Homo sapiens,IC50
7951439,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL518060,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50
7951440,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL1922225,=,nM,4850.0,CHEMBL279,Homo sapiens,IC50
7951441,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL456936,=,nM,6010.0,CHEMBL279,Homo sapiens,IC50
7951442,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL517956,=,nM,4350.0,CHEMBL279,Homo sapiens,IC50
7959820,CHEMBL1932884,Inhibition of KDR,B,CHEMBL103667,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
7968520,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929552,=,nM,5080.0,CHEMBL279,Homo sapiens,IC50
7968521,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929553,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
7968522,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929554,=,nM,32100.0,CHEMBL279,Homo sapiens,IC50
7968523,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929555,=,nM,620.0,CHEMBL279,Homo sapiens,IC50
7968524,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929556,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
7968525,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929557,=,nM,56700.0,CHEMBL279,Homo sapiens,IC50
7987189,CHEMBL1935944,Inhibition of VEGFR2,B,CHEMBL1933552,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50
7991125,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934320,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
7991126,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934321,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
7991127,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934322,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
7991128,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934323,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
7991129,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934324,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
7991130,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934325,=,nM,237.0,CHEMBL279,Homo sapiens,IC50
7991131,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934326,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
7991132,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934327,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
7991133,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934328,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
7991134,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934329,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
7991135,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934330,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
7991136,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934331,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
7991137,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934332,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
7991138,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1933080,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
7991139,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934333,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
7997492,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940181,=,nM,186.0,CHEMBL279,Homo sapiens,IC50
7997494,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940180,=,nM,759.0,CHEMBL279,Homo sapiens,IC50
7997495,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1738797,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
7997497,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940179,=,nM,3124.0,CHEMBL279,Homo sapiens,IC50
7997498,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940178,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50
7997501,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940175,=,nM,2521.0,CHEMBL279,Homo sapiens,IC50
7997502,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940174,=,nM,882.0,CHEMBL279,Homo sapiens,IC50
8001414,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940718,=,nM,287.28,CHEMBL279,Homo sapiens,IC50
8001415,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940841,=,nM,184.53,CHEMBL279,Homo sapiens,IC50
8001416,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1938421,=,nM,169.17,CHEMBL279,Homo sapiens,IC50
8001417,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940842,=,nM,176.24,CHEMBL279,Homo sapiens,IC50
8001418,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940843,=,nM,453.41,CHEMBL279,Homo sapiens,IC50
8001419,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940844,=,nM,87.11,CHEMBL279,Homo sapiens,IC50
8001420,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940845,=,nM,107.23,CHEMBL279,Homo sapiens,IC50
8001421,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940846,=,nM,81.43,CHEMBL279,Homo sapiens,IC50
8001422,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940847,=,nM,129.26,CHEMBL279,Homo sapiens,IC50
8001423,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940848,=,nM,112.52,CHEMBL279,Homo sapiens,IC50
8001424,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940849,=,nM,154.27,CHEMBL279,Homo sapiens,IC50
8001425,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940850,=,nM,207.51,CHEMBL279,Homo sapiens,IC50
8001426,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940851,=,nM,157.21,CHEMBL279,Homo sapiens,IC50
8001427,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940852,=,nM,139.36,CHEMBL279,Homo sapiens,IC50
8001428,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940853,=,nM,129.54,CHEMBL279,Homo sapiens,IC50
8001429,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940854,=,nM,561.29,CHEMBL279,Homo sapiens,IC50
8001430,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940855,=,nM,82.71,CHEMBL279,Homo sapiens,IC50
8001431,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940856,=,nM,92.23,CHEMBL279,Homo sapiens,IC50
8001432,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940857,=,nM,73.41,CHEMBL279,Homo sapiens,IC50
8001433,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940858,=,nM,112.26,CHEMBL279,Homo sapiens,IC50
8001434,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940859,=,nM,103.82,CHEMBL279,Homo sapiens,IC50
8001435,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940860,=,nM,148.31,CHEMBL279,Homo sapiens,IC50
8001436,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940861,=,nM,389.16,CHEMBL279,Homo sapiens,IC50
8001437,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940862,=,nM,267.27,CHEMBL279,Homo sapiens,IC50
8001438,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940863,=,nM,232.78,CHEMBL279,Homo sapiens,IC50
8001439,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940864,=,nM,261.88,CHEMBL279,Homo sapiens,IC50
8001441,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940866,=,nM,129.56,CHEMBL279,Homo sapiens,IC50
8001442,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940867,=,nM,189.07,CHEMBL279,Homo sapiens,IC50
8001443,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940868,=,nM,357.81,CHEMBL279,Homo sapiens,IC50
8001444,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940869,=,nM,312.98,CHEMBL279,Homo sapiens,IC50
8001445,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940870,=,nM,367.32,CHEMBL279,Homo sapiens,IC50
8001446,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940871,=,nM,481.97,CHEMBL279,Homo sapiens,IC50
8013110,CHEMBL1948129,Inhibition of KDR using ATP as substrate,B,CHEMBL1945559,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50
8020216,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945804,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
8020217,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945803,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
8020218,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945801,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
8020219,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945502,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
8020220,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945501,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
8020221,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945499,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
8020222,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945498,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
8020223,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945497,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
8020224,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945173,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
8020225,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945172,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
8020226,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945171,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
8020227,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945170,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
8023574,CHEMBL1948267,Inhibition of VEGFR2,B,CHEMBL1946171,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
8039801,CHEMBL1952837,Inhibition of human recombinant EE-tagged intracellular domain of KDR using biotin-EEEEYFELVAKKKK as substrate by HTRF assay,B,CHEMBL1952210,=,nM,44.0,CHEMBL279,Homo sapiens,IC50
8039889,CHEMBL1952837,Inhibition of human recombinant EE-tagged intracellular domain of KDR using biotin-EEEEYFELVAKKKK as substrate by HTRF assay,B,CHEMBL1952211,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
8058302,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL514014,=,nM,9420.0,CHEMBL279,Homo sapiens,IC50
8058303,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1956885,=,nM,8280.0,CHEMBL279,Homo sapiens,IC50
8058304,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1956887,=,nM,5970.0,CHEMBL279,Homo sapiens,IC50
8058367,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956889,=,nM,113400.0,CHEMBL279,Homo sapiens,IC50
8058368,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956891,=,nM,65300.0,CHEMBL279,Homo sapiens,IC50
8058369,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956894,=,nM,64500.0,CHEMBL279,Homo sapiens,IC50
8058370,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956898,=,nM,25700.0,CHEMBL279,Homo sapiens,IC50
8058371,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956888,=,nM,23800.0,CHEMBL279,Homo sapiens,IC50
8058372,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956897,=,nM,22900.0,CHEMBL279,Homo sapiens,IC50
8058373,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956896,=,nM,22900.0,CHEMBL279,Homo sapiens,IC50
8058374,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956890,=,nM,17900.0,CHEMBL279,Homo sapiens,IC50
8058375,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956895,=,nM,14900.0,CHEMBL279,Homo sapiens,IC50
8060124,CHEMBL1961229,"Inhibition of human recombinant VEGF-R2 expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting",B,CHEMBL6246,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
10842341,CHEMBL2013786,Inhibition of KDR,B,CHEMBL2012881,=,nM,319.0,CHEMBL279,Homo sapiens,IC50
10843924,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010876,=,nM,271.0,CHEMBL279,Homo sapiens,IC50
10843925,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010878,=,nM,256.0,CHEMBL279,Homo sapiens,IC50
10843926,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2011061,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
10843927,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010875,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
10843928,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010873,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
10843929,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010877,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
10843930,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010869,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
10843931,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010871,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10843932,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010872,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10843933,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010870,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10844840,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011305,=,nM,27000.0,CHEMBL279,Homo sapiens,IC50
10844841,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011304,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
10844842,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011303,=,nM,87000.0,CHEMBL279,Homo sapiens,IC50
10844843,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011302,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50
10844844,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011301,=,nM,48000.0,CHEMBL279,Homo sapiens,IC50
10844846,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011299,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50
10844847,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011298,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50
10844848,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011297,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
10844849,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011296,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
10844850,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011295,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
10844851,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011294,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
10844852,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011293,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
10844853,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011292,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50
10844854,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011291,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
10855861,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL94191,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50
10855862,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL328106,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
10855865,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018745,=,nM,7300.0,CHEMBL279,Homo sapiens,IC50
10855866,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018746,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50
10855867,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018747,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
10855870,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018748,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
10855871,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018749,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
10855872,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018750,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50
10855873,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018751,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50
10855874,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018752,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
10855875,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018753,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
10855876,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018754,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
10855877,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018755,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
10855878,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018756,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
10855879,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018757,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
10855880,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018758,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
10855881,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018759,=,nM,5250.0,CHEMBL279,Homo sapiens,IC50
10855882,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018760,=,nM,5550.0,CHEMBL279,Homo sapiens,IC50
10855883,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018761,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
10855884,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018762,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
10855885,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2016600,=,nM,4650.0,CHEMBL279,Homo sapiens,IC50
10855886,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018763,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50
10855888,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018764,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50
10855890,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018765,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50
10855891,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018766,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
10855892,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018767,=,nM,6450.0,CHEMBL279,Homo sapiens,IC50
10855893,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018768,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
10855894,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018769,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50
10855895,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018770,=,nM,6950.0,CHEMBL279,Homo sapiens,IC50
10855896,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018771,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50
10855897,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018772,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
10855898,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018773,=,nM,7450.0,CHEMBL279,Homo sapiens,IC50
10855899,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018774,=,nM,7250.0,CHEMBL279,Homo sapiens,IC50
10855900,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018775,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50
10855901,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018776,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50
10855902,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018777,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
10855903,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018878,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50
10855904,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018879,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50
10855907,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018880,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50
10855920,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018881,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
10855921,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018882,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10855922,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018883,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
10855923,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018884,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10855924,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018885,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10855925,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018886,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10858871,CHEMBL2020689,Inhibition of VEGFR-2 kinase,B,CHEMBL2016894,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
10858874,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016895,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
10858875,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016896,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
10858876,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016897,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
10858877,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016898,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
10858878,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016899,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
10858879,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016900,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
10858880,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016901,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
10858881,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016902,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
10858882,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016903,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
10858883,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016904,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
10858884,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016905,=,nM,4.9,CHEMBL279,Homo sapiens,IC50
10858885,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016906,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
10858886,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016907,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
10858887,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016908,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
10858888,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016909,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
10858889,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016910,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
10858890,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016911,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
10858891,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016912,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
10858892,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016913,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50
10858893,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016914,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
10858894,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016915,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
10858895,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016916,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
10858896,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016917,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
10858897,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016918,=,nM,740.0,CHEMBL279,Homo sapiens,IC50
10858898,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016919,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
10858899,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016920,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
10858900,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016921,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
10858901,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016922,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
10858902,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016923,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
10858903,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016924,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
10858904,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016925,=,nM,6.7,CHEMBL279,Homo sapiens,IC50
10858905,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016926,=,nM,8.6,CHEMBL279,Homo sapiens,IC50
10858906,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016927,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
10858907,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016928,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
10858908,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016929,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
10862655,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023220,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862656,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1979883,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
10862657,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023221,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10862659,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023222,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
10862660,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023223,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
10862661,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2021941,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10862662,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023224,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862663,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1969102,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10862664,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1967116,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862665,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023225,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10862666,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1982466,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862667,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023226,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862668,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023227,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862669,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1970317,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862670,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023228,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
10862671,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023229,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
10862672,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023230,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862673,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023231,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862674,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023232,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862675,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022850,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10862676,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1993941,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
10862677,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022851,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
10862678,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022852,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
10862679,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022853,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
10862680,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022854,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10862681,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022855,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10862682,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1980297,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10862683,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022856,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10862684,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022857,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10868262,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023485,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10868268,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023486,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10868282,CHEMBL2027406,Inhibition of KDR,B,CHEMBL1940274,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
10868289,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023476,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
10868290,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023482,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
10868294,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023494,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
10868302,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023118,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
10868305,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023117,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
10868311,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023490,=,nM,183.0,CHEMBL279,Homo sapiens,IC50
10868317,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023800,=,nM,245.0,CHEMBL279,Homo sapiens,IC50
10868322,CHEMBL2027406,Inhibition of KDR,B,CHEMBL1940275,=,nM,485.0,CHEMBL279,Homo sapiens,IC50
10868327,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023483,=,nM,515.0,CHEMBL279,Homo sapiens,IC50
10868335,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023484,=,nM,1277.0,CHEMBL279,Homo sapiens,IC50
10868337,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023478,=,nM,1624.0,CHEMBL279,Homo sapiens,IC50
10868340,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023477,=,nM,1919.0,CHEMBL279,Homo sapiens,IC50
10868342,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023119,=,nM,2073.0,CHEMBL279,Homo sapiens,IC50
10868343,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023492,=,nM,2481.0,CHEMBL279,Homo sapiens,IC50
10868352,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023488,=,nM,3954.0,CHEMBL279,Homo sapiens,IC50
10868353,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023475,=,nM,4066.0,CHEMBL279,Homo sapiens,IC50
10868354,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023474,=,nM,4282.0,CHEMBL279,Homo sapiens,IC50
10868356,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023495,=,nM,4718.0,CHEMBL279,Homo sapiens,IC50
10868357,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023116,=,nM,4773.0,CHEMBL279,Homo sapiens,IC50
10868358,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023802,=,nM,4819.0,CHEMBL279,Homo sapiens,IC50
10868375,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023489,=,nM,10990.0,CHEMBL279,Homo sapiens,IC50
10870915,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL1739550,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
10870916,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022369,=,nM,234.0,CHEMBL279,Homo sapiens,IC50
10870917,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022373,=,nM,481.0,CHEMBL279,Homo sapiens,IC50
10870918,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022379,=,nM,108.0,CHEMBL279,Homo sapiens,IC50
10870919,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022711,=,nM,253.0,CHEMBL279,Homo sapiens,IC50
10889085,CHEMBL2032454,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL2031893,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
10912552,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036871,=,nM,85000.0,CHEMBL279,Homo sapiens,IC50
10913462,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036725,=,nM,13400.0,CHEMBL279,Homo sapiens,IC50
10913478,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036726,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50
10913494,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036727,=,nM,38000.0,CHEMBL279,Homo sapiens,IC50
10913510,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036728,=,nM,69000.0,CHEMBL279,Homo sapiens,IC50
10913542,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036868,=,nM,44000.0,CHEMBL279,Homo sapiens,IC50
10913558,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036869,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
10913563,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036870,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
10913568,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036865,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50
10913573,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036866,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50
10913588,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL1200485,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
10942457,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL2046839,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
10942458,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL2046840,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
10944940,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047253,=,nM,197100.0,CHEMBL279,Homo sapiens,IC50
10944941,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047252,=,nM,72900.0,CHEMBL279,Homo sapiens,IC50
10944942,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047251,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50
10944944,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047249,=,nM,30100.0,CHEMBL279,Homo sapiens,IC50
10944947,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047242,=,nM,133900.0,CHEMBL279,Homo sapiens,IC50
10944948,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047241,=,nM,89300.0,CHEMBL279,Homo sapiens,IC50
10944949,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047246,=,nM,55700.0,CHEMBL279,Homo sapiens,IC50
10944950,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047245,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
10944952,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047243,=,nM,171200.0,CHEMBL279,Homo sapiens,IC50
10960297,CHEMBL2061196,Inhibition of human VEGFR2 by fluorescence-based electrophoretic mobility-shift assay,B,CHEMBL2058042,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
10974332,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063319,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
10974333,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063318,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
10974334,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063320,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
10974336,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063321,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
10974337,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063322,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
10974338,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063323,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
10974339,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063324,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
10974340,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063325,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
10974341,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063326,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
10974342,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063327,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
10974343,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063328,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
10974346,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063331,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
10974347,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063332,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
10974350,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063335,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
10974353,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063338,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
10974356,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063436,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
10974357,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL576982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
10975686,CHEMBL2064937,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL1990583,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50
10986018,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL1614709,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
10986019,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071194,=,nM,329.0,CHEMBL279,Homo sapiens,IC50
10986021,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071196,=,nM,467.0,CHEMBL279,Homo sapiens,IC50
10986022,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071197,=,nM,922.0,CHEMBL279,Homo sapiens,IC50
10986023,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071198,=,nM,1540.0,CHEMBL279,Homo sapiens,IC50
10986024,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071199,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
10986025,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071200,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
10986026,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071201,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
10986027,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071202,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
10986028,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071203,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
10986029,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071204,=,nM,827.0,CHEMBL279,Homo sapiens,IC50
10986030,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071205,=,nM,264.0,CHEMBL279,Homo sapiens,IC50
10986031,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071206,=,nM,68.0,CHEMBL279,Homo sapiens,IC50
10986032,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071207,=,nM,292.0,CHEMBL279,Homo sapiens,IC50
10986033,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071208,=,nM,266.0,CHEMBL279,Homo sapiens,IC50
10986034,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071209,=,nM,431.0,CHEMBL279,Homo sapiens,IC50
10986035,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071210,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
10986036,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071211,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
10986037,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071212,=,nM,693.0,CHEMBL279,Homo sapiens,IC50
10986038,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071213,=,nM,169.0,CHEMBL279,Homo sapiens,IC50
10986039,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071214,=,nM,246.0,CHEMBL279,Homo sapiens,IC50
10986040,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071215,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
10986041,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071216,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
10986042,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071217,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
10986043,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071270,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10986044,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071271,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
10986045,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071272,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
10986046,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071273,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
10986047,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071274,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
10986048,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071275,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10986049,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071276,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
10986050,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071277,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
10988660,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL1929485,=,nM,620.0,CHEMBL279,Homo sapiens,IC50
10988661,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069624,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
10988662,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069625,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50
10993476,CHEMBL2073059,Inhibition of VEGFR2 expressed in porcine aortic endothelial cells,B,CHEMBL411043,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
11019246,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086744,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
11019247,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086397,=,nM,128.0,CHEMBL279,Homo sapiens,IC50
11019248,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086745,=,nM,1804.0,CHEMBL279,Homo sapiens,IC50
11019249,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086747,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50
11019250,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086748,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50
11019251,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086749,=,nM,213.0,CHEMBL279,Homo sapiens,IC50
11019252,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086750,=,nM,496.0,CHEMBL279,Homo sapiens,IC50
11019253,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086751,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
11019254,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086752,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
11019257,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086755,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
11019260,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086758,=,nM,235.0,CHEMBL279,Homo sapiens,IC50
11019261,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086759,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
11019262,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086760,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
11019263,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087167,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
11019264,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087168,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
11019265,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087169,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
11020090,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086721,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
11020091,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086722,=,nM,119.0,CHEMBL279,Homo sapiens,IC50
11020092,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086723,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
11020093,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086724,=,nM,633.0,CHEMBL279,Homo sapiens,IC50
11020094,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086725,=,nM,125.0,CHEMBL279,Homo sapiens,IC50
11020095,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086726,=,nM,106.0,CHEMBL279,Homo sapiens,IC50
11020096,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086727,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
11020097,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086728,=,nM,19903.0,CHEMBL279,Homo sapiens,IC50
11020098,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086729,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50
11020099,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086730,=,nM,327.0,CHEMBL279,Homo sapiens,IC50
11020100,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086731,=,nM,9876.0,CHEMBL279,Homo sapiens,IC50
11020101,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086732,=,nM,68.0,CHEMBL279,Homo sapiens,IC50
11020102,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086733,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
11020103,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086734,=,nM,4880.0,CHEMBL279,Homo sapiens,IC50
11020104,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086735,=,nM,4880.0,CHEMBL279,Homo sapiens,IC50
11020105,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086736,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
11020106,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086737,=,nM,213.0,CHEMBL279,Homo sapiens,IC50
11020107,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086738,=,nM,23633.0,CHEMBL279,Homo sapiens,IC50
11020108,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086739,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
11020109,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086740,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
11020110,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086741,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
11020111,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086742,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
11020112,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086743,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
11020116,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086746,=,nM,1134.0,CHEMBL279,Homo sapiens,IC50
11020123,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086753,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
11020124,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086754,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
11020126,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086756,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
11020127,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086757,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
12085693,CHEMBL2168091,Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis,B,CHEMBL685,=,nM,8800.0,CHEMBL279,Homo sapiens,IC50
12138517,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180602,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
12138526,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180603,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
12138532,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180604,=,nM,0.95,CHEMBL279,Homo sapiens,IC50
12138535,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL587723,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
12138552,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180605,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
12138559,CHEMBL2186465,Inhibition of VEGFR2 phosphorylation in HUVEC,B,CHEMBL1230609,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
12150570,CHEMBL2188507,Inhibition of human recombinant VEGFR2 by radiometric kinase assay,B,CHEMBL2178352,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
12152536,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180882,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
12152537,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180881,=,nM,373.0,CHEMBL279,Homo sapiens,IC50
12152538,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2177142,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
12152539,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180878,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
12175203,CHEMBL2210729,Inhibition of VEGFR2 in HUVEC assessed as reduction of VGF-stimulated cell proliferation after 5 days,B,CHEMBL2204532,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
12175224,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204533,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
12175226,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204531,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
12175227,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204530,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
12175228,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204529,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
12175229,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204528,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
12175230,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204527,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
12175231,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204526,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
12187782,CHEMBL2208529,Inhibition of VEGFR2,B,CHEMBL1235529,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
12191219,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206668,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
12191220,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206667,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
12191221,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206666,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
12191222,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206665,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
12191224,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2203321,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
12191225,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206663,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
12191226,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206662,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
12191227,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206661,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
12193800,CHEMBL2212841,Inhibition of KDR,B,CHEMBL2208034,=,nM,483.6,CHEMBL279,Homo sapiens,IC50
12201569,CHEMBL2211750,Inhibition of KDR,B,CHEMBL2208237,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50
12205591,CHEMBL2216951,"Inhibition of human recombinant VEGFR2 expressed in Sf9 insect cells assessed as inhibition of poly(Glu,Tyr) 4:1 substrate phosphorylation by radiometric assay",B,CHEMBL2216905,=,nM,80000.0,CHEMBL279,Homo sapiens,IC50
12205592,CHEMBL2216951,"Inhibition of human recombinant VEGFR2 expressed in Sf9 insect cells assessed as inhibition of poly(Glu,Tyr) 4:1 substrate phosphorylation by radiometric assay",B,CHEMBL2216906,=,nM,22500.0,CHEMBL279,Homo sapiens,IC50
12627682,CHEMBL2317039,Inhibition of VEGFR2/FLK1 (unknown origin),B,CHEMBL2312304,=,nM,15960.0,CHEMBL279,Homo sapiens,IC50
12627683,CHEMBL2317039,Inhibition of VEGFR2/FLK1 (unknown origin),B,CHEMBL2312303,=,nM,13310.0,CHEMBL279,Homo sapiens,IC50
12656065,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325101,=,nM,1830.0,CHEMBL279,Homo sapiens,IC50
12656066,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325100,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50
12656067,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325092,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
12656068,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325087,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
12656069,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2324873,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
12656070,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325106,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
12656875,CHEMBL2327153,Inhibition of KDR (unknown origin),B,CHEMBL1980391,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
12658078,CHEMBL2327153,Inhibition of KDR (unknown origin),B,CHEMBL2322701,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
12658663,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322139,=,nM,720.0,CHEMBL279,Homo sapiens,IC50
12658664,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2159198,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
12658665,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322138,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50
12659908,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322134,=,nM,910.0,CHEMBL279,Homo sapiens,IC50
12659909,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322143,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
12659910,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322142,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
12659911,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322141,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
12659912,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322137,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
12659913,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322136,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
12659914,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322135,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
12674105,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2333163,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
12674106,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL505637,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
12674107,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL360190,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
12675494,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2332840,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
12675495,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2331570,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
12675496,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2332849,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
12684844,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337372,=,nM,41000.0,CHEMBL279,Homo sapiens,IC50
12684845,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337371,=,nM,31200.0,CHEMBL279,Homo sapiens,IC50
12684846,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337370,=,nM,89100.0,CHEMBL279,Homo sapiens,IC50
12684847,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337369,=,nM,21300.0,CHEMBL279,Homo sapiens,IC50
12684848,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337368,=,nM,47800.0,CHEMBL279,Homo sapiens,IC50
12684849,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337367,=,nM,192000.0,CHEMBL279,Homo sapiens,IC50
12684850,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337366,=,nM,70100.0,CHEMBL279,Homo sapiens,IC50
12684851,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337365,=,nM,86100.0,CHEMBL279,Homo sapiens,IC50
12684852,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337364,=,nM,38900.0,CHEMBL279,Homo sapiens,IC50
12684853,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337363,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50
12684854,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337362,=,nM,30300.0,CHEMBL279,Homo sapiens,IC50
12684855,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337374,=,nM,123800.0,CHEMBL279,Homo sapiens,IC50
12692762,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335019,=,nM,150900.0,CHEMBL279,Homo sapiens,IC50
12692764,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335017,=,nM,125600.0,CHEMBL279,Homo sapiens,IC50
12692766,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335014,=,nM,124500.0,CHEMBL279,Homo sapiens,IC50
12692771,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335016,=,nM,89300.0,CHEMBL279,Homo sapiens,IC50
12692774,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335376,=,nM,49900.0,CHEMBL279,Homo sapiens,IC50
12692775,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335379,=,nM,43600.0,CHEMBL279,Homo sapiens,IC50
12692779,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335377,=,nM,24100.0,CHEMBL279,Homo sapiens,IC50
12692784,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335018,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50
12692785,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335013,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50
12697488,CHEMBL2343630,Inhibition of KDR (unknown origin) after 20 mins by scintillation counting,B,CHEMBL2332119,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
12700076,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL2036343,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
12700088,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL2338333,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
12700101,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL574646,=,nM,660.0,CHEMBL279,Homo sapiens,IC50
12700163,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL379849,=,nM,770.0,CHEMBL279,Homo sapiens,IC50
12718786,CHEMBL2350670,Inhibition of KDR (unknown origin) after 10 mins by mobility shift assay,B,CHEMBL2347053,=,nM,7.7,CHEMBL279,Homo sapiens,IC50
12730658,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348989,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
12730661,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348996,=,nM,0.19,CHEMBL279,Homo sapiens,IC50
12730678,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348990,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
12730679,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348991,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
12730680,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348992,=,nM,5.1,CHEMBL279,Homo sapiens,IC50
12730681,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348993,=,nM,4.7,CHEMBL279,Homo sapiens,IC50
12730682,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348994,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
12730684,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349012,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
12730685,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348995,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
12730687,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348997,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
12730688,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348998,=,nM,0.96,CHEMBL279,Homo sapiens,IC50
12730689,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348999,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
12730690,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349000,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
12730691,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349001,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
12730692,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349002,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
12730693,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349003,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
12730694,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349004,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
12730695,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349005,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
12730696,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349006,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
12730697,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349007,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
12730698,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349008,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
12730699,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349010,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
12730700,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349009,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
12730701,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349011,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
13293931,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377495,=,nM,45200.0,CHEMBL279,Homo sapiens,IC50
13293932,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377475,=,nM,26200.0,CHEMBL279,Homo sapiens,IC50
13294809,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377456,=,nM,15300.0,CHEMBL279,Homo sapiens,IC50
13294810,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377476,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50
13294811,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377479,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
13294812,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377464,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50
13307690,CHEMBL2382765,Inhibition of human recombinant VEGFR2 expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 to 60 mins by fluorescence assay,B,CHEMBL2381858,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
13320099,CHEMBL2388734,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL574125,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
13320106,CHEMBL2390320,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL2385195,=,nM,15.37,CHEMBL279,Homo sapiens,IC50
13321800,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL502351,=,nM,19700.0,CHEMBL279,Homo sapiens,IC50
13321809,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385582,=,nM,5330.0,CHEMBL279,Homo sapiens,IC50
13321811,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL511563,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
13321822,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385591,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50
13321825,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385596,=,nM,1520.0,CHEMBL279,Homo sapiens,IC50
13321843,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL513147,=,nM,214.7,CHEMBL279,Homo sapiens,IC50
13322787,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385586,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
13322789,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385600,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
13322793,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385579,=,nM,1.68,CHEMBL279,Homo sapiens,IC50
13327787,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2105709,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
13327788,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386810,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
13327789,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386809,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
13327790,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386808,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
13327791,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386807,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
13327792,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386806,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13327793,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386805,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
13327794,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386804,=,nM,620.0,CHEMBL279,Homo sapiens,IC50
13327795,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386803,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
13327796,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386802,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
13327797,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386801,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
13327798,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386800,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
13327799,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386799,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
13327800,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386798,=,nM,82.0,CHEMBL279,Homo sapiens,IC50
13327801,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386797,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
13327802,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386796,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
13327803,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386795,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
13327804,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386794,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13327805,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386793,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
13327806,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386792,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13327808,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386790,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
13327809,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386789,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13327810,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386788,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
13327811,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386818,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
13327812,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386817,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
13327813,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386816,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
13327815,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386814,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
13327816,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386813,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
13327817,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386812,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
13330068,CHEMBL2389574,Inhibition of KDR (unknown origin),B,CHEMBL2386994,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50
13365810,CHEMBL2405542,Inhibition of TEL-fused KDR (unknown origin) by cell-based assay,B,CHEMBL2403108,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50
13372341,CHEMBL2406470,Inhibition of KDR autophosphorylation in HUVEC,B,CHEMBL2401832,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
13379768,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403378,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
13379769,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403377,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
13379770,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403376,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
13379771,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403375,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
13379772,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403374,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
13379773,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403373,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
13379774,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403372,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
13379775,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403371,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
13379776,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403370,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
13379777,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403369,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
13379778,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403368,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
13379779,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403367,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
13379780,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403366,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
13389894,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409778,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
13389899,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409790,=,nM,3.6,CHEMBL279,Homo sapiens,IC50
13389921,CHEMBL2410829,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate preincubated for 60 mins followed by ATP addition measured after overnight incubation under dark condition by AlphaScreen assay,B,CHEMBL2409789,=,nM,3.1,CHEMBL279,Homo sapiens,IC50
13389998,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409788,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
13389999,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409787,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
13390000,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409786,=,nM,1.9,CHEMBL279,Homo sapiens,IC50
13390001,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409785,=,nM,0.48,CHEMBL279,Homo sapiens,IC50
13390002,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409784,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
13390003,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409783,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
13390004,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409782,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
13390005,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409781,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
13390006,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409780,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
13390007,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409779,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
13390008,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409777,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
13390009,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409776,=,nM,1.9,CHEMBL279,Homo sapiens,IC50
13390010,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409775,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
13392461,CHEMBL2411325,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA",B,CHEMBL598022,=,nM,27640.0,CHEMBL279,Homo sapiens,IC50
13392462,CHEMBL2411325,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA",B,CHEMBL598852,=,nM,48940.0,CHEMBL279,Homo sapiens,IC50
13395045,CHEMBL2410112,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407900,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
13396517,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408732,=,nM,19900.0,CHEMBL279,Homo sapiens,IC50
13396519,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408615,=,nM,18300.0,CHEMBL279,Homo sapiens,IC50
13396525,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408613,=,nM,8200.0,CHEMBL279,Homo sapiens,IC50
13396539,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408617,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
13396563,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408614,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
13396564,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408610,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
13414490,CHEMBL2422323,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2419760,=,nM,848.0,CHEMBL279,Homo sapiens,IC50
13433373,CHEMBL2421431,"Inhibition of KDR (unknown origin) using poly(Glu,Tyr) as substrate after 30 mins by HTRF assay",B,CHEMBL2419669,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
13461941,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430253,=,nM,11.8,CHEMBL279,Homo sapiens,IC50
13461942,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430252,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
13461943,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430251,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
13461944,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430250,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
13461945,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430249,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
13461946,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430248,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
13461947,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430247,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
13461948,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430198,=,nM,11.4,CHEMBL279,Homo sapiens,IC50
13461949,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430262,=,nM,1.1,CHEMBL279,Homo sapiens,IC50
13461950,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430261,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
13461951,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430260,=,nM,9.7,CHEMBL279,Homo sapiens,IC50
13461952,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430259,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
13461953,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430258,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
13461954,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430257,=,nM,112.4,CHEMBL279,Homo sapiens,IC50
13461955,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430256,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
13461956,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2429872,=,nM,330.3,CHEMBL279,Homo sapiens,IC50
13461957,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430255,=,nM,167.2,CHEMBL279,Homo sapiens,IC50
13461958,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430254,=,nM,25.7,CHEMBL279,Homo sapiens,IC50
13461959,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430267,=,nM,24.6,CHEMBL279,Homo sapiens,IC50
13461960,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430266,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
13461961,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430265,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
13461962,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430264,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
13461964,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430263,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
13484278,CHEMBL2437776,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) (4:1) as substrate after 30 mins by spectrophotometric analysis",B,CHEMBL2435999,=,nM,531.9,CHEMBL279,Homo sapiens,IC50
13846453,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093579,=,nM,0.54,CHEMBL279,Homo sapiens,IC50
13846454,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093581,=,nM,0.14,CHEMBL279,Homo sapiens,IC50
13846455,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093582,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
13846456,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093584,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
13846457,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093583,=,nM,0.42,CHEMBL279,Homo sapiens,IC50
13846458,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093585,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
13846459,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093587,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
13846507,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093586,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
13846508,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093588,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13867566,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099455,=,nM,81.2,CHEMBL279,Homo sapiens,IC50
13867567,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099482,=,nM,129.0,CHEMBL279,Homo sapiens,IC50
13867568,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099481,=,nM,40.9,CHEMBL279,Homo sapiens,IC50
13867570,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099479,=,nM,14.3,CHEMBL279,Homo sapiens,IC50
13868167,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098312,=,nM,43300.0,CHEMBL279,Homo sapiens,IC50
13868168,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098319,=,nM,39300.0,CHEMBL279,Homo sapiens,IC50
13868172,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098318,=,nM,26900.0,CHEMBL279,Homo sapiens,IC50
13868173,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098313,=,nM,23400.0,CHEMBL279,Homo sapiens,IC50
13868176,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL525527,=,nM,7790.0,CHEMBL279,Homo sapiens,IC50
13868179,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098322,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
13868180,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098326,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
13868182,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098325,=,nM,1170.0,CHEMBL279,Homo sapiens,IC50
13868183,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098317,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50
13868185,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098321,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
13868189,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099476,=,nM,33.3,CHEMBL279,Homo sapiens,IC50
13868190,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099475,=,nM,23.9,CHEMBL279,Homo sapiens,IC50
13868191,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099474,=,nM,69.9,CHEMBL279,Homo sapiens,IC50
13868193,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099472,=,nM,17.6,CHEMBL279,Homo sapiens,IC50
13868194,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099471,=,nM,16.7,CHEMBL279,Homo sapiens,IC50
13868195,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099470,=,nM,71.4,CHEMBL279,Homo sapiens,IC50
13868197,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099469,=,nM,23.8,CHEMBL279,Homo sapiens,IC50
13868199,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099467,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
13868200,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099466,=,nM,5.26,CHEMBL279,Homo sapiens,IC50
13868201,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099465,=,nM,4.55,CHEMBL279,Homo sapiens,IC50
13868202,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099464,=,nM,128.0,CHEMBL279,Homo sapiens,IC50
13868204,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099462,=,nM,4.06,CHEMBL279,Homo sapiens,IC50
13868206,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099460,=,nM,179.0,CHEMBL279,Homo sapiens,IC50
13868207,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099459,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
13868208,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099458,=,nM,17.5,CHEMBL279,Homo sapiens,IC50
13878344,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL50,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
13878346,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104855,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
13878347,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104854,=,nM,5960.0,CHEMBL279,Homo sapiens,IC50
13878349,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104852,=,nM,26400.0,CHEMBL279,Homo sapiens,IC50
13878350,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104851,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
13890716,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109337,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
13890717,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109356,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
13890718,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109338,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
13890720,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109355,=,nM,206.0,CHEMBL279,Homo sapiens,IC50
13890721,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109354,=,nM,215.0,CHEMBL279,Homo sapiens,IC50
13890722,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109353,=,nM,173.0,CHEMBL279,Homo sapiens,IC50
13890723,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109352,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
13890724,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109351,=,nM,475.0,CHEMBL279,Homo sapiens,IC50
13890725,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109350,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
13890726,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109349,=,nM,718.0,CHEMBL279,Homo sapiens,IC50
13890727,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109348,=,nM,203.0,CHEMBL279,Homo sapiens,IC50
13890728,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109347,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
13890730,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109345,=,nM,166.0,CHEMBL279,Homo sapiens,IC50
13890731,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109344,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
13890732,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109343,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
13890733,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109342,=,nM,389.0,CHEMBL279,Homo sapiens,IC50
13890734,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109341,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
13890735,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109340,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
13890736,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109339,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
13896689,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109278,=,nM,31.2,CHEMBL279,Homo sapiens,IC50
13896695,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109275,=,nM,51.2,CHEMBL279,Homo sapiens,IC50
13896696,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109276,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
13896697,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109277,=,nM,202.0,CHEMBL279,Homo sapiens,IC50
13896700,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109274,=,nM,15.1,CHEMBL279,Homo sapiens,IC50
13897433,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109404,=,nM,4810.0,CHEMBL279,Homo sapiens,IC50
13897434,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109402,=,nM,3660.0,CHEMBL279,Homo sapiens,IC50
13897435,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109401,=,nM,2220.0,CHEMBL279,Homo sapiens,IC50
13902313,CHEMBL3118139,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 after 30 mins by HTRF assay",B,CHEMBL3116440,=,nM,384.1,CHEMBL279,Homo sapiens,IC50
13910040,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114030,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
13910041,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114029,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
13910042,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114028,=,nM,108.0,CHEMBL279,Homo sapiens,IC50
13910043,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114027,=,nM,72.0,CHEMBL279,Homo sapiens,IC50
13910044,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114026,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
13910045,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114025,=,nM,72.0,CHEMBL279,Homo sapiens,IC50
13910046,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114024,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
13910047,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114023,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
13910048,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114022,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
13910049,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114021,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
13910050,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114019,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
13910051,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114018,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
13910052,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114020,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
13918705,CHEMBL3118225,Inhibition of human KDR,B,CHEMBL3116050,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
13945363,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128227,=,nM,52500.0,CHEMBL279,Homo sapiens,IC50
13945364,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128226,=,nM,2230.0,CHEMBL279,Homo sapiens,IC50
13945365,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128225,=,nM,7210.0,CHEMBL279,Homo sapiens,IC50
13945366,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128224,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50
13945367,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128223,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50
13945368,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128222,=,nM,2890.0,CHEMBL279,Homo sapiens,IC50
13945369,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128221,=,nM,4890.0,CHEMBL279,Homo sapiens,IC50
13945370,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128220,=,nM,4960.0,CHEMBL279,Homo sapiens,IC50
13945371,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128219,=,nM,6740.0,CHEMBL279,Homo sapiens,IC50
13945372,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128218,=,nM,3270.0,CHEMBL279,Homo sapiens,IC50
13945373,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128239,=,nM,1090.0,CHEMBL279,Homo sapiens,IC50
13945374,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128238,=,nM,1090.0,CHEMBL279,Homo sapiens,IC50
13945375,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128237,=,nM,3170.0,CHEMBL279,Homo sapiens,IC50
13945376,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128236,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
13945377,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128235,=,nM,2160.0,CHEMBL279,Homo sapiens,IC50
13945378,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128234,=,nM,6450.0,CHEMBL279,Homo sapiens,IC50
13945379,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128233,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50
13945380,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128232,=,nM,2660.0,CHEMBL279,Homo sapiens,IC50
13945381,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128231,=,nM,3290.0,CHEMBL279,Homo sapiens,IC50
13945382,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128230,=,nM,5370.0,CHEMBL279,Homo sapiens,IC50
13945383,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128229,=,nM,3480.0,CHEMBL279,Homo sapiens,IC50
13945384,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128228,=,nM,8570.0,CHEMBL279,Homo sapiens,IC50
13948254,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125890,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
13948255,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125889,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
13948256,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125888,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
13948257,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125887,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
13948258,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125886,=,nM,660.0,CHEMBL279,Homo sapiens,IC50
13948259,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125885,=,nM,730.0,CHEMBL279,Homo sapiens,IC50
13948260,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125884,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
13948261,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125883,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
13948262,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125882,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
13948263,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125881,=,nM,7.4,CHEMBL279,Homo sapiens,IC50
13948264,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3124950,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
13948265,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125893,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
13948266,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125891,=,nM,76.0,CHEMBL279,Homo sapiens,IC50
13948267,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125892,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
13948281,CHEMBL3130307,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2063743,=,nM,2.8,CHEMBL279,Homo sapiens,IC50
13973671,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133758,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
13973672,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133757,=,nM,91.0,CHEMBL279,Homo sapiens,IC50
13973673,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133756,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
13973674,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133755,=,nM,2165.0,CHEMBL279,Homo sapiens,IC50
13973675,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133754,=,nM,8568.0,CHEMBL279,Homo sapiens,IC50
13973677,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133752,=,nM,213.0,CHEMBL279,Homo sapiens,IC50
13973678,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133751,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
14537569,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219509,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
14537570,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3217774,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
14537571,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219510,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
14537572,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219511,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
14537573,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219512,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
14537574,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219513,=,nM,860.0,CHEMBL279,Homo sapiens,IC50
14544391,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220328,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
14544392,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220327,=,nM,3.77,CHEMBL279,Homo sapiens,IC50
14544393,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220326,=,nM,9.87,CHEMBL279,Homo sapiens,IC50
14544394,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220325,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
14544396,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220323,=,nM,1.08,CHEMBL279,Homo sapiens,IC50
14544398,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220321,=,nM,4.08,CHEMBL279,Homo sapiens,IC50
14544399,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220320,=,nM,7.01,CHEMBL279,Homo sapiens,IC50
14544400,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220319,=,nM,203.0,CHEMBL279,Homo sapiens,IC50
14544401,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220318,=,nM,1.28,CHEMBL279,Homo sapiens,IC50
14544402,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220317,=,nM,5.77,CHEMBL279,Homo sapiens,IC50
14547460,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221546,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
14547461,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221541,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
14547462,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221560,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
14547463,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221542,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
14547464,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221547,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
14547465,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221554,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
14547468,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221545,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
14547469,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221552,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
14547470,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221556,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
14547474,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221269,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
14547487,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221258,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
14547488,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221544,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
14547489,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221267,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50
14547495,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221265,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50
14547496,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221548,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
14547497,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221259,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
14547502,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221550,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
14547503,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221558,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50
14547506,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221557,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
14547509,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221261,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50
14547511,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221561,=,nM,5550.0,CHEMBL279,Homo sapiens,IC50
14547512,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221549,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
14547514,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221543,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50
14547523,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221555,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
14547524,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221551,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
14549669,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221266,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
14549674,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221268,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50
14549677,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221553,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50
14549682,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221262,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
14549687,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221260,=,nM,9900.0,CHEMBL279,Homo sapiens,IC50
14595663,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236669,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50
14595664,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236668,=,nM,70000.0,CHEMBL279,Homo sapiens,IC50
14595665,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236670,=,nM,52000.0,CHEMBL279,Homo sapiens,IC50
14595666,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL458248,=,nM,66000.0,CHEMBL279,Homo sapiens,IC50
14659748,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL3260567,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
14659750,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL492634,=,nM,2440.0,CHEMBL279,Homo sapiens,IC50
14659751,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL2364611,=,nM,442.0,CHEMBL279,Homo sapiens,IC50
14712161,CHEMBL3293746,Inhibition of KDR (unknown origin),B,CHEMBL3290931,=,nM,425.42,CHEMBL279,Homo sapiens,IC50
14712178,CHEMBL3293757,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
14732554,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287223,=,nM,182.3,CHEMBL279,Homo sapiens,IC50
14732555,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287222,=,nM,21.3,CHEMBL279,Homo sapiens,IC50
14732556,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287221,=,nM,50.1,CHEMBL279,Homo sapiens,IC50
14732557,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287220,=,nM,40.6,CHEMBL279,Homo sapiens,IC50
14732558,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287219,=,nM,30.1,CHEMBL279,Homo sapiens,IC50
14733302,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287303,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
14733303,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287304,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
14733304,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287305,=,nM,30.3,CHEMBL279,Homo sapiens,IC50
14733305,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287306,=,nM,61.5,CHEMBL279,Homo sapiens,IC50
14733306,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287307,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
14733307,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287308,=,nM,219.9,CHEMBL279,Homo sapiens,IC50
14733308,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287309,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
14733309,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287310,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
14733310,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287311,=,nM,46.6,CHEMBL279,Homo sapiens,IC50
14733311,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287312,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
14733312,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287313,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
14733313,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287315,=,nM,12.7,CHEMBL279,Homo sapiens,IC50
14733314,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287316,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
14733315,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287317,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
14733316,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287318,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
14733317,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287319,=,nM,83.6,CHEMBL279,Homo sapiens,IC50
14733318,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287320,=,nM,44.5,CHEMBL279,Homo sapiens,IC50
14735373,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287321,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
14735374,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287588,=,nM,24.5,CHEMBL279,Homo sapiens,IC50
14735375,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287591,=,nM,255.6,CHEMBL279,Homo sapiens,IC50
14735376,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287592,=,nM,181.0,CHEMBL279,Homo sapiens,IC50
14735377,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287595,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
14735378,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287596,=,nM,4394.0,CHEMBL279,Homo sapiens,IC50
14735379,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287597,=,nM,196.2,CHEMBL279,Homo sapiens,IC50
14735380,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287598,=,nM,2716.0,CHEMBL279,Homo sapiens,IC50
14735381,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287599,=,nM,2468.5,CHEMBL279,Homo sapiens,IC50
14735382,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287601,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
14735383,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287603,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
14735395,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL1171837,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
14746894,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288526,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
14746895,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288505,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
14746896,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288518,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
14746897,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288506,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
14746899,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288502,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
14746900,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288515,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
14746902,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288504,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
14746903,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288512,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
14746905,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288519,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
14746906,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288514,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
14746907,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288523,=,nM,2.8,CHEMBL279,Homo sapiens,IC50
14746908,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288516,=,nM,3.1,CHEMBL279,Homo sapiens,IC50
14746909,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288509,=,nM,3.3,CHEMBL279,Homo sapiens,IC50
14746910,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288508,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
14746912,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288517,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
14746913,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288510,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
14746916,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288520,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
14746918,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288511,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
14746920,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288524,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
14746921,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288522,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
14746923,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288525,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
14746925,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288507,=,nM,7.3,CHEMBL279,Homo sapiens,IC50
14746927,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288513,=,nM,9.2,CHEMBL279,Homo sapiens,IC50
14746933,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288521,=,nM,20.2,CHEMBL279,Homo sapiens,IC50
14746938,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288503,=,nM,26.7,CHEMBL279,Homo sapiens,IC50
14746972,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288527,=,nM,40.8,CHEMBL279,Homo sapiens,IC50
14752089,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297900,=,nM,8.5,CHEMBL279,Homo sapiens,IC50
14752108,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297899,=,nM,10.6,CHEMBL279,Homo sapiens,IC50
14752115,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297999,=,nM,15.6,CHEMBL279,Homo sapiens,IC50
14752117,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297898,=,nM,19.1,CHEMBL279,Homo sapiens,IC50
14752125,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3298000,=,nM,20.2,CHEMBL279,Homo sapiens,IC50
14752136,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297897,=,nM,43.1,CHEMBL279,Homo sapiens,IC50
14752137,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297891,=,nM,32.2,CHEMBL279,Homo sapiens,IC50
14752143,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297998,=,nM,34.4,CHEMBL279,Homo sapiens,IC50
14752145,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297894,=,nM,58.2,CHEMBL279,Homo sapiens,IC50
14752148,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297895,=,nM,70.2,CHEMBL279,Homo sapiens,IC50
14752151,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297893,=,nM,66.2,CHEMBL279,Homo sapiens,IC50
14752157,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297892,=,nM,76.3,CHEMBL279,Homo sapiens,IC50
14752159,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297816,=,nM,50.3,CHEMBL279,Homo sapiens,IC50
14752169,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297896,=,nM,102.1,CHEMBL279,Homo sapiens,IC50
14992859,CHEMBL3372230,Inhibition of recombinant KDR (unknown origin) after 60 mins by z'-lyte kinase assay,B,CHEMBL3361128,=,nM,5960.0,CHEMBL279,Homo sapiens,IC50
15025276,CHEMBL3362101,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] substrate by radioisotope-based P81 filter-binding assay,B,CHEMBL3322563,=,nM,1771.5,CHEMBL279,Homo sapiens,IC50
15025277,CHEMBL3362101,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] substrate by radioisotope-based P81 filter-binding assay,B,CHEMBL3322566,=,nM,20.7,CHEMBL279,Homo sapiens,IC50
15038294,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323592,=,nM,2480.0,CHEMBL279,Homo sapiens,IC50
15038296,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323594,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50
15038297,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323595,=,nM,4650.0,CHEMBL279,Homo sapiens,IC50
15038299,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323597,=,nM,9530.0,CHEMBL279,Homo sapiens,IC50
15038300,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323598,=,nM,5490.0,CHEMBL279,Homo sapiens,IC50
15038302,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323600,=,nM,3520.0,CHEMBL279,Homo sapiens,IC50
15038303,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323601,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50
15038305,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323603,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50
15038306,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323604,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
15038307,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323605,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
15038311,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323611,=,nM,8350.0,CHEMBL279,Homo sapiens,IC50
15038312,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323612,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
15038313,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323613,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
15038314,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323614,=,nM,7820.0,CHEMBL279,Homo sapiens,IC50
15044433,CHEMBL3376778,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3310052,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
15044434,CHEMBL3376778,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3310053,=,nM,2.72,CHEMBL279,Homo sapiens,IC50
15044764,CHEMBL3367410,"Inhibition of VEGFR2 (unknown origin) after 30 mins using poly (Glu,Tyr)4:1 substrate",B,CHEMBL3309402,=,nM,70.41,CHEMBL279,Homo sapiens,IC50
15047891,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321894,=,nM,6570.0,CHEMBL279,Homo sapiens,IC50
15047892,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321893,=,nM,9350.0,CHEMBL279,Homo sapiens,IC50
15047893,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321892,=,nM,830.0,CHEMBL279,Homo sapiens,IC50
15047916,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321895,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50
15047919,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321898,=,nM,8690.0,CHEMBL279,Homo sapiens,IC50
15047920,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321899,=,nM,6350.0,CHEMBL279,Homo sapiens,IC50
15047921,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321900,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
15047922,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321901,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
15047923,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321902,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50
15047924,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321903,=,nM,1580.0,CHEMBL279,Homo sapiens,IC50
15047925,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321904,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
15047926,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321905,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
15047929,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321908,=,nM,8850.0,CHEMBL279,Homo sapiens,IC50
15047931,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321910,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
15047932,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321911,=,nM,1840.0,CHEMBL279,Homo sapiens,IC50
15047933,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321912,=,nM,8520.0,CHEMBL279,Homo sapiens,IC50
15047934,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3039525,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
15055297,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358999,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
15055298,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358996,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
15055299,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358994,=,nM,56000.0,CHEMBL279,Homo sapiens,IC50
15055300,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358992,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50
15055301,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358977,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
15055302,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358966,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
15061529,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353347,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
15061530,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353341,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
15061531,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353340,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
15061534,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353337,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
15061536,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407897,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
15061537,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407749,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
15061710,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353344,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
15061711,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353348,=,nM,910.0,CHEMBL279,Homo sapiens,IC50
15061712,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353349,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50
15061713,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353354,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
15061714,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353355,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50
15061715,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353358,=,nM,7900.0,CHEMBL279,Homo sapiens,IC50
15061716,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353359,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
15061717,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353362,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
15112616,CHEMBL3381420,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay",B,CHEMBL3343366,=,nM,65.42,CHEMBL279,Homo sapiens,IC50
15135631,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3352835,=,nM,3290.0,CHEMBL279,Homo sapiens,IC50
15135632,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354185,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50
15135633,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354186,=,nM,219.0,CHEMBL279,Homo sapiens,IC50
15135634,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354187,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
15135635,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354188,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
15135636,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354189,=,nM,2270.0,CHEMBL279,Homo sapiens,IC50
15135638,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354191,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50
15135639,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354192,=,nM,2240.0,CHEMBL279,Homo sapiens,IC50
15139263,CHEMBL3385131,Inhibition of KDR (unknown origin),B,CHEMBL3339360,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
15147989,CHEMBL3396150,Inhibition of human recombinant VEGFR2 incubated for 1 hr using [gamma-32P]ATP by top count assay,B,CHEMBL3393803,=,nM,18600.0,CHEMBL279,Homo sapiens,IC50
15147991,CHEMBL3396150,Inhibition of human recombinant VEGFR2 incubated for 1 hr using [gamma-32P]ATP by top count assay,B,CHEMBL3393897,=,nM,23400.0,CHEMBL279,Homo sapiens,IC50
15154922,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397925,=,nM,624.66,CHEMBL279,Homo sapiens,IC50
15154924,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397927,=,nM,359.63,CHEMBL279,Homo sapiens,IC50
15154925,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397928,=,nM,31.98,CHEMBL279,Homo sapiens,IC50
15154926,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397929,=,nM,214.87,CHEMBL279,Homo sapiens,IC50
15154927,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397930,=,nM,62.52,CHEMBL279,Homo sapiens,IC50
15154928,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397931,=,nM,54.26,CHEMBL279,Homo sapiens,IC50
15154929,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397932,=,nM,14.48,CHEMBL279,Homo sapiens,IC50
15154930,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397933,=,nM,2.02,CHEMBL279,Homo sapiens,IC50
15154931,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397934,=,nM,8.74,CHEMBL279,Homo sapiens,IC50
15154932,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397935,=,nM,4.86,CHEMBL279,Homo sapiens,IC50
15154933,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397936,=,nM,44.32,CHEMBL279,Homo sapiens,IC50
15154934,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397937,=,nM,129.25,CHEMBL279,Homo sapiens,IC50
15154936,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397939,=,nM,85.32,CHEMBL279,Homo sapiens,IC50
15154937,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397940,=,nM,27.58,CHEMBL279,Homo sapiens,IC50
15154938,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397941,=,nM,158.46,CHEMBL279,Homo sapiens,IC50
15154939,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397942,=,nM,17.85,CHEMBL279,Homo sapiens,IC50
15154941,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397944,=,nM,77.45,CHEMBL279,Homo sapiens,IC50
15154942,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397945,=,nM,125.82,CHEMBL279,Homo sapiens,IC50
15154944,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397946,=,nM,71.89,CHEMBL279,Homo sapiens,IC50
15154945,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397947,=,nM,344.61,CHEMBL279,Homo sapiens,IC50
15154946,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397915,=,nM,69.4,CHEMBL279,Homo sapiens,IC50
15154947,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397916,=,nM,182.82,CHEMBL279,Homo sapiens,IC50
15154948,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397917,=,nM,4.38,CHEMBL279,Homo sapiens,IC50
15154949,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397918,=,nM,15.04,CHEMBL279,Homo sapiens,IC50
15154951,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397920,=,nM,9.41,CHEMBL279,Homo sapiens,IC50
15154953,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397922,=,nM,130.17,CHEMBL279,Homo sapiens,IC50
15154954,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397923,=,nM,22.85,CHEMBL279,Homo sapiens,IC50
15154955,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397924,=,nM,94.69,CHEMBL279,Homo sapiens,IC50
15175202,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403513,=,nM,6.7,CHEMBL279,Homo sapiens,IC50
15175216,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403512,=,nM,19.9,CHEMBL279,Homo sapiens,IC50
15175244,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403510,=,nM,18.6,CHEMBL279,Homo sapiens,IC50
15175258,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403509,=,nM,32.3,CHEMBL279,Homo sapiens,IC50
15176259,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403514,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
15176333,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403515,=,nM,20.9,CHEMBL279,Homo sapiens,IC50
15176361,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403517,=,nM,33.2,CHEMBL279,Homo sapiens,IC50
15176436,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403518,=,nM,38.5,CHEMBL279,Homo sapiens,IC50
15176450,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403519,=,nM,121.3,CHEMBL279,Homo sapiens,IC50
15193435,CHEMBL3411881,Inhibition of human VEGFR2,B,CHEMBL3039504,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
15196090,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409414,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
15196091,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409415,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
15196092,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409416,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
15196093,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL353584,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
15196094,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409417,=,nM,214.0,CHEMBL279,Homo sapiens,IC50
15196095,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409418,=,nM,119.0,CHEMBL279,Homo sapiens,IC50
15237119,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422066,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
15237120,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422067,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50
15237122,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422069,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
15237123,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422070,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
15237124,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422071,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50
15249767,CHEMBL3429404,Inhibition of recombinant VEGFR2 (unknown origin) by cell-free assay,B,CHEMBL3426917,=,nM,2.38,CHEMBL279,Homo sapiens,IC50
15458388,CHEMBL3538196,Inhibition of human recombinant VEGFR-2,B,CHEMBL3527569,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
15469036,CHEMBL3538196,Inhibition of human recombinant VEGFR-2,B,CHEMBL3526621,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
15605082,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577124,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50
15605083,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577123,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
15605084,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577122,=,nM,540.0,CHEMBL279,Homo sapiens,IC50
15605085,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577121,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
15605086,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577120,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
15605087,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577119,=,nM,750.0,CHEMBL279,Homo sapiens,IC50
15605088,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577117,=,nM,750.0,CHEMBL279,Homo sapiens,IC50
15605089,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577116,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
15605090,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577115,=,nM,1.9,CHEMBL279,Homo sapiens,IC50
15605091,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577114,=,nM,0.46,CHEMBL279,Homo sapiens,IC50
15605092,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL1229517,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
15616241,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582442,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
15616242,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582441,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
15616243,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582439,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
15616244,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582427,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
15625871,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586049,=,nM,0.36,CHEMBL279,Homo sapiens,IC50
15625873,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586051,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
15625874,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586052,=,nM,63.08,CHEMBL279,Homo sapiens,IC50
15625878,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586056,=,nM,2.19,CHEMBL279,Homo sapiens,IC50
15625879,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586057,=,nM,0.22,CHEMBL279,Homo sapiens,IC50
15625881,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586058,=,nM,722.38,CHEMBL279,Homo sapiens,IC50
15625888,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586065,=,nM,13.26,CHEMBL279,Homo sapiens,IC50
15625893,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586070,=,nM,99.58,CHEMBL279,Homo sapiens,IC50
15625894,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586071,=,nM,0.15,CHEMBL279,Homo sapiens,IC50
15625895,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586072,=,nM,0.14,CHEMBL279,Homo sapiens,IC50
15637416,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589737,=,nM,5610.0,CHEMBL279,Homo sapiens,IC50
15637417,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589738,=,nM,4260.0,CHEMBL279,Homo sapiens,IC50
15637418,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589739,=,nM,5090.0,CHEMBL279,Homo sapiens,IC50
15637420,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589741,=,nM,2580.0,CHEMBL279,Homo sapiens,IC50
15637421,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589742,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50
15637425,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589746,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50
15637428,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589748,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
15637429,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589749,=,nM,1930.0,CHEMBL279,Homo sapiens,IC50
15637430,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589807,=,nM,2670.0,CHEMBL279,Homo sapiens,IC50
15637435,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589812,=,nM,3920.0,CHEMBL279,Homo sapiens,IC50
15637436,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589813,=,nM,750.0,CHEMBL279,Homo sapiens,IC50
15637437,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589814,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
15637439,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589200,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
15637769,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590225,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
15637770,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590224,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
15637771,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590223,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
15637772,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590222,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
15637773,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590221,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
15637774,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590220,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
15637775,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590219,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
15648701,CHEMBL3594717,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3594105,=,nM,92.6,CHEMBL279,Homo sapiens,IC50
15650083,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL608533,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
15650084,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593296,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
15650086,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593294,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
15650087,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593293,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
15650088,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593292,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
15650089,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593291,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
15650090,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593290,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
15650091,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593289,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
15650092,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593288,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
15650093,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593287,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
15650094,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593286,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
15650095,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593285,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
15650096,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593284,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
15650097,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593283,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
15655423,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596873,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
15655424,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596879,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
15655497,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596893,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
15655498,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596892,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
15678972,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604466,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
15678977,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604467,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
15678982,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604468,=,nM,122.0,CHEMBL279,Homo sapiens,IC50
15678986,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604469,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
15678991,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4442620,=,nM,163.0,CHEMBL279,Homo sapiens,IC50
15687007,CHEMBL3607491,"Inhibition of KDR (unknown origin) using poly (Glu-Tyr, 4:1) substrate incubated for 60 mins by ELISA method",B,CHEMBL3605107,=,nM,284.0,CHEMBL279,Homo sapiens,IC50
15687008,CHEMBL3607491,"Inhibition of KDR (unknown origin) using poly (Glu-Tyr, 4:1) substrate incubated for 60 mins by ELISA method",B,CHEMBL3605102,=,nM,343.0,CHEMBL279,Homo sapiens,IC50
15708414,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612227,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
15708415,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612228,=,nM,107.0,CHEMBL279,Homo sapiens,IC50
15709008,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612229,=,nM,206.0,CHEMBL279,Homo sapiens,IC50
15709009,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612230,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
15709010,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612231,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
15709011,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612232,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
15709012,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612233,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
15709013,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612234,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
15709014,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612235,=,nM,1160.0,CHEMBL279,Homo sapiens,IC50
15709015,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612323,=,nM,1390.0,CHEMBL279,Homo sapiens,IC50
15709016,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612324,=,nM,8360.0,CHEMBL279,Homo sapiens,IC50
15709017,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612325,=,nM,988.0,CHEMBL279,Homo sapiens,IC50
15709018,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612326,=,nM,1947.0,CHEMBL279,Homo sapiens,IC50
15709948,CHEMBL3614378,Inhibition of KDR (unknown origin) after 1 hr by ELISA based assay,B,CHEMBL3612840,=,nM,191.0,CHEMBL279,Homo sapiens,IC50
15731018,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL393636,=,nM,405.5,CHEMBL279,Homo sapiens,IC50
15731021,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621299,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
15731024,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621296,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
15731026,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621294,=,nM,237.0,CHEMBL279,Homo sapiens,IC50
15736009,CHEMBL3627024,Inhibition of KDR (unknown origin) pre-incubated for 30 mins at room temperature before substrate addition and measured 1 hr after substrate addition by cell free kinase assay,B,CHEMBL3622956,=,nM,191.9,CHEMBL279,Homo sapiens,IC50
15736011,CHEMBL3627024,Inhibition of KDR (unknown origin) pre-incubated for 30 mins at room temperature before substrate addition and measured 1 hr after substrate addition by cell free kinase assay,B,CHEMBL3622958,=,nM,653.0,CHEMBL279,Homo sapiens,IC50
15736632,CHEMBL3625819,Inhibition of human recombinant KDR,B,CHEMBL3623375,=,nM,2458.0,CHEMBL279,Homo sapiens,IC50
15745910,CHEMBL3624484,Inhibition of recombinant KDR (unknown origin) after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP,B,CHEMBL3623290,=,nM,156.0,CHEMBL279,Homo sapiens,IC50
15753879,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628814,=,nM,17500.0,CHEMBL279,Homo sapiens,IC50
15753897,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628537,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
15753978,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628536,=,nM,8200.0,CHEMBL279,Homo sapiens,IC50
15754000,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628818,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
15759981,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628907,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
15759982,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628906,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
15759983,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628811,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
15759984,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628810,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
15759985,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628809,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
15759986,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628808,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
15759987,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628807,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
15759988,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628806,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
15759991,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628805,=,nM,1140.0,CHEMBL279,Homo sapiens,IC50
15759992,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628804,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
15759993,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628803,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
15759994,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628802,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50
15759998,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628799,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
15759999,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628798,=,nM,1160.0,CHEMBL279,Homo sapiens,IC50
15760000,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628797,=,nM,91.0,CHEMBL279,Homo sapiens,IC50
15760001,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628796,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
15760002,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628795,=,nM,3140.0,CHEMBL279,Homo sapiens,IC50
15760004,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628793,=,nM,3820.0,CHEMBL279,Homo sapiens,IC50
15765229,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633686,=,nM,3.47,CHEMBL279,Homo sapiens,IC50
15765231,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633684,=,nM,1.38,CHEMBL279,Homo sapiens,IC50
15765233,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633304,=,nM,0.79,CHEMBL279,Homo sapiens,IC50
15765234,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633303,=,nM,41.8,CHEMBL279,Homo sapiens,IC50
15765235,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633302,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
15765236,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633301,=,nM,205.0,CHEMBL279,Homo sapiens,IC50
15765239,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633298,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
15765240,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633297,=,nM,331.0,CHEMBL279,Homo sapiens,IC50
15765241,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633296,=,nM,2.28,CHEMBL279,Homo sapiens,IC50
15765242,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633295,=,nM,2.36,CHEMBL279,Homo sapiens,IC50
15765243,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633294,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
15765244,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633293,=,nM,116.0,CHEMBL279,Homo sapiens,IC50
15765245,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633292,=,nM,2.15,CHEMBL279,Homo sapiens,IC50
15765246,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633291,=,nM,59.2,CHEMBL279,Homo sapiens,IC50
15765247,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633290,=,nM,53.6,CHEMBL279,Homo sapiens,IC50
15765249,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633289,=,nM,14900.0,CHEMBL279,Homo sapiens,IC50
15765250,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633288,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50
15765258,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633280,=,nM,8400.0,CHEMBL279,Homo sapiens,IC50
15765260,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633278,=,nM,37700.0,CHEMBL279,Homo sapiens,IC50
15765261,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633271,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
15765263,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633273,=,nM,62.0,CHEMBL279,Homo sapiens,IC50
15765264,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633274,=,nM,53000.0,CHEMBL279,Homo sapiens,IC50
15765265,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633275,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50
15765266,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633276,=,nM,51900.0,CHEMBL279,Homo sapiens,IC50
15765267,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633277,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
15765338,CHEMBL3636171,Inhibition of GST-tagged human KDR expressed in Sf21 cells using 4:1 polyglutamic acid/tyrosine substrate incubated for 15 mins by scintillation counting method,B,CHEMBL3633689,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
15765340,CHEMBL3636170,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3633687,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
15765341,CHEMBL3636169,Inhibition of His6-tagged KDR 789 to 1354 residues (unknown origin) using biotin-Ahx-AEEEYFFLA-amide substrate incubated for 60 mins by HTRF assay,B,CHEMBL3633688,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
15765350,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633696,=,nM,42000.0,CHEMBL279,Homo sapiens,IC50
15765354,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633692,=,nM,6960.0,CHEMBL279,Homo sapiens,IC50
15765356,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633690,=,nM,40100.0,CHEMBL279,Homo sapiens,IC50
15774313,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633758,=,nM,476.0,CHEMBL279,Homo sapiens,IC50
15774314,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633759,=,nM,352.0,CHEMBL279,Homo sapiens,IC50
15774315,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633760,=,nM,613.0,CHEMBL279,Homo sapiens,IC50
15774316,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633761,=,nM,501.0,CHEMBL279,Homo sapiens,IC50
15774317,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633762,=,nM,625.0,CHEMBL279,Homo sapiens,IC50
15774318,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633763,=,nM,434.0,CHEMBL279,Homo sapiens,IC50
15774319,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633764,=,nM,415.0,CHEMBL279,Homo sapiens,IC50
15774320,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633765,=,nM,462.0,CHEMBL279,Homo sapiens,IC50
15774321,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633766,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
15774322,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633767,=,nM,138.0,CHEMBL279,Homo sapiens,IC50
15774323,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633768,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
15774324,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633769,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
15774325,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633770,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50
15774326,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633771,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50
15774327,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633772,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
15774328,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633773,=,nM,2450.0,CHEMBL279,Homo sapiens,IC50
16258395,CHEMBL3707510,"Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 M. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 M. Reactions were carried out in 10 M ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.",B,CHEMBL3975634,=,nM,39.49,CHEMBL279,Homo sapiens,IC50
16258738,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648112,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
16260892,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3639591,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16261148,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656114,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
16261666,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660305,=,nM,7007.0,CHEMBL279,Homo sapiens,IC50
16262231,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660291,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16262440,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656059,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
16263046,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660306,=,nM,3505.0,CHEMBL279,Homo sapiens,IC50
16264237,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656028,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16264238,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656049,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
16264255,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656035,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16265448,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648098,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
16265504,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648074,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16265680,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656115,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
16267030,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656119,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
16267181,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648123,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
16267218,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648084,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
16267807,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696091,=,nM,1210.0,CHEMBL279,Homo sapiens,IC50
16267998,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622955,=,nM,357.0,CHEMBL279,Homo sapiens,IC50
16268421,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656116,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
16268484,CHEMBL3708006,"Inhibition Assay: The inhibitory activity measurement against the kinases mentioned above was measured in the kinase inhibition reaction mixture containing 2 ul purified kinase protein (10-50 ng), 20 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 0.5 mM dithiothreitol, 0.01 mM ATP, 4 ug of poly(D4Y)n peptide substrate (Promega), 0.2 uCi of 32P-ATP and the each compound shown in tablel. The mixture was incubated for 15 min at 30 C. and the reaction was then ended by adding a half volume of 30% phosphoric acid solution. Subsequently, the reaction mixture solution was spotted in avidin coated membrane (Promega). This membrane was washed using 50 mM phosphate, 0.1N NaCl buffer (pH 6.0) solution for 10 min 5 times and then the radioactivity of each spot was quantified by using a BAS image analyzer (Fuji).",B,CHEMBL2336005,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
16268847,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656069,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
16268978,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648124,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
16269010,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656039,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16269453,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696083,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
16269458,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648090,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
16269608,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696076,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16269902,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648092,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
16270070,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696073,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16270794,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656030,=,nM,506.0,CHEMBL279,Homo sapiens,IC50
16271063,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648103,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
16272573,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656108,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
16272690,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660274,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
16273074,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656109,=,nM,477.0,CHEMBL279,Homo sapiens,IC50
16273100,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656099,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16273295,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656085,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
16273398,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657552,=,nM,581.0,CHEMBL279,Homo sapiens,IC50
16273810,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657553,=,nM,9458.0,CHEMBL279,Homo sapiens,IC50
16274050,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 M N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 L final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL3646211,=,nM,1.83,CHEMBL279,Homo sapiens,IC50
16274279,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696072,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16274425,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656080,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16274548,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656097,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16274933,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657554,=,nM,8372.0,CHEMBL279,Homo sapiens,IC50
16275093,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699446,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
16275268,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656026,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16275963,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660279,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
16275969,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696078,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
16276460,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696084,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
16276471,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660269,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16276483,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656121,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
16277510,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648114,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16277616,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648097,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
16278109,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678948,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16278657,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3639549,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16278899,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656053,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16279224,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657546,=,nM,3895.0,CHEMBL279,Homo sapiens,IC50
16279334,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656084,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16279336,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656090,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16280383,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656075,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
16280521,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696087,=,nM,176.0,CHEMBL279,Homo sapiens,IC50
16280758,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656079,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
16281759,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648078,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
16282059,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696074,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
16282273,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656086,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16283662,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656066,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16284253,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656058,=,nM,2610.0,CHEMBL279,Homo sapiens,IC50
16284330,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660287,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16284578,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660296,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
16284746,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648102,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
16284974,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657556,=,nM,731.0,CHEMBL279,Homo sapiens,IC50
16285319,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696098,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
16285386,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660288,=,nM,53.0,CHEMBL279,Homo sapiens,IC50
16285548,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660268,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16285610,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660294,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16285823,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656037,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
16285972,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648127,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
16286253,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656078,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
16287213,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656029,=,nM,2956.0,CHEMBL279,Homo sapiens,IC50
16287217,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656054,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
16287249,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656112,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16287607,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656047,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
16288000,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656074,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16288490,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656031,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
16288573,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657558,=,nM,647.0,CHEMBL279,Homo sapiens,IC50
16288736,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657550,=,nM,483.0,CHEMBL279,Homo sapiens,IC50
16289183,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656038,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
16289192,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656100,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
16289474,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656127,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16289570,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678947,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
16291045,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648096,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
16291149,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648081,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
16291295,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656055,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
16291438,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656044,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16291542,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656036,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16292279,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 M. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 M ATP and test compounds.",B,CHEMBL2385590,=,nM,214.7,CHEMBL279,Homo sapiens,IC50
16292868,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660276,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16293142,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656124,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16293277,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648071,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
16293317,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656105,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
16293363,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696080,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16293745,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696081,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16294237,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660301,=,nM,2704.0,CHEMBL279,Homo sapiens,IC50
16296899,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656113,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
16296967,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660300,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
16297195,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696075,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
16297700,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656025,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16297770,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656034,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
16299064,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648115,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
16300014,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648119,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
16300188,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648116,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
16300318,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678953,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16300584,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696096,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
16300634,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660302,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
16300731,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657555,=,nM,2109.0,CHEMBL279,Homo sapiens,IC50
16301068,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656126,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16301175,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656042,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
16301234,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648094,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
16301672,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696077,=,nM,4520.0,CHEMBL279,Homo sapiens,IC50
16301878,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656041,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16302255,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656092,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16303718,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657559,=,nM,486.0,CHEMBL279,Homo sapiens,IC50
16303779,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656125,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16303812,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696071,=,nM,3280.0,CHEMBL279,Homo sapiens,IC50
16304260,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660307,=,nM,1382.0,CHEMBL279,Homo sapiens,IC50
16305052,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622961,=,nM,1117.0,CHEMBL279,Homo sapiens,IC50
16306270,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622959,=,nM,1872.0,CHEMBL279,Homo sapiens,IC50
16307012,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656102,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
16307138,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656122,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16308718,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648082,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
16308840,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660277,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
16309091,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660297,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
16309287,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648101,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
16309766,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660290,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
16310360,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660270,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
16310559,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660275,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16311728,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656083,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
16312072,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656051,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
16312079,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678950,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
16312831,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656061,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
16313343,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648093,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
16313413,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657547,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16313547,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656101,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
16313620,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660273,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
16313760,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648085,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
16314281,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648095,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
16314421,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648077,=,nM,910.0,CHEMBL279,Homo sapiens,IC50
16314505,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648079,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
16315228,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656056,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
16316143,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660303,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
16316344,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656095,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
16316667,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699444,=,nM,251.0,CHEMBL279,Homo sapiens,IC50
16317511,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696095,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
16317921,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 M N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 L final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL3646210,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
16318613,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656106,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16318716,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648108,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
16319347,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3639469,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
16319562,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648118,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
16319652,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656065,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16319661,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696085,=,nM,2520.0,CHEMBL279,Homo sapiens,IC50
16320418,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656093,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16320616,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648075,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
16320815,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656046,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16320863,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656060,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16321708,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657545,=,nM,1913.0,CHEMBL279,Homo sapiens,IC50
16321808,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648091,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
16321903,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656098,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
16322340,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656118,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
16322790,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660281,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16323157,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656071,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
16323689,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660304,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
16324003,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656120,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
16324015,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656045,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
16324523,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656063,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
16324549,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660292,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16326992,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656107,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16327241,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648104,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
16327466,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648099,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
16328009,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648126,=,nM,70.0,CHEMBL279,Homo sapiens,IC50
16328194,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656096,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16328330,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656072,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
16328381,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656091,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16328947,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656077,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16329234,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660298,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16329418,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648089,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
16330099,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656081,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16330683,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660271,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
16330847,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656082,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
16331733,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648107,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
16332083,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660267,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16332490,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660282,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
16332492,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656057,=,nM,10028.0,CHEMBL279,Homo sapiens,IC50
16332974,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657557,=,nM,4272.0,CHEMBL279,Homo sapiens,IC50
16333620,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656076,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16334594,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660272,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
16334931,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656104,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
16335278,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648086,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
16336301,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656087,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16336764,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648111,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16337846,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648072,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
16337985,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648087,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
16338128,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696097,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16338131,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656111,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16338170,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657548,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
16338374,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660285,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16338529,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696079,=,nM,4520.0,CHEMBL279,Homo sapiens,IC50
16339084,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 M. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 M ATP and test compounds.",B,CHEMBL3668019,=,nM,2062.0,CHEMBL279,Homo sapiens,IC50
16339541,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660283,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16340184,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 M. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 M ATP and test compounds.",B,CHEMBL3668018,=,nM,2418.0,CHEMBL279,Homo sapiens,IC50
16340207,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656123,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
16340333,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660280,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
16340763,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622952,=,nM,1688.0,CHEMBL279,Homo sapiens,IC50
16340976,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648100,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
16341054,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656050,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
16341542,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656033,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
16341761,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656073,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
16342063,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656110,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
16342263,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648121,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
16342513,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 M N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 L final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL2004290,=,nM,5.01,CHEMBL279,Homo sapiens,IC50
16342676,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660299,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16342985,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660289,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
16343274,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656088,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
16343446,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657549,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
16343670,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648088,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
16344393,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648080,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
16345914,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660278,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
16346085,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656062,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
16347487,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660284,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
16347672,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657551,=,nM,502.0,CHEMBL279,Homo sapiens,IC50
16347725,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696092,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50
16348085,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656067,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16348197,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648083,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
16348237,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648076,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
16348592,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656043,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16348856,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656103,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
16348889,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656068,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16349062,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656094,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
16349140,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656048,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
16349423,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657544,=,nM,345.6,CHEMBL279,Homo sapiens,IC50
16349652,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656040,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16349751,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696088,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16349829,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656070,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
16350824,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648113,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
16351083,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660293,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16351090,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648125,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
16351187,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656089,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
16351803,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656064,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
16352948,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656052,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
16353798,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648073,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
16353833,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678957,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
16353837,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656027,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16354397,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622957,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16354420,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656032,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16355387,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648120,=,nM,470.0,CHEMBL279,Homo sapiens,IC50
16355711,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660295,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
16356653,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656117,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16356972,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660286,=,nM,116.0,CHEMBL279,Homo sapiens,IC50
16394849,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741876,=,nM,2.2,CHEMBL279,Homo sapiens,IC50
16394850,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741316,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
16394851,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740781,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
16394852,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741965,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
16394853,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741625,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
16394854,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741966,=,nM,0.6,CHEMBL279,Homo sapiens,IC50
16394855,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3742328,=,nM,7.2,CHEMBL279,Homo sapiens,IC50
16394856,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741311,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
16394857,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739732,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
16394858,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739633,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
16394859,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739656,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
16394860,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739569,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
16394861,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741411,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
16394862,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740087,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
16394863,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741413,=,nM,26.1,CHEMBL279,Homo sapiens,IC50
16394864,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740073,=,nM,19.8,CHEMBL279,Homo sapiens,IC50
16394865,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3742168,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
16394866,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740487,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
16394867,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739936,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
16394868,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741916,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
16394869,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741484,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
16394870,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739572,=,nM,8.8,CHEMBL279,Homo sapiens,IC50
16394872,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740673,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
16394873,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740554,=,nM,3.2,CHEMBL279,Homo sapiens,IC50
16394874,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741187,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
16394875,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740788,=,nM,2.2,CHEMBL279,Homo sapiens,IC50
16394876,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740721,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
16394877,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740574,=,nM,1.8,CHEMBL279,Homo sapiens,IC50
16394878,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741621,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
16394879,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740276,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
16394880,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741592,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
16394881,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739726,=,nM,4.9,CHEMBL279,Homo sapiens,IC50
16394882,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740856,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
16394883,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741641,=,nM,0.9,CHEMBL279,Homo sapiens,IC50
16394884,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740530,=,nM,5.2,CHEMBL279,Homo sapiens,IC50
16394885,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739627,=,nM,19.2,CHEMBL279,Homo sapiens,IC50
16394886,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739835,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
16394887,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740163,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
16395733,CHEMBL3745462,Inhibition of VEGFR-2 (unknown origin) assessed as ATP level by luminescence analysis,B,CHEMBL3740910,=,nM,565.0,CHEMBL279,Homo sapiens,IC50
16398658,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739750,=,nM,4490.0,CHEMBL279,Homo sapiens,IC50
16398659,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740247,=,nM,8770.0,CHEMBL279,Homo sapiens,IC50
16398660,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739587,=,nM,4340.0,CHEMBL279,Homo sapiens,IC50
16398661,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740131,=,nM,2340.0,CHEMBL279,Homo sapiens,IC50
16398662,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742349,=,nM,7560.0,CHEMBL279,Homo sapiens,IC50
16398663,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741526,=,nM,2870.0,CHEMBL279,Homo sapiens,IC50
16398664,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740930,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16398665,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740713,=,nM,4330.0,CHEMBL279,Homo sapiens,IC50
16398666,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740385,=,nM,3490.0,CHEMBL279,Homo sapiens,IC50
16398667,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741069,=,nM,2340.0,CHEMBL279,Homo sapiens,IC50
16398668,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740582,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16398669,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742060,=,nM,4360.0,CHEMBL279,Homo sapiens,IC50
16398670,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741655,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50
16398671,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740923,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16398672,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739586,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50
16398673,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742200,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16398674,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740003,=,nM,2450.0,CHEMBL279,Homo sapiens,IC50
16398675,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741960,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16398676,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740492,=,nM,4560.0,CHEMBL279,Homo sapiens,IC50
16428209,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747182,=,nM,118.0,CHEMBL279,Homo sapiens,IC50
16428210,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747481,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
16428211,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3745924,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
16428212,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746897,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
16428213,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747266,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
16428214,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746357,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
16428215,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747226,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
16428216,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746204,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
16428217,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747063,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
16428218,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746595,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
16428219,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746370,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16428220,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747273,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
16428221,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746122,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
16428222,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746141,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
16428223,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747565,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
16428224,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3745816,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
16428225,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747669,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16428226,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746226,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16428227,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746273,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16428229,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746776,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16428230,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746562,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
16428231,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747084,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
16428232,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3745943,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
16428233,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746953,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
16428234,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746735,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16428238,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746052,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
16428246,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746359,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16428280,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746941,=,nM,0.5,CHEMBL279,Homo sapiens,IC50
16432609,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752786,=,nM,4540.0,CHEMBL279,Homo sapiens,IC50
16432610,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752606,=,nM,4260.0,CHEMBL279,Homo sapiens,IC50
16432611,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754141,=,nM,4290.0,CHEMBL279,Homo sapiens,IC50
16432617,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754450,=,nM,3420.0,CHEMBL279,Homo sapiens,IC50
16432618,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754319,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50
16432624,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753353,=,nM,4160.0,CHEMBL279,Homo sapiens,IC50
16432641,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752391,=,nM,3510.0,CHEMBL279,Homo sapiens,IC50
16432658,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752096,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
16432687,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753051,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
16432807,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753162,=,nM,2380.0,CHEMBL279,Homo sapiens,IC50
16432841,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753226,=,nM,3110.0,CHEMBL279,Homo sapiens,IC50
16434297,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753739,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50
16435119,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754709,=,nM,291.21,CHEMBL279,Homo sapiens,IC50
16435120,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753142,=,nM,57.36,CHEMBL279,Homo sapiens,IC50
16435122,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754556,=,nM,86.67,CHEMBL279,Homo sapiens,IC50
16435123,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753811,=,nM,106.52,CHEMBL279,Homo sapiens,IC50
16435124,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753157,=,nM,390.4,CHEMBL279,Homo sapiens,IC50
16435125,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752248,=,nM,68.62,CHEMBL279,Homo sapiens,IC50
16435126,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753532,=,nM,33.23,CHEMBL279,Homo sapiens,IC50
16435127,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754301,=,nM,222.59,CHEMBL279,Homo sapiens,IC50
16435128,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752825,=,nM,355.15,CHEMBL279,Homo sapiens,IC50
16435129,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752129,=,nM,420.15,CHEMBL279,Homo sapiens,IC50
16435130,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752916,=,nM,285.39,CHEMBL279,Homo sapiens,IC50
16435171,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754785,=,nM,79.4,CHEMBL279,Homo sapiens,IC50
16435172,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753208,=,nM,86.74,CHEMBL279,Homo sapiens,IC50
16436356,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752370,=,nM,22.16,CHEMBL279,Homo sapiens,IC50
16436358,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753886,=,nM,128.15,CHEMBL279,Homo sapiens,IC50
16436359,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752008,=,nM,21.57,CHEMBL279,Homo sapiens,IC50
16436360,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753904,=,nM,364.14,CHEMBL279,Homo sapiens,IC50
16436361,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752404,=,nM,93.02,CHEMBL279,Homo sapiens,IC50
16436362,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754722,=,nM,491.9,CHEMBL279,Homo sapiens,IC50
16436364,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753836,=,nM,213.48,CHEMBL279,Homo sapiens,IC50
16436365,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754057,=,nM,52.2,CHEMBL279,Homo sapiens,IC50
16446733,CHEMBL3757136,Inhibition of recombinant human VGFR2 by radiometric assay in presence of [gamma-33P]-ATP,B,CHEMBL3753341,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
16449287,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752508,=,nM,4680.0,CHEMBL279,Homo sapiens,IC50
16449288,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753656,=,nM,4270.0,CHEMBL279,Homo sapiens,IC50
16449289,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752752,=,nM,3660.0,CHEMBL279,Homo sapiens,IC50
16449304,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752671,=,nM,4350.0,CHEMBL279,Homo sapiens,IC50
16449322,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753854,=,nM,3950.0,CHEMBL279,Homo sapiens,IC50
16449336,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754335,=,nM,4070.0,CHEMBL279,Homo sapiens,IC50
16449337,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753534,=,nM,3840.0,CHEMBL279,Homo sapiens,IC50
16449350,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754627,=,nM,3390.0,CHEMBL279,Homo sapiens,IC50
16449365,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754536,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50
16449366,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753316,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50
16449370,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754257,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
16452119,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759186,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
16452120,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758697,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
16452121,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758940,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
16452716,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759232,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
16452721,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758839,=,nM,215.0,CHEMBL279,Homo sapiens,IC50
16452722,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759261,=,nM,313.0,CHEMBL279,Homo sapiens,IC50
16452723,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758489,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
16452724,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758229,=,nM,182.0,CHEMBL279,Homo sapiens,IC50
16452725,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759279,=,nM,364.0,CHEMBL279,Homo sapiens,IC50
16452726,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759149,=,nM,685.0,CHEMBL279,Homo sapiens,IC50
16452727,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759853,=,nM,832.0,CHEMBL279,Homo sapiens,IC50
16452728,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759278,=,nM,857.0,CHEMBL279,Homo sapiens,IC50
16452729,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758380,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
16452730,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759565,=,nM,524.0,CHEMBL279,Homo sapiens,IC50
16452731,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759041,=,nM,455.0,CHEMBL279,Homo sapiens,IC50
16452732,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759798,=,nM,376.0,CHEMBL279,Homo sapiens,IC50
16452733,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759313,=,nM,754.0,CHEMBL279,Homo sapiens,IC50
16452734,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759111,=,nM,918.0,CHEMBL279,Homo sapiens,IC50
16452735,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758922,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
16452736,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3760069,=,nM,865.0,CHEMBL279,Homo sapiens,IC50
16461827,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759848,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
16461828,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759015,=,nM,2990.0,CHEMBL279,Homo sapiens,IC50
16461829,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758363,=,nM,2480.0,CHEMBL279,Homo sapiens,IC50
16461830,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758875,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
16461831,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758796,=,nM,4190.0,CHEMBL279,Homo sapiens,IC50
16461832,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759754,=,nM,2620.0,CHEMBL279,Homo sapiens,IC50
16461833,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759155,=,nM,4720.0,CHEMBL279,Homo sapiens,IC50
16461834,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759830,=,nM,2020.0,CHEMBL279,Homo sapiens,IC50
16461835,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758585,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
16461836,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3760090,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50
16461837,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759190,=,nM,1710.0,CHEMBL279,Homo sapiens,IC50
16461838,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758749,=,nM,1810.0,CHEMBL279,Homo sapiens,IC50
16461839,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759127,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
16465596,CHEMBL3766503,Inhibition of recombinant N-terminal 6His-tagged VEGFR-2 (unknown origin) using FL-Peptide 22 as substrate after 90 mins by mobility shift assay,B,CHEMBL3764045,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
16466192,CHEMBL3766514,Competitive inhibition of VEGFR2 (unknown origin) in presence of ATP,B,CHEMBL2143592,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16466198,CHEMBL3767457,Inhibition of VEGFR-2 (unknown origin) by tumor cell growth inhibition assay,B,CHEMBL3764474,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
16466202,CHEMBL3767461,Inhibition of VEGFR-2 (unknown origin) by AlphaScreen assay,B,CHEMBL3765306,=,nM,2.2,CHEMBL279,Homo sapiens,IC50
16478664,CHEMBL3768351,"Inhibition of KDR (unknown origin) using poly(glu,Tyr)4:1 as substrate incubated for 30 mins by homogeneous time-resolved fluorescence assay",B,CHEMBL3764279,=,nM,210.2,CHEMBL279,Homo sapiens,IC50
16479892,CHEMBL3766408,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,B,CHEMBL3763360,=,nM,886.0,CHEMBL279,Homo sapiens,IC50
16479893,CHEMBL3766408,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,B,CHEMBL3763790,=,nM,478.0,CHEMBL279,Homo sapiens,IC50
16496306,CHEMBL3779157,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3774451,=,nM,86.25,CHEMBL279,Homo sapiens,IC50
16498843,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775903,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
16498845,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775840,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
16498846,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775164,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50
16498847,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774580,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
16498848,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL169473,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50
16498849,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3220401,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50
16498850,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL405130,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50
16498902,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775879,=,nM,72.0,CHEMBL279,Homo sapiens,IC50
16498904,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL235851,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
16498905,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774563,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
16498906,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775934,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
16498907,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775086,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
16498908,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774904,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
16498909,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774489,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
16498910,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774951,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
16498911,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775169,=,nM,9.5,CHEMBL279,Homo sapiens,IC50
16498912,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775190,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
16498914,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775415,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
16498915,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775336,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
16498916,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775557,=,nM,69.0,CHEMBL279,Homo sapiens,IC50
16498917,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775511,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
16498918,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774913,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50
16498919,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775940,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50
16498921,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775560,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
16498922,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775585,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
16498923,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774953,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
16498924,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774935,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50
16498925,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775672,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
16498926,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775376,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
16498927,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774430,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50
16509850,CHEMBL3783049,Inhibition of VEGF2 receptor (unknown origin) by ELISA,B,CHEMBL3545414,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
16517144,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781479,=,nM,2060.0,CHEMBL279,Homo sapiens,IC50
16517153,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780758,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
16517154,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780515,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50
16517155,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781651,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
16517156,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780637,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50
16517158,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781795,=,nM,17060.0,CHEMBL279,Homo sapiens,IC50
16517161,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781989,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50
16517162,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780632,=,nM,6120.0,CHEMBL279,Homo sapiens,IC50
16517163,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3782019,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
16517164,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780971,=,nM,2050.0,CHEMBL279,Homo sapiens,IC50
16517165,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781696,=,nM,3310.0,CHEMBL279,Homo sapiens,IC50
16517166,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781028,=,nM,11050.0,CHEMBL279,Homo sapiens,IC50
16517167,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781610,=,nM,8840.0,CHEMBL279,Homo sapiens,IC50
16518591,CHEMBL3782293,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3780676,=,nM,542.6,CHEMBL279,Homo sapiens,IC50
16522574,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780276,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
16522575,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780547,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
16522576,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780741,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
16522577,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781261,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
16522578,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780136,=,nM,118.0,CHEMBL279,Homo sapiens,IC50
16522579,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3782044,=,nM,141.0,CHEMBL279,Homo sapiens,IC50
16522580,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780780,=,nM,381.0,CHEMBL279,Homo sapiens,IC50
16522581,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780236,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
16522582,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780231,=,nM,473.0,CHEMBL279,Homo sapiens,IC50
16522583,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781034,=,nM,636.0,CHEMBL279,Homo sapiens,IC50
16522584,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780261,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50
16522585,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780052,=,nM,754.0,CHEMBL279,Homo sapiens,IC50
16522586,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780121,=,nM,1340.0,CHEMBL279,Homo sapiens,IC50
16522587,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781003,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50
16522588,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781176,=,nM,4670.0,CHEMBL279,Homo sapiens,IC50
16522589,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780801,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50
16522590,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781927,=,nM,5120.0,CHEMBL279,Homo sapiens,IC50
16522591,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780570,=,nM,3970.0,CHEMBL279,Homo sapiens,IC50
16522592,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780536,=,nM,5760.0,CHEMBL279,Homo sapiens,IC50
16539471,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL1614712,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
16539472,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL3787112,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
16539473,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL3787614,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
16579420,CHEMBL3804160,Inhibition of recombinant KDR (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay,B,CHEMBL3800021,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50
16579449,CHEMBL3804160,Inhibition of recombinant KDR (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay,B,CHEMBL3799843,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
16580844,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3797507,=,nM,17.5,CHEMBL279,Homo sapiens,IC50
16580845,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3797416,=,nM,35.8,CHEMBL279,Homo sapiens,IC50
16580846,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3800526,=,nM,21.5,CHEMBL279,Homo sapiens,IC50
16580849,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3348846,=,nM,29.5,CHEMBL279,Homo sapiens,IC50
16588212,CHEMBL3806821,Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATP,B,CHEMBL3805771,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
16588213,CHEMBL3806821,Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATP,B,CHEMBL3806189,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16595597,CHEMBL3811336,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3989914,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
16607618,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808921,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
16607619,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809643,=,nM,134.0,CHEMBL279,Homo sapiens,IC50
16607620,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808957,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
16607621,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809754,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
16607622,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808653,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
16607623,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809144,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
16607624,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808450,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
16607625,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3810154,=,nM,36.0,CHEMBL279,Homo sapiens,IC50
16607626,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3810135,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
16607638,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809254,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
16607639,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809077,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
16607640,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809912,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50
16607641,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808854,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
16607642,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809895,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50
16607643,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808728,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50
16607644,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809588,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
16607645,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809608,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
16607646,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808619,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
16607648,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3808622,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
16617046,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814311,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
16617047,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814321,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
16617048,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3813791,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
16617049,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3815081,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
16617050,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814773,=,nM,890.0,CHEMBL279,Homo sapiens,IC50
16617051,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3815128,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
16617052,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814828,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
16617053,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814710,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
16624309,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3817989,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
16624310,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818768,=,nM,57.9,CHEMBL279,Homo sapiens,IC50
16624311,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818193,=,nM,24.5,CHEMBL279,Homo sapiens,IC50
16624315,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819410,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
16624316,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819461,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
16624317,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818017,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
16624318,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818404,=,nM,237.0,CHEMBL279,Homo sapiens,IC50
16624319,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819253,=,nM,168.0,CHEMBL279,Homo sapiens,IC50
16624320,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818283,=,nM,201.0,CHEMBL279,Homo sapiens,IC50
16624340,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819389,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
16638335,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL237347,=,nM,186.0,CHEMBL279,Homo sapiens,IC50
16638337,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3822791,=,nM,2385.0,CHEMBL279,Homo sapiens,IC50
16638340,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL237345,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
16638342,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3823527,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
16638343,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3822938,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16639376,CHEMBL3826396,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 30 mins by HTRF assay",B,CHEMBL3823520,=,nM,96.68,CHEMBL279,Homo sapiens,IC50
16645030,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827870,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50
16645031,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827137,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50
16645042,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827098,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
16645043,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3828416,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
16645044,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827045,=,nM,99.0,CHEMBL279,Homo sapiens,IC50
16645045,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827784,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
16655116,CHEMBL3830416,"Inhibition of N-terminal His6-tagged recombinant human KDR (790 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3735648,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
16759974,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681244,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
16759975,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3895337,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
16759976,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3676329,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
16759977,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681317,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16759978,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681314,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
16759979,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681278,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
16759980,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3891894,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
16759981,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3952373,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
16759982,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3959997,=,nM,6.5,CHEMBL279,Homo sapiens,IC50
16759983,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3941474,=,nM,52.0,CHEMBL279,Homo sapiens,IC50
16759984,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681287,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50
16759985,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3907479,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
16759986,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3934547,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
16759987,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3984621,=,nM,2.4,CHEMBL279,Homo sapiens,IC50
16759988,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3956001,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
16759989,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3976548,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
16759990,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3947281,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
16759991,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3981956,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
16759992,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3905685,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50
16770507,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3975807,=,nM,720.0,CHEMBL279,Homo sapiens,IC50
16770508,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3957826,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
16770509,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3926927,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
16782526,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL3931691,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
16782527,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL3890887,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
16804131,CHEMBL3869723,Inhibition of human N-terminal 6His-tagged VEGFR2 (807 to 1171 residues) expressed in Sf9 insect cells using 5-carboxyfluorescein(FAM)-EEPLYWSFPAKKK-NH2 as substrate after 1 hr in presence of ATP by electrophoretic mobility shift assay,B,CHEMBL3979920,=,nM,135.0,CHEMBL279,Homo sapiens,IC50
16808973,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL590878,=,nM,5.09,CHEMBL279,Homo sapiens,IC50
16808974,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3897723,=,nM,0.41,CHEMBL279,Homo sapiens,IC50
16808975,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3983586,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
16808976,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3900264,=,nM,0.55,CHEMBL279,Homo sapiens,IC50
16808977,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3963403,=,nM,0.88,CHEMBL279,Homo sapiens,IC50
16808978,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3966129,=,nM,0.69,CHEMBL279,Homo sapiens,IC50
16808979,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3903713,=,nM,0.42,CHEMBL279,Homo sapiens,IC50
16808980,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3974626,=,nM,2.4,CHEMBL279,Homo sapiens,IC50
16808981,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3912723,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
16808982,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3982619,=,nM,3.5,CHEMBL279,Homo sapiens,IC50
16808983,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3921710,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
16808984,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3893698,=,nM,3.6,CHEMBL279,Homo sapiens,IC50
16808985,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3938794,=,nM,4.4,CHEMBL279,Homo sapiens,IC50
16808986,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3927914,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
16808987,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3896476,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
16808988,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3924500,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
16808989,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3905411,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
16808990,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL1380839,=,nM,7.3,CHEMBL279,Homo sapiens,IC50
16808991,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3977192,=,nM,7.5,CHEMBL279,Homo sapiens,IC50
16808992,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3906533,=,nM,0.54,CHEMBL279,Homo sapiens,IC50
16808993,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3937949,=,nM,0.68,CHEMBL279,Homo sapiens,IC50
16808994,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3915508,=,nM,0.43,CHEMBL279,Homo sapiens,IC50
16808995,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3979610,=,nM,0.67,CHEMBL279,Homo sapiens,IC50
16808996,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3950630,=,nM,0.77,CHEMBL279,Homo sapiens,IC50
16808997,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3908272,=,nM,8.5,CHEMBL279,Homo sapiens,IC50
16808998,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3978686,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
16808999,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3899216,=,nM,9.7,CHEMBL279,Homo sapiens,IC50
16809000,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3970399,=,nM,8.6,CHEMBL279,Homo sapiens,IC50
16809001,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3926223,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
16815390,CHEMBL3871602,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3939307,=,nM,0.2,CHEMBL279,Homo sapiens,IC50
16829739,CHEMBL3874955,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL3931223,=,nM,589.0,CHEMBL279,Homo sapiens,IC50
16837405,CHEMBL3876063,Inhibition of human recombinant His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system,B,CHEMBL3884319,=,nM,1445.0,CHEMBL279,Homo sapiens,IC50
16847225,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3923551,=,nM,576.0,CHEMBL279,Homo sapiens,IC50
16847226,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3905242,=,nM,815.0,CHEMBL279,Homo sapiens,IC50
16847227,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3896615,=,nM,588.0,CHEMBL279,Homo sapiens,IC50
16847228,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3933568,=,nM,1986.0,CHEMBL279,Homo sapiens,IC50
16847229,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3905552,=,nM,214.0,CHEMBL279,Homo sapiens,IC50
16847230,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3979264,=,nM,261.0,CHEMBL279,Homo sapiens,IC50
16847231,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3962233,=,nM,279.0,CHEMBL279,Homo sapiens,IC50
16847232,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3938494,=,nM,178.0,CHEMBL279,Homo sapiens,IC50
16847233,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3968039,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
16847234,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3929448,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16847235,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3957025,=,nM,528.0,CHEMBL279,Homo sapiens,IC50
16847236,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3920551,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
16847237,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3948354,=,nM,1873.0,CHEMBL279,Homo sapiens,IC50
16847239,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3939588,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
16847240,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3975598,=,nM,275.0,CHEMBL279,Homo sapiens,IC50
16847241,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3904787,=,nM,404.0,CHEMBL279,Homo sapiens,IC50
16847242,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3917723,=,nM,966.0,CHEMBL279,Homo sapiens,IC50
16880724,CHEMBL3880861,Inhibition of human KDR after 40 mins in presence of [gamma33P-ATP] by scintillation counting,B,CHEMBL1097700,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
16894514,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL598377,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894516,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL596761,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894794,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3907491,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894796,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3945421,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894797,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3903506,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894798,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3972249,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894799,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3938265,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894800,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3916600,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894801,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3900967,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894802,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3977186,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894803,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3899385,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894804,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3902161,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894806,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3961102,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894807,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3921652,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894808,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3924346,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894809,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3952709,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894810,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3950023,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894811,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984573,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894812,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3905131,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894813,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3939306,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894814,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3936547,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894815,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3901236,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894816,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3898480,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894817,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917105,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894818,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3914322,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894819,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3985004,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894820,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917670,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894821,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3981584,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894822,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984055,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894823,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3929290,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894824,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3932057,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894825,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3968968,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894827,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917093,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16894830,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3986286,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894919,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3973966,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894922,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984477,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894923,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3963327,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
16894928,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3891395,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16895017,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3937516,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16895018,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3920254,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16905377,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951527,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906430,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968192,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906431,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977450,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906432,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959516,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906433,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3956820,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906436,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946242,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906438,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3908311,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906439,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905501,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906440,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924147,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906450,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3922278,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906453,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893416,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906454,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3934134,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906455,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931427,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906457,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900059,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906461,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983466,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906462,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3917294,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906463,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3920036,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906464,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946590,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906465,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986404,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906466,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961005,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906467,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958481,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906468,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919145,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906469,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895424,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906470,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3964605,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906471,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955486,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906472,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924380,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906473,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921689,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906474,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955359,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906475,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3964556,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906476,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910031,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906477,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907230,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906480,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932115,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906481,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929354,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906482,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968322,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906483,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965901,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906484,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928696,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906485,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3926038,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906486,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952048,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906487,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949434,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906488,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914264,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906489,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904510,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906490,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958507,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906491,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955873,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906492,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3922630,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906493,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3943632,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906494,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979687,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906495,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3954731,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906496,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919501,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906497,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929188,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906498,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949535,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906499,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968843,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906500,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905012,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906501,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907764,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906502,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909626,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906503,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896044,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906504,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976826,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906505,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916485,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906506,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3936025,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906507,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3960730,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906508,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913860,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906509,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945353,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906510,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942671,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906512,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3984213,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906514,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945860,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906516,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900858,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906521,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985840,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906522,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983201,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906523,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3963620,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906524,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937857,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906525,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929002,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906526,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951099,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906527,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933848,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906528,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944502,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906529,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895848,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906530,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893128,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906531,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952493,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906532,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961982,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906533,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900296,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906534,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3903022,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906535,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946018,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906536,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3948661,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906537,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914671,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906540,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971864,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906543,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952023,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906544,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949400,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906545,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900567,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906546,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939717,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906547,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3938621,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906548,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3927549,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906551,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893575,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906552,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3930406,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906554,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3897215,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906555,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3898627,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906556,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910064,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906557,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959195,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906560,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986301,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906561,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947408,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906562,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944780,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906563,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909596,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906564,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3906789,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906565,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933123,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906566,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3930429,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906568,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983179,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906571,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899485,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906572,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923013,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906573,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937598,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906575,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3918670,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906580,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910102,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906581,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979195,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906582,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3981613,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906583,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942082,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906585,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985254,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906590,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919493,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906591,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958678,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906592,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3956056,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906593,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893032,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906594,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3890263,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906595,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944702,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906596,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3912287,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906597,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3906715,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906598,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896927,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906601,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949155,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906603,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904192,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906604,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913993,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906606,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968030,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906608,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900295,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906609,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928180,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906610,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921228,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906611,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895890,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906612,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893176,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906613,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933897,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906615,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979728,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906616,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951403,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906618,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985896,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906620,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895645,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906621,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965938,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906622,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929942,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906623,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932698,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906624,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976896,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906625,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979317,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906626,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916297,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906628,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946469,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906629,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965160,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906630,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955447,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906631,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932218,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906632,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3898138,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906633,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916567,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906635,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947769,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906637,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914394,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906638,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928439,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906639,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3925803,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906641,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3953937,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906642,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913496,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906644,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937092,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906646,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3892030,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906647,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3901787,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906648,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958778,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906649,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961472,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906650,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933398,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906651,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923692,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906652,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893845,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906653,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3970332,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906654,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947700,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906655,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945062,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906656,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986123,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906657,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983450,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906658,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3941200,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906659,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959038,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906660,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942387,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906661,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3982666,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906662,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3920114,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906663,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3894418,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906664,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929966,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906665,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3969472,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906666,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976226,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906667,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931724,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906668,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3953606,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906669,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3918306,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906670,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907879,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906671,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905114,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906673,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3966429,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906674,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3962355,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906679,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3892117,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906680,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907215,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906681,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904460,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906684,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913719,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906685,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3911207,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906686,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958466,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906687,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955824,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906688,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899410,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906690,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899440,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906691,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977221,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906692,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986102,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906693,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942161,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906694,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3940839,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906695,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971050,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906697,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931393,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906698,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3934095,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906700,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928601,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906701,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3962203,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906702,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959495,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906703,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916953,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906705,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977503,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906706,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968233,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906707,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939133,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906711,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921390,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906712,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924098,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906718,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893846,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906719,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3981432,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906724,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895129,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906725,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3935851,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906726,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933130,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906727,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3891130,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906728,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909603,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906729,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965625,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906730,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986082,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906731,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945028,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906732,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947643,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906733,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921861,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906734,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3972940,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906735,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923645,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906736,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933359,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906737,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893363,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906738,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896067,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906739,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976788,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906740,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3974328,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906741,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909572,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906742,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3927849,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906743,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961417,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906744,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958721,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906745,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3943734,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906746,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971560,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906747,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939828,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
16906748,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937048,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906749,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916828,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906750,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924442,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906751,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3890300,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906752,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893058,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906753,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985116,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
16906754,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3938869,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
17601221,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3940661,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
17601256,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644032,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
17601260,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644033,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
17601264,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644034,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
17601743,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676391,=,nM,985.0,CHEMBL279,Homo sapiens,IC50
17601744,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676392,=,nM,279.0,CHEMBL279,Homo sapiens,IC50
17601746,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676393,=,nM,433.0,CHEMBL279,Homo sapiens,IC50
17601748,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676394,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17602080,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642835,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50
17613852,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642830,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
17613853,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642838,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17613854,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642839,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
17613855,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642840,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17613856,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642841,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50
17613858,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642836,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50
17613859,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642837,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
17642175,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690476,=,nM,427.0,CHEMBL279,Homo sapiens,IC50
17642176,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690477,=,nM,8450.0,CHEMBL279,Homo sapiens,IC50
17642177,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686060,=,nM,45.1,CHEMBL279,Homo sapiens,IC50
17642178,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686061,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
17642179,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686062,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
17642180,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686063,=,nM,10.6,CHEMBL279,Homo sapiens,IC50
17642181,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686064,=,nM,66.9,CHEMBL279,Homo sapiens,IC50
17642182,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686065,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17642183,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686066,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
17642184,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690373,=,nM,24.9,CHEMBL279,Homo sapiens,IC50
17642185,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690478,=,nM,1340.0,CHEMBL279,Homo sapiens,IC50
17642186,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690374,=,nM,81.2,CHEMBL279,Homo sapiens,IC50
17642187,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690375,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
17642188,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690376,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
17642189,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690377,=,nM,13.3,CHEMBL279,Homo sapiens,IC50
17642190,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690378,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
17642191,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690379,=,nM,195.0,CHEMBL279,Homo sapiens,IC50
17642192,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690380,=,nM,11.5,CHEMBL279,Homo sapiens,IC50
17642193,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690381,=,nM,950.0,CHEMBL279,Homo sapiens,IC50
17642194,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690382,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
17642195,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690383,=,nM,198.0,CHEMBL279,Homo sapiens,IC50
17642196,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690384,=,nM,349.0,CHEMBL279,Homo sapiens,IC50
17642197,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690385,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
17642198,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690386,=,nM,80.4,CHEMBL279,Homo sapiens,IC50
17642199,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690387,=,nM,7.85,CHEMBL279,Homo sapiens,IC50
17642200,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690388,=,nM,9.45,CHEMBL279,Homo sapiens,IC50
17642201,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690389,=,nM,89.3,CHEMBL279,Homo sapiens,IC50
17642202,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690390,=,nM,5090.0,CHEMBL279,Homo sapiens,IC50
17642203,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690391,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
17642204,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690392,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
17642205,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690393,=,nM,139.0,CHEMBL279,Homo sapiens,IC50
17642206,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690394,=,nM,269.0,CHEMBL279,Homo sapiens,IC50
17642207,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690395,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
17642208,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690396,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50
17642209,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690397,=,nM,11.2,CHEMBL279,Homo sapiens,IC50
17642210,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639892,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
17642211,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690398,=,nM,59.9,CHEMBL279,Homo sapiens,IC50
17642212,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690399,=,nM,757.0,CHEMBL279,Homo sapiens,IC50
17642213,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690400,=,nM,9.06,CHEMBL279,Homo sapiens,IC50
17642214,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690401,=,nM,12.6,CHEMBL279,Homo sapiens,IC50
17642215,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690402,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17642216,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690403,=,nM,47.5,CHEMBL279,Homo sapiens,IC50
17642217,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690404,=,nM,10.6,CHEMBL279,Homo sapiens,IC50
17642218,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690405,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17642219,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690406,=,nM,593.0,CHEMBL279,Homo sapiens,IC50
17642220,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690407,=,nM,285.0,CHEMBL279,Homo sapiens,IC50
17642221,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690408,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17642222,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690409,=,nM,10.3,CHEMBL279,Homo sapiens,IC50
17642223,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690410,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
17642224,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690411,=,nM,15.5,CHEMBL279,Homo sapiens,IC50
17642226,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690413,=,nM,94.4,CHEMBL279,Homo sapiens,IC50
17642227,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690414,=,nM,31.5,CHEMBL279,Homo sapiens,IC50
17642228,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690415,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
17642229,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690416,=,nM,7.85,CHEMBL279,Homo sapiens,IC50
17642230,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690417,=,nM,18.2,CHEMBL279,Homo sapiens,IC50
17642231,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690418,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
17642232,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690419,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
17642233,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690420,=,nM,351.0,CHEMBL279,Homo sapiens,IC50
17642234,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690421,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
17642235,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690422,=,nM,628.0,CHEMBL279,Homo sapiens,IC50
17642236,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690423,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
17642237,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690424,=,nM,77.5,CHEMBL279,Homo sapiens,IC50
17642238,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690425,=,nM,33.9,CHEMBL279,Homo sapiens,IC50
17642239,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690426,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17642240,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690427,=,nM,125.0,CHEMBL279,Homo sapiens,IC50
17642241,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690428,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
17642242,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690429,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17642243,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690430,=,nM,14.3,CHEMBL279,Homo sapiens,IC50
17642244,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690431,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
17642245,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690432,=,nM,50.8,CHEMBL279,Homo sapiens,IC50
17642246,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690433,=,nM,20.8,CHEMBL279,Homo sapiens,IC50
17642247,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690434,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
17642248,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690435,=,nM,47.5,CHEMBL279,Homo sapiens,IC50
17642249,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690436,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17642250,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690437,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17642251,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690438,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
17642252,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690479,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
17642253,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690439,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17642254,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690440,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50
17642255,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690441,=,nM,58.9,CHEMBL279,Homo sapiens,IC50
17642256,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690442,=,nM,73.4,CHEMBL279,Homo sapiens,IC50
17642257,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690443,=,nM,17.7,CHEMBL279,Homo sapiens,IC50
17642258,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690444,=,nM,14.9,CHEMBL279,Homo sapiens,IC50
17642259,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690445,=,nM,12.5,CHEMBL279,Homo sapiens,IC50
17642260,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690446,=,nM,32.5,CHEMBL279,Homo sapiens,IC50
17642261,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690447,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50
17642262,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690448,=,nM,118.0,CHEMBL279,Homo sapiens,IC50
17642263,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690449,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642264,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690450,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
17642265,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690451,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
17642266,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690452,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
17642267,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690453,=,nM,235.0,CHEMBL279,Homo sapiens,IC50
17642268,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690454,=,nM,26.9,CHEMBL279,Homo sapiens,IC50
17642269,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690455,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
17642270,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690456,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17642271,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690457,=,nM,83.4,CHEMBL279,Homo sapiens,IC50
17642272,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690458,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17642273,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690459,=,nM,50.4,CHEMBL279,Homo sapiens,IC50
17642274,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690460,=,nM,86.9,CHEMBL279,Homo sapiens,IC50
17642275,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690461,=,nM,58.3,CHEMBL279,Homo sapiens,IC50
17642276,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690462,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
17642277,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690463,=,nM,329.0,CHEMBL279,Homo sapiens,IC50
17642278,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690464,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
17642279,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690465,=,nM,268.0,CHEMBL279,Homo sapiens,IC50
17642280,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690466,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
17642281,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690467,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
17642282,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690480,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
17642283,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690468,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
17642284,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690469,=,nM,21.4,CHEMBL279,Homo sapiens,IC50
17642285,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690470,=,nM,32.4,CHEMBL279,Homo sapiens,IC50
17642286,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690471,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
17642287,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690472,=,nM,398.0,CHEMBL279,Homo sapiens,IC50
17642288,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690473,=,nM,313.0,CHEMBL279,Homo sapiens,IC50
17642289,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690474,=,nM,31.5,CHEMBL279,Homo sapiens,IC50
17642290,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690475,=,nM,7.79,CHEMBL279,Homo sapiens,IC50
17642291,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690481,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50
17642292,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690482,=,nM,383.0,CHEMBL279,Homo sapiens,IC50
17642293,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690483,=,nM,847.0,CHEMBL279,Homo sapiens,IC50
17642294,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690484,=,nM,18.5,CHEMBL279,Homo sapiens,IC50
17642295,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690485,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17642296,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690486,=,nM,19.1,CHEMBL279,Homo sapiens,IC50
17642297,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690487,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50
17642298,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690499,=,nM,455.0,CHEMBL279,Homo sapiens,IC50
17642299,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690488,=,nM,38.4,CHEMBL279,Homo sapiens,IC50
17642300,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690506,=,nM,15.3,CHEMBL279,Homo sapiens,IC50
17642301,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690489,=,nM,39.4,CHEMBL279,Homo sapiens,IC50
17642302,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690505,=,nM,581.0,CHEMBL279,Homo sapiens,IC50
17642303,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690494,=,nM,465.0,CHEMBL279,Homo sapiens,IC50
17642304,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690493,=,nM,189.0,CHEMBL279,Homo sapiens,IC50
17642305,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639893,=,nM,980.0,CHEMBL279,Homo sapiens,IC50
17642306,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690501,=,nM,13.5,CHEMBL279,Homo sapiens,IC50
17642307,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690500,=,nM,35.3,CHEMBL279,Homo sapiens,IC50
17642308,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690490,=,nM,24.7,CHEMBL279,Homo sapiens,IC50
17642309,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690491,=,nM,15.9,CHEMBL279,Homo sapiens,IC50
17642310,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690497,=,nM,455.0,CHEMBL279,Homo sapiens,IC50
17642311,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690492,=,nM,9.73,CHEMBL279,Homo sapiens,IC50
17642312,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690504,=,nM,157.0,CHEMBL279,Homo sapiens,IC50
17642313,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690498,=,nM,448.0,CHEMBL279,Homo sapiens,IC50
17642314,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690513,=,nM,97.3,CHEMBL279,Homo sapiens,IC50
17642315,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694657,=,nM,319.0,CHEMBL279,Homo sapiens,IC50
17642316,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694723,=,nM,453.0,CHEMBL279,Homo sapiens,IC50
17642317,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694672,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50
17642318,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690515,=,nM,680.0,CHEMBL279,Homo sapiens,IC50
17642319,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690516,=,nM,588.0,CHEMBL279,Homo sapiens,IC50
17642320,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694718,=,nM,298.0,CHEMBL279,Homo sapiens,IC50
17642321,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690518,=,nM,574.0,CHEMBL279,Homo sapiens,IC50
17642322,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690519,=,nM,235.0,CHEMBL279,Homo sapiens,IC50
17642323,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690495,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
17642324,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690520,=,nM,332.0,CHEMBL279,Homo sapiens,IC50
17642325,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694717,=,nM,686.0,CHEMBL279,Homo sapiens,IC50
17642326,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690511,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50
17642327,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694724,=,nM,706.0,CHEMBL279,Homo sapiens,IC50
17642328,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694661,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
17642329,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694708,=,nM,23.9,CHEMBL279,Homo sapiens,IC50
17642331,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694716,=,nM,199.0,CHEMBL279,Homo sapiens,IC50
17642332,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690521,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
17642333,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690522,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50
17642334,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690503,=,nM,131.0,CHEMBL279,Homo sapiens,IC50
17642335,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690523,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17642336,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690524,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
17642337,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690525,=,nM,354.0,CHEMBL279,Homo sapiens,IC50
17642338,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690526,=,nM,449.0,CHEMBL279,Homo sapiens,IC50
17642339,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690496,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
17642340,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690527,=,nM,419.0,CHEMBL279,Homo sapiens,IC50
17642341,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690528,=,nM,391.0,CHEMBL279,Homo sapiens,IC50
17642342,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690507,=,nM,43.1,CHEMBL279,Homo sapiens,IC50
17642344,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694660,=,nM,95.4,CHEMBL279,Homo sapiens,IC50
17642345,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690510,=,nM,173.0,CHEMBL279,Homo sapiens,IC50
17642346,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690530,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
17642348,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690532,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
17642349,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690533,=,nM,351.0,CHEMBL279,Homo sapiens,IC50
17642350,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690534,=,nM,647.0,CHEMBL279,Homo sapiens,IC50
17642351,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690535,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642352,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690536,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17642353,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694656,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
17642354,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690509,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
17642355,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690537,=,nM,171.0,CHEMBL279,Homo sapiens,IC50
17642356,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694662,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
17642358,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690538,=,nM,95.4,CHEMBL279,Homo sapiens,IC50
17642360,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690539,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
17642361,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690540,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
17642362,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690541,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50
17642363,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694674,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
17642364,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694659,=,nM,403.0,CHEMBL279,Homo sapiens,IC50
17642367,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694709,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
17642368,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690545,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
17642369,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690546,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
17642372,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690508,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
17642373,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690547,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17642374,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690548,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
17642375,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690549,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17642376,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690550,=,nM,570.0,CHEMBL279,Homo sapiens,IC50
17642377,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690551,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
17642378,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694714,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
17642379,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694655,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642380,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694707,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17642381,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690552,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
17642382,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690553,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
17642383,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694649,=,nM,830.0,CHEMBL279,Homo sapiens,IC50
17642384,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690554,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17642385,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690555,=,nM,59.0,CHEMBL279,Homo sapiens,IC50
17642386,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690556,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17642387,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694703,=,nM,820.0,CHEMBL279,Homo sapiens,IC50
17642388,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694702,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17642389,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694650,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
17642390,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690557,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
17642391,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690558,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
17642392,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690559,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
17642394,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690562,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17642395,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690563,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
17642397,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694705,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
17642398,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690565,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
17642399,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690566,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
17642400,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690567,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
17642401,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690568,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
17642402,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694664,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17642403,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690569,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642404,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694663,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
17642405,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639935,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17642406,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690570,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
17642407,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690571,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
17642408,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690573,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
17642409,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690574,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17642410,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690575,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
17642411,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694706,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
17642412,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694678,=,nM,8.5,CHEMBL279,Homo sapiens,IC50
17642413,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694710,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17642414,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694679,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
17642415,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690576,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17642416,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690577,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
17642417,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690578,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17642418,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694680,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
17642419,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694711,=,nM,930.0,CHEMBL279,Homo sapiens,IC50
17642420,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694669,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17642421,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690579,=,nM,790.0,CHEMBL279,Homo sapiens,IC50
17642422,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690580,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
17642423,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694665,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
17642424,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694719,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17642425,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694720,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
17642426,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690582,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
17642427,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690583,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17642428,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690584,=,nM,6400.0,CHEMBL279,Homo sapiens,IC50
17642429,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690585,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
17642430,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694671,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50
17642431,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694646,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17642432,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694682,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
17642433,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690588,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17642434,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690589,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
17642435,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690590,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17642436,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690591,=,nM,5640.0,CHEMBL279,Homo sapiens,IC50
17642437,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690592,=,nM,683.0,CHEMBL279,Homo sapiens,IC50
17642438,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694722,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
17642439,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694712,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
17642440,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694654,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17642441,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694721,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
17642442,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694645,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17642444,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694668,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17642445,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694670,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
17642447,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694651,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
17642448,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694684,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642449,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694685,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
17642450,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694653,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17642451,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694688,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
17642452,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694687,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
17642453,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694690,=,nM,956.0,CHEMBL279,Homo sapiens,IC50
17642454,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694689,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
17642455,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694691,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
17642456,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694713,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17642457,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694692,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
17642458,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694693,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
17642459,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694647,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17642460,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694694,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
17642461,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694695,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
17642462,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694686,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
17642463,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694696,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17642464,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694698,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
17642465,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694699,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
17643291,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644019,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
17643292,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644020,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
17643293,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644021,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
17643294,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644022,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
17643295,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644023,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
17643296,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644024,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17643297,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644025,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
17643298,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644026,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
17643299,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644027,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
17643300,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644028,=,nM,610.0,CHEMBL279,Homo sapiens,IC50
17643302,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644030,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
17643303,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644031,=,nM,890.0,CHEMBL279,Homo sapiens,IC50
17648862,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671475,=,nM,131.0,CHEMBL279,Homo sapiens,IC50
17648863,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671476,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648864,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671477,=,nM,108.0,CHEMBL279,Homo sapiens,IC50
17648865,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671478,=,nM,136.0,CHEMBL279,Homo sapiens,IC50
17648866,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671479,=,nM,203.0,CHEMBL279,Homo sapiens,IC50
17648867,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671480,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
17648868,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671481,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648869,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671482,=,nM,148.0,CHEMBL279,Homo sapiens,IC50
17648870,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671483,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
17648871,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671484,=,nM,55.0,CHEMBL279,Homo sapiens,IC50
17648872,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671485,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
17648873,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671486,=,nM,347.0,CHEMBL279,Homo sapiens,IC50
17648874,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671487,=,nM,157.0,CHEMBL279,Homo sapiens,IC50
17648875,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671488,=,nM,591.0,CHEMBL279,Homo sapiens,IC50
17648876,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3639703,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
17648877,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671489,=,nM,208.0,CHEMBL279,Homo sapiens,IC50
17648878,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671490,=,nM,154.0,CHEMBL279,Homo sapiens,IC50
17648879,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671491,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
17648880,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671492,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
17648881,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671493,=,nM,545.0,CHEMBL279,Homo sapiens,IC50
17648882,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671494,=,nM,513.0,CHEMBL279,Homo sapiens,IC50
17648883,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671495,=,nM,523.0,CHEMBL279,Homo sapiens,IC50
17648884,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671496,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648885,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671497,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648886,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671498,=,nM,584.0,CHEMBL279,Homo sapiens,IC50
17648887,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671499,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648888,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671500,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17648889,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671501,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
17648890,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671502,=,nM,545.0,CHEMBL279,Homo sapiens,IC50
17648891,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671503,=,nM,513.0,CHEMBL279,Homo sapiens,IC50
17648892,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671504,=,nM,523.0,CHEMBL279,Homo sapiens,IC50
17648893,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671505,=,nM,259.0,CHEMBL279,Homo sapiens,IC50
17648894,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671506,=,nM,369.0,CHEMBL279,Homo sapiens,IC50
17648895,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671507,=,nM,458.0,CHEMBL279,Homo sapiens,IC50
17648896,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671508,=,nM,457.0,CHEMBL279,Homo sapiens,IC50
17648897,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671509,=,nM,354.0,CHEMBL279,Homo sapiens,IC50
17648898,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671510,=,nM,895.0,CHEMBL279,Homo sapiens,IC50
17648899,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671511,=,nM,324.0,CHEMBL279,Homo sapiens,IC50
17648900,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671512,=,nM,264.0,CHEMBL279,Homo sapiens,IC50
17648901,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671513,=,nM,155.0,CHEMBL279,Homo sapiens,IC50
17648902,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671514,=,nM,134.0,CHEMBL279,Homo sapiens,IC50
17648903,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671515,=,nM,687.0,CHEMBL279,Homo sapiens,IC50
17648904,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671516,=,nM,785.0,CHEMBL279,Homo sapiens,IC50
17648905,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671517,=,nM,161.0,CHEMBL279,Homo sapiens,IC50
17648906,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671518,=,nM,325.0,CHEMBL279,Homo sapiens,IC50
17648907,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671519,=,nM,635.0,CHEMBL279,Homo sapiens,IC50
17648908,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671520,=,nM,209.0,CHEMBL279,Homo sapiens,IC50
17648909,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671521,=,nM,698.0,CHEMBL279,Homo sapiens,IC50
17648910,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671522,=,nM,854.0,CHEMBL279,Homo sapiens,IC50
17648911,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671523,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
17648912,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671524,=,nM,954.0,CHEMBL279,Homo sapiens,IC50
17648913,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671525,=,nM,354.0,CHEMBL279,Homo sapiens,IC50
17648914,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671526,=,nM,875.0,CHEMBL279,Homo sapiens,IC50
17648915,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671527,=,nM,423.0,CHEMBL279,Homo sapiens,IC50
17648916,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676390,=,nM,471.0,CHEMBL279,Homo sapiens,IC50
17648917,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671528,=,nM,654.0,CHEMBL279,Homo sapiens,IC50
17648918,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671529,=,nM,235.0,CHEMBL279,Homo sapiens,IC50
17648919,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671530,=,nM,954.0,CHEMBL279,Homo sapiens,IC50
17648920,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671531,=,nM,198.0,CHEMBL279,Homo sapiens,IC50
17648921,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671532,=,nM,685.0,CHEMBL279,Homo sapiens,IC50
17648922,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671533,=,nM,354.0,CHEMBL279,Homo sapiens,IC50
17648923,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671534,=,nM,749.0,CHEMBL279,Homo sapiens,IC50
17648924,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671535,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
17648925,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671536,=,nM,231.0,CHEMBL279,Homo sapiens,IC50
17648926,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671537,=,nM,954.0,CHEMBL279,Homo sapiens,IC50
17648927,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671538,=,nM,125.0,CHEMBL279,Homo sapiens,IC50
17648928,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671539,=,nM,215.0,CHEMBL279,Homo sapiens,IC50
17648929,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671540,=,nM,687.0,CHEMBL279,Homo sapiens,IC50
17648930,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671541,=,nM,251.0,CHEMBL279,Homo sapiens,IC50
17648931,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671542,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
17648932,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671543,=,nM,668.0,CHEMBL279,Homo sapiens,IC50
17648933,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671544,=,nM,372.0,CHEMBL279,Homo sapiens,IC50
17648934,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671545,=,nM,658.0,CHEMBL279,Homo sapiens,IC50
17648935,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671546,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648936,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671547,=,nM,365.0,CHEMBL279,Homo sapiens,IC50
17648937,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671548,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648938,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671549,=,nM,1432.0,CHEMBL279,Homo sapiens,IC50
17648939,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671550,=,nM,77.0,CHEMBL279,Homo sapiens,IC50
17648940,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671551,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
17648941,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671552,=,nM,158.0,CHEMBL279,Homo sapiens,IC50
17648942,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671553,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
17648943,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671554,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
17648944,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671555,=,nM,784.0,CHEMBL279,Homo sapiens,IC50
17648945,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671556,=,nM,98.0,CHEMBL279,Homo sapiens,IC50
17648946,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671557,=,nM,698.0,CHEMBL279,Homo sapiens,IC50
17648947,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671558,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648948,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671559,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648949,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671560,=,nM,477.0,CHEMBL279,Homo sapiens,IC50
17648950,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671561,=,nM,587.0,CHEMBL279,Homo sapiens,IC50
17648951,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671562,=,nM,129.0,CHEMBL279,Homo sapiens,IC50
17648952,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671563,=,nM,197.0,CHEMBL279,Homo sapiens,IC50
17648953,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671564,=,nM,698.0,CHEMBL279,Homo sapiens,IC50
17648954,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671565,=,nM,782.0,CHEMBL279,Homo sapiens,IC50
17648955,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671566,=,nM,358.0,CHEMBL279,Homo sapiens,IC50
17648956,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671567,=,nM,658.0,CHEMBL279,Homo sapiens,IC50
17648957,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671568,=,nM,965.0,CHEMBL279,Homo sapiens,IC50
17648958,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671569,=,nM,997.0,CHEMBL279,Homo sapiens,IC50
17648960,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671570,=,nM,857.0,CHEMBL279,Homo sapiens,IC50
17648961,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671571,=,nM,654.0,CHEMBL279,Homo sapiens,IC50
17648962,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671572,=,nM,782.0,CHEMBL279,Homo sapiens,IC50
17648963,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671573,=,nM,945.0,CHEMBL279,Homo sapiens,IC50
17648964,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671574,=,nM,654.0,CHEMBL279,Homo sapiens,IC50
17648965,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671575,=,nM,853.0,CHEMBL279,Homo sapiens,IC50
17648966,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671576,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
17648967,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671577,=,nM,486.0,CHEMBL279,Homo sapiens,IC50
17648968,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671578,=,nM,478.0,CHEMBL279,Homo sapiens,IC50
17648969,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671579,=,nM,951.0,CHEMBL279,Homo sapiens,IC50
17648970,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671580,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648971,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671581,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
17648972,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671582,=,nM,268.0,CHEMBL279,Homo sapiens,IC50
17648973,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671583,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648974,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671584,=,nM,854.0,CHEMBL279,Homo sapiens,IC50
17648975,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671585,=,nM,758.0,CHEMBL279,Homo sapiens,IC50
17648976,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676338,=,nM,945.0,CHEMBL279,Homo sapiens,IC50
17648977,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676339,=,nM,489.0,CHEMBL279,Homo sapiens,IC50
17648978,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3639752,=,nM,782.0,CHEMBL279,Homo sapiens,IC50
17648979,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676340,=,nM,127.0,CHEMBL279,Homo sapiens,IC50
17648980,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676341,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
17648981,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676342,=,nM,789.0,CHEMBL279,Homo sapiens,IC50
17648982,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676343,=,nM,268.0,CHEMBL279,Homo sapiens,IC50
17648983,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676344,=,nM,136.0,CHEMBL279,Homo sapiens,IC50
17648984,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676345,=,nM,218.0,CHEMBL279,Homo sapiens,IC50
17648985,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676346,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
17648986,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676347,=,nM,958.0,CHEMBL279,Homo sapiens,IC50
17648987,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676348,=,nM,823.0,CHEMBL279,Homo sapiens,IC50
17648988,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676349,=,nM,357.0,CHEMBL279,Homo sapiens,IC50
17648989,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676350,=,nM,853.0,CHEMBL279,Homo sapiens,IC50
17648990,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676351,=,nM,756.0,CHEMBL279,Homo sapiens,IC50
17648991,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676352,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17648992,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676353,=,nM,419.0,CHEMBL279,Homo sapiens,IC50
17648993,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676354,=,nM,172.0,CHEMBL279,Homo sapiens,IC50
17648994,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676355,=,nM,784.0,CHEMBL279,Homo sapiens,IC50
17648995,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676356,=,nM,856.0,CHEMBL279,Homo sapiens,IC50
17648996,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676357,=,nM,954.0,CHEMBL279,Homo sapiens,IC50
17648997,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676358,=,nM,823.0,CHEMBL279,Homo sapiens,IC50
17648998,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676359,=,nM,657.0,CHEMBL279,Homo sapiens,IC50
17648999,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676360,=,nM,751.0,CHEMBL279,Homo sapiens,IC50
17649000,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676361,=,nM,56.0,CHEMBL279,Homo sapiens,IC50
17649001,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676362,=,nM,106.0,CHEMBL279,Homo sapiens,IC50
17649002,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676363,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
17649003,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676364,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
17649004,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676365,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
17649005,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676366,=,nM,257.0,CHEMBL279,Homo sapiens,IC50
17649006,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676367,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
17649007,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676368,=,nM,206.0,CHEMBL279,Homo sapiens,IC50
17649008,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676369,=,nM,147.0,CHEMBL279,Homo sapiens,IC50
17649009,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676370,=,nM,278.0,CHEMBL279,Homo sapiens,IC50
17649010,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676371,=,nM,309.0,CHEMBL279,Homo sapiens,IC50
17649011,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676372,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17649012,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676373,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17649013,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676374,=,nM,249.0,CHEMBL279,Homo sapiens,IC50
17649014,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676375,=,nM,687.0,CHEMBL279,Homo sapiens,IC50
17649015,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676376,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17649016,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676377,=,nM,419.0,CHEMBL279,Homo sapiens,IC50
17649017,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676378,=,nM,984.0,CHEMBL279,Homo sapiens,IC50
17649018,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676379,=,nM,1117.0,CHEMBL279,Homo sapiens,IC50
17649019,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676380,=,nM,797.0,CHEMBL279,Homo sapiens,IC50
17649022,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676381,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
17649023,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676382,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
17649024,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676383,=,nM,462.0,CHEMBL279,Homo sapiens,IC50
17649025,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676384,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
17649026,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676385,=,nM,128.0,CHEMBL279,Homo sapiens,IC50
17649027,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676386,=,nM,189.0,CHEMBL279,Homo sapiens,IC50
17649028,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676387,=,nM,136.0,CHEMBL279,Homo sapiens,IC50
17649029,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676388,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
17649030,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676389,=,nM,165.0,CHEMBL279,Homo sapiens,IC50
17655873,CHEMBL3887086,"Aurora B Kinase Inhibition Assay: The in vitro inhibitory activity of the compound against Aurora B kinase activity was assayed with reference to a method described in patent publication (JP-A-2008-81492). The purified recombinant human Aurora B protein used in the test was purchased from Carna Biosciences, Inc. For the inhibitory activity assay on the compound, the compound of the present invention was first serially diluted with dimethyl sulfoxide (DMSO). Next, the purified human Aurora B protein FL-Peptide 21 (Caliper Life Sciences, Inc., final concentration: 100 nM), magnesium chloride (final concentration: 1 mM), ATP (final concentration: 40 uM), and each DMSO solution of the compound of the present invention (final concentration of DMSO: 5%) were added into a buffer solution for reaction (20 mM HEPES pH 7.4, 2 mM DTT, 0.01% Tween-20), and the mixture was then incubated at 25 C. for 60 minutes to perform kinase reaction. The kinase reaction was stopped by the addition thereto of IMAP.TM.",B,CHEMBL475251,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17656201,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702601,=,nM,2980.0,CHEMBL279,Homo sapiens,IC50
17656202,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702602,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
17656203,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702603,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
17656204,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702604,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
17656205,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702605,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
17656206,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702606,=,nM,783.0,CHEMBL279,Homo sapiens,IC50
17656207,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702607,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
17656208,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702608,=,nM,145.0,CHEMBL279,Homo sapiens,IC50
17656209,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702609,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
17656210,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702610,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
17656211,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702611,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50
17656212,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702612,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
17656216,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702616,=,nM,4050.0,CHEMBL279,Homo sapiens,IC50
17656217,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702617,=,nM,307.0,CHEMBL279,Homo sapiens,IC50
17656218,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702618,=,nM,2130.0,CHEMBL279,Homo sapiens,IC50
17656219,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702619,=,nM,5710.0,CHEMBL279,Homo sapiens,IC50
17656220,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702620,=,nM,566.0,CHEMBL279,Homo sapiens,IC50
17656221,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702621,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50
17656242,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702642,=,nM,6360.0,CHEMBL279,Homo sapiens,IC50
17656243,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702643,=,nM,2129.0,CHEMBL279,Homo sapiens,IC50
17656256,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702656,=,nM,764.0,CHEMBL279,Homo sapiens,IC50
17656257,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702657,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
17656259,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702659,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
17656261,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702661,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17656262,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702662,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17656263,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702663,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17656264,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702664,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17656265,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702665,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
17656266,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702666,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
17656267,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702667,=,nM,638.0,CHEMBL279,Homo sapiens,IC50
17656268,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702668,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17656269,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702669,=,nM,159.0,CHEMBL279,Homo sapiens,IC50
17656272,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644544,=,nM,584.0,CHEMBL279,Homo sapiens,IC50
17656273,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644545,=,nM,149.0,CHEMBL279,Homo sapiens,IC50
17656275,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644547,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
17656278,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644550,=,nM,308.0,CHEMBL279,Homo sapiens,IC50
17656279,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644551,=,nM,454.0,CHEMBL279,Homo sapiens,IC50
17656280,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644552,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
17656281,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644553,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17656282,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644554,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
17656283,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644555,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17656284,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644556,=,nM,367.0,CHEMBL279,Homo sapiens,IC50
17656285,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644557,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
17656286,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644558,=,nM,49.0,CHEMBL279,Homo sapiens,IC50
17656287,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644559,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
17656288,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644560,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17705584,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL3984441,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
17705585,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL4107720,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
17705586,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 L of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL3919169,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
17706582,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-Blue system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3908700,=,nM,990.0,CHEMBL279,Homo sapiens,IC50
17706585,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-Blue system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3893595,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
17706590,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-Blue system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3957739,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50
17708948,CHEMBL3887309,"KDR Kinase Inhibition Assay: Conditions for assaying the in vitro inhibitory activity of the compound against KDR kinase activity were set with reference to the statement in the LabChip.TM. series reagent supplies price list of Caliper Life Sciences, Inc. that FL-Peptide 22 is adaptable as a substrate peptide to KDR kinase activity assay. The purified recombinant human KDR protein used in the test is a house purified product. For the inhibitory activity assay on the compound, the compound of the present invention was first serially diluted with dimethyl sulfoxide (DMSO). Next, the purified human KDR protein FL-Peptide 22 (final concentration: 1.5 uM), magnesium chloride (final concentration: 10 mM), ATP (final concentration: 200 uM), and each DMSO solution of the compound of the present invention (final concentration of DMSO: 5%) were added into a buffer solution for reaction (100 mM HEPES pH 7.5, 1 mM DTT, 0.003% Brij 35, 0.04% Tween-20, 0.05% CHAPSO) supplemented with a phosphatase inhibitor cocktail.",B,CHEMBL3940859,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
17713692,CHEMBL3887387,In vitro Enzyme Assay: The effects of compound of formula II on inhibiting VEGFR were compared against that of sunitinib in vitro.,B,CHEMBL3950152,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
17720191,CHEMBL3887556,"Kinase Inhibition Assay: This example shows that the inhibitory activity of the compound, N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 in cells against kinases including ALK, AXL, FLT3, VEGFR2, c-KIT, c-MET, PDGFR-beta, RET and SRC (tested by Advanced Cellular Dynamics, 3550 General Atomics Court, Building 2, Room 639, San Diego, CA 92121. www.advancedcelldynamics.com and Carna Biosciences, Inc.(www.carnabio.com)) measured according to the method described in the literature (Reference: Daley, G. Q.; Baltimore, D. Proc. Natl. Acd. Sci. USA 1988, 85(23), 9312). Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 2 mM, then the stock solution was diluted with DMSO following a 7 half-log series to concentrations ranging from 2 uM to 600 pM.",B,CHEMBL3981567,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17732794,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3961214,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
17732795,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3939257,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
17732796,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3972326,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
17732797,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3948032,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
17732798,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3977286,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
17732799,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3960179,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
17732800,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3985362,=,nM,127.0,CHEMBL279,Homo sapiens,IC50
17732801,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3968883,=,nM,267.0,CHEMBL279,Homo sapiens,IC50
17732802,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3897714,=,nM,448.0,CHEMBL279,Homo sapiens,IC50
17732803,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3919314,=,nM,1433.0,CHEMBL279,Homo sapiens,IC50
17732804,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3894814,=,nM,3177.0,CHEMBL279,Homo sapiens,IC50
17732805,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3910382,=,nM,1308.0,CHEMBL279,Homo sapiens,IC50
17732806,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3980495,=,nM,2297.0,CHEMBL279,Homo sapiens,IC50
17732807,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3904823,=,nM,1688.0,CHEMBL279,Homo sapiens,IC50
17732808,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3972455,=,nM,2934.0,CHEMBL279,Homo sapiens,IC50
17732809,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3895870,=,nM,1248.0,CHEMBL279,Homo sapiens,IC50
17732811,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3981416,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
17732812,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3956039,=,nM,279.0,CHEMBL279,Homo sapiens,IC50
17732813,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3903593,=,nM,295.0,CHEMBL279,Homo sapiens,IC50
17732814,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3932553,=,nM,464.0,CHEMBL279,Homo sapiens,IC50
17732815,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3952283,=,nM,1607.0,CHEMBL279,Homo sapiens,IC50
17732816,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3895469,=,nM,1617.0,CHEMBL279,Homo sapiens,IC50
17732817,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3955638,=,nM,2363.0,CHEMBL279,Homo sapiens,IC50
17732818,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3890006,=,nM,3244.0,CHEMBL279,Homo sapiens,IC50
17732819,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3950335,=,nM,4695.0,CHEMBL279,Homo sapiens,IC50
17732820,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3979359,=,nM,1805.0,CHEMBL279,Homo sapiens,IC50
17732821,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3923842,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
17732822,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3928457,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
17732823,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3927104,=,nM,90.0,CHEMBL279,Homo sapiens,IC50
17732861,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3967141,=,nM,4404.0,CHEMBL279,Homo sapiens,IC50
17734262,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3909401,=,nM,283.0,CHEMBL279,Homo sapiens,IC50
17734263,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3948670,=,nM,1789.0,CHEMBL279,Homo sapiens,IC50
17734264,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3903877,=,nM,2036.0,CHEMBL279,Homo sapiens,IC50
17734265,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3931458,=,nM,4083.0,CHEMBL279,Homo sapiens,IC50
17734266,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3922174,=,nM,6608.0,CHEMBL279,Homo sapiens,IC50
17734267,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3917694,=,nM,629.0,CHEMBL279,Homo sapiens,IC50
17734268,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3893200,=,nM,897.0,CHEMBL279,Homo sapiens,IC50
17734271,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3918309,=,nM,257.0,CHEMBL279,Homo sapiens,IC50
17734272,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3963494,=,nM,357.0,CHEMBL279,Homo sapiens,IC50
17734273,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3980022,=,nM,1996.0,CHEMBL279,Homo sapiens,IC50
17734274,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3891581,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
17734275,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3954050,=,nM,393.0,CHEMBL279,Homo sapiens,IC50
17734276,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3982717,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
17734277,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3959306,=,nM,248.0,CHEMBL279,Homo sapiens,IC50
17734278,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3893827,=,nM,1755.0,CHEMBL279,Homo sapiens,IC50
17734279,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3970373,=,nM,73.0,CHEMBL279,Homo sapiens,IC50
17734280,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3890328,=,nM,209.0,CHEMBL279,Homo sapiens,IC50
17734281,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3960972,=,nM,3786.0,CHEMBL279,Homo sapiens,IC50
17734282,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3933224,=,nM,8171.0,CHEMBL279,Homo sapiens,IC50
17734283,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3970712,=,nM,138.0,CHEMBL279,Homo sapiens,IC50
17734284,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3981577,=,nM,370.0,CHEMBL279,Homo sapiens,IC50
17734285,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3950340,=,nM,2224.0,CHEMBL279,Homo sapiens,IC50
17734286,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3900906,=,nM,394.0,CHEMBL279,Homo sapiens,IC50
17734287,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL4110384,=,nM,518.0,CHEMBL279,Homo sapiens,IC50
17734288,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3895625,=,nM,382.0,CHEMBL279,Homo sapiens,IC50
17739757,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3895520,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17739758,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3911073,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17739759,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3984316,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17739760,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3950471,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17739761,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3937330,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17739762,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3899614,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17739763,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3890120,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17739764,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3966912,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743222,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3978649,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17743223,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3917187,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17743224,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3986945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17743225,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3914411,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17743226,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3901672,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17743227,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3938643,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17743228,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910699,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17743229,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3985264,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743230,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3919069,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17743231,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3980266,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17743232,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910155,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17743233,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909047,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743234,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933421,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17743235,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3896486,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743236,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924505,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743237,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3923411,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743238,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983308,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743239,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983941,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17743240,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924066,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743241,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3946490,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17743242,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918628,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743243,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3900571,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743244,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3974963,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17743245,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3891572,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743246,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3960598,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17743247,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3970053,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17743248,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918345,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17743249,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920861,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17743250,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3963696,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17743251,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933295,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743252,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3957336,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
17743253,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906392,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743254,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4112857,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17743255,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911919,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17743256,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3943327,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17743257,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3985051,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17743258,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3915272,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17743259,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3925180,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17743260,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3897137,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17743261,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3934064,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743262,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909723,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17743263,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4107561,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17751197,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3916154,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50
17751201,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3952249,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17751202,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3981059,=,nM,443.0,CHEMBL279,Homo sapiens,IC50
17751203,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3895612,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17751204,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3920116,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17751205,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3938141,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17751206,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3967722,=,nM,274.0,CHEMBL279,Homo sapiens,IC50
17751207,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3943535,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17751208,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3976229,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17751209,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3919045,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17751210,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3946852,=,nM,1850.0,CHEMBL279,Homo sapiens,IC50
17762417,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3954009,=,nM,626.0,CHEMBL279,Homo sapiens,IC50
17762418,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3955038,=,nM,945.0,CHEMBL279,Homo sapiens,IC50
17762419,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3927422,=,nM,457.0,CHEMBL279,Homo sapiens,IC50
17762423,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3976501,=,nM,2790.0,CHEMBL279,Homo sapiens,IC50
17762981,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3898974,=,nM,286.0,CHEMBL279,Homo sapiens,IC50
17762983,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893580,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
17762984,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911476,=,nM,327.0,CHEMBL279,Homo sapiens,IC50
17762985,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3984713,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
17766104,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911339,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17766105,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3986507,=,nM,29.0,CHEMBL279,Homo sapiens,IC50
17766106,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3970603,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
17766107,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3897675,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
17766108,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911858,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50
17766114,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910302,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17766115,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933264,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17766116,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3916843,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17766118,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3944753,=,nM,126.0,CHEMBL279,Homo sapiens,IC50
17766119,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911718,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
17766120,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3917483,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
17766121,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3932948,=,nM,39.0,CHEMBL279,Homo sapiens,IC50
17766122,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3896004,=,nM,0.8,CHEMBL279,Homo sapiens,IC50
17766123,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3918564,=,nM,0.3,CHEMBL279,Homo sapiens,IC50
17766124,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3890520,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766125,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3906005,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17766126,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3964131,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
17766127,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3910242,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17766128,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL4109002,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17766129,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3978824,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17766130,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3986984,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17766131,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3958277,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17766132,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3898150,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17766133,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3972800,=,nM,328.0,CHEMBL279,Homo sapiens,IC50
17766134,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3936588,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
17766135,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3933714,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17766136,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3918251,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17766137,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3919480,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
17766138,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3897945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17766139,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3926026,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17766140,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3906088,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17766141,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3939959,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
17766142,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3961927,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17766143,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3934424,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766144,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3891953,=,nM,162.0,CHEMBL279,Homo sapiens,IC50
17766145,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3937925,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17766146,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3929416,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
17766147,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3907284,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17766148,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3920518,=,nM,64.0,CHEMBL279,Homo sapiens,IC50
17766149,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 M) or at concentrations ranging from 0.01 to 10.0 M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3944929,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766154,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3904954,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17766155,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4107173,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17766160,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3979830,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17766161,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3972255,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17766162,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3975323,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
17766163,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3966952,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17766164,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3895671,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17766165,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3965868,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17766166,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3890891,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766167,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3951242,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
17766168,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3980166,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
17766169,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3934764,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17766170,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3967877,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17766179,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3966382,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17766181,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3905688,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17766184,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3942670,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
17766186,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3944578,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17766187,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924912,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
17766188,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3927233,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17766195,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3916459,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
17766197,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3977907,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766198,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3948737,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17766200,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906367,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17766201,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3919076,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17766202,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3949914,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17766203,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3943862,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17766204,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3896274,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17766205,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983962,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
17766206,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 L reaction volumes containing 3.6 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 l of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3968013,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17774351,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3895384,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
17774352,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3893131,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17774353,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3944202,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17774354,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3968343,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17774355,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3938792,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17774356,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3920784,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17774357,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3896265,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17774358,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3911854,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17774359,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3981808,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17774360,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3939918,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
17774361,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3908397,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
17774362,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3979836,=,nM,174.0,CHEMBL279,Homo sapiens,IC50
17774363,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3909658,=,nM,276.0,CHEMBL279,Homo sapiens,IC50
17774364,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3894099,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
17774365,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3918574,=,nM,254.0,CHEMBL279,Homo sapiens,IC50
17774366,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3966485,=,nM,249.0,CHEMBL279,Homo sapiens,IC50
17774367,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3895175,=,nM,334.0,CHEMBL279,Homo sapiens,IC50
17774368,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3971758,=,nM,1174.0,CHEMBL279,Homo sapiens,IC50
17774369,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3904099,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
17774370,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3945521,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
17774371,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3974900,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
17774372,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3918687,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
17774373,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3985195,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
17774374,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3965529,=,nM,131.0,CHEMBL279,Homo sapiens,IC50
17774375,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3904259,=,nM,3185.0,CHEMBL279,Homo sapiens,IC50
17774376,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3894545,=,nM,3647.0,CHEMBL279,Homo sapiens,IC50
17775010,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3957965,=,nM,10.9,CHEMBL279,Homo sapiens,IC50
17775011,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908050,=,nM,5.4,CHEMBL279,Homo sapiens,IC50
17775012,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961158,=,nM,16.7,CHEMBL279,Homo sapiens,IC50
17775013,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973469,=,nM,292.0,CHEMBL279,Homo sapiens,IC50
17775014,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3943975,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17775015,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3981466,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
17775016,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3949308,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
17775017,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952636,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
17775018,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3924928,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
17775019,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3960088,=,nM,13.7,CHEMBL279,Homo sapiens,IC50
17775020,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932595,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17775021,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971161,=,nM,9.9,CHEMBL279,Homo sapiens,IC50
17775022,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3938078,=,nM,14.2,CHEMBL279,Homo sapiens,IC50
17775023,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976169,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17775024,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946883,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
17775025,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3955460,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
17775026,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931364,=,nM,29.2,CHEMBL279,Homo sapiens,IC50
17775027,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969955,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
17775028,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940400,=,nM,22.3,CHEMBL279,Homo sapiens,IC50
17775029,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952726,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
17775030,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3984709,=,nM,7.5,CHEMBL279,Homo sapiens,IC50
17775031,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947363,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
17775032,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976632,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
17775033,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946238,=,nM,33.8,CHEMBL279,Homo sapiens,IC50
17775034,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972376,=,nM,14.9,CHEMBL279,Homo sapiens,IC50
17775035,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961406,=,nM,18.2,CHEMBL279,Homo sapiens,IC50
17775037,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926946,=,nM,12.7,CHEMBL279,Homo sapiens,IC50
17775038,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894725,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
17775039,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896485,=,nM,12.4,CHEMBL279,Homo sapiens,IC50
17775040,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961993,=,nM,14.5,CHEMBL279,Homo sapiens,IC50
17775041,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985263,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
17775042,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3956594,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
17775043,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910983,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
17775044,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3984219,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17775045,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3901963,=,nM,15.6,CHEMBL279,Homo sapiens,IC50
17775046,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973002,=,nM,13.5,CHEMBL279,Homo sapiens,IC50
17775047,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986500,=,nM,8.2,CHEMBL279,Homo sapiens,IC50
17775048,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954419,=,nM,14.2,CHEMBL279,Homo sapiens,IC50
17775049,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979437,=,nM,15.2,CHEMBL279,Homo sapiens,IC50
17775050,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909183,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
17775051,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3962502,=,nM,11.5,CHEMBL279,Homo sapiens,IC50
17775052,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889965,=,nM,18.1,CHEMBL279,Homo sapiens,IC50
17775053,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3966058,=,nM,14.2,CHEMBL279,Homo sapiens,IC50
17775054,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894710,=,nM,15.4,CHEMBL279,Homo sapiens,IC50
17775055,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971285,=,nM,16.6,CHEMBL279,Homo sapiens,IC50
17775056,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3903645,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
17775057,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986639,=,nM,7.3,CHEMBL279,Homo sapiens,IC50
17775058,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916910,=,nM,9.9,CHEMBL279,Homo sapiens,IC50
17775059,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944909,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
17775060,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916992,=,nM,5.2,CHEMBL279,Homo sapiens,IC50
17775061,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953630,=,nM,15.5,CHEMBL279,Homo sapiens,IC50
17775062,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929401,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17775063,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930543,=,nM,15.3,CHEMBL279,Homo sapiens,IC50
17775064,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3902552,=,nM,14.5,CHEMBL279,Homo sapiens,IC50
17775065,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939532,=,nM,17.5,CHEMBL279,Homo sapiens,IC50
17775066,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908005,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17775067,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937184,=,nM,13.7,CHEMBL279,Homo sapiens,IC50
17775068,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909258,=,nM,8.2,CHEMBL279,Homo sapiens,IC50
17775069,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952894,=,nM,34.3,CHEMBL279,Homo sapiens,IC50
17775070,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978551,=,nM,3.73,CHEMBL279,Homo sapiens,IC50
17775071,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940692,=,nM,7.18,CHEMBL279,Homo sapiens,IC50
17775072,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970244,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
17775073,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931682,=,nM,11.9,CHEMBL279,Homo sapiens,IC50
17775074,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3941664,=,nM,6.5,CHEMBL279,Homo sapiens,IC50
17775075,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926270,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17775076,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953910,=,nM,26.6,CHEMBL279,Homo sapiens,IC50
17775077,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3917278,=,nM,15.7,CHEMBL279,Homo sapiens,IC50
17775078,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3941740,=,nM,17.1,CHEMBL279,Homo sapiens,IC50
17775079,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913166,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17775080,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986456,=,nM,13.3,CHEMBL279,Homo sapiens,IC50
17775081,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3904153,=,nM,8.9,CHEMBL279,Homo sapiens,IC50
17775082,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975035,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17775083,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3898689,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
17775084,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3966540,=,nM,13.1,CHEMBL279,Homo sapiens,IC50
17775085,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889762,=,nM,12.5,CHEMBL279,Homo sapiens,IC50
17775086,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3958800,=,nM,14.3,CHEMBL279,Homo sapiens,IC50
17775087,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3920945,=,nM,13.3,CHEMBL279,Homo sapiens,IC50
17775088,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896430,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17775089,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889544,=,nM,8.1,CHEMBL279,Homo sapiens,IC50
17775090,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3917570,=,nM,13.3,CHEMBL279,Homo sapiens,IC50
17775091,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3895044,=,nM,6.8,CHEMBL279,Homo sapiens,IC50
17775092,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926547,=,nM,14.3,CHEMBL279,Homo sapiens,IC50
17775093,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3903969,=,nM,12.2,CHEMBL279,Homo sapiens,IC50
17775094,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931966,=,nM,10.7,CHEMBL279,Homo sapiens,IC50
17775095,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916488,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
17775096,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940976,=,nM,12.9,CHEMBL279,Homo sapiens,IC50
17775097,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3925474,=,nM,11.4,CHEMBL279,Homo sapiens,IC50
17775098,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953141,=,nM,15.2,CHEMBL279,Homo sapiens,IC50
17775099,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3942331,=,nM,12.2,CHEMBL279,Homo sapiens,IC50
17775100,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3914330,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
17775101,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3923206,=,nM,192.0,CHEMBL279,Homo sapiens,IC50
17775102,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3919864,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
17775103,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3928634,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
17775104,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3900665,=,nM,434.0,CHEMBL279,Homo sapiens,IC50
17775105,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937667,=,nM,624.0,CHEMBL279,Homo sapiens,IC50
17775106,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913168,=,nM,62.8,CHEMBL279,Homo sapiens,IC50
17775107,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906467,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
17775108,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977137,=,nM,41.0,CHEMBL279,Homo sapiens,IC50
17775109,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3912594,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
17775110,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3950516,=,nM,12.5,CHEMBL279,Homo sapiens,IC50
17775111,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3907102,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
17775112,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935064,=,nM,12.4,CHEMBL279,Homo sapiens,IC50
17775113,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905825,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
17775114,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930387,=,nM,11.3,CHEMBL279,Homo sapiens,IC50
17775115,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893417,=,nM,10.4,CHEMBL279,Homo sapiens,IC50
17775116,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3921434,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17775117,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975481,=,nM,8.6,CHEMBL279,Homo sapiens,IC50
17775118,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908195,=,nM,10.9,CHEMBL279,Homo sapiens,IC50
17775119,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977258,=,nM,7.3,CHEMBL279,Homo sapiens,IC50
17775120,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906608,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17775121,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982058,=,nM,14.5,CHEMBL279,Homo sapiens,IC50
17775122,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976140,=,nM,8.1,CHEMBL279,Homo sapiens,IC50
17775123,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961936,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
17775124,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3892923,=,nM,9.5,CHEMBL279,Homo sapiens,IC50
17775125,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3914631,=,nM,7.9,CHEMBL279,Homo sapiens,IC50
17775126,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3963823,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17775127,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940325,=,nM,7.4,CHEMBL279,Homo sapiens,IC50
17775128,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969861,=,nM,14.9,CHEMBL279,Homo sapiens,IC50
17775129,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973125,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17775130,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947019,=,nM,11.5,CHEMBL279,Homo sapiens,IC50
17775131,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3962147,=,nM,8.7,CHEMBL279,Homo sapiens,IC50
17775132,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3934657,=,nM,7.4,CHEMBL279,Homo sapiens,IC50
17775133,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905711,=,nM,13.8,CHEMBL279,Homo sapiens,IC50
17775134,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964796,=,nM,8.7,CHEMBL279,Homo sapiens,IC50
17775135,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977445,=,nM,30.2,CHEMBL279,Homo sapiens,IC50
17775136,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3948208,=,nM,11.8,CHEMBL279,Homo sapiens,IC50
17775137,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3965770,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
17775138,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939438,=,nM,14.2,CHEMBL279,Homo sapiens,IC50
17775139,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3958722,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
17775140,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3983977,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
17775141,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939419,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17775142,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975944,=,nM,9.1,CHEMBL279,Homo sapiens,IC50
17775143,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986769,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17775144,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970862,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
17775145,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932302,=,nM,6.6,CHEMBL279,Homo sapiens,IC50
17775146,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959805,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
17775147,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968567,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
17775148,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929084,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17775149,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982410,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17775150,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964861,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
17775151,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913290,=,nM,10.4,CHEMBL279,Homo sapiens,IC50
17775152,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968087,=,nM,9.5,CHEMBL279,Homo sapiens,IC50
17775153,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969593,=,nM,11.4,CHEMBL279,Homo sapiens,IC50
17775154,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3928460,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
17775155,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977612,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17775156,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944994,=,nM,11.1,CHEMBL279,Homo sapiens,IC50
17775157,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3892248,=,nM,6.2,CHEMBL279,Homo sapiens,IC50
17775158,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961228,=,nM,25.4,CHEMBL279,Homo sapiens,IC50
17775159,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939655,=,nM,11.5,CHEMBL279,Homo sapiens,IC50
17775160,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969197,=,nM,4.5,CHEMBL279,Homo sapiens,IC50
17775161,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3951823,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
17775162,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977627,=,nM,15.2,CHEMBL279,Homo sapiens,IC50
17775163,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3925225,=,nM,11.3,CHEMBL279,Homo sapiens,IC50
17775164,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952920,=,nM,12.1,CHEMBL279,Homo sapiens,IC50
17775165,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930655,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
17775166,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961613,=,nM,5.9,CHEMBL279,Homo sapiens,IC50
17775167,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931839,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
17775168,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959327,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17775169,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3924816,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17775170,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893285,=,nM,12.2,CHEMBL279,Homo sapiens,IC50
17775171,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3949794,=,nM,6.8,CHEMBL279,Homo sapiens,IC50
17775172,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985563,=,nM,11.6,CHEMBL279,Homo sapiens,IC50
17775173,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939238,=,nM,30.7,CHEMBL279,Homo sapiens,IC50
17775174,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3943475,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
17775175,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939020,=,nM,11.5,CHEMBL279,Homo sapiens,IC50
17775176,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3902261,=,nM,16.1,CHEMBL279,Homo sapiens,IC50
17775177,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964493,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
17775178,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929131,=,nM,14.6,CHEMBL279,Homo sapiens,IC50
17775179,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913927,=,nM,5.6,CHEMBL279,Homo sapiens,IC50
17775180,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3945350,=,nM,12.4,CHEMBL279,Homo sapiens,IC50
17775181,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908510,=,nM,14.8,CHEMBL279,Homo sapiens,IC50
17775182,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3936457,=,nM,22.5,CHEMBL279,Homo sapiens,IC50
17775183,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935348,=,nM,5.4,CHEMBL279,Homo sapiens,IC50
17775184,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959341,=,nM,4.9,CHEMBL279,Homo sapiens,IC50
17775185,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3922912,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
17775186,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3963883,=,nM,9.5,CHEMBL279,Homo sapiens,IC50
17775187,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906129,=,nM,5.3,CHEMBL279,Homo sapiens,IC50
17775188,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937703,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
17775189,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3921563,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
17775190,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893548,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
17775191,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930516,=,nM,14.7,CHEMBL279,Homo sapiens,IC50
17775192,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3898941,=,nM,13.6,CHEMBL279,Homo sapiens,IC50
17775193,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935930,=,nM,7.6,CHEMBL279,Homo sapiens,IC50
17775194,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3907975,=,nM,12.3,CHEMBL279,Homo sapiens,IC50
17775195,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944876,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
17775196,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3920464,=,nM,6.8,CHEMBL279,Homo sapiens,IC50
17775197,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913774,=,nM,17.2,CHEMBL279,Homo sapiens,IC50
17775198,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3983575,=,nM,10.7,CHEMBL279,Homo sapiens,IC50
17775199,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972070,=,nM,11.9,CHEMBL279,Homo sapiens,IC50
17775200,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3900935,=,nM,11.8,CHEMBL279,Homo sapiens,IC50
17775201,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977041,=,nM,17.5,CHEMBL279,Homo sapiens,IC50
17775202,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909992,=,nM,10.9,CHEMBL279,Homo sapiens,IC50
17775203,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985123,=,nM,10.5,CHEMBL279,Homo sapiens,IC50
17775204,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3915341,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
17775205,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970841,=,nM,11.8,CHEMBL279,Homo sapiens,IC50
17775206,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896185,=,nM,5.7,CHEMBL279,Homo sapiens,IC50
17775207,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979083,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
17775208,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908737,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
17775209,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896869,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
17775210,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971555,=,nM,11.4,CHEMBL279,Homo sapiens,IC50
17775211,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916041,=,nM,12.7,CHEMBL279,Homo sapiens,IC50
17775212,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979341,=,nM,16.2,CHEMBL279,Homo sapiens,IC50
17775213,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910653,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
17775214,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977680,=,nM,25.1,CHEMBL279,Homo sapiens,IC50
17775215,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961868,=,nM,14.6,CHEMBL279,Homo sapiens,IC50
17775216,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972701,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
17775217,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953943,=,nM,14.9,CHEMBL279,Homo sapiens,IC50
17775218,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908336,=,nM,8.4,CHEMBL279,Homo sapiens,IC50
17775219,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905323,=,nM,11.8,CHEMBL279,Homo sapiens,IC50
17775220,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972921,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17775221,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896385,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
17775222,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3967596,=,nM,10.7,CHEMBL279,Homo sapiens,IC50
17775223,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3919838,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
17775224,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3895343,=,nM,13.2,CHEMBL279,Homo sapiens,IC50
17775225,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910894,=,nM,10.6,CHEMBL279,Homo sapiens,IC50
17775226,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3980939,=,nM,9.9,CHEMBL279,Homo sapiens,IC50
17775227,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913137,=,nM,9.1,CHEMBL279,Homo sapiens,IC50
17775228,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909831,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17775229,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954891,=,nM,14.9,CHEMBL279,Homo sapiens,IC50
17775230,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910713,=,nM,6.7,CHEMBL279,Homo sapiens,IC50
17775231,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969348,=,nM,8.7,CHEMBL279,Homo sapiens,IC50
17775232,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894696,=,nM,6.9,CHEMBL279,Homo sapiens,IC50
17775233,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3904994,=,nM,9.5,CHEMBL279,Homo sapiens,IC50
17775234,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976542,=,nM,10.7,CHEMBL279,Homo sapiens,IC50
17775235,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946208,=,nM,9.1,CHEMBL279,Homo sapiens,IC50
17775236,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978687,=,nM,17.2,CHEMBL279,Homo sapiens,IC50
17775237,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947334,=,nM,14.7,CHEMBL279,Homo sapiens,IC50
17775238,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976600,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17775239,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969741,=,nM,11.7,CHEMBL279,Homo sapiens,IC50
17775240,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940199,=,nM,11.6,CHEMBL279,Homo sapiens,IC50
17775241,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978101,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
17775242,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3945523,=,nM,8.1,CHEMBL279,Homo sapiens,IC50
17775243,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982896,=,nM,9.9,CHEMBL279,Homo sapiens,IC50
17775244,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954230,=,nM,13.4,CHEMBL279,Homo sapiens,IC50
17775246,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968631,=,nM,13.9,CHEMBL279,Homo sapiens,IC50
17775247,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959862,=,nM,15.6,CHEMBL279,Homo sapiens,IC50
17775248,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932357,=,nM,9.7,CHEMBL279,Homo sapiens,IC50
17775249,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3938359,=,nM,19.1,CHEMBL279,Homo sapiens,IC50
17775250,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971428,=,nM,17.9,CHEMBL279,Homo sapiens,IC50
17775251,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30 C.; then add ATP (final concentration: 90 M) and the substrate (final concentration 50 M). React for 2 hrs at 30 C. After the reaction, add antibody and reaction for 60 min at 30 C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932860,=,nM,16.7,CHEMBL279,Homo sapiens,IC50
17775656,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3983434,=,nM,1885.0,CHEMBL279,Homo sapiens,IC50
17775657,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3919644,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
17775658,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3969156,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
17775660,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3961887,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
17775662,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3956492,=,nM,1209.0,CHEMBL279,Homo sapiens,IC50
17775663,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3925481,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50
17775664,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3947828,=,nM,2827.0,CHEMBL279,Homo sapiens,IC50
17776384,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964812,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
17776386,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3962340,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
17776387,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3912498,=,nM,4750.0,CHEMBL279,Homo sapiens,IC50
17776388,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3967803,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
17776389,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893979,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50
17776390,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964305,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
17776391,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3976026,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
17776392,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3962623,=,nM,4030.0,CHEMBL279,Homo sapiens,IC50
17776394,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964582,=,nM,1470.0,CHEMBL279,Homo sapiens,IC50
17776396,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3963229,=,nM,6380.0,CHEMBL279,Homo sapiens,IC50
17776405,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3979299,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
17776406,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mLs per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909001,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
17777437,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893498,=,nM,764.0,CHEMBL279,Homo sapiens,IC50
17777438,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920210,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
17777440,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964320,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
17777501,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3978214,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
17777502,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3940300,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17777505,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3894122,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
17777506,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3954328,=,nM,6.0,CHEMBL279,Homo sapiens,IC50
17777507,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3982995,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
17779507,CHEMBL3888790,"Inhibition Assay: In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 M) and the IC50 values of the inventive compound of Example 1 against various kinases were obtained by using Kinase Profiling Service (Invitrogen) according to the manufacturer's instructions.",B,CHEMBL3967980,=,nM,261.0,CHEMBL279,Homo sapiens,IC50
17780472,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3950267,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
17780473,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3913556,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17780474,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3941533,=,nM,17.0,CHEMBL279,Homo sapiens,IC50
17780475,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 L reaction volumes containing 2.7 M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T. 100 l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 l of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3975267,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
17784801,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 l of ATP solution (in H2O), 20 l of assay buffer (see below), 5 l of test sample in 10% DMSO, 10 l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 M Na-orthovanadate, 1.2 mM DTT, 50 g/ml PEG20000, 1 M [-33P]-ATP (approx. 810^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 g/ml Phosphatidylserine and 1 g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30 C. for 80 minutes. The reaction was stopped with 50 l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL3958081,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
17786158,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3902576,=,nM,167500.0,CHEMBL279,Homo sapiens,IC50
17786159,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3976755,=,nM,132900.0,CHEMBL279,Homo sapiens,IC50
17786160,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3977751,=,nM,163100.0,CHEMBL279,Homo sapiens,IC50
17786161,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3948546,=,nM,198500.0,CHEMBL279,Homo sapiens,IC50
17786162,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3985894,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50
17786163,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3953855,=,nM,73000.0,CHEMBL279,Homo sapiens,IC50
17786164,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3983639,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50
17796714,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3951451,=,nM,5.1,CHEMBL279,Homo sapiens,IC50
17796715,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3920239,=,nM,4.3,CHEMBL279,Homo sapiens,IC50
17796716,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3892076,=,nM,30.4,CHEMBL279,Homo sapiens,IC50
17796717,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3914717,=,nM,47.8,CHEMBL279,Homo sapiens,IC50
17796718,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3916527,=,nM,48.3,CHEMBL279,Homo sapiens,IC50
17796719,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37 C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37 C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 102 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at 20 C. after subpackage.",B,CHEMBL3963292,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
17955634,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4086694,=,nM,34.67,CHEMBL279,Homo sapiens,IC50
17955635,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4104599,=,nM,5.58,CHEMBL279,Homo sapiens,IC50
17955637,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4092519,=,nM,35.75,CHEMBL279,Homo sapiens,IC50
17955639,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4072514,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
17955640,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4100979,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
17955641,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4083001,=,nM,700.53,CHEMBL279,Homo sapiens,IC50
17955642,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4075266,=,nM,1.35,CHEMBL279,Homo sapiens,IC50
17955645,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4063920,=,nM,32.37,CHEMBL279,Homo sapiens,IC50
17955649,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4069517,=,nM,1.05,CHEMBL279,Homo sapiens,IC50
17955650,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4089043,=,nM,1.42,CHEMBL279,Homo sapiens,IC50
17955651,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4060841,=,nM,0.31,CHEMBL279,Homo sapiens,IC50
17955652,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4066813,=,nM,11.41,CHEMBL279,Homo sapiens,IC50
17955653,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4088100,=,nM,33.02,CHEMBL279,Homo sapiens,IC50
17957938,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4069394,=,nM,51.7,CHEMBL279,Homo sapiens,IC50
17957939,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4070403,=,nM,164.62,CHEMBL279,Homo sapiens,IC50
17957940,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4091341,=,nM,152.71,CHEMBL279,Homo sapiens,IC50
17957941,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4059568,=,nM,137.51,CHEMBL279,Homo sapiens,IC50
17957945,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4079087,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
17957947,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4086939,=,nM,167.51,CHEMBL279,Homo sapiens,IC50
17957953,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4098962,=,nM,164.54,CHEMBL279,Homo sapiens,IC50
17957954,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4061361,=,nM,96.22,CHEMBL279,Homo sapiens,IC50
17966161,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL96149,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
17966162,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL4081227,=,nM,24.0,CHEMBL279,Homo sapiens,IC50
17966163,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL4082186,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
17979726,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4069672,=,nM,38.7,CHEMBL279,Homo sapiens,IC50
17979727,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4099682,=,nM,26.7,CHEMBL279,Homo sapiens,IC50
17979728,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4060996,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
17979729,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4104515,=,nM,32.9,CHEMBL279,Homo sapiens,IC50
17979730,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4099329,=,nM,27.3,CHEMBL279,Homo sapiens,IC50
17979731,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4072383,=,nM,84.3,CHEMBL279,Homo sapiens,IC50
17979938,CHEMBL3998332,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2220486,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
17982170,CHEMBL3998813,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by scintillation counting method,B,CHEMBL4099337,=,nM,162.6,CHEMBL279,Homo sapiens,IC50
17995005,CHEMBL4001115,Inhibition of recombinant human VEGFR2 expressed in Sf9 cells using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE method,B,CHEMBL4066412,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
18006661,CHEMBL4003361,Inhibition of VEGFR2 (unknown origin) using substrate after 30 mins in presence of [gamma-33P]ATP by liquid scintillation counting,B,CHEMBL4086603,=,nM,23.0,CHEMBL279,Homo sapiens,IC50
18029890,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4060383,=,nM,160300.0,CHEMBL279,Homo sapiens,IC50
18029891,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4088617,=,nM,193100.0,CHEMBL279,Homo sapiens,IC50
18029892,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4069070,=,nM,10200.0,CHEMBL279,Homo sapiens,IC50
18029893,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4096329,=,nM,182200.0,CHEMBL279,Homo sapiens,IC50
18031757,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL2006765,=,nM,886.0,CHEMBL279,Homo sapiens,IC50
18031760,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL4069365,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50
18031761,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL4062803,=,nM,8540.0,CHEMBL279,Homo sapiens,IC50
18052782,CHEMBL4011797,Inhibition of VEGFR2 (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,B,CHEMBL4071058,=,nM,18700.0,CHEMBL279,Homo sapiens,IC50
18057666,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103890,=,nM,3109.0,CHEMBL279,Homo sapiens,IC50
18057667,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4091975,=,nM,1845.0,CHEMBL279,Homo sapiens,IC50
18057672,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4085010,=,nM,2391.0,CHEMBL279,Homo sapiens,IC50
18057702,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4078084,=,nM,3503.0,CHEMBL279,Homo sapiens,IC50
18057703,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4071997,=,nM,1791.0,CHEMBL279,Homo sapiens,IC50
18057704,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4092765,=,nM,4079.0,CHEMBL279,Homo sapiens,IC50
18057714,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4085974,=,nM,6229.0,CHEMBL279,Homo sapiens,IC50
18057724,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4073536,=,nM,41966.0,CHEMBL279,Homo sapiens,IC50
18057725,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4092638,=,nM,5352.0,CHEMBL279,Homo sapiens,IC50
18057726,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4064941,=,nM,6920.0,CHEMBL279,Homo sapiens,IC50
18057727,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4084878,=,nM,9046.0,CHEMBL279,Homo sapiens,IC50
18057728,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4102831,=,nM,15935.0,CHEMBL279,Homo sapiens,IC50
18057731,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4060326,=,nM,4322.0,CHEMBL279,Homo sapiens,IC50
18057732,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4088552,=,nM,5613.0,CHEMBL279,Homo sapiens,IC50
18057733,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4069008,=,nM,6228.0,CHEMBL279,Homo sapiens,IC50
18057734,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4096271,=,nM,4050.0,CHEMBL279,Homo sapiens,IC50
18057735,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4065800,=,nM,1921.0,CHEMBL279,Homo sapiens,IC50
18057736,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4087221,=,nM,6235.0,CHEMBL279,Homo sapiens,IC50
18057737,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101778,=,nM,8008.0,CHEMBL279,Homo sapiens,IC50
18057747,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4091741,=,nM,1856.0,CHEMBL279,Homo sapiens,IC50
18057748,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100645,=,nM,1224.0,CHEMBL279,Homo sapiens,IC50
18057838,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101428,=,nM,3857.0,CHEMBL279,Homo sapiens,IC50
18057839,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074745,=,nM,10917.0,CHEMBL279,Homo sapiens,IC50
18057847,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100492,=,nM,9760.0,CHEMBL279,Homo sapiens,IC50
18057884,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4066145,=,nM,11382.0,CHEMBL279,Homo sapiens,IC50
18057885,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4093721,=,nM,4523.0,CHEMBL279,Homo sapiens,IC50
18057886,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103897,=,nM,5002.0,CHEMBL279,Homo sapiens,IC50
18057900,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074755,=,nM,10462.0,CHEMBL279,Homo sapiens,IC50
18057901,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101438,=,nM,8634.0,CHEMBL279,Homo sapiens,IC50
18057907,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4062187,=,nM,4164.0,CHEMBL279,Homo sapiens,IC50
18057908,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4083910,=,nM,26163.0,CHEMBL279,Homo sapiens,IC50
18057909,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100372,=,nM,36890.0,CHEMBL279,Homo sapiens,IC50
18057912,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4104034,=,nM,6235.0,CHEMBL279,Homo sapiens,IC50
18057913,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4087656,=,nM,3940.0,CHEMBL279,Homo sapiens,IC50
18057914,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4066302,=,nM,3695.0,CHEMBL279,Homo sapiens,IC50
18057915,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4072731,=,nM,2280.0,CHEMBL279,Homo sapiens,IC50
18057916,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4099624,=,nM,6816.0,CHEMBL279,Homo sapiens,IC50
18057919,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4083050,=,nM,4920.0,CHEMBL279,Homo sapiens,IC50
18057920,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4059958,=,nM,3360.0,CHEMBL279,Homo sapiens,IC50
18057923,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074518,=,nM,1208.0,CHEMBL279,Homo sapiens,IC50
18057924,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074713,=,nM,4293.0,CHEMBL279,Homo sapiens,IC50
18057925,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103605,=,nM,1225.0,CHEMBL279,Homo sapiens,IC50
18057926,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4079338,=,nM,3145.0,CHEMBL279,Homo sapiens,IC50
18074033,CHEMBL4016015,Inhibition of human recombinant VEGFR2 using CAGAGAIETDKEYYTVKD as substrate after 60 mins by Lance method,B,CHEMBL4081711,=,nM,5330.0,CHEMBL279,Homo sapiens,IC50
18085940,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4105329,=,nM,3.7,CHEMBL279,Homo sapiens,IC50
18085941,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4067871,=,nM,0.8,CHEMBL279,Homo sapiens,IC50
18085942,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4062877,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
18085943,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4075917,=,nM,2.6,CHEMBL279,Homo sapiens,IC50
18096337,CHEMBL4021224,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 5 to 10 mins followed by substrate/ATP addition measured after 30 to 60 mins by mobility shift assay,B,CHEMBL4074262,=,nM,18364.0,CHEMBL279,Homo sapiens,IC50
18107305,CHEMBL4022987,Inhibition of recombinant human VEGFR2 expressed in Sf9 cells,B,CHEMBL3655081,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
18149415,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4075561,=,nM,33.36,CHEMBL279,Homo sapiens,IC50
18149416,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4092026,=,nM,8.7,CHEMBL279,Homo sapiens,IC50
18149417,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4071203,=,nM,1.88,CHEMBL279,Homo sapiens,IC50
18149418,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4073263,=,nM,0.92,CHEMBL279,Homo sapiens,IC50
18149419,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4099365,=,nM,0.75,CHEMBL279,Homo sapiens,IC50
18149420,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4075886,=,nM,3937.0,CHEMBL279,Homo sapiens,IC50
18149422,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4102191,=,nM,17.85,CHEMBL279,Homo sapiens,IC50
18149423,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4077930,=,nM,28.79,CHEMBL279,Homo sapiens,IC50
18149424,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4083278,=,nM,15.29,CHEMBL279,Homo sapiens,IC50
18152583,CHEMBL4034168,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4066684,=,nM,671.8,CHEMBL279,Homo sapiens,IC50
18267648,CHEMBL4057892,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4082724,=,nM,151.52,CHEMBL279,Homo sapiens,IC50
18273762,CHEMBL4059198,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition measure after 120 mins by filter binding method,B,CHEMBL4075720,=,nM,35.1,CHEMBL279,Homo sapiens,IC50
18274248,CHEMBL4059315,Inhibition of human KDR cytoplasmic domain (807 to 1356 residues) after 60 mins by TR-FRET assay,B,CHEMBL4077373,=,nM,5.5,CHEMBL279,Homo sapiens,IC50
18274257,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4076909,=,nM,0.7,CHEMBL279,Homo sapiens,IC50
18274259,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4092692,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
18274260,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4065008,=,nM,10.1,CHEMBL279,Homo sapiens,IC50
18274261,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4084937,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
18274262,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4102888,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
18274263,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4074672,=,nM,8.8,CHEMBL279,Homo sapiens,IC50
18274326,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4076112,=,nM,17.4,CHEMBL279,Homo sapiens,IC50
18274327,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079003,=,nM,273.0,CHEMBL279,Homo sapiens,IC50
18274328,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4103267,=,nM,2.8,CHEMBL279,Homo sapiens,IC50
18274329,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4064471,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
18274330,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4086718,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
18274332,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4087814,=,nM,5.8,CHEMBL279,Homo sapiens,IC50
18274333,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4097955,=,nM,9.4,CHEMBL279,Homo sapiens,IC50
18274334,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079937,=,nM,25.2,CHEMBL279,Homo sapiens,IC50
18274336,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079318,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
18274337,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079917,=,nM,89.0,CHEMBL279,Homo sapiens,IC50
18274338,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4077291,=,nM,7.9,CHEMBL279,Homo sapiens,IC50
18274339,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4068360,=,nM,245.0,CHEMBL279,Homo sapiens,IC50
18274340,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4065713,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
18274341,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4100555,=,nM,17.9,CHEMBL279,Homo sapiens,IC50
18274342,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4102438,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
18274344,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079136,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
18274345,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4103383,=,nM,12.8,CHEMBL279,Homo sapiens,IC50
18274346,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4086998,=,nM,1720.0,CHEMBL279,Homo sapiens,IC50
18274352,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4104297,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
18274353,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4080062,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
18314084,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4169257,=,nM,384.7,CHEMBL279,Homo sapiens,IC50
18314085,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4177112,=,nM,257.2,CHEMBL279,Homo sapiens,IC50
18314086,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4165827,=,nM,138.3,CHEMBL279,Homo sapiens,IC50
18314087,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4173756,=,nM,106.1,CHEMBL279,Homo sapiens,IC50
18314089,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4165429,=,nM,69.1,CHEMBL279,Homo sapiens,IC50
18314090,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4166696,=,nM,81.3,CHEMBL279,Homo sapiens,IC50
18314091,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4161991,=,nM,104.6,CHEMBL279,Homo sapiens,IC50
18314093,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4172205,=,nM,808.5,CHEMBL279,Homo sapiens,IC50
18314094,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4173078,=,nM,431.2,CHEMBL279,Homo sapiens,IC50
18314095,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4162400,=,nM,646.5,CHEMBL279,Homo sapiens,IC50
18328406,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4165234,=,nM,40.37,CHEMBL279,Homo sapiens,IC50
18328410,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4162947,=,nM,125.32,CHEMBL279,Homo sapiens,IC50
18328411,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4170879,=,nM,108.08,CHEMBL279,Homo sapiens,IC50
18328412,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4166401,=,nM,21.37,CHEMBL279,Homo sapiens,IC50
18328419,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4175773,=,nM,2.1,CHEMBL279,Homo sapiens,IC50
18328423,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4171943,=,nM,7.97,CHEMBL279,Homo sapiens,IC50
18328424,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4169668,=,nM,325.82,CHEMBL279,Homo sapiens,IC50
18328428,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4171543,=,nM,2.35,CHEMBL279,Homo sapiens,IC50
18328432,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4174261,=,nM,28.95,CHEMBL279,Homo sapiens,IC50
18328433,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4163581,=,nM,34.68,CHEMBL279,Homo sapiens,IC50
18330857,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4177014,=,nM,1.9,CHEMBL279,Homo sapiens,IC50
18330858,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4172546,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
18330859,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4161897,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
18330860,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4175951,=,nM,4.9,CHEMBL279,Homo sapiens,IC50
18330861,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4165331,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
18330862,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4160821,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
18330863,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4169611,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
18330864,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4166187,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
18330865,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4162743,=,nM,51.0,CHEMBL279,Homo sapiens,IC50
18330866,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4170680,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
18330867,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4171244,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
18330869,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4168811,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
18330870,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4161551,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
18330871,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4172155,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
18330872,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4165455,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
18330873,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4173370,=,nM,300.0,CHEMBL279,Homo sapiens,IC50
18330874,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4166319,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
18339288,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL4165836,=,nM,18.0,CHEMBL279,Homo sapiens,IC50
18339290,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL4164979,=,nM,564000.0,CHEMBL279,Homo sapiens,IC50
18343766,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4164946,=,nM,640.0,CHEMBL279,Homo sapiens,IC50
18343767,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4172854,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50
18343768,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4173279,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50
18355951,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4160854,=,nM,3.45,CHEMBL279,Homo sapiens,IC50
18355952,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4168788,=,nM,7.94,CHEMBL279,Homo sapiens,IC50
18355953,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175949,=,nM,24.33,CHEMBL279,Homo sapiens,IC50
18355954,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4167759,=,nM,19.97,CHEMBL279,Homo sapiens,IC50
18355955,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175943,=,nM,7.66,CHEMBL279,Homo sapiens,IC50
18355956,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4165320,=,nM,6.17,CHEMBL279,Homo sapiens,IC50
18355957,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4160813,=,nM,7.05,CHEMBL279,Homo sapiens,IC50
18355959,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4164213,=,nM,11.9,CHEMBL279,Homo sapiens,IC50
18355962,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175530,=,nM,122.81,CHEMBL279,Homo sapiens,IC50
18355965,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4159244,=,nM,19.2,CHEMBL279,Homo sapiens,IC50
18355967,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4174374,=,nM,11.19,CHEMBL279,Homo sapiens,IC50
18355969,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4170942,=,nM,415.21,CHEMBL279,Homo sapiens,IC50
18355972,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4159645,=,nM,297.02,CHEMBL279,Homo sapiens,IC50
18355973,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4164127,=,nM,310.64,CHEMBL279,Homo sapiens,IC50
18355975,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4161287,=,nM,31.4,CHEMBL279,Homo sapiens,IC50
18359638,CHEMBL4141527,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL4165199,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50
18368871,CHEMBL4143278,Inhibition of KDR (unknown origin),B,CHEMBL4165354,=,nM,3330.0,CHEMBL279,Homo sapiens,IC50
18390490,CHEMBL4147639,"Inhibition of KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4171115,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
18431184,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173438,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
18431185,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4160549,=,nM,90.5,CHEMBL279,Homo sapiens,IC50
18431186,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4163939,=,nM,49.8,CHEMBL279,Homo sapiens,IC50
18431187,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4177247,=,nM,134.5,CHEMBL279,Homo sapiens,IC50
18431188,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4169073,=,nM,17.1,CHEMBL279,Homo sapiens,IC50
18431189,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173458,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
18431190,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4165904,=,nM,29.9,CHEMBL279,Homo sapiens,IC50
18431191,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173144,=,nM,41.7,CHEMBL279,Homo sapiens,IC50
18431192,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4162460,=,nM,120.4,CHEMBL279,Homo sapiens,IC50
18431193,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173415,=,nM,111.5,CHEMBL279,Homo sapiens,IC50
18431194,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4169626,=,nM,150.2,CHEMBL279,Homo sapiens,IC50
18431195,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4175295,=,nM,63.2,CHEMBL279,Homo sapiens,IC50
18431196,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4159393,=,nM,73.4,CHEMBL279,Homo sapiens,IC50
18431197,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4170025,=,nM,77.9,CHEMBL279,Homo sapiens,IC50
18431198,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173465,=,nM,424.0,CHEMBL279,Homo sapiens,IC50
18432393,CHEMBL4155896,Inhibition of human KDR by Hotspot assay,B,CHEMBL4163870,=,nM,94.62,CHEMBL279,Homo sapiens,IC50
18453553,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL4217207,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
18453555,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL4205052,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50
18467496,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4205605,=,nM,48.0,CHEMBL279,Homo sapiens,IC50
18467497,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208845,=,nM,83.0,CHEMBL279,Homo sapiens,IC50
18467498,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208454,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
18467499,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4211614,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
18467500,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208557,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
18481854,CHEMBL4185096,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins in presence of ATP by HTRF assay",B,CHEMBL4204920,=,nM,291.3,CHEMBL279,Homo sapiens,IC50
18487172,CHEMBL4186565,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,B,CHEMBL4215703,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
18499423,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4213775,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
18499424,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4208852,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
18499425,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4218175,=,nM,66.0,CHEMBL279,Homo sapiens,IC50
18499426,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL3809489,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
18499428,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4217649,=,nM,7700.0,CHEMBL279,Homo sapiens,IC50
18499429,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4218369,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50
18499433,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4209569,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50
18499434,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4214476,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50
18499435,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4213003,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
18523812,CHEMBL4194204,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4210100,=,nM,62.5,CHEMBL279,Homo sapiens,IC50
18531075,CHEMBL4195389,Inhibition of VEGFR-2 (unknown origin) after 40 mins by kinase-Glo assay,B,CHEMBL4212117,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
18531076,CHEMBL4195389,Inhibition of VEGFR-2 (unknown origin) after 40 mins by kinase-Glo assay,B,CHEMBL4213341,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
18551696,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4205803,=,nM,5.9,CHEMBL279,Homo sapiens,IC50
18551697,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4210670,=,nM,95.3,CHEMBL279,Homo sapiens,IC50
18551698,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218013,=,nM,20.8,CHEMBL279,Homo sapiens,IC50
18551699,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4206308,=,nM,68.5,CHEMBL279,Homo sapiens,IC50
18551700,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4213626,=,nM,136.6,CHEMBL279,Homo sapiens,IC50
18551701,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218563,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
18551702,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4209229,=,nM,1830.3,CHEMBL279,Homo sapiens,IC50
18551703,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4214146,=,nM,91.7,CHEMBL279,Homo sapiens,IC50
18551704,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218127,=,nM,10.2,CHEMBL279,Homo sapiens,IC50
18551705,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4205243,=,nM,11.7,CHEMBL279,Homo sapiens,IC50
18551706,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4203429,=,nM,20.6,CHEMBL279,Homo sapiens,IC50
18551707,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4212513,=,nM,215.8,CHEMBL279,Homo sapiens,IC50
18551708,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL3355010,=,nM,40.1,CHEMBL279,Homo sapiens,IC50
18551709,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL3355009,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
18573668,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4228120,=,nM,169.9,CHEMBL279,Homo sapiens,IC50
18573669,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4229213,=,nM,237.3,CHEMBL279,Homo sapiens,IC50
18573670,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4226907,=,nM,133.2,CHEMBL279,Homo sapiens,IC50
18573671,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4227281,=,nM,151.5,CHEMBL279,Homo sapiens,IC50
18585466,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225623,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
18585467,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4227378,=,nM,57.0,CHEMBL279,Homo sapiens,IC50
18585468,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225895,=,nM,210.0,CHEMBL279,Homo sapiens,IC50
18585469,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225317,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
18585470,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4226159,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
18585471,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225576,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
18585769,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224704,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
18585770,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4227572,=,nM,508.0,CHEMBL279,Homo sapiens,IC50
18585771,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4229181,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
18585773,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225772,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
18585777,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225238,=,nM,8663.0,CHEMBL279,Homo sapiens,IC50
18585778,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226090,=,nM,74.0,CHEMBL279,Homo sapiens,IC50
18585780,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226340,=,nM,277.0,CHEMBL279,Homo sapiens,IC50
18585781,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224707,=,nM,3864.0,CHEMBL279,Homo sapiens,IC50
18585782,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225562,=,nM,5986.0,CHEMBL279,Homo sapiens,IC50
18585783,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224973,=,nM,61.0,CHEMBL279,Homo sapiens,IC50
18585784,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225828,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
18585785,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226283,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
18585787,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4228868,=,nM,4016.0,CHEMBL279,Homo sapiens,IC50
18585788,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225256,=,nM,6915.0,CHEMBL279,Homo sapiens,IC50
18585789,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4227092,=,nM,887.0,CHEMBL279,Homo sapiens,IC50
18656213,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4238493,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
18656214,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4248513,=,nM,730.0,CHEMBL279,Homo sapiens,IC50
18656217,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4238320,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
18656218,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4240970,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
18656226,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4248398,=,nM,620.0,CHEMBL279,Homo sapiens,IC50
18656233,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4240958,=,nM,970.0,CHEMBL279,Homo sapiens,IC50
18656468,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL1488812,=,nM,51600.0,CHEMBL279,Homo sapiens,IC50
18656469,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4238771,=,nM,7730.0,CHEMBL279,Homo sapiens,IC50
18656470,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL47173,=,nM,1130.0,CHEMBL279,Homo sapiens,IC50
18656471,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4241633,=,nM,17800.0,CHEMBL279,Homo sapiens,IC50
18656472,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL273103,=,nM,21600.0,CHEMBL279,Homo sapiens,IC50
18656473,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4237913,=,nM,92700.0,CHEMBL279,Homo sapiens,IC50
18656474,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4239930,=,nM,67000.0,CHEMBL279,Homo sapiens,IC50
18656475,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL172517,=,nM,9610.0,CHEMBL279,Homo sapiens,IC50
18656477,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL1704021,=,nM,47000.0,CHEMBL279,Homo sapiens,IC50
18658153,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4246128,=,nM,174.0,CHEMBL279,Homo sapiens,IC50
18658160,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4248249,=,nM,203.0,CHEMBL279,Homo sapiens,IC50
18658162,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4245780,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
18658164,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4242446,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
18658169,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4248225,=,nM,85.0,CHEMBL279,Homo sapiens,IC50
18676712,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4245415,=,nM,15.6,CHEMBL279,Homo sapiens,IC50
18676713,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250210,=,nM,12.7,CHEMBL279,Homo sapiens,IC50
18676714,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4239716,=,nM,13.6,CHEMBL279,Homo sapiens,IC50
18676715,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4242522,=,nM,7.8,CHEMBL279,Homo sapiens,IC50
18676716,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4237916,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
18676717,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250273,=,nM,23.4,CHEMBL279,Homo sapiens,IC50
18676718,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4241638,=,nM,67.3,CHEMBL279,Homo sapiens,IC50
18676719,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4245874,=,nM,38.1,CHEMBL279,Homo sapiens,IC50
18676723,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250191,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
18678984,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4238195,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
18678985,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4245241,=,nM,696.0,CHEMBL279,Homo sapiens,IC50
18678987,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4241470,=,nM,259.0,CHEMBL279,Homo sapiens,IC50
18678990,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4242710,=,nM,685.0,CHEMBL279,Homo sapiens,IC50
18678991,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4243899,=,nM,105.0,CHEMBL279,Homo sapiens,IC50
18679027,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4238294,=,nM,167.0,CHEMBL279,Homo sapiens,IC50
18679030,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4251080,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
18679031,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4240969,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
18679032,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4247248,=,nM,177.0,CHEMBL279,Homo sapiens,IC50
18679033,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4237289,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
18679034,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4243470,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
18686989,CHEMBL4252289,Inhibition of human VEGFR2 after 2 hrs by ELISA,B,CHEMBL4278922,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
18689611,CHEMBL4252892,"Inhibition of VEGFR2 (unknown origin) using poly(Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4289577,=,nM,152.3,CHEMBL279,Homo sapiens,IC50
18701232,CHEMBL4254925,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4285414,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50
18701233,CHEMBL4254925,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4279863,=,nM,14400.0,CHEMBL279,Homo sapiens,IC50
18725094,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4293385,=,nM,870.0,CHEMBL279,Homo sapiens,IC50
18725095,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4294041,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
18725096,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4283873,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
18725097,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4283690,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50
18769824,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4293912,=,nM,30.3,CHEMBL279,Homo sapiens,IC50
18769825,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4280932,=,nM,30.0,CHEMBL279,Homo sapiens,IC50
18769826,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4291572,=,nM,198.5,CHEMBL279,Homo sapiens,IC50
18769828,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282864,=,nM,209.3,CHEMBL279,Homo sapiens,IC50
18769829,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4293467,=,nM,205.2,CHEMBL279,Homo sapiens,IC50
18769830,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4291146,=,nM,429.8,CHEMBL279,Homo sapiens,IC50
18769831,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4283293,=,nM,101.6,CHEMBL279,Homo sapiens,IC50
18769832,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4294551,=,nM,156.6,CHEMBL279,Homo sapiens,IC50
18769833,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4286642,=,nM,110.1,CHEMBL279,Homo sapiens,IC50
18769834,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282473,=,nM,329.5,CHEMBL279,Homo sapiens,IC50
18769835,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4290345,=,nM,317.6,CHEMBL279,Homo sapiens,IC50
18769836,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4290758,=,nM,140.9,CHEMBL279,Homo sapiens,IC50
18769837,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4280119,=,nM,83.7,CHEMBL279,Homo sapiens,IC50
18769838,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4294161,=,nM,697.3,CHEMBL279,Homo sapiens,IC50
18769877,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4286011,=,nM,84.5,CHEMBL279,Homo sapiens,IC50
18769878,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4278759,=,nM,8.3,CHEMBL279,Homo sapiens,IC50
18769879,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4289433,=,nM,24.7,CHEMBL279,Homo sapiens,IC50
18769880,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282231,=,nM,21.6,CHEMBL279,Homo sapiens,IC50
18772486,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4292884,=,nM,4.1,CHEMBL279,Homo sapiens,IC50
18772487,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4285034,=,nM,12.4,CHEMBL279,Homo sapiens,IC50
18772488,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4287439,=,nM,12.2,CHEMBL279,Homo sapiens,IC50
18772489,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4276790,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
18772490,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4292983,=,nM,7.2,CHEMBL279,Homo sapiens,IC50
18772491,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4282387,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
18772492,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4277848,=,nM,6.6,CHEMBL279,Homo sapiens,IC50
18772493,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4285792,=,nM,6.1,CHEMBL279,Homo sapiens,IC50
18772496,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL2103868,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
18772570,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4286385,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
18772571,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3989926,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
18772572,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3545365,=,nM,9.2,CHEMBL279,Homo sapiens,IC50
18786383,CHEMBL4271714,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA based spectrophotometric method",B,CHEMBL4290371,=,nM,2.9,CHEMBL279,Homo sapiens,IC50
18786404,CHEMBL4271735,Inhibition of human N-terminal GST-tagged VEGFR2 (790 to 1356 residues) cytoplasmic domain expressed in baculovirus expression system after 60 mins by off-chip mobility shift assay,B,CHEMBL4294625,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
18791171,CHEMBL4272805,Inhibition of human VEGFR-2 incubated for 2.5 hrs by ELISA,B,CHEMBL4286023,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50
18791172,CHEMBL4272805,Inhibition of human VEGFR-2 incubated for 2.5 hrs by ELISA,B,CHEMBL4291192,=,nM,1970.0,CHEMBL279,Homo sapiens,IC50
18851331,CHEMBL4305823,Inhibition of KDR (unknown origin),B,CHEMBL4448494,=,nM,3934.0,CHEMBL279,Homo sapiens,IC50
18854163,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1946170,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
18856438,CHEMBL4307557,Inhibition of VEGFR2 (unknown origin) using TK substrate incubated for 60 mins by FRET assay,B,CHEMBL4520064,=,nM,46.4,CHEMBL279,Homo sapiens,IC50
18902127,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4437124,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
18902128,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4561931,=,nM,40000.0,CHEMBL279,Homo sapiens,IC50
18902129,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4475515,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50
18902130,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4558980,=,nM,7940.0,CHEMBL279,Homo sapiens,IC50
18902131,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4535795,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50
18902132,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4475766,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
18902133,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4551566,=,nM,5010.0,CHEMBL279,Homo sapiens,IC50
18902135,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4527824,=,nM,7940.0,CHEMBL279,Homo sapiens,IC50
18922438,CHEMBL4323751,Inhibition of VEGFR2 in HUVEC assessed as inhibition of VEGF-induced tube formation incubated for 8 hrs by inverted microscopic method,B,CHEMBL4537518,=,nM,40400.0,CHEMBL279,Homo sapiens,IC50
18937518,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4436272,=,nM,114.0,CHEMBL279,Homo sapiens,IC50
18937519,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4468005,=,nM,101.0,CHEMBL279,Homo sapiens,IC50
18937520,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4543095,=,nM,125.0,CHEMBL279,Homo sapiens,IC50
18937521,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4551158,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
18937522,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4562341,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
18937523,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4542816,=,nM,104.0,CHEMBL279,Homo sapiens,IC50
18937524,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4591664,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
18937525,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4552156,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
18937526,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4585345,=,nM,131.0,CHEMBL279,Homo sapiens,IC50
18937527,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4592212,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
18937528,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4554056,=,nM,117.0,CHEMBL279,Homo sapiens,IC50
18937529,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4449964,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
18947831,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4452256,=,nM,1.63,CHEMBL279,Homo sapiens,IC50
18947833,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4470400,=,nM,10.56,CHEMBL279,Homo sapiens,IC50
18947834,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4449700,=,nM,96.17,CHEMBL279,Homo sapiens,IC50
18947835,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4556899,=,nM,11.07,CHEMBL279,Homo sapiens,IC50
18947836,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4528844,=,nM,75.86,CHEMBL279,Homo sapiens,IC50
18947837,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4441465,=,nM,1.85,CHEMBL279,Homo sapiens,IC50
18947838,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4473253,=,nM,0.52,CHEMBL279,Homo sapiens,IC50
18947839,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4447552,=,nM,668.7,CHEMBL279,Homo sapiens,IC50
18947840,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4454065,=,nM,300.42,CHEMBL279,Homo sapiens,IC50
18947841,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4556134,=,nM,36.16,CHEMBL279,Homo sapiens,IC50
18947842,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4519953,=,nM,15.9,CHEMBL279,Homo sapiens,IC50
18947843,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4570075,=,nM,1.33,CHEMBL279,Homo sapiens,IC50
18948036,CHEMBL4330448,Inhibition of KDR (unknown origin) using FAM-labelled peptide and ATP incubated for 10 mins by mobility shift assay,B,CHEMBL4587222,=,nM,850.0,CHEMBL279,Homo sapiens,IC50
18948237,CHEMBL4330494,Inhibition of VEGFR-2 (unknown origin) after 15 mins in presence of [33P]ATP by scintillation counting analysis,B,CHEMBL4556620,=,nM,10300.0,CHEMBL279,Homo sapiens,IC50
18948710,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4583526,=,nM,1240.0,CHEMBL279,Homo sapiens,IC50
18948711,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4553770,=,nM,510.0,CHEMBL279,Homo sapiens,IC50
18948712,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4580040,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
18948713,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4471270,=,nM,450.0,CHEMBL279,Homo sapiens,IC50
18948714,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4457815,=,nM,270.0,CHEMBL279,Homo sapiens,IC50
18948715,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4577116,=,nM,2730.0,CHEMBL279,Homo sapiens,IC50
18948716,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4461094,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
18948717,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4454772,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
18948718,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4473172,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50
18948719,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4435024,=,nM,4540.0,CHEMBL279,Homo sapiens,IC50
18948720,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4467628,=,nM,4160.0,CHEMBL279,Homo sapiens,IC50
18948721,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4473129,=,nM,3630.0,CHEMBL279,Homo sapiens,IC50
18948722,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4469902,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
18948723,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4452275,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50
18948724,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4590694,=,nM,4220.0,CHEMBL279,Homo sapiens,IC50
18948725,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4577123,=,nM,3950.0,CHEMBL279,Homo sapiens,IC50
18948726,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4582488,=,nM,3520.0,CHEMBL279,Homo sapiens,IC50
18948727,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4590038,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
18948728,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4520313,=,nM,4380.0,CHEMBL279,Homo sapiens,IC50
18948729,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4443027,=,nM,4320.0,CHEMBL279,Homo sapiens,IC50
18948730,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4436907,=,nM,3980.0,CHEMBL279,Homo sapiens,IC50
18948731,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4559188,=,nM,3740.0,CHEMBL279,Homo sapiens,IC50
18948732,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4540917,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
18948733,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4465659,=,nM,4120.0,CHEMBL279,Homo sapiens,IC50
18948734,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4458736,=,nM,3790.0,CHEMBL279,Homo sapiens,IC50
18948735,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4450127,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
18948736,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4469330,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
18948764,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4438911,=,nM,3420.0,CHEMBL279,Homo sapiens,IC50
18948765,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4439297,=,nM,2980.0,CHEMBL279,Homo sapiens,IC50
18948766,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4463359,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
18948767,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4476746,=,nM,1830.0,CHEMBL279,Homo sapiens,IC50
18950283,CHEMBL4331130,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay,B,CHEMBL4473820,=,nM,6259.0,CHEMBL279,Homo sapiens,IC50
18955286,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4539051,=,nM,51.9,CHEMBL279,Homo sapiens,IC50
18955287,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4589270,=,nM,30.5,CHEMBL279,Homo sapiens,IC50
18955288,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4548316,=,nM,30.1,CHEMBL279,Homo sapiens,IC50
18955294,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4531086,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
18955295,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4590229,=,nM,45.0,CHEMBL279,Homo sapiens,IC50
18955296,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4453846,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
18955297,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4464237,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
18973954,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4515000,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
18973955,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4515912,=,nM,940.0,CHEMBL279,Homo sapiens,IC50
18973956,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4452766,=,nM,86.0,CHEMBL279,Homo sapiens,IC50
18973959,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4530473,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
18973960,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4453304,=,nM,3.56,CHEMBL279,Homo sapiens,IC50
18973962,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4533447,=,nM,54.0,CHEMBL279,Homo sapiens,IC50
18973965,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4303275,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
18985837,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4453147,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
18985840,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4448243,=,nM,180.0,CHEMBL279,Homo sapiens,IC50
18985842,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4582099,=,nM,520.0,CHEMBL279,Homo sapiens,IC50
18985843,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4441332,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
18985870,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4463108,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
18985871,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4584918,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
18989188,CHEMBL4340736,Inhibition of recombinant human N-terminal GST-fused VEGFR2 C-terminal domain (D807 to V1356 residues) expressed in Sf9 insect cells using Poly(Glu:Tyr)4:1 as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method,B,CHEMBL4446681,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50
18994674,CHEMBL4342018,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay",B,CHEMBL4533153,=,nM,95.0,CHEMBL279,Homo sapiens,IC50
18997266,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4436951,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
18997267,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4579615,=,nM,5480.0,CHEMBL279,Homo sapiens,IC50
18997268,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4515066,=,nM,2270.0,CHEMBL279,Homo sapiens,IC50
18997582,CHEMBL4342891,Inhibition of human recombinant GST-tagged VEGFR2 (catalytic domain 805 to 1356 residues) expressed in Sf9 insect cells incubated for 45 mins by Kinase-Glo assay,B,CHEMBL4544826,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
18997584,CHEMBL4342894,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4547332,=,nM,103.0,CHEMBL279,Homo sapiens,IC50
19012793,CHEMBL4345871,Inhibition of KDR (unknown origin) expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay,B,CHEMBL4561280,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50
19063666,CHEMBL4359452,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using peptide substrate preincubated for 60 mins followed by substrate addition by microfluidic assay,B,CHEMBL4473213,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
19072846,CHEMBL4362048,Inhibition of VEGFR (unknown origin),B,CHEMBL4466350,=,nM,3.6,CHEMBL279,Homo sapiens,IC50
19072852,CHEMBL4362048,Inhibition of VEGFR (unknown origin),B,CHEMBL4439680,=,nM,3.6,CHEMBL279,Homo sapiens,IC50
19073775,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4453429,=,nM,86.84,CHEMBL279,Homo sapiens,IC50
19073776,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4535949,=,nM,517.33,CHEMBL279,Homo sapiens,IC50
19073777,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4463765,=,nM,183.56,CHEMBL279,Homo sapiens,IC50
19073778,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4521028,=,nM,36.78,CHEMBL279,Homo sapiens,IC50
19073779,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4515673,=,nM,4082.09,CHEMBL279,Homo sapiens,IC50
19073780,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4540303,=,nM,407.47,CHEMBL279,Homo sapiens,IC50
19073809,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4463898,=,nM,27.13,CHEMBL279,Homo sapiens,IC50
19073810,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4468893,=,nM,1883.43,CHEMBL279,Homo sapiens,IC50
19073811,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4532084,=,nM,244.76,CHEMBL279,Homo sapiens,IC50
19073812,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4531912,=,nM,2865.05,CHEMBL279,Homo sapiens,IC50
19073813,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4435233,=,nM,216.77,CHEMBL279,Homo sapiens,IC50
19073814,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4471491,=,nM,67.84,CHEMBL279,Homo sapiens,IC50
19073815,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4460151,=,nM,864.18,CHEMBL279,Homo sapiens,IC50
19073816,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4560187,=,nM,1196.59,CHEMBL279,Homo sapiens,IC50
19073817,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4576032,=,nM,1104.22,CHEMBL279,Homo sapiens,IC50
19077803,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4446068,=,nM,980.0,CHEMBL279,Homo sapiens,IC50
19077804,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4445854,=,nM,647.0,CHEMBL279,Homo sapiens,IC50
19077805,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4534317,=,nM,132.0,CHEMBL279,Homo sapiens,IC50
19077806,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4465698,=,nM,97.0,CHEMBL279,Homo sapiens,IC50
19077807,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4573769,=,nM,109.0,CHEMBL279,Homo sapiens,IC50
19077808,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4446129,=,nM,256.0,CHEMBL279,Homo sapiens,IC50
19077809,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4562600,=,nM,187.0,CHEMBL279,Homo sapiens,IC50
19077810,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4536596,=,nM,212.0,CHEMBL279,Homo sapiens,IC50
19092251,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4474232,=,nM,279.9,CHEMBL279,Homo sapiens,IC50
19092252,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4553056,=,nM,63.2,CHEMBL279,Homo sapiens,IC50
19092254,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4442365,=,nM,261.1,CHEMBL279,Homo sapiens,IC50
19092255,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4449612,=,nM,102.6,CHEMBL279,Homo sapiens,IC50
19092256,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4438194,=,nM,23.1,CHEMBL279,Homo sapiens,IC50
19092257,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4591255,=,nM,147.9,CHEMBL279,Homo sapiens,IC50
19092258,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4592597,=,nM,44.9,CHEMBL279,Homo sapiens,IC50
19092260,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4454810,=,nM,450.7,CHEMBL279,Homo sapiens,IC50
19092261,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4443305,=,nM,17.3,CHEMBL279,Homo sapiens,IC50
19110229,CHEMBL4370314,Inhibition of VEGFR2 (unknown origin),B,CHEMBL80302,=,nM,140.0,CHEMBL279,Homo sapiens,IC50
19110230,CHEMBL4370314,Inhibition of VEGFR2 (unknown origin),B,CHEMBL76432,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
19118513,CHEMBL4372357,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells using MBP as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP,B,CHEMBL4483816,=,nM,527.0,CHEMBL279,Homo sapiens,IC50
19125175,CHEMBL4373576,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (D807 to V1356 residues) expressed in sf9 cells using Poly(Glu,Tyr) 4:1 as substrate after 60 mins in presence of [gamma33P]-ATP by scintillation counting method",B,CHEMBL4465918,=,nM,530.0,CHEMBL279,Homo sapiens,IC50
19125188,CHEMBL4373576,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (D807 to V1356 residues) expressed in sf9 cells using Poly(Glu,Tyr) 4:1 as substrate after 60 mins in presence of [gamma33P]-ATP by scintillation counting method",B,CHEMBL4473548,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
19130923,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL3353658,=,nM,140000.0,CHEMBL279,Homo sapiens,IC50
19130924,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4551715,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
19130925,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4513608,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
19130926,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4449692,=,nM,560.0,CHEMBL279,Homo sapiens,IC50
19130927,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL3545376,=,nM,37.0,CHEMBL279,Homo sapiens,IC50
19137708,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4453974,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
19137711,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4520209,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
19137714,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4532350,=,nM,5410.0,CHEMBL279,Homo sapiens,IC50
19140642,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4580861,=,nM,10450.0,CHEMBL279,Homo sapiens,IC50
19140643,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4578452,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50
19140644,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4584949,=,nM,22910.0,CHEMBL279,Homo sapiens,IC50
19140646,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4513894,=,nM,288.9,CHEMBL279,Homo sapiens,IC50
19140647,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4575352,=,nM,58.9,CHEMBL279,Homo sapiens,IC50
19140649,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4567013,=,nM,61.2,CHEMBL279,Homo sapiens,IC50
19140650,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4434974,=,nM,8.8,CHEMBL279,Homo sapiens,IC50
19140652,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4468880,=,nM,230.1,CHEMBL279,Homo sapiens,IC50
19140653,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4443752,=,nM,26.9,CHEMBL279,Homo sapiens,IC50
19140654,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4530342,=,nM,19.4,CHEMBL279,Homo sapiens,IC50
19140655,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4529670,=,nM,20.2,CHEMBL279,Homo sapiens,IC50
19140656,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4459121,=,nM,38.1,CHEMBL279,Homo sapiens,IC50
19140657,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4580644,=,nM,68.0,CHEMBL279,Homo sapiens,IC50
19163558,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4458485,=,nM,260.64,CHEMBL279,Homo sapiens,IC50
19163559,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4536441,=,nM,383.61,CHEMBL279,Homo sapiens,IC50
19163560,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4533369,=,nM,462.38,CHEMBL279,Homo sapiens,IC50
19163561,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4569077,=,nM,207.04,CHEMBL279,Homo sapiens,IC50
19181926,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4576626,=,nM,7160.0,CHEMBL279,Homo sapiens,IC50
19181927,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4549295,=,nM,2880.0,CHEMBL279,Homo sapiens,IC50
19181928,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4459564,=,nM,3710.0,CHEMBL279,Homo sapiens,IC50
19181929,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4442932,=,nM,16230.0,CHEMBL279,Homo sapiens,IC50
19181930,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4448424,=,nM,14490.0,CHEMBL279,Homo sapiens,IC50
19181931,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4470214,=,nM,6850.0,CHEMBL279,Homo sapiens,IC50
19181932,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4445843,=,nM,10140.0,CHEMBL279,Homo sapiens,IC50
19181933,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4522594,=,nM,25180.0,CHEMBL279,Homo sapiens,IC50
19181934,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4554486,=,nM,5970.0,CHEMBL279,Homo sapiens,IC50
19181935,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4471464,=,nM,5150.0,CHEMBL279,Homo sapiens,IC50
19181936,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4460897,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
19181937,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4439053,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50
19181938,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4455321,=,nM,17350.0,CHEMBL279,Homo sapiens,IC50
19181939,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4520103,=,nM,9220.0,CHEMBL279,Homo sapiens,IC50
19181940,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4530048,=,nM,10420.0,CHEMBL279,Homo sapiens,IC50
19181941,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4549604,=,nM,580.0,CHEMBL279,Homo sapiens,IC50
19181942,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4459052,=,nM,3260.0,CHEMBL279,Homo sapiens,IC50
19181943,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4552065,=,nM,20410.0,CHEMBL279,Homo sapiens,IC50
19211855,CHEMBL4393292,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,B,CHEMBL4446992,=,nM,18.7,CHEMBL279,Homo sapiens,IC50
19225806,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4531859,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
19225807,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4470543,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
19225808,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4466426,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
19225809,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4514617,=,nM,2.4,CHEMBL279,Homo sapiens,IC50
19225810,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4435366,=,nM,4.2,CHEMBL279,Homo sapiens,IC50
19225811,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4528373,=,nM,1.7,CHEMBL279,Homo sapiens,IC50
19225812,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4472616,=,nM,11.2,CHEMBL279,Homo sapiens,IC50
19225813,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4461971,=,nM,1081.0,CHEMBL279,Homo sapiens,IC50
19225814,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4449250,=,nM,1.5,CHEMBL279,Homo sapiens,IC50
19225815,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4455006,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
19225816,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4581503,=,nM,2.4,CHEMBL279,Homo sapiens,IC50
19225817,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4516513,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
19236951,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4541917,=,nM,578.8,CHEMBL279,Homo sapiens,IC50
19236952,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4516406,=,nM,357.2,CHEMBL279,Homo sapiens,IC50
19236953,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4441017,=,nM,338.3,CHEMBL279,Homo sapiens,IC50
19236954,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4584893,=,nM,386.4,CHEMBL279,Homo sapiens,IC50
19236955,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4454848,=,nM,258.8,CHEMBL279,Homo sapiens,IC50
19236956,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4462301,=,nM,97.3,CHEMBL279,Homo sapiens,IC50
19236957,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4441199,=,nM,165.9,CHEMBL279,Homo sapiens,IC50
19236958,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4555386,=,nM,232.6,CHEMBL279,Homo sapiens,IC50
19236959,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4459889,=,nM,443.8,CHEMBL279,Homo sapiens,IC50
19236960,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4516973,=,nM,488.7,CHEMBL279,Homo sapiens,IC50
19236961,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4584219,=,nM,842.4,CHEMBL279,Homo sapiens,IC50
19236962,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4570785,=,nM,987.7,CHEMBL279,Homo sapiens,IC50
19236963,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4464066,=,nM,542.2,CHEMBL279,Homo sapiens,IC50
19236964,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4590471,=,nM,418.7,CHEMBL279,Homo sapiens,IC50
19236965,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4557230,=,nM,51.4,CHEMBL279,Homo sapiens,IC50
19236966,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4471675,=,nM,73.7,CHEMBL279,Homo sapiens,IC50
19238816,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4561629,=,nM,950.0,CHEMBL279,Homo sapiens,IC50
19238817,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4465126,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
19238818,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4474922,=,nM,740.0,CHEMBL279,Homo sapiens,IC50
19238819,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4474945,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
19238821,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4539297,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
19238822,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4574832,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
19238823,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4590013,=,nM,280.0,CHEMBL279,Homo sapiens,IC50
19238824,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4467107,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
19238827,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4558790,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
19238829,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4434973,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50
19238830,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4438418,=,nM,570.0,CHEMBL279,Homo sapiens,IC50
19238832,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4471650,=,nM,1960.0,CHEMBL279,Homo sapiens,IC50
19238833,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4573547,=,nM,170.0,CHEMBL279,Homo sapiens,IC50
19238834,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4448435,=,nM,410.0,CHEMBL279,Homo sapiens,IC50
19238835,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4566054,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
19238836,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4469216,=,nM,340.0,CHEMBL279,Homo sapiens,IC50
19238837,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4449189,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
19238838,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4570955,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50
19238839,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4470636,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
19238840,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4549103,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
19276228,CHEMBL4407925,Inhibition of recombinant human VEGFR2 (790 to end residues) using myelin ba as substrate incubated for 40 mins by [gamma-33P]-ATP based radiometric assay,B,CHEMBL4445335,=,nM,46.0,CHEMBL279,Homo sapiens,IC50
19279712,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4516916,=,nM,10500.0,CHEMBL279,Homo sapiens,IC50
19279713,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4516736,=,nM,10770.0,CHEMBL279,Homo sapiens,IC50
19279714,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4557318,=,nM,25640.0,CHEMBL279,Homo sapiens,IC50
19288129,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4570139,=,nM,734.9,CHEMBL279,Homo sapiens,IC50
19288130,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4437475,=,nM,362.7,CHEMBL279,Homo sapiens,IC50
19288131,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4460817,=,nM,64.8,CHEMBL279,Homo sapiens,IC50
19292297,CHEMBL4411548,Inhibition of recombinant human VEGFR2 using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins,B,CHEMBL4458435,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
19326426,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4522385,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326453,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4459013,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326476,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4536156,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326478,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4572765,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326484,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4585626,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326485,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4581670,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326489,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4447901,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19326493,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4476415,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
19364847,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4459732,=,nM,7.63,CHEMBL279,Homo sapiens,IC50
19364849,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4452405,=,nM,11.06,CHEMBL279,Homo sapiens,IC50
19364850,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4553163,=,nM,2.57,CHEMBL279,Homo sapiens,IC50
19364852,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4448354,=,nM,55.95,CHEMBL279,Homo sapiens,IC50
19364853,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4447942,=,nM,125.06,CHEMBL279,Homo sapiens,IC50
19364855,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4472113,=,nM,0.53,CHEMBL279,Homo sapiens,IC50
19364858,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4469077,=,nM,3.17,CHEMBL279,Homo sapiens,IC50
19364859,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4453627,=,nM,500.28,CHEMBL279,Homo sapiens,IC50
19364860,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4543212,=,nM,0.57,CHEMBL279,Homo sapiens,IC50
19364863,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4476000,=,nM,58.1,CHEMBL279,Homo sapiens,IC50
19364865,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4539395,=,nM,4.15,CHEMBL279,Homo sapiens,IC50
19406095,CHEMBL4426405,"Inhibition of recombinant human VEGFR2 using poly (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL4437058,=,nM,548.4,CHEMBL279,Homo sapiens,IC50
19406117,CHEMBL4426405,"Inhibition of recombinant human VEGFR2 using poly (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL4469836,=,nM,365.9,CHEMBL279,Homo sapiens,IC50
19435646,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4434704,=,nM,630.0,CHEMBL279,Homo sapiens,IC50
19435647,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4516793,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50
19435648,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4448596,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50
19435649,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4553351,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50
19437263,CHEMBL4430713,Inhibition of biotinylated VEGF-A165 binding to recombinant KDR (unknown origin) measured after 2 hrs by competition binding assay relative to VEGF-A165,B,CHEMBL4576666,=,nM,306000.0,CHEMBL279,Homo sapiens,IC50
19449742,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4516917,=,nM,753.0,CHEMBL279,Homo sapiens,IC50
19449743,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4436488,=,nM,319.0,CHEMBL279,Homo sapiens,IC50
19449744,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4521454,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
19449745,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4536372,=,nM,120.0,CHEMBL279,Homo sapiens,IC50
19449746,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4558158,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
19449747,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4517008,=,nM,650.0,CHEMBL279,Homo sapiens,IC50
19449748,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4567879,=,nM,1730.0,CHEMBL279,Homo sapiens,IC50
19449749,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4437803,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
19449750,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4584717,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
19449751,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4449758,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
19449752,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4582195,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
19449753,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4467322,=,nM,221.0,CHEMBL279,Homo sapiens,IC50
19449754,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4438721,=,nM,772.0,CHEMBL279,Homo sapiens,IC50
19449755,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4440653,=,nM,1084.0,CHEMBL279,Homo sapiens,IC50
19449756,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4513911,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
19449757,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4570460,=,nM,286.0,CHEMBL279,Homo sapiens,IC50
19449758,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4543044,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
19449759,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4466088,=,nM,96.0,CHEMBL279,Homo sapiens,IC50
19449760,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4465496,=,nM,302.0,CHEMBL279,Homo sapiens,IC50
19449761,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4443510,=,nM,113.0,CHEMBL279,Homo sapiens,IC50
19449762,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4529255,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
19449763,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4437943,=,nM,94.0,CHEMBL279,Homo sapiens,IC50
19449764,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4469407,=,nM,396.0,CHEMBL279,Homo sapiens,IC50
19469108,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4593348,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50
19469109,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4560522,=,nM,82000.0,CHEMBL279,Homo sapiens,IC50
19469111,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4166405,=,nM,79000.0,CHEMBL279,Homo sapiens,IC50
19475351,CHEMBL4479446,Inhibition of human VEGFR2,B,CHEMBL4068255,=,nM,20618.0,CHEMBL279,Homo sapiens,IC50
19476689,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4550702,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
19476789,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4568087,=,nM,3.5,CHEMBL279,Homo sapiens,IC50
19476889,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4552628,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50
20600446,CHEMBL4603303,Inhibition of recombinant human His-tagged KDR (789 to 1356 residues) expressed in baculovirus expression system using Tyr1 as substrate incubated for 1 hr in presence of ATP by Z'-LYTE assay,B,CHEMBL4634634,=,nM,37610.0,CHEMBL279,Homo sapiens,IC50
20609565,CHEMBL4605807,Inhibition of KDR (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay,B,CHEMBL4634073,=,nM,26.0,CHEMBL279,Homo sapiens,IC50
20609566,CHEMBL4605807,Inhibition of KDR (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay,B,CHEMBL4636995,=,nM,240.0,CHEMBL279,Homo sapiens,IC50
20669684,CHEMBL4620455,Inhibition of human recombinant VEGFR2 in presence of substrate Ulight-CAGAGAIETDKEYYTVKD and Km ATP,B,CHEMBL4635625,=,nM,284.0,CHEMBL279,Homo sapiens,IC50
20681210,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4642920,=,nM,492.0,CHEMBL279,Homo sapiens,IC50
20681211,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4641639,=,nM,248.0,CHEMBL279,Homo sapiens,IC50
20681212,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4647154,=,nM,472.0,CHEMBL279,Homo sapiens,IC50
20681213,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4639539,=,nM,584.0,CHEMBL279,Homo sapiens,IC50
20681216,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4640617,=,nM,147.6,CHEMBL279,Homo sapiens,IC50
20681217,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4644718,=,nM,6.5,CHEMBL279,Homo sapiens,IC50
20681218,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4634687,=,nM,100.8,CHEMBL279,Homo sapiens,IC50
20681219,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4649259,=,nM,227.7,CHEMBL279,Homo sapiens,IC50
20681220,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4638817,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
20681221,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4640302,=,nM,288.0,CHEMBL279,Homo sapiens,IC50
20681222,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4639712,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
20681223,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4648781,=,nM,485.0,CHEMBL279,Homo sapiens,IC50
20681224,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4643300,=,nM,65.0,CHEMBL279,Homo sapiens,IC50
20702861,CHEMBL4627705,Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA,B,CHEMBL4649124,=,nM,660.0,CHEMBL279,Homo sapiens,IC50
20702862,CHEMBL4627705,Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA,B,CHEMBL4642069,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
22415175,CHEMBL4672268,Inhibition of VEGFR-2 (unknown origin) relative to control,B,CHEMBL4751362,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
22421707,CHEMBL4673681,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell incubated for 45 mins by Kinase-Glo max reagent-based luminescence assay,B,CHEMBL4752986,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
22458805,CHEMBL4682588,Inhibition of human N-terminal GST-fused KDR cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using CSKtide as substrate measured after 1 hr by mobility shift assay,B,CHEMBL4776125,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
22458806,CHEMBL4682588,Inhibition of human N-terminal GST-fused KDR cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using CSKtide as substrate measured after 1 hr by mobility shift assay,B,CHEMBL4764463,=,nM,81.0,CHEMBL279,Homo sapiens,IC50
22468735,CHEMBL4684708,Inhibition of VEGFR2 in human RPMI-8226 cells incubated for 2 hrs by ELISA,B,CHEMBL4778826,=,nM,388.0,CHEMBL279,Homo sapiens,IC50
22472884,CHEMBL4685524,Inhibition of KDR (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4747900,=,nM,198.0,CHEMBL279,Homo sapiens,IC50
22476305,CHEMBL4686392,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4779315,=,nM,295.0,CHEMBL279,Homo sapiens,IC50
22791931,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4764656,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
22791932,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4748292,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
22791933,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4282338,=,nM,163.0,CHEMBL279,Homo sapiens,IC50
22798387,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4778145,=,nM,174.0,CHEMBL279,Homo sapiens,IC50
22798388,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4785888,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
22798389,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4751105,=,nM,263.0,CHEMBL279,Homo sapiens,IC50
22798390,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4795322,=,nM,175.0,CHEMBL279,Homo sapiens,IC50
22798391,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4762730,=,nM,153.0,CHEMBL279,Homo sapiens,IC50
22798392,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4757787,=,nM,102.0,CHEMBL279,Homo sapiens,IC50
22798393,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4754205,=,nM,67.0,CHEMBL279,Homo sapiens,IC50
22798394,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4793580,=,nM,133.0,CHEMBL279,Homo sapiens,IC50
22798395,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4752530,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
22798396,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4759423,=,nM,92.0,CHEMBL279,Homo sapiens,IC50
22798397,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4762111,=,nM,78.0,CHEMBL279,Homo sapiens,IC50
22798398,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4750035,=,nM,88.0,CHEMBL279,Homo sapiens,IC50
22798400,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4741847,=,nM,422.0,CHEMBL279,Homo sapiens,IC50
22798401,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4743088,=,nM,158.0,CHEMBL279,Homo sapiens,IC50
22814210,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL492399,=,nM,8.4,CHEMBL279,Homo sapiens,IC50
22814213,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL2420866,=,nM,9.3,CHEMBL279,Homo sapiens,IC50
22814214,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL516047,=,nM,14.7,CHEMBL279,Homo sapiens,IC50
22814215,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL4746488,=,nM,16.8,CHEMBL279,Homo sapiens,IC50
22814216,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL3604205,=,nM,111.1,CHEMBL279,Homo sapiens,IC50
22814217,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL444724,=,nM,97.5,CHEMBL279,Homo sapiens,IC50
22814218,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL2420867,=,nM,55.2,CHEMBL279,Homo sapiens,IC50
22822945,CHEMBL4716854,Inhibition of KDR (unknown origin),B,CHEMBL3651854,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50
22854959,CHEMBL4724605,Inhibition of human N-terminal GST-tagged VEGFR2 (790 to end residues) expressed in baculovirus expression system using CSKtide as substrate incubated for 30 mins in presence of ATP by off-chip mobility shift assay,B,CHEMBL4763773,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
22884300,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4740381,=,nM,5930.0,CHEMBL279,Homo sapiens,IC50
22884301,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4788859,=,nM,13410.0,CHEMBL279,Homo sapiens,IC50
22884302,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4786529,=,nM,20560.0,CHEMBL279,Homo sapiens,IC50
22884303,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4742906,=,nM,9350.0,CHEMBL279,Homo sapiens,IC50
22884304,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4778971,=,nM,36900.0,CHEMBL279,Homo sapiens,IC50
22916329,CHEMBL4735616,Inhibition of KDR (unknown origin) in presence of [gamma33]-ATP by liquid scintillation counting analysis,B,CHEMBL4797840,=,nM,173.0,CHEMBL279,Homo sapiens,IC50
22920177,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4776567,=,nM,115.0,CHEMBL279,Homo sapiens,IC50
22920178,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4765039,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
22920179,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4788768,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50
22920180,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758444,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50
22920181,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4790511,=,nM,380.0,CHEMBL279,Homo sapiens,IC50
22920182,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4776193,=,nM,260.0,CHEMBL279,Homo sapiens,IC50
22920183,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4753664,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
22920184,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4800071,=,nM,47.0,CHEMBL279,Homo sapiens,IC50
22920186,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4795436,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
22920187,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4793877,=,nM,75.0,CHEMBL279,Homo sapiens,IC50
22920189,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4757998,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
22920190,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4750711,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
22920191,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4787977,=,nM,250.0,CHEMBL279,Homo sapiens,IC50
22920192,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4777407,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
22920193,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758900,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
22920194,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4799534,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50
22920195,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758393,=,nM,580.0,CHEMBL279,Homo sapiens,IC50
22920196,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4742893,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
22920197,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4756717,=,nM,360.0,CHEMBL279,Homo sapiens,IC50
22920199,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4790424,=,nM,460.0,CHEMBL279,Homo sapiens,IC50
22950589,CHEMBL4766156,Inhibition of human recombinant KDR (790 to end residues) using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis,B,CHEMBL4798527,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
22953072,CHEMBL4767009,Inhibition of human KDR (790 to end residues) using myelin basic protein as substrate after 40 mins by [gamma-33ATP] radiometric assay,B,CHEMBL4793380,=,nM,892.0,CHEMBL279,Homo sapiens,IC50
22964324,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL3542344,=,nM,505.0,CHEMBL279,Homo sapiens,IC50
22964325,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4788980,=,nM,480.0,CHEMBL279,Homo sapiens,IC50
22964326,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4779166,=,nM,189.0,CHEMBL279,Homo sapiens,IC50
22964327,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4786972,=,nM,206.0,CHEMBL279,Homo sapiens,IC50
22964328,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4794096,=,nM,391.0,CHEMBL279,Homo sapiens,IC50
22964329,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4800500,=,nM,848.0,CHEMBL279,Homo sapiens,IC50
22964330,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4788376,=,nM,1328.0,CHEMBL279,Homo sapiens,IC50
22964331,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4781578,=,nM,3820.0,CHEMBL279,Homo sapiens,IC50
22964332,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4795330,=,nM,2164.0,CHEMBL279,Homo sapiens,IC50
22964333,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4796639,=,nM,2260.0,CHEMBL279,Homo sapiens,IC50
22969432,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4786985,=,nM,1920.0,CHEMBL279,Homo sapiens,IC50
22969433,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4797262,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50
22969434,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789458,=,nM,1210.0,CHEMBL279,Homo sapiens,IC50
22969435,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4782392,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
22969436,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4797072,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
22969437,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780987,=,nM,1820.0,CHEMBL279,Homo sapiens,IC50
22969438,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796999,=,nM,1130.0,CHEMBL279,Homo sapiens,IC50
22969439,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4788820,=,nM,4550.0,CHEMBL279,Homo sapiens,IC50
22969440,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4783119,=,nM,3230.0,CHEMBL279,Homo sapiens,IC50
22969441,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4782982,=,nM,2610.0,CHEMBL279,Homo sapiens,IC50
22969442,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4792614,=,nM,330.0,CHEMBL279,Homo sapiens,IC50
22969443,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4791531,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
22969444,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4791160,=,nM,2740.0,CHEMBL279,Homo sapiens,IC50
22969445,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789042,=,nM,1710.0,CHEMBL279,Homo sapiens,IC50
22969446,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4798001,=,nM,4150.0,CHEMBL279,Homo sapiens,IC50
22969447,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4784961,=,nM,920.0,CHEMBL279,Homo sapiens,IC50
22969448,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780971,=,nM,670.0,CHEMBL279,Homo sapiens,IC50
22969449,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4799658,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50
22969450,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4794056,=,nM,4860.0,CHEMBL279,Homo sapiens,IC50
22969451,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796056,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
22969452,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780565,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
22969453,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4785657,=,nM,5220.0,CHEMBL279,Homo sapiens,IC50
22969454,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4777374,=,nM,1330.0,CHEMBL279,Homo sapiens,IC50
22969455,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796483,=,nM,2820.0,CHEMBL279,Homo sapiens,IC50
22969456,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4794661,=,nM,3510.0,CHEMBL279,Homo sapiens,IC50
22969457,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789638,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50
22969458,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4784540,=,nM,1810.0,CHEMBL279,Homo sapiens,IC50
22972841,CHEMBL4771078,"Inhibition of VEGFR 2 (unknown origin) using poly (Glu, Tyr)4:1 as substrate in presence of ATP measured after 30 mins by HTRF assay",B,CHEMBL4799113,=,nM,673.0,CHEMBL279,Homo sapiens,IC50
22983297,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4794619,=,nM,208.66,CHEMBL279,Homo sapiens,IC50
22983301,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4780189,=,nM,208.15,CHEMBL279,Homo sapiens,IC50
22983303,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4789418,=,nM,80.42,CHEMBL279,Homo sapiens,IC50
22987198,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790899,=,nM,121.4,CHEMBL279,Homo sapiens,IC50
22987199,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4795648,=,nM,79.2,CHEMBL279,Homo sapiens,IC50
22987200,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4786463,=,nM,33.0,CHEMBL279,Homo sapiens,IC50
22987201,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4786987,=,nM,47.6,CHEMBL279,Homo sapiens,IC50
22987202,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790527,=,nM,139.9,CHEMBL279,Homo sapiens,IC50
22987203,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4793436,=,nM,21.7,CHEMBL279,Homo sapiens,IC50
22987204,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4792804,=,nM,68.0,CHEMBL279,Homo sapiens,IC50
22987205,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4776554,=,nM,93.9,CHEMBL279,Homo sapiens,IC50
22987207,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4789492,=,nM,226.7,CHEMBL279,Homo sapiens,IC50
22987208,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4784644,=,nM,127.9,CHEMBL279,Homo sapiens,IC50
22987209,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4794496,=,nM,267.3,CHEMBL279,Homo sapiens,IC50
22987210,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4798752,=,nM,97.3,CHEMBL279,Homo sapiens,IC50
22987211,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4780196,=,nM,12.3,CHEMBL279,Homo sapiens,IC50
22987212,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4792576,=,nM,52.9,CHEMBL279,Homo sapiens,IC50
22987213,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4787904,=,nM,163.5,CHEMBL279,Homo sapiens,IC50
22987214,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790015,=,nM,145.4,CHEMBL279,Homo sapiens,IC50
22987215,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4779200,=,nM,207.6,CHEMBL279,Homo sapiens,IC50
22987217,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4784431,=,nM,111.3,CHEMBL279,Homo sapiens,IC50
22987218,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4788196,=,nM,454.9,CHEMBL279,Homo sapiens,IC50
23148920,CHEMBL4810014,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4868909,=,nM,42.0,CHEMBL279,Homo sapiens,IC50
23154659,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4877180,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
23154660,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4860634,=,nM,18.4,CHEMBL279,Homo sapiens,IC50
23154661,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4871761,=,nM,10.7,CHEMBL279,Homo sapiens,IC50
23154662,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4846532,=,nM,26.7,CHEMBL279,Homo sapiens,IC50
23154663,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4847003,=,nM,27.9,CHEMBL279,Homo sapiens,IC50
23154664,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4856747,=,nM,4.6,CHEMBL279,Homo sapiens,IC50
23154665,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4849165,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
23154666,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4878575,=,nM,49.5,CHEMBL279,Homo sapiens,IC50
23154667,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4868604,=,nM,21.7,CHEMBL279,Homo sapiens,IC50
23154668,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4868897,=,nM,13.8,CHEMBL279,Homo sapiens,IC50
23154669,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4850662,=,nM,29.6,CHEMBL279,Homo sapiens,IC50
23154670,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4857634,=,nM,34.9,CHEMBL279,Homo sapiens,IC50
23154671,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4866887,=,nM,63.4,CHEMBL279,Homo sapiens,IC50
23154672,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4861773,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
23154673,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4860596,=,nM,6.8,CHEMBL279,Homo sapiens,IC50
23154674,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4851244,=,nM,22.9,CHEMBL279,Homo sapiens,IC50
23154675,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4852800,=,nM,49.5,CHEMBL279,Homo sapiens,IC50
23154676,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4846648,=,nM,11.7,CHEMBL279,Homo sapiens,IC50
23154677,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4863157,=,nM,4.7,CHEMBL279,Homo sapiens,IC50
23154678,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4864736,=,nM,8.7,CHEMBL279,Homo sapiens,IC50
23154679,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4871200,=,nM,9.8,CHEMBL279,Homo sapiens,IC50
23196751,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856891,=,nM,93110.0,CHEMBL279,Homo sapiens,IC50
23196752,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4873974,=,nM,110600.0,CHEMBL279,Homo sapiens,IC50
23196753,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4864168,=,nM,44670.0,CHEMBL279,Homo sapiens,IC50
23196754,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4874971,=,nM,26380.0,CHEMBL279,Homo sapiens,IC50
23196755,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856794,=,nM,115420.0,CHEMBL279,Homo sapiens,IC50
23196757,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4877343,=,nM,198540.0,CHEMBL279,Homo sapiens,IC50
23196760,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4872149,=,nM,162810.0,CHEMBL279,Homo sapiens,IC50
23196761,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4878880,=,nM,169420.0,CHEMBL279,Homo sapiens,IC50
23196763,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4872013,=,nM,178910.0,CHEMBL279,Homo sapiens,IC50
23196764,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4864073,=,nM,108360.0,CHEMBL279,Homo sapiens,IC50
23196765,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4847439,=,nM,99670.0,CHEMBL279,Homo sapiens,IC50
23196766,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4863263,=,nM,71550.0,CHEMBL279,Homo sapiens,IC50
23196767,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4857454,=,nM,89160.0,CHEMBL279,Homo sapiens,IC50
23196768,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866291,=,nM,36900.0,CHEMBL279,Homo sapiens,IC50
23196769,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4876341,=,nM,139500.0,CHEMBL279,Homo sapiens,IC50
23196770,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4877074,=,nM,171120.0,CHEMBL279,Homo sapiens,IC50
23196771,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4853198,=,nM,192510.0,CHEMBL279,Homo sapiens,IC50
23196772,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856663,=,nM,119930.0,CHEMBL279,Homo sapiens,IC50
23196773,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4854778,=,nM,186440.0,CHEMBL279,Homo sapiens,IC50
23196774,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4871475,=,nM,170180.0,CHEMBL279,Homo sapiens,IC50
23196775,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4847210,=,nM,187240.0,CHEMBL279,Homo sapiens,IC50
23196776,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866203,=,nM,193410.0,CHEMBL279,Homo sapiens,IC50
23196777,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866727,=,nM,190070.0,CHEMBL279,Homo sapiens,IC50
23196778,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4846157,=,nM,168890.0,CHEMBL279,Homo sapiens,IC50
23200120,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4863009,=,nM,892.0,CHEMBL279,Homo sapiens,IC50
23200121,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4876592,=,nM,143.0,CHEMBL279,Homo sapiens,IC50
23200122,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4849476,=,nM,249.0,CHEMBL279,Homo sapiens,IC50
23200123,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4852434,=,nM,220.0,CHEMBL279,Homo sapiens,IC50
23200124,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4856065,=,nM,407.0,CHEMBL279,Homo sapiens,IC50
23200125,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4879197,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
23200126,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4861302,=,nM,7.4,CHEMBL279,Homo sapiens,IC50
23200127,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4853592,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
23200128,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4873983,=,nM,22.0,CHEMBL279,Homo sapiens,IC50
23200129,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4846198,=,nM,14.0,CHEMBL279,Homo sapiens,IC50
23200130,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4858003,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
23200131,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4860732,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
23200132,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4870465,=,nM,1.6,CHEMBL279,Homo sapiens,IC50
23200133,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4869697,=,nM,28.0,CHEMBL279,Homo sapiens,IC50
23200134,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4861155,=,nM,15.0,CHEMBL279,Homo sapiens,IC50
23200135,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4874982,=,nM,11.0,CHEMBL279,Homo sapiens,IC50
23200136,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4872941,=,nM,2.3,CHEMBL279,Homo sapiens,IC50
23200137,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4878552,=,nM,0.73,CHEMBL279,Homo sapiens,IC50
23200138,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4858980,=,nM,38.0,CHEMBL279,Homo sapiens,IC50
23200139,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4857358,=,nM,60.0,CHEMBL279,Homo sapiens,IC50
23200141,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4866941,=,nM,27.0,CHEMBL279,Homo sapiens,IC50
23200142,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4857488,=,nM,307.0,CHEMBL279,Homo sapiens,IC50
23200143,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4871126,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
23210854,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4864800,=,nM,281.5,CHEMBL279,Homo sapiens,IC50
23210855,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4855595,=,nM,111.9,CHEMBL279,Homo sapiens,IC50
23210856,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4871367,=,nM,46.83,CHEMBL279,Homo sapiens,IC50
23210857,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4860285,=,nM,169.7,CHEMBL279,Homo sapiens,IC50
23210858,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4866817,=,nM,295.8,CHEMBL279,Homo sapiens,IC50
23210859,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4853870,=,nM,51.09,CHEMBL279,Homo sapiens,IC50
23210860,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4859066,=,nM,222.6,CHEMBL279,Homo sapiens,IC50
23210861,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4851319,=,nM,62.7,CHEMBL279,Homo sapiens,IC50
23210862,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4873088,=,nM,167.3,CHEMBL279,Homo sapiens,IC50
23210863,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4876616,=,nM,174.5,CHEMBL279,Homo sapiens,IC50
23216543,CHEMBL4823741,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins in presence of ATP by mobility shift assay,B,CHEMBL4869059,=,nM,136.9,CHEMBL279,Homo sapiens,IC50
23218536,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL4850588,=,nM,146.8,CHEMBL279,Homo sapiens,IC50
23218537,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL4874046,=,nM,291.8,CHEMBL279,Homo sapiens,IC50
23218538,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL3137331,=,nM,273.2,CHEMBL279,Homo sapiens,IC50
23240292,CHEMBL4829093,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4876135,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
23256967,CHEMBL4832316,Inhibition of KDR (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method,B,CHEMBL4866102,=,nM,710.0,CHEMBL279,Homo sapiens,IC50
23265635,CHEMBL4834276,Inhibition of KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4858720,=,nM,150.0,CHEMBL279,Homo sapiens,IC50
23265636,CHEMBL4834276,Inhibition of KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL169390,=,nM,58.0,CHEMBL279,Homo sapiens,IC50
23265689,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4854822,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50
23265692,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4855562,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50
23265693,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4853155,=,nM,760.0,CHEMBL279,Homo sapiens,IC50
23265695,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4877264,=,nM,840.0,CHEMBL279,Homo sapiens,IC50
23265696,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4874648,=,nM,660.0,CHEMBL279,Homo sapiens,IC50
23265697,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4857808,=,nM,440.0,CHEMBL279,Homo sapiens,IC50
23265698,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4859681,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
23284800,CHEMBL4838110,Inhibition of human N-terminal GST-fusion tagged VEGFR2 cytoplasmic domain (790 to 1356 end residues) expressed in Sf21 insect cells,B,CHEMBL4862576,=,nM,14.4,CHEMBL279,Homo sapiens,IC50
23299503,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL1992306,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
23299504,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL1233853,=,nM,20.0,CHEMBL279,Homo sapiens,IC50
23299505,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856623,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
23299506,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870490,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
23299507,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4857725,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
23299508,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868251,=,nM,10.0,CHEMBL279,Homo sapiens,IC50
23299509,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856992,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
23299511,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4852364,=,nM,3.2,CHEMBL279,Homo sapiens,IC50
23299512,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4869054,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
23299513,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4861519,=,nM,32.0,CHEMBL279,Homo sapiens,IC50
23299514,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4863580,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
23299515,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4849349,=,nM,7.9,CHEMBL279,Homo sapiens,IC50
23299516,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850251,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
23299517,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4873277,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50
23299518,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4876578,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
23299519,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4872243,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
23299520,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4864463,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
23299521,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4873406,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
23299522,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4877505,=,nM,19.0,CHEMBL279,Homo sapiens,IC50
23299523,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4865829,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
23299524,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4871527,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
23299525,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4847826,=,nM,200.0,CHEMBL279,Homo sapiens,IC50
23299526,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859309,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
23299527,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4854957,=,nM,320.0,CHEMBL279,Homo sapiens,IC50
23299528,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4845883,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
23299529,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4875220,=,nM,0.4,CHEMBL279,Homo sapiens,IC50
23299530,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867760,=,nM,3.2,CHEMBL279,Homo sapiens,IC50
23299531,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856147,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50
23299532,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4855081,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
23299533,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859818,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
23299534,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867053,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
23299535,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870079,=,nM,130.0,CHEMBL279,Homo sapiens,IC50
23299536,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850964,=,nM,79.0,CHEMBL279,Homo sapiens,IC50
23299537,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868391,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
23299538,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850780,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
23299539,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4066096,=,nM,16.0,CHEMBL279,Homo sapiens,IC50
23299540,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4863203,=,nM,6.3,CHEMBL279,Homo sapiens,IC50
23299541,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4857556,=,nM,2.5,CHEMBL279,Homo sapiens,IC50
23299542,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4874491,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
23299543,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870768,=,nM,13.0,CHEMBL279,Homo sapiens,IC50
23299544,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4875166,=,nM,160.0,CHEMBL279,Homo sapiens,IC50
23299545,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859380,=,nM,63.0,CHEMBL279,Homo sapiens,IC50
23299546,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868757,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
23299547,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870044,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
23299548,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4869303,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
23299549,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4865373,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
23299550,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856606,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
23299551,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867552,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
24515636,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5087583,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50
24515637,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5087770,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50
24516776,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5087926,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
24516778,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081704,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50
24516783,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5090743,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50
24516784,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081487,=,nM,700.0,CHEMBL279,Homo sapiens,IC50
24516785,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL4575134,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50
24516786,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081055,=,nM,40.0,CHEMBL279,Homo sapiens,IC50
24660997,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5196797,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50
24660998,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5195888,=,nM,773.6,CHEMBL279,Homo sapiens,IC50
24660999,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5192921,=,nM,229.1,CHEMBL279,Homo sapiens,IC50
24661000,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5209158,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50
24661001,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5182130,=,nM,4692.0,CHEMBL279,Homo sapiens,IC50
24661002,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183691,=,nM,11.4,CHEMBL279,Homo sapiens,IC50
24661003,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183603,=,nM,79.27,CHEMBL279,Homo sapiens,IC50
24661004,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5191301,=,nM,89.6,CHEMBL279,Homo sapiens,IC50
24661005,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5181778,=,nM,82.93,CHEMBL279,Homo sapiens,IC50
24661006,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183701,=,nM,70.36,CHEMBL279,Homo sapiens,IC50
24661007,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5191338,=,nM,64.85,CHEMBL279,Homo sapiens,IC50
24661008,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5174735,=,nM,63.09,CHEMBL279,Homo sapiens,IC50
24661009,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5180534,=,nM,158.0,CHEMBL279,Homo sapiens,IC50
24661010,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5186357,=,nM,55.83,CHEMBL279,Homo sapiens,IC50
24661011,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5201819,=,nM,60.18,CHEMBL279,Homo sapiens,IC50
24661012,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5207255,=,nM,53.12,CHEMBL279,Homo sapiens,IC50
24661013,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5199374,=,nM,66.26,CHEMBL279,Homo sapiens,IC50
24661014,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5182544,=,nM,158.0,CHEMBL279,Homo sapiens,IC50
24661015,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5173892,=,nM,145.5,CHEMBL279,Homo sapiens,IC50
24661016,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5171314,=,nM,119.2,CHEMBL279,Homo sapiens,IC50
24661017,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5179660,=,nM,301.3,CHEMBL279,Homo sapiens,IC50
24661018,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5189958,=,nM,407.2,CHEMBL279,Homo sapiens,IC50
24661019,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5205436,=,nM,37.63,CHEMBL279,Homo sapiens,IC50
24661020,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5177815,=,nM,43.16,CHEMBL279,Homo sapiens,IC50
24687335,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5208686,=,nM,1.3,CHEMBL279,Homo sapiens,IC50
24687336,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5177149,=,nM,1.4,CHEMBL279,Homo sapiens,IC50
24687337,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5202124,=,nM,60.7,CHEMBL279,Homo sapiens,IC50
24687338,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5186748,=,nM,0.12,CHEMBL279,Homo sapiens,IC50
24687376,CHEMBL5104373,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) substrate incubated for 40 mins in presence of ATP by ADP-Glo kinase assay",B,CHEMBL5205255,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50
24687380,CHEMBL5104376,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5189340,=,nM,0.023,CHEMBL279,Homo sapiens,IC50
24687440,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5208660,=,nM,910.0,CHEMBL279,Homo sapiens,IC50
24687441,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5181360,=,nM,110.0,CHEMBL279,Homo sapiens,IC50
24687442,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5204637,=,nM,310.0,CHEMBL279,Homo sapiens,IC50
24694042,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3813873,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
24694044,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171304,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50
24694051,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193071,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
24694288,CHEMBL5106444,Inhibition of VEGFR2 (unknown origin) measured by spectrophotometric analysis,B,CHEMBL5176985,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50
24694290,CHEMBL5106444,Inhibition of VEGFR2 (unknown origin) measured by spectrophotometric analysis,B,CHEMBL5186979,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50
24722920,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5183938,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50
24722924,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5207269,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50
24722927,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5201057,=,nM,900.0,CHEMBL279,Homo sapiens,IC50
24722928,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5194115,=,nM,800.0,CHEMBL279,Homo sapiens,IC50
24722930,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5194089,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50
24722934,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5196567,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50
24722938,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5173289,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50
24724722,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5182307,=,nM,61800.0,CHEMBL279,Homo sapiens,IC50
24724723,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5170911,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
24724724,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5202279,=,nM,4.8,CHEMBL279,Homo sapiens,IC50
24724725,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5175388,=,nM,3.9,CHEMBL279,Homo sapiens,IC50
24733680,CHEMBL5116337,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5177616,=,nM,5.92,CHEMBL279,Homo sapiens,IC50
24733681,CHEMBL5116337,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208297,=,nM,3.4,CHEMBL279,Homo sapiens,IC50
24746615,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5186340,=,nM,757.0,CHEMBL279,Homo sapiens,IC50
24746616,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5195158,=,nM,420.0,CHEMBL279,Homo sapiens,IC50
24746617,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5193231,=,nM,171.0,CHEMBL279,Homo sapiens,IC50
24746618,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5191460,=,nM,490.0,CHEMBL279,Homo sapiens,IC50
24746620,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5173016,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
24746624,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5171199,=,nM,960.0,CHEMBL279,Homo sapiens,IC50
24746625,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5197535,=,nM,500.0,CHEMBL279,Homo sapiens,IC50
24746626,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5199099,=,nM,413.0,CHEMBL279,Homo sapiens,IC50
24746628,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5198427,=,nM,690.0,CHEMBL279,Homo sapiens,IC50
24746629,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5169941,=,nM,430.0,CHEMBL279,Homo sapiens,IC50
24746630,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5189763,=,nM,290.0,CHEMBL279,Homo sapiens,IC50
24746632,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5205778,=,nM,997.0,CHEMBL279,Homo sapiens,IC50
24746634,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5172448,=,nM,600.0,CHEMBL279,Homo sapiens,IC50
24750634,CHEMBL5121022,Inhibition of human VEGFR2 in HUVEC cells assessed as reduction in VEGFR2 phosphorylation incubated for 30 mins by anti-phospho VEGF Tyr 1175 antibody based assay,B,CHEMBL5174358,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50
24759618,CHEMBL5123387,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4741442,=,nM,34.0,CHEMBL279,Homo sapiens,IC50
24772952,CHEMBL5127079,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193247,=,nM,103.0,CHEMBL279,Homo sapiens,IC50
24772959,CHEMBL5127083,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5207327,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
24772960,CHEMBL5127083,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5192572,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
24779506,CHEMBL5129164,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate incubated for 45 mins by kinase-glo max reagent based luminescence analysis,B,CHEMBL5170855,=,nM,139800.0,CHEMBL279,Homo sapiens,IC50
24796291,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5176146,=,nM,549.0,CHEMBL279,Homo sapiens,IC50
24796292,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5195498,=,nM,403.0,CHEMBL279,Homo sapiens,IC50
24796293,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5206046,=,nM,486.0,CHEMBL279,Homo sapiens,IC50
24796294,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5196624,=,nM,702.0,CHEMBL279,Homo sapiens,IC50
24796295,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208251,=,nM,383.0,CHEMBL279,Homo sapiens,IC50
24796296,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5206533,=,nM,498.0,CHEMBL279,Homo sapiens,IC50
24796297,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171479,=,nM,309.0,CHEMBL279,Homo sapiens,IC50
24796298,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5174013,=,nM,412.0,CHEMBL279,Homo sapiens,IC50
24796299,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5192184,=,nM,188.0,CHEMBL279,Homo sapiens,IC50
24796300,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5203784,=,nM,171.0,CHEMBL279,Homo sapiens,IC50
24796301,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171983,=,nM,162.0,CHEMBL279,Homo sapiens,IC50
24796302,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193370,=,nM,548.0,CHEMBL279,Homo sapiens,IC50
24796303,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208645,=,nM,238.0,CHEMBL279,Homo sapiens,IC50
24796304,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208151,=,nM,412.0,CHEMBL279,Homo sapiens,IC50
24796305,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5209402,=,nM,745.0,CHEMBL279,Homo sapiens,IC50
24796306,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193750,=,nM,549.0,CHEMBL279,Homo sapiens,IC50
24796307,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5182805,=,nM,580.0,CHEMBL279,Homo sapiens,IC50
24796308,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5209858,=,nM,369.0,CHEMBL279,Homo sapiens,IC50
24796309,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5205265,=,nM,295.0,CHEMBL279,Homo sapiens,IC50
24796310,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5201110,=,nM,163.0,CHEMBL279,Homo sapiens,IC50
24796311,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5181045,=,nM,152.0,CHEMBL279,Homo sapiens,IC50
24796312,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208397,=,nM,178.0,CHEMBL279,Homo sapiens,IC50
24814271,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5175208,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
24814272,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5172665,=,nM,31.0,CHEMBL279,Homo sapiens,IC50
24814273,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5202879,=,nM,40.4,CHEMBL279,Homo sapiens,IC50
24814274,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5199108,=,nM,83.8,CHEMBL279,Homo sapiens,IC50
24814275,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5169624,=,nM,10.3,CHEMBL279,Homo sapiens,IC50
24814276,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5184038,=,nM,3.8,CHEMBL279,Homo sapiens,IC50
24814277,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5187154,=,nM,7.1,CHEMBL279,Homo sapiens,IC50
24814278,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171763,=,nM,21.3,CHEMBL279,Homo sapiens,IC50
24814279,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5183413,=,nM,4.9,CHEMBL279,Homo sapiens,IC50
24848737,CHEMBL5147309,Inhibition of VEGFR2 (unknown origin) by kinase-glo luminescent assay,B,CHEMBL5178919,=,nM,71.0,CHEMBL279,Homo sapiens,IC50
24862961,CHEMBL5150852,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5176837,=,nM,5.0,CHEMBL279,Homo sapiens,IC50
24862987,CHEMBL5150877,Inhibition of VEGFR-2 (unknown origin) preincubated for 20 mins followed 33P ATP addition and measured after 120 min by hotspot assay,B,CHEMBL5176427,=,nM,35.1,CHEMBL279,Homo sapiens,IC50
24862988,CHEMBL5150877,Inhibition of VEGFR-2 (unknown origin) preincubated for 20 mins followed 33P ATP addition and measured after 120 min by hotspot assay,B,CHEMBL5173625,=,nM,24.7,CHEMBL279,Homo sapiens,IC50
24862989,CHEMBL5150878,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5206146,=,nM,435.0,CHEMBL279,Homo sapiens,IC50
24866087,CHEMBL5151658,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1276317,=,nM,950.0,CHEMBL279,Homo sapiens,IC50
24867148,CHEMBL5151933,Inhibition of VEGFR2 (unknown origin) by ELISA method,B,CHEMBL5201128,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
24867188,CHEMBL5151973,Inhibition of VEGFR2 (unknown origin) by FISH assay,B,CHEMBL5201102,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
24867225,CHEMBL5152010,Inhibition of VEGFR2 (unknown origin) by kinomescan assay,B,CHEMBL2029988,=,nM,43.0,CHEMBL279,Homo sapiens,IC50
24867252,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL4559134,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
24867253,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL5171764,=,nM,35.0,CHEMBL279,Homo sapiens,IC50
24927928,CHEMBL5168176,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by trilux reader method,B,CHEMBL3828009,=,nM,7.0,CHEMBL279,Homo sapiens,IC50
24957521,CHEMBL5213189,"Selectivity interaction (SelectScreen (Invitrogen, enzymatic assay with 100 M ATP)) EUB0000697a KDR",B,CHEMBL3639728,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50
24958341,CHEMBL5213102,Selectivity interaction (Kinase panel (literature or Upstate/Millipore)) EUB0000665a KDR,B,CHEMBL3990456,=,nM,8.0,CHEMBL279,Homo sapiens,IC50
24958849,CHEMBL5215100,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5220848,=,nM,84.0,CHEMBL279,Homo sapiens,IC50
24959152,CHEMBL5215242,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5218459,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
24959153,CHEMBL5215242,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5218990,=,nM,80.0,CHEMBL279,Homo sapiens,IC50
24984427,CHEMBL5227285,Inhibition of human VEGFR2 incubated for 40 mins by scintillation counter analysis,B,CHEMBL4787515,=,nM,12.0,CHEMBL279,Homo sapiens,IC50
24985439,CHEMBL5227744,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5282499,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50
24987545,CHEMBL5228558,Inhibition of human VEGFR2 using TMB as substrate by ELISA,B,CHEMBL5290309,=,nM,590.0,CHEMBL279,Homo sapiens,IC50
24987546,CHEMBL5228558,Inhibition of human VEGFR2 using TMB as substrate by ELISA,B,CHEMBL5268406,=,nM,1290.0,CHEMBL279,Homo sapiens,IC50
24987578,CHEMBL5228580,Inhibition of VEGFR2 (unknown origin) by ELISA,B,CHEMBL5266387,=,nM,126.0,CHEMBL279,Homo sapiens,IC50
24993584,CHEMBL5230848,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5199520,=,nM,390.0,CHEMBL279,Homo sapiens,IC50
24993634,CHEMBL5230863,Inhibition of human VEGFR2 incubated for 10 mins in presence of ATP by mobility shift assay,B,CHEMBL5278037,=,nM,93.0,CHEMBL279,Homo sapiens,IC50
24995148,CHEMBL5231470,"Inhibition of VEGFR2 (unknown origin) at 25 nM using Poly(Glu, Tyr) as substrate by Kinase-Glo plus luminescent kinase assay",B,CHEMBL5289303,=,nM,11.9,CHEMBL279,Homo sapiens,IC50
24995149,CHEMBL5231470,"Inhibition of VEGFR2 (unknown origin) at 25 nM using Poly(Glu, Tyr) as substrate by Kinase-Glo plus luminescent kinase assay",B,CHEMBL5274698,=,nM,13.6,CHEMBL279,Homo sapiens,IC50
25002453,CHEMBL5233458,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5267844,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
25030041,CHEMBL5241386,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 60 mins by ELISA analysis,B,CHEMBL4278642,=,nM,1.2,CHEMBL279,Homo sapiens,IC50
25030049,CHEMBL5241394,Inhibition of recombinant VEGFR2 (unknown origin) in the presence of [p33]-ATP,B,CHEMBL3964954,=,nM,9.0,CHEMBL279,Homo sapiens,IC50
25030078,CHEMBL5241423,Inhibition of N-terminal 6-His tagged recombinant VEGFR2 Kinase domain (unknown origin) expressed in baculovirus expression system incubated for 30 mins in the presence of [33p]-ATP by scintillation counting analysis,B,CHEMBL1214783,=,nM,25.0,CHEMBL279,Homo sapiens,IC50
25036572,CHEMBL5243518,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5280361,=,nM,87.0,CHEMBL279,Homo sapiens,IC50
25036573,CHEMBL5243518,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5268244,=,nM,475.0,CHEMBL279,Homo sapiens,IC50
25046091,CHEMBL5246168,Inhibition of human VEGFR2 (unknown origin) incubated for 1 hrs in presence of ATP by ELISA assay,B,CHEMBL5276696,=,nM,190.0,CHEMBL279,Homo sapiens,IC50
25056501,CHEMBL5249089,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL5272444,=,nM,2.7,CHEMBL279,Homo sapiens,IC50
25056502,CHEMBL5249089,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL5275552,=,nM,0.42,CHEMBL279,Homo sapiens,IC50
25070247,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5268513,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
25070248,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5269027,=,nM,50.0,CHEMBL279,Homo sapiens,IC50
25070249,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5283863,=,nM,1.0,CHEMBL279,Homo sapiens,IC50
25070250,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5280119,=,nM,3.0,CHEMBL279,Homo sapiens,IC50
25070251,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5276611,=,nM,4.0,CHEMBL279,Homo sapiens,IC50
25070253,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5278387,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50
25070254,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5272957,=,nM,21.0,CHEMBL279,Homo sapiens,IC50
25070255,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5288744,=,nM,2.0,CHEMBL279,Homo sapiens,IC50
25070256,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5266162,=,nM,400.0,CHEMBL279,Homo sapiens,IC50
25070258,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL574738,=,nM,230.0,CHEMBL279,Homo sapiens,IC50
25084786,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5287545,=,nM,1486.0,CHEMBL279,Homo sapiens,IC50
25084787,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5268467,=,nM,7010.0,CHEMBL279,Homo sapiens,IC50
25084788,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701241,=,nM,3029.0,CHEMBL279,Homo sapiens,IC50
25084789,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5269016,=,nM,3377.0,CHEMBL279,Homo sapiens,IC50
25084790,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701255,=,nM,1770.0,CHEMBL279,Homo sapiens,IC50
25084791,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701243,=,nM,3686.0,CHEMBL279,Homo sapiens,IC50
25084792,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5278505,=,nM,1206.0,CHEMBL279,Homo sapiens,IC50
25084793,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701238,=,nM,2358.0,CHEMBL279,Homo sapiens,IC50
25091433,CHEMBL5258371,Inhibition of KDR (unknown origin) using peptide substrate incubated for 90 mins in presence of ATP by HTRF method,B,CHEMBL5286909,=,nM,184.0,CHEMBL279,Homo sapiens,IC50
25104812,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL185637,=,nM,118.0,CHEMBL279,Homo sapiens,IC50
25104813,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL188304,=,nM,100.0,CHEMBL279,Homo sapiens,IC50
25104814,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL186080,=,nM,151.0,CHEMBL279,Homo sapiens,IC50
25104815,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL184311,=,nM,3250.0,CHEMBL279,Homo sapiens,IC50
25104819,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL187431,=,nM,29400.0,CHEMBL279,Homo sapiens,IC50
25104821,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5273702,=,nM,350.0,CHEMBL279,Homo sapiens,IC50
